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Abstract 
Background 
Task-related training can aid functional recovery post-stroke but has not been 
investigated in people with severe stroke. Orthostatic hypotension (OH) may 
limit rehabilitation, therefore, the effects of undertaking prolonged standing and 
sit to stand repetitions (functional standing frame programme) early after severe 
stroke during inpatient sub-acute rehabilitation is unknown. 
Methods 
A systematic review of non-pharmacological interventions to treat OH in people 
with neurological conditions was undertaken to inform a protocol for the 
management of OH during the functional standing frame programme. The 
feasibility of a blinded randomised controlled trial (RCT) investigating the effects 
of a functional standing frame programme compared to usual physiotherapy for 
people with severe stroke was conducted. 
Primary (Barthel Index, Edmans ADL Index for Stroke) and secondary 
outcomes (including lower limb joint range of movement, knee extensor 
strength, and quality of life) were assessed at baseline, post-intervention and 
15-, 29- and 55-weeks post-randomisation. 
Semi-structured interviews were conducted with a subset of participants, 
relatives and physiotherapists to explore experiences of the intervention and 
trial procedures.  
Data were analysed using thematic analysis and descriptive analysis. 
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Results 
The systematic review included randomised controlled trials (n=13), quasi-
experimental (n=27), case control (n=1) and case report (n=2). A meta-analysis 
of seven studies concluded electrical stimulation, lower limb compression and 
resistance exercise training were favourable in treating or reducing OH. 
Forty-five participants (51-96 years; 42% male, mRS 4=80% 5=20%) were 
recruited; n=22 randomised to intervention, n=23 to control. Twenty-seven 
participants completed the trial: n=12 died (n=7 intervention), n=2 moved out of 
area, n=4 withdrawn. 
Adherence to the intervention was low: 38-51% of possible sessions being 
completed; average session duration 39.40 minutes (±18.8); standing duration 
12.52 minutes (±8.8); and mean sit-to-stand repetitions 4.64 (±3.9 SD) per 
session. 91% of sessions were enjoyed. Adherence was affected by patient, 
physiotherapist and organisational factors. 
Conclusion 
A definitive RCT of a functional standing frame programme is feasible for 
people with severe stroke. However, intervention adherence need to be 
addressed before progressing to a definitive trial, which will investigate clinical 
and cost effectiveness. 
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Chapter 1 Introduction and background 
1.1 Introduction 
Stroke is a sudden and devastating condition affecting over 100,000 people in 
the United Kingdom (UK)1 and approximately 14 million people globally2 per 
annum. It is the largest cause of complex adult disability, with wide variations in 
aetiology, age at onset and comorbidities and presents a major global public 
health challenge. Stroke is categorised as: ischaemic (lack of blood and oxygen 
to an area of the brain) or haemorrhagic (bleeding from a burst or leaking blood 
vessel with accumulation of blood either inside the brain or spinal cord, or on 
the surface of the brain (subarachnoid haemorrhage)). Approximately 85% of 
strokes are ischaemic,10% due to primary haemorrhage, and 5% due to 
subarachnoid haemorrhage3. 
Research in the field of early mobilisation post-stroke has had an unequivocal 
impact on stroke care and rehabilitation3. Reasons why this area of clinical 
practice is important for people with stroke is discussed in this chapter. Several 
areas are explored in the existing body of evidence to provide background and 
context for this thesis and rationale for my research question. Evidence is used 
to critically evaluate what was already known and available in clinical practice, 
prior to commencement of this thesis, and identify knowledge gaps to define a 
relevant and meaningful research question. 
Firstly, this chapter presents an overview of the impact of stroke, current 
management and mechanisms underlying recovery. Secondly, the knowledge 
base and impact of early mobilisation is presented. Thirdly, the evidence for 
standing practice and task-specific strength training is appraised in relation to 
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the early sub-acute phase of inpatient stroke rehabilitation. Lastly, my research 
approach is introduced providing the rationale and structure of this thesis. 
1.2 Stroke impact and management 
A stroke can have devastating and life changing effects, the severity of which 
are dependent on the location and extent of the brain damage4. The World 
Health Organization5 provide a framework for the long-term management of 
stroke. The framework is articulated in terms of: Pathology (the disease 
processes within organs); Impairment (symptoms/signs; the manifestations of 
disease in the individual); Activities (the impact of impairments on the person’s 
usual activities); Participation (the impact of activity limitations on a person’s 
place in family and society). Stroke can result in impairments in motor (e.g. 
weakness, altered tone), sensation (e.g. touch, joint position sense, pain), 
cognition (e.g. perception, attention, memory), communication (e.g. speech and 
language), mood and wellbeing (e.g. anxiety, depression), continence, 
swallowing vision, fatigue (extreme tiredness). All of these impairments can 
cause significant disability that severely affect activities, participation and quality 
of life3. Impairments are present from stroke onset with some recovering rapidly 
and completely. Other impairments, however, will persist over weeks, months 
and years and may even increase over time due to the challenges and 
restrictions of life after stroke and ageing. The restrictions in activities and 
participation lead to a high economic burden on relatives/informal carers, the 
National Health Service (NHS) and social care, with direct and indirect care 
costs estimated at £1.7 billion per annum6. 
The cornerstone of stroke rehabilitation is to provide people the opportunity to 
acquire knowledge and skills to optimise their physical, psychological and social 
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function, aiming to reduce restrictions in activities and participation7. Current 
government and clinical guidelines recommend that following diagnosis of a 
stroke, people are admitted to an Acute Stroke Unit (ASU) to receive stroke 
specialist multi-disciplinary care. This is based on unequivocal evidence of 
reduced mortality and improved functional outcomes when patients are treated 
in specialist stroke units by co-ordinated multi-disciplinary teams8,9. The UK 
Stroke Pathway10 and National Clinical Guidelines3 advocate that people with 
mild or moderate stroke (i.e. modified Rankin Scale (mRS) 1-3; able to perform 
all usual activities, slight or moderate disability but able to walk without 
assistance) are discharged from the ASU to the Early Supported Discharge 
(ESD) service, which provides specialist stroke rehabilitation in a home-based 
setting. People with severe strokes (mRS 4-5; moderately severe disability or 
severe disability and bedridden) are typically transferred from the ASU to a 
specialist Stroke Rehabilitation Unit (SRU) for early sub-acute rehabilitation 
usually within seven days. The early sub-acute phase spans from seven days to 
three months11, with the local average time from stroke onset to admission on a 
SRU being six days (one to 37 days)12. Some ESD services in the UK admit 
people with a mRS of 4 but this is currently not standard care nationally. The 
implementation of ESD has caused a change in patient caseload nationally for 
SRUs3 resulting in the majority of people admitted to SRUs having severe 
impairments and complex needs. This change in caseload necessitates the 
design and evaluation of interventions for people in SRUs that target people 
with severe deficits. 
The most common physical deficit caused by stroke is motor impairment, 
regarded as a loss or limitation of function in muscle control or movement13. 
Motor impairment after stroke typically affects the control of movement of one 
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side of the body (face, arm, trunk and leg) and is seen in approximately 80% of 
people14. It is the single most disabling factor in terms of limiting a person’s 
mobility, their ability to participate in activities of daily living (ADL) and live 
independently15. Mobility encompasses a wide range of activities necessary for 
daily functioning: moving in bed; getting in/out of bed, on/off toilet; sitting out of 
bed, standing and walking3. These activities are particularly affected in the 
15.5% of people with severe stroke1 who require the assistance of two people 
to undertake ADL and are unable to sit unsupported, stand or walk without 
assistance and/or equipment16. They typically spend much of their time in bed 
and are dependent on careful positioning and specialist seating when sitting out 
of bed to provide postural support17. 
Although immobility post-stroke is primarily caused by neurological damage, it 
can be exacerbated by bed rest and sedentary behaviour. This can have a 
detrimental impact on the nervous, musculoskeletal and cardiorespiratory 
systems. Changes in the musculoskeletal system include muscle wasting18, 
reduced muscle length, increased muscle stiffness19 and joint contracture20 
which may cause aches and pains and muscle fatigue21. Additionally, loss of 
bone density (disuse osteoporosis) can occur and may be accelerated when the 
duration of immobility is prolonged22. Changes in the cardiorespiratory system 
such as orthostatic hypotension (OH) and reduced cardiorespiratory fitness may 
further impede recovery and participation in ADL and rehabilitation 
programmes. Orthostatic hypotension is a sudden drop in blood pressure when 
moving from lying to standing, leading to symptoms of feeling faint, generalised 
weakness, cognitive slowing and gradual or sudden loss of consciousness23. 
This can limit standing time and is discussed further in Section 1.7. 
Cardiorespiratory fitness is the ability of heart, lungs, blood vessels and skeletal 
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muscles to work together to deliver oxygen and remove metabolic by-products 
during physical activity24. Cardiorespiratory fitness facilitates the ability to 
perform physical activity for an extended period of time (endurance) and can be 
reduced as a result of inactivity or immobility post-stroke25. 
Immobility has a significant impact on recovery following stroke, thus providing 
people with stroke opportunities to improve mobility by practising functional 
tasks such as standing and moving between sitting and standing early after 
stroke is a key focus of rehabilitation26. Early rehabilitation has been defined as 
occurring within 48 hours of a stroke3. Rehabilitation comprises an interaction 
between the impact of the disease, the characteristics of the individual and the 
nature of their environment27. It covers a broad philosophy and range of 
interventions aiming to help an individual minimise the impact of a disabling 
health condition on their level of dependence28. In stroke, early rehabilitation 
typically addresses key impairments and offers the opportunity to reduce the 
burden of disability. This includes interventions that aim to optimise 
independence in self-care activities, swallow, speech and language, vision, 
cognition, motor function, balance and mobility28.  
The concept of an enriched environment in stroke rehabilitation is gaining 
increasing attention. This concept stemmed from animal model studies, 
whereby a stimulating environment was created to facilitate physical, sensory, 
cognitive and social activities29,30. In animal models an enriched environment 
has resulted in enhanced adaptive neuroplasticity31 (Section 1.3). However, 
what constitutes this within the clinical scenario is still ambiguous as 
standardised guidelines are lacking. 
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1.3 Stroke and mechanisms of recovery 
Motor impairment following stroke is defined by the International Classification 
of Functioning, Disability and Health as any loss, abnormality or failure of 
physiological or anatomical structure or function deriving from underlying 
pathology32. It can have a detrimental impact on motor function affecting a 
person’s mobility, resulting in limited participation in activities of daily life such 
as eating, drinking, washing, dressing, cooking, standing, walking, and family 
and leisure activities. 
Recovery of motor function following stroke is complex, non-linear and 
improvements may be attributed to different mechanisms that are not mutually 
exclusive: restoration (also known as resolution) or compensation33,34 which 
may be spontaneous and/or learning-dependent35. Restoration refers to the 
resolution of pathophysiological changes and reactivation of brain areas that 
were dysfunctional after they were initially damaged. This is characterised by a 
person’s ability to perform movements using the same muscle activation 
patterns and body parts or segments in the same manner prior to the stroke35. 
Compensation occurs when residual neural tissue takes over a motor function 
lost due to the ischaemia and is defined as using alternative strategies 
(including mechanical aids or physical assistance) or movements (different body 
parts/segments) to accomplish a motor task34. 
Following stroke, changes occur in the areas surrounding the stroke (focal 
changes) as well as areas distant to the stroke36. These changes occur over a 
short- (hours to days post stroke) and/or long-term (weeks to months post 
stroke) period. In acute ischaemic stroke, neurons are deprived of oxygen and 
glucose causing a complex cascade of events resulting in neuronal cell death. 
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Immediately following ischaemic stroke, blood flow and oxygen transport is also 
reduced to neurons surrounding the ischaemia (the penumbra), and oedema 
occurs due a cascade of pathophysiological events, leading to cell damage and 
risk of further neuron death37. Neuron death occurs primarily through 
excitotoxicity; cell death induced by high levels of glutamate38. 
The area surrounding the ischaemic injury undergoes changes in neuronal 
excitability due to excitatory (glutamate) and inhibitory (GABA) 
neurotransmitters, which alter the brains’ representation of motor and sensory 
functions39. Neuronal changes and dysfunction also occurs in regions 
anatomically connected to the stroke site stroke40. This is known as diaschisis 
which refers to reduced activity, typically measured by blood flow and/or 
metabolism, in uninjured brain areas that have strong connections with injured 
brain areas41. This can occur in the same hemisphere as the stroke 
(ipsilesional) and the opposite hemisphere (contralesional).  
Although brain damage resulting from the stroke is permanent and irreversible 
in the core of the lesion, peri-lesional tissue remains structurally intact, and 
during restoration in the acute and sub-acute phase, the penumbra undergoes 
reperfusion due to redundant collateral circulation, and oedema and diaschisis 
are resolved or reversed resulting in neurons being saved from death42,43. This 
often results in improvements in movement and function and is referred to as 
spontaneous biological recovery. Spontaneous biological recovery is thought to 
be augmented by a rebalance in the inhibitory-excitatory balance of GABA and 
glutamate44 which have a profound impact on neuroplasticity. Neuroplasticity is 
a neurophysiological feature that occurs dynamically throughout life and is 
defined as the ability of the central nervous system (CNS) to adapt in response 
to lesions or environment45. This may include structural and functional changes 
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in neuronal properties, such as recruitment of new or different neural networks, 
changes in the strength of internal connections of neural networks or 
reorganisation of specific motor and sensory brain areas responsible for 
performing a particular task46-48. One way changes occur in the CNS is through 
potentiation, or the strengthening of the nerve synapses. Long-term potentiation 
(LTP) is the persistent strengthening of synapses based on recent patterns of 
activity. Both glutamate and GABA receptors control different steps in the LTP 
process46. The process of neural plasticity is important to acknowledge because 
it is felt to underpin improvements in function resulting from learning and 
relearning after stroke. 
Frequent opportunities to relearn through practising and experiencing 
movement such as sitting to standing and standing early after stroke may result 
in greater functional gains due to elevated brain-derived neurotrophic factor 
(BDNF)49. Conversely, lack of movement leads to weakening and loss of 
synapses that may result in reduced functional gains or increased disability 50. 
Thus, it is important to provide people with stroke the opportunity to move and 
practice meaningful tasks, and evidence suggests this should be encouraged 
during the critical period post-stroke. 
The critical period for neuroplasticity is widely acknowledged in the literature 
and evidence from human and animal stroke studies suggests that 
neuroplasticity takes place maximally in a specific time window after an 
ischaemic lesion34,51. This appears to vary from six to 10 weeks52 with longer 
periods for people with severe strokes53. Whilst there is no definitive time 
period, there is agreement that this critical period appears to be limited54. 
Understanding the pathophysiological changes and mechanisms underlying 
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stroke recovery are thus important for clinicians to understand to optimise 
functional recovery following stroke. 
Recovery or compensation 
It is also important to consider whether any behavioural improvements, e.g. 
movement and function, occurs as a result of recovery or compensation. 
Recovery relates to restoration or resolution of physiological and molecular 
changes, and also, from a clinical perspective, to functional improvement and/or 
return to usual activities of daily living55. These functional improvements may 
occur as a result of the adoption of compensatory movements. Compensatory 
movements of muscles, joints and body parts, which can occur on either the 
non-paretic or paretic side, is the use of alternative muscles to accomplish a 
task, that deviate from normal movement following stroke56. Compensatory 
movements are often encouraged to enable a quick resumption of some 
activities of daily living57. This, however, has the potential disadvantage of being 
associated with long-term problems such as reduced range of movement in 
joints, pain, further muscle weakness and phenomenon such as learned non-
use58. This is an example of maladaptive neuroplasticity35. 
For someone with a severe stroke, compensatory movements may be the only 
means of gaining improvement in function. Severity of stroke also appears to 
affect where neural reorganization occurs37. In mild to moderate strokes, local 
reorganization is observed with new connections and sprouting in intact 
ipsilateral brain cells37. In more severe strokes, reorganisation is observed 
distant to the stroke contralaterally, with dendritic growth and pruning, and 
synapse formation37. This is because ipsilesional plasticity mechanisms are 
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limited due to extensive damage to the cortex. The site of cortical reorganisation 
may in turn affect the degree of recovery. 
Predicting recovery 
Clinically there remains uncertainty about the potential for recovery in all 
severity of strokes, raising questions as to why some people recover, and 
others do not44. The proportional recovery rule59 suggests that amount of 
function regained is a proportion of the initial deficit. The rule suggests that, 
regardless of severity, within three months people will regain approximately 
70% of function that had been lost on day three after stroke. However, the 
generalisability of this rule has been questioned as it has not been tested in 
people with severe stroke60,61. Furthermore, the rule is based on prediction of 
upper limb recovery that is heavily dependent on the integrity of the 
corticospinal tract. 
Motor evoked potentials (MEPs) using transcranial magnetic stimulation (TMS) 
are non-invasive and widely used to test the integrity of the corticospinal tract. 
They have been deemed reliable predictors of upper limb recovery 62 although 
the presence of perilesional oedema and hyperexcitability within the cortex have 
been identified as factors that may negatively affect the accuracy of these 
tests63. However, the integrity of the corticospinal tract is not a strong 
determinant of walking64 and the degree of lower limb motor recovery cannot be 
predicted by the magnitude of corticospinal MEP amplitude or the integrity of 
the corticospinal tract as ascertained by imaging, especially in people with 
severe or very severe stroke62,65. Given that some people with severe stroke 
return to walking but do not regain upper limb function, this suggests that the 
mechanisms involved are different. Jones et al., (2016) suggests that the 
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corticospinal tract has limited impact on walking and that sub-cortical structures 
such as the putamen, insula, brainstem and thalamus play a significant role in 
lower limb function and walking. Alternatively, walking and standing recovery 
may involve compensatory strategies such as over use of the non-paretic side. 
There is a wealth of research predicting upper limb recovery66-68. However, 
much less in lower limb recovery69 and a paucity of evidence in people with 
severe stroke. The ability to accurately predict functional recovery and outcome 
following stroke would enable realistic goal-setting, guide the type and duration 
of rehabilitation, and help to manage expectations70. Predictive data from 
neurophysiology and neuroimaging has been used in isolation and in 
combination with clinical variables (e.g. age, severity of muscle weakness), and 
clinical outcome measures61,62,71. However, there is no conclusive evidence to 
suggest one efficient, effective and accurate method of prediction following 
stroke.  
1.4 Early mobilisation 
Early mobilisation is the commencement of sitting out of bed, standing and 
walking training within 48 hours post-stroke3,26. There are several principles 
underpinning the rationale for early mobilisation. First, there is a wealth of 
evidence suggesting immobility has a detrimental impact on the neurological, 
musculoskeletal and cardiorespiratory systems (Sections 1.2 and 1.3)18-
20,22,24,25, which negatively affect recovery and functional outcome. Second, 
early after stroke in hospital, people are inactive and immobile for most of their 
day72 despite supporting evidence that it is feasible for people to be more 
active, even for those with severe stroke72. Theoretically these common and 
serious complications can be prevented or minimised by early mobilisation73,74. 
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Finally, the current concepts of biological recovery following stroke, suggest a 
critical period of opportunity for neuroplasticity and repair75. If the brain 
remodels itself based on experience76, this supports practicing task-specific 
activities early after stroke to optimize recovery. These principles are supported 
by the National clinical guidelines3,77 which therefore recommend early 
mobilisation after a stroke. 
Despite evidence supporting early mobilisation, the outcomes of several 
randomised controlled trials (RCTs) have been mixed with concerns about its 
potential harms. For example, less favourable outcomes occurred when early 
mobilisation was instigated ≤24 hours post-stroke78 compared to a reduction in 
complications when instigated ≥24 hours79. This finding is supported by other 
studies in which early mobilisation implemented ≥24 hours post-stroke was 
associated with increased independence in ADL and a faster return to 
walking80. However, heterogeneity of primary end-points makes direct 
comparison of effectiveness of early mobilisation interventions difficult. 
Whilst early mobilisation is deemed to be safe ≥24 hours post-stroke78-81, 
uncertainties have been identified with regards to dose (time in rehabilitation or 
number of repetitions82) and frequency. The AVERT Trial Collaborative Group 
suggest that shorter, more frequent mobilisation is preferable and this is 
reflected in the latest guidelines from the Royal College of Physicians3 
recommending patients accumulate at least 45 minutes daily. However, the 
main limitation of the RCTs is they did not specify time spent mobilising, 
intensity, frequency, or distinguish content of early mobilisation sessions in 
people with different severities of stroke. Therefore, it is possible that, other 
than transferring in and out of bed, no specialised equipment was used to 
facilitate standing for people with severe stroke. Further, active sitting was also 
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defined as a form of early mobilisation so people with a more severe stroke may 
have only participated in this activity with no opportunity to stand. 
Opportunities to practice standing and sit to stand are important, because early 
training is associated positively with structural plasticity in animal models of 
stroke recovery. For example, after an ischemic cortical infarct, movement 
representation in the motor cortex was greater when training was initiated at 
one week rather than one month83. Findings in such animal studies and RCTs 
suggest that the ideal time to introduce task-skilled rehabilitative training to 
induce experience-dependent plasticity is early, but not immediately, after 
stroke. However, the exact time window for beneficial structural and functional 
outcomes remains unclear. 
Despite the supporting evidence and clinical guidelines recommending early 
mobilisation, there is no evidence-based guidance as to how to implement early 
mobilisation specifically with people who have suffered a severe stroke. 
Arguably, these individuals are at the greatest risk of secondary changes 
because of their immobility. My personal experience of working in this area is 
that whilst there are regular opportunities for sitting people out of bed and 
facilitating them to undertake activities in lying and sitting, there is a lack of 
opportunity for regular standing and sit to standing practice early after stroke. 
The lack of opportunity to do so during the critical three-month post-stroke 
period, when maximal structural plasticity occurs, might negatively impact on 
functional outcome and quality of life.  
1.5 Supported standing in people with stroke 
Standing up early after a stroke is important, relevant and meaningful for people 
who have suffered a stroke. This was identified in discussions with people who 
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had suffered a stroke and their relatives when defining the research question 
and in the design of this feasibility trial. Patients reported that they believed the 
functional standing frame programme would “help me get back to normal”, 
“allow me to do things on my own” and for those of working age “help me get 
back to work”. Some participants cried when talking about being able to stand 
up, stating it is “really important to me”. Relatives of people with stroke 
commented that knowing their relative was practicing standing up was an 
“important milestone in their recovery”. Additionally, from a theoretical 
perspective, standing up and practising purposeful and meaningful activities of 
daily living have demonstrated to be important for adaptive plasticity. 
People who have suffered a severe stroke have limited options and 
opportunities to stand up and are reliant on physical assistance and equipment. 
Supported standing devices such as a motorised standing frame allow people 
with severe stroke to attain and maintain a standing position through stabilising 
hips, knees and ankles with supports and/or straps84. Supported standing 
programmes have been commonly used as an adjunctive therapeutic 
intervention in clinical practice in people with neurological conditions such as 
multiple sclerosis and spinal cord injury85. Conversely supported standing 
programmes are not routinely used in sub-acute inpatient stroke rehabilitation86 
and standing frames have never been issued on patient’s discharge from SRUs 
in the South West of England where I have worked clinically. 
Evidence from people with spinal cord injury, multiple sclerosis, stroke and 
traumatic brain injury indicates there are multiple benefits of supported 
standing. Stretching contracted muscles, decreasing spasticity, strengthening 
muscles, improving bladder and bowel function, relieving pressure areas, 
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reducing OH, improving bone strength87-93 can be observed with 30 minutes of 
daily standing ranging from three to seven days per week. 
Despite the aforementioned benefits of supported standing, currently there are 
no evidence-based guidelines for its use in adults with stroke or neurological 
conditions, and evidence on effectiveness has been identified as insufficient 85 
and contradictory94. A positive trend for improvements in gross motor function 
and trunk control and a significant improvement in balance for individuals with 
stroke was observed following a standing intervention of 45 minutes of standing 
in addition to 45 minutes of usual physiotherapy in a RCT95. Conversely, a RCT 
of 14 consecutive 30-minute standing frame sessions found no difference in 
functional outcomes between groups in people with a sub-acute severe 
stroke96. The lack of functional improvement may be due to variation in the 
duration and intensity of treatment. Two systematic reviews highlighted the 
variation in duration and frequency of standing. Duration varied from 10 to 60 
minutes and frequency of standing ranged from two to seven days per week 
with duration dependent on inpatient length of stay and participant recovery84,85. 
The lack of functional improvement may also be reflective of the heterogeneity 
and sensitivity of the various outcome measures used (Rivermead Mobility 
Index, Functional Independence Measure, Berg Balance Scale, Trunk Control 
Test, Barthel Index and Modified Ashworth Scale). Additionally, treatment was 
not standardised and was left to the therapists’ discretion. A more recent RCT 
also failed to demonstrate any patient benefits above and beyond usual 
physiotherapy following 20 or 40 minutes of standing per day in people with 
sub-acute stroke94. Aside from dose and frequency, the passive element of the 
prolonged standing warrants acknowledgement. In these trials, participants 
undertook prolonged standing only and the addition of task-specific training, 
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such as repeated sit to stand may have resulted in greater improvement in 
functional outcomes. 
1.6 Task-specific training 
Task-specific training or repetitive task training, is based on the principle that in 
order to improve the performance of a particular task, that particular task needs 
to be practiced numerous times97. A meta-analysis demonstrated that if tasks 
were practised more intensively, (e.g. more repetitions), this resulted in 
improved recovery of ADL post-stroke98. Improvements were greater if the task 
had a functional goal99. Task-specific training combines both intensity of 
practice and functional relevance97. 
Sit to stand is one of the most frequently performed functional tasks of daily 
living and is an essential pre-requisite to walking100. The ability to stand up 
without assistance is also an important factor for independence in ADL100 and 
falls prevention101. People with stroke commonly experience sensorimotor 
impairments which compromise their ability to sit to stand independently101. A 
Cochrane Review assessed the evidence of the effectiveness of therapy and 
training interventions aimed at improving the ability to sit to stand post-stroke. 
The review concluded that task-specific training to improve sit to stand is 
beneficial within stroke rehabilitation102. However, this moderate quality 
evidence included people who could already sit to stand independently after 
stroke. It is disappointing that people with severe stroke who are unable to sit to 
stand, stand or walk without mechanical and/or physical assistance were not 
included or acknowledged in this systematic review. People with severe stroke 
are arguably at the greatest risk of secondary neuromuscular complications and 
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are possibly being denied the opportunity to explore the potential benefits of this 
aspect of task-specific training. 
It has been suggested that the search continues for new therapies that can be 
widely incorporated into clinical practice to treat people with stroke103. There is 
also a need to rigorously test existing clinical practice with specific patient 
populations (e.g. people with severe stroke) at optimal times (e.g. during the 
critical sub-acute period) to make meaningful recommendations for current and 
future clinical practice. The Cochrane Review ‘Interventions for improving sit-to-
stand ability following stroke’102 clearly demonstrates that task-specific training 
with sit to stand has not been adequately evaluated in people with severe 
stroke. This is the rationale for incorporating task-specific training (repeated sit 
to stand) into the functional standing frame programme that is being evaluated 
in this feasibility trial. 
The functional standing frame programme will combine two physiotherapy 
interventions that have separately been evaluated and reported in the literature: 
prolonged standing and repeated sit to stand. Given that sit to stand and 
standing are functionally linked tasks as well as common functional tasks, it is 
surprising that their combined effects have not been previously tested in stroke. 
Therefore, development and evaluation of this novel combination of 
interventions in people with severe stroke is warranted. 
A significant limitation of task-specific training and early mobilisation in people 
with severe stroke is orthostatic hypotension (OH). It can be a barrier to 
rehabilitation and can contribute to increased morbidity and disability and thus 
also warrants being addressed. 
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1.7 Orthostatic hypotension 
OH is defined by consensus as a sustained drop in systolic blood pressure of at 
least 20 mmHg and/or diastolic blood pressure of at least 10 mmHg within 3 
minutes of moving from supine to standing or following head-up tilt to at least 60 
degrees104,105. 
Orthostatic hypotension is associated with ischemic stroke and can affect 
rehabilitation outcomes 106-108. Prevalence of OH varies from 10%109 to 52.1%108 
during acute- and sub-acute stroke rehabilitation hospitalisation. A reason for 
the variation in prevalence may be due to the severity of stroke for people 
included in studies. Participants in the study by Kong & Chuo (2003) had 
predominantly severe strokes who were more likely to suffer from immobility, 
which is a predisposing factor for OH, which may account for the high 
prevalence in this study. 
Immobility or bed rest has a negative impact on the cardiovascular system110. 
Adequate functioning of the cardiovascular system in everyday physical activity 
is highly dependent on exposure to gravitational stress that naturally 
accompanies an upright standing position111. During bed rest, the 
cardiovascular system quickly (two to four days) adapts112. Once bed rest is 
discontinued, however, the cardiovascular system has difficulty reversing this 
adaptation. Its compensatory mechanisms fail to adequately increase cardiac 
output and the person experiences OH; a hallmark of bed rest 
deconditioning112. However, these studies were conducted in healthy 
individuals, and people with stroke, especially severe stroke may likely have 
muscle weakness which may impede the ability of their lower limb and 
abdominal muscles to prevent blood pooling. 
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The presence of OH can interfere with and limit rehabilitation, especially in 
stroke where mobilisation (out-of-bed activities such as sitting, standing and 
walking) is recommended at the earliest opportunity3. The goal of treating OH is 
to raise a person’s standing blood pressure without also raising their resting 
blood pressure, specifically to reduce OH symptoms, increase the time they can 
stand and improve their ability to perform ADLs. Being able to treat OH 
effectively and efficiently to minimise any disruptions to rehabilitation is of 
paramount importance. Knowledge about the most effective manner in which to 
achieve this is the rationale for undertaking the systematic review, reported in 
Chapter 2. 
1.8 Research considerations 
Rehabilitation interventions in stroke are predominately considered complex 
interventions, as they typically comprise several interacting components113. For 
example, the functional standing frame programme depends on behaviours 
required by those delivering and receiving the intervention and the surrounding 
organisational culture. The intervention also has multiple outcomes (e.g. 
function, physical disability, psychological wellbeing and quality of life). It is vital 
that complex interventions are evaluated, and this frequently requires an 
assessment of the feasibility of delivering a clinical trial. This feasibility trial asks 
whether the functional standing frame programme can be delivered as part of 
an RCT to people with severe stroke at a specific time and within the NHS SRU 
setting. A process evaluation of the feasibility trial enabled the multifaceted and 
interacting components to be evaluated to establish clinical feasibility, 
acceptability and compliance. A process evaluation aims to examine factors 
such as how interventions are implemented, how participants respond to 
interventions and change their behaviour (or not), and contextual factors which 
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affect different stages of the intervention114. The Medical Research Council 
framework115 (Figure 1.1) was used in this feasibility trial, which includes both 
qualitative and quantitative methods. 
 
Figure 1.1 Medical Research Council Framework 
This framework was used as a modelling process to inform feasibility for a 
larger, future RCT. A pragmatic and iterative approach was used to answer a 
question relevant to people with severe stroke. Furthermore, the framework 
enabled unknown aspects of the trial such as acceptability, feasibility and 
recruitment to be identified, so that weaknesses could be addressed in a 
subsequent main trial. 
An important aspect of the process evaluation and overall assessment of 
feasibility involved stakeholder perspectives. Stakeholders are individuals or 
groups responsible for or affected by health- and healthcare-related 
decisions116. Perspectives of trial participants, their relatives and 
physiotherapists delivering the intervention and recruiting participants were 
considered critical to understanding the feasibility of this trial and providing 
valuable insights into the design and delivery of a subsequent main trial. Their 
involvement is expanded on in Chapter 3, methodology. 
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1.9 Summary 
Clinical experience and discussions with people who have had a severe stroke 
have highlighted their priorities and goals to “stand up early after stroke”. This is 
aligned with current national clinical guidelines but is not standard clinical 
practice for people with severe stroke. 
Stroke has a devastating impact on people’s lives, severely affecting their ability 
to be independent in ADL. People who have suffered a severe stroke are 
immobile and although the immobility is primarily caused by neurological 
damage, it can be worsened by bed rest and sedentary behaviour. This can 
have a detrimental impact on neurological, musculoskeletal and 
cardiorespiratory systems (including blood pressure) and further impede 
functional ability and reduce quality of life. Harmful changes in these systems 
can theoretically be prevented or minimised by early mobilisation, specifically 
standing up early after stroke. One factor that may limit standing time in severe 
stroke is OH. The impact of OH on standing for people who have suffered a 
stroke has been identified in this chapter and provides the rationale for the 
systematic review of non-pharmacological interventions to treat OH, presented 
in Chapter 2. 
Standing practice using a standing frame is commonly used with people with 
neurological conditions but not routinely in sub-acute stroke rehabilitation. This 
is aligned with current clinical practice in Cornwall and Devon (location of the 
feasibility trial), where standing practice as part of sub-acute inpatient 
rehabilitation for people with a severe stroke varies. Evidence on the 
effectiveness of supported standing for people with stroke has been identified 
as insufficient and contradictory. Conversely, the evidence for task-specific 
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training, (e.g. repeated sit to stand) has reported functional benefits when 
compared to usual care. Existing rehabilitation interventions/practices have not 
been appropriately and rigorously tested with people with severe stroke; this 
underpins the rationale for this feasibility trial. 
Standing and sit to stand are important functionally linked tasks, and currently it 
is not known whether this novel combination of physiotherapy interventions for 
people with severe stroke is effective in everyday clinical practice. These two 
interventions were combined to create a functional standing frame programme. 
This is my original contribution to the existing knowledge-base for the 
rehabilitation of people who have had a severe stroke. The functional standing 
frame programme addresses a key concern for people who have suffered a 
severe stroke. However, several uncertainties exist which need to be 
understood prior to progressing to a full-scale RCT, including acceptability and 
tolerance of the intervention and practicality of the trial procedures. This 
feasibility trial will provide important insights to resolve these uncertainties and 
enable a protocol to be finalised for use in an anticipated definitive trial. 
1.10 Thesis aim and structure 
This thesis aims to determine the feasibility of undertaking a RCT to evaluate 
the effectiveness of a functional standing frame programme for people with 
severe stroke during their inpatient sub-acute rehabilitation, using a feasibility 
RCT and nested qualitative component. In my role as a researcher and 
practising physiotherapist, my intention is to ensure that this research is 
clinically relevant and meaningful to people with severe stroke. This thesis is 
derived from, and informed by, patients, their families, clinicians, methodologists 
and public involvement. 
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This chapter has provided an introduction and background to the feasibility trial, 
identifying why this research is warranted. Chapter 2 presents a systematic 
review that summarizes the best available evidence regarding the effectiveness 
of non-pharmacological interventions to treat OH in people with stroke. Chapter 
3 presents the research methodology with justification of the trial design of a 
randomised controlled feasibility trial and nested qualitative component. 
Chapter 4 presents the results in two parts: Part A: the quantitative results from 
the intervention and control group sessions, baseline and follow-up 
assessments; Part B the qualitative data from the interviews and focus group. 
The final chapter discusses all data and addresses the feasibility objectives, 
providing conclusions and recommendations for future research. 
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Chapter 2 Systematic review 
2.1 Introduction 
Orthostatic hypotension (OH) is common in people with stroke and can interfere 
with and limit rehabilitation, especially in sub-acute rehabilitation where early 
mobilisation is recommended. Stroke is common, although not exclusive, to 
elderly people, with the majority (59%) of strokes occurring in people over 65 
years of age. However, nearly one third (31%) of strokes occur in people aged 
50-69 years of age. The prevalence of OH in elderly people is high, both in the 
United Kingdom and internationally, and higher in elderly people who are 
hospitalised than those living in the community. Elderly people and people with 
stroke are more likely to have multimorbidity117 and thus are at risk of 
polypharmacy (taking at least five medications)118. Therefore, identifying non-
pharmacological interventions to treat OH in people with stroke and elderly 
people is of paramount importance to minimise any disruptions to rehabilitation. 
This chapter presents a summary of the best available evidence regarding the 
effectiveness of non-pharmacological interventions to treat OH in people with 
stroke. The findings informed the development of the intervention to ensure OH 
was assessed and treated effectively, ensure the intervention was reflective of 
clinical practice and optimise recruitment. 
2.2 Background and rationale 
Orthostatic hypotension is a common clinical phenomenon in elderly people, 
people with stroke and other neurological conditions108,119-121. It is defined by 
consensus as a sustained drop in systolic blood pressure (sBP) of at least 20 
mmHg and/or diastolic BP (dBP) of at least 10 mmHg within three minutes of 
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moving from supine to standing or following head-up tilt to at least 60 
degrees105,122. 
Orthostatic hypotension has both non-neurogenic and neurogenic causes and 
can be acute or chronic6. Non-neurogenic causes fall into three categories: 
hypovolemia (reduced blood volume), cardiac pump failure and venous pooling. 
Neurogenic OH is associated with neurological diseases and can be caused by 
abnormalities in either the central nervous system (e.g. stroke, spinal cord injury 
or Parkinson’s disease) or peripheral nervous system (e.g. Guillain Barre´ 
syndrome or diabetic neuropathy)123. 
A variety of symptoms are caused by OH which is a frequent cause of syncope 
(transient loss of consciousness, rapid onset and short duration) that may 
contribute to morbidity, disability and even death.105 Other characteristic 
symptoms include: (a) dizziness/light headedness and pre-syncope; (b) 
weakness, fatigue and lethargy; (c) palpitations and sweating; (d) visual 
disturbances; (e) hearing disturbances; and (f) neck, shoulder and low back 
pain124,125. These symptoms relate to the degree of the fall in blood pressure 
(BP) and hypoperfusion (reduced blood flow) of the brain and other organs and 
can vary in severity. 
The prevalence of OH in older people (defined for this review as aged 50 years 
and over126) is high, both in the UK and internationally, but variable depending 
on the characteristics of the population studied. It is more common in elderly 
people who are hospitalised and institutionalised (up to 68%)127 than in those 
living in the community (30%)128; likely a reflection of the presence of multiple 
disease processes in the former group. In addition, orthostatic changes in BP 
become more exaggerated after prolonged immobilisation110. Orthostatic 
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hypotension is common in people with stroke129, occurring in up to 52%108. It is 
common in other neurological conditions and occurring in approximately 40%120 
of people with Parkinson’s disease and 50–82% of people with spinal cord 
injury, depending on the level of lesion121. Given that stroke is predominately 
but not exclusively, seen in elderly people, it is possible that the prevalence of 
OH post-stroke may be much higher. This aligns with current European 
guidelines that highlight OH is underdiagnosed105. The inclusion of older people, 
stroke and other neurological conditions in this systematic review is justified for 
two reasons. Firstly, the limited number of studies available that are specific to 
stroke, and secondly because there are overlaps in its mechanism of causation 
and presentation amongst these populations. The presence of OH can interfere 
with and limit rehabilitation, especially in stroke where early mobilisation is 
recommended at the earliest opportunity3. Early mobilisation has demonstrated 
improved functional outcomes79 however, early mobilisation studies for people 
with acute stroke excluded people from the intervention arm if they had OH on 
three consecutive occasions81,94. Given the high incidence of OH in this 
population such exclusion criterion could impact on recruitment rates and 
generalisability of the findings of early mobilisation intervention trials influencing 
the number of people potentially benefitting from these interventions. 
The risk of harm with OH must be acknowledged and addressed. In acute and 
sub-acute stroke, OH has the potential to cause further brain damage, both in 
the area surrounding the stroke (penumbra), and throughout the brain, due to 
hypoperfusion, a consequence of impaired cerebral autoregulation.130 This may 
result in increased disability and mortality. Given this risk of harm, it is surprising 
that current guidelines for the management of people with stroke3,131,132 do not 
provide guidance on managing OH. 
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The goal of managing OH is to raise the patient’s standing BP without also 
raising their resting BP, and specifically to reduce OH symptoms, increase the 
time they can stand and improve ADLs performance133. Currently, there is no 
specific intervention that achieves all these goals, despite the multitude of 
pharmacological and non-pharmacological interventions available. A recent 
systematic review highlighted that although there were multiple pharmacological 
interventions available in the UK, Europe and United States of America (USA), 
there is little high-quality data as to which is the best134. The burden of 
pharmacological interventions warrants consideration. People with stroke and 
elderly people are more likely to have multimorbidity117, thus are at risk of 
polypharmacy118. Therefore, identifying non-pharmacological interventions to 
treat OH in these populations is of paramount importance. 
Reviews135 and guidelines105,136 from the USA and Europe for the management 
of OH recommend non-pharmacological interventions as the first line approach 
before progressing to pharmacological interventions. However, people with 
stroke often have complex needs and severe disability, thus some non-
pharmacological interventions may not be appropriate. For example, 
undertaking physical manoeuvres such as squatting and leg crossing require a 
specific level of mobility and balance, and functional electrical simulation may 
be contraindicated due to other medical conditions or skin frailty. Therefore, 
these guideline recommendations cannot be automatically translated to people 
with stroke, which underpins the rationale for this review. Identifying non-
pharmacological interventions to treat OH in people with neurological conditions 
has been highlighted as a research priority85,137. 
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An initial search of the literature – MEDLINE, Embase, CINAHL, Cochrane 
Database and PROSPERO – identified one systematic review examining 
studies that evaluated non-pharmacological interventions to treat OH138. 
However, this review was broad, covering various patient populations and not 
restricted to people with stroke or other neurological conditions, or elderly 
people. Furthermore, the review did not focus on any specific outcomes such as 
impact on mobilisation or functional ability. The initial search also identified a 
paucity of evidence for non-pharmacological interventions to treat people with 
stroke. Thus, this systematic review included people with other neurological 
conditions such as Parkinson’s disease and spinal cord injury. The systematic 
review will allow the development of a protocol to implement into the feasibility 
trial of the functional standing frame programme. 
2.3 Review question 
What is the evidence base for non-pharmacological interventions in treating OH 
in elderly people and people with a neurological condition? 
2.4 Review objectives 
The objectives of the review are to determine the effectiveness of non-
pharmacological interventions for OH in elderly people and people with a 
neurological condition in terms of: 
• OH, resting BP and cerebral blood flow 
• mobilization (especially standing); engagement in activities of daily living 
and/or participation in rehabilitation programs 
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2.5 Inclusion criteria 
2.5.1 Participants 
The current review considered studies that included participants diagnosed with 
OH by a medical professional using criteria such as the International 
Classification of Diseases and Related Health Problems (ICD-10)139. 
Participants were included if they were aged 50 years and over to represent the 
elderly population. Currently, there is no agreed definition of “elderly” ‘‘older’’ or 
‘‘old people’’, with 50 years accepted as the definition of older people based on 
the World Health Organization Older Adult Health and Ageing in Africa 
project126; this was used for the purposes of this review. In addition, participants 
aged 18 years and over with either a progressive or sudden, non-progressive 
neurological condition of the central nervous system were included. Peripheral 
nervous system conditions were excluded. 
Participants receiving treatment for acute or chronic OH were included, which 
encompassed treatment carried out in hospitals, outpatient clinics, in-patient 
rehabilitation units and the community (either in their own homes or in a 
residential or nursing home setting). 
2.5.2 Interventions 
The review considered studies that evaluated non-pharmacological 
interventions to treat OH. These included compression garments (e.g. lower 
limb compression stockings or abdominal corset); neuromuscular stimulation; 
physical manoeuvres (e.g. squatting and bending at the waist) and isometric 
exercises for arms, lower limbs and abdominal muscles during standing; raising 
head of bed at night time or increasing fluid and salt intake. However, a full 
systematic search identified additional interventions that were considered (e.g. 
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frequency and size of meals). Interventions of any duration, frequency or 
intensity were considered. 
2.5.3 Comparator 
The review considered studies that compared the non-pharmacological 
interventions listed above with no intervention, pharmacological interventions 
and/or other non-pharmacological interventions. 
2.5.4 Outcomes 
Outcomes considered included: sBP, dBP (both lying and standing using 
manual or automated device), time to symptoms and time to recovery; resting 
heart rate (HR) (assessed using a manual or automatic device); cerebral blood 
flow (assessed using transcranial Doppler or correlation spectroscopy etc.); 
observed and/or perceived symptoms; duration of standing or sitting in minutes; 
tolerance of therapy (e.g. ability to participate in therapy measured in length and 
frequency of sessions); function/ADL and adverse events/effects where this 
information was provided. 
2.5.5 Types of studies 
This review considered experimental and epidemiological study designs 
including RCTs, non-RCTs, quasi-experimental, before and after studies, 
prospective and retrospective cohort studies case-control studies and analytical 
cross-sectional studies. In addition, descriptive epidemiological study designs 
including case series, individual case reports and descriptive cross-sectional 
studies were also considered. 
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2.6 Methods 
This systematic review was conducted in accordance with the Joanna Briggs 
Institute (JBI) methodology for systematic review of effectiveness140 and, 
according to an a priori published protocol141. 
2.7 Search Strategy 
The search strategy was carried out in January 2017 and updated in April 2018 
and aimed to find both published and unpublished studies. A three-step search 
strategy was utilized. An initial limited search of MEDLINE, AMED, CINAHL and 
Embase was undertaken, followed by analysis of the text words contained in the 
title and abstract, and of the index terms used to describe the articles. A second 
search using all identified keywords and index terms was then undertaken 
across all included databases. The key terms were: stroke, cerebrovascular 
accident, CVA, upper motor neuron disorder, neurological, Parkinson’s Disease, 
Multiple Sclerosis, spinal cord injury, non-pharmacological, compression, 
bandages, splint, abdominal, legs, lower limbs, orthostatic hypotension, postural 
hypotension, orthostasis, low BP, autonomic dysfunction, vascular response, 
cerebral blood flow, function, functional outcome, activities of daily living, quality 
of life. Third, the reference list of all studies that met the inclusion criteria and 
articles were searched for additional studies. The search was restricted to 
studies published in English as team members were unable to translate other 
languages. There were no date limiters. Databases that were searched 
included: MEDLINE (Ovid), Embase (Ovid), The Cochrane Central Register of 
Controlled Trials, CINAHL, AMED (EBSCO), PEDro, http://clinicaltrials.gov and 
OpenGrey. A search for unpublished studies was conducted in Google Scholar, 
Conference Papers Index. Appendix 1 provides an example of the search 
strategy used in all databases. 
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2.8 Study selection 
Following the search, all identified citations were loaded into EndNote 
bibliographic software142 and duplicates removed. Titles and abstracts were 
screened by two independent reviewers for assessment against the inclusion 
criteria for the review. The full text of potentially eligible studies was retrieved 
and assessed in detail against the inclusion criteria by two independent 
reviewers. The details of studies that met the inclusion criteria were imported 
into the Joanna Briggs Institute’s System for the Unified Management, 
Assessment and Review of Information (JBI SUMARI)143 and JBI Critical 
Appraisal Checklist for Randomized Controlled Trial, Quasi-Experimental 
Studies, Case Control Study, Case Reports were used to critically appraise 
included studies depending on the study design. Full text studies that did not 
meet the inclusion criteria were excluded and reasons for their exclusion are 
provided in Appendix 2. Any disagreements that arose between the 
independent reviewers were resolved through discussion, or with a third 
reviewer. 
2.9 Assessment of methodological quality 
Selected studies were critically appraised by two independent reviewers for 
methodological quality using the standardized critical appraisal instruments from 
the JBI. Disagreements were resolved through discussions, negating the 
requirement for a third reviewer. 
2.10 Data extraction 
Quantitative data were extracted from papers using the standardized data 
extraction tool available in JBI SUMARI144 by two independent reviewers. The 
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data extracted included specific details about the interventions, populations, 
study methods, outcomes of significance and specific objectives. 
Authors of papers were contacted to request missing or additional data where 
required. Thirteen authors were contacted. Responses were received from five. 
2.11 Data synthesis 
Due to the variability and heterogeneity in the parameters of the papers 
presented, it was not possible to include all papers in the meta-analyses. For 
papers not included in the meta-analyses, data are presented as mean +/- SD 
unless otherwise stated, alongside the narrative summary. 
Outcomes for papers included in the meta-analyses were: the change in mean 
arterial BP between supine and maximum upright stand or tilt (depending on 
what the studies measured) at the earliest measurement point (e.g. selecting 
measurements at one minute rather than two minutes if both available). Where 
mean arterial pressure (MAP) was not available it was calculated with constant 
proportions between dBP and sBP blood pressures: MAP = 1/3 sBP + 2/3 dBP 
(mmHg).145 Where dBP data was not available, the change in sBP was used. 
Results, where possible, were pooled in statistical meta-analysis using JBI 
SUMARI. Effect sizes are expressed as standardized mean differences and 
their 95% confidence intervals calculated for analysis. Heterogeneity was 
assessed statistically using the standard chi-squared and I squared tests. The 
choice of random effects model, and methods for meta-analysis were based on 
the guidance by Tufunaru et al. 2015146. There were insufficient individualized 
data to conduct subgroup analyses144, and insufficient number of studies to 
generate a funnel plot147. 
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2.12 Assessing confidence 
A 'Summary of findings' table (Appendix 3) was created using GRADEPro GDT 
software for all studies included in the meta-analysis. The GRADE approach for 
grading the quality of evidence was followed. The 'Summary of Findings' table 
presents the following information where appropriate: absolute risks for 
treatment and control, estimates of relative risk, and a ranking of the quality of 
the evidence based on study limitations (risk of bias), indirectness, 
inconsistency, imprecision and publication bias148-151. Outcomes included in the 
'Summary of findings' table: 
Mean arterial blood pressure and systolic blood pressure. 
2.13 Results 
2.13.1 Study inclusion 
The results of the search and study selection process are presented in Figure 
2.1. A total of 4,481 potentially relevant studies were identified. Of those, 1,080 
were duplicates. From the remaining 3,401 records, 3,316 were excluded after 
title and abstract assessment. The eligibility of 85 full-text articles were 
assessed, 34 of which were excluded. The methodological quality of the 
remaining 51 studies were assessed. From those 51 studies, 13 were 
randomised control trials, 34 quasi-experimental, one case control study and 
three were case report studies. Eight studies were excluded. The reasons for 
study exclusion are detailed in Appendix 2. 
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Full-text articles 
assessed for eligibility 
(n=85) 
Full-text articles excluded (n=34) 
(n=8 no intervention) 
(n=6 ≤18 years of age) 
(n=11 participants did not have OH) 
(n=1 no OH outcome) 
(n=1 duplicate: same authors different 
title) 
(n=3 OH not measured) 
(n=1 idiopathic OH) 
(n=3 postprandial OH) 
Studies included in 
critical appraisal (n=51) Studies excluded (n=8) 
(n=4 ≤18 years of age) 
(n=1 combined treatments) 
(n=1 not an intervention) 
(n=2 no orthostatic testing) Studies included in 
review (n=43) 
Duplicates (n=1,080) 
Records excluded from 
reading abstract 
(n=3,316) 
Figure 2.1 PRISMA Flowchart of the study selection and inclusion 
process 
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2.13.2 Methodological quality 
Methodological quality of the studies was not addressed until the final selection 
of studies had been made for this systematic review. Methodological quality of 
individual studies was critically appraised using JBI’s instruments and included 
in the study analysis. Methodological quality in all studies varied.  
During the process of assessing methodological quality, eight studies were 
deemed ineligible and not included in the review. One study had combined 
treatments and the effect of a given intervention was not clear. Seven other 
studies did not meet the inclusion criteria. All seven studies are marked with an 
Asterix and reasons for excluding the eight studies are detailed in Appendix 2. 
Table 2.1 presents the critical appraisal of the 13 RCTs included in the 
systematic review. True randomization was not used in one study, unclear in six 
and used in six studies. Concealed allocation to treatment was used in five 
studies and unclear in four studies. Blinding of participants and of those 
delivering the intervention and outcome assessors were low in most studies. 
Follow-up was either complete, or strategies to address incomplete follow-up 
were utilized in nine studies, and eight studies analysed participants in the 
groups to which they were randomised. 
64 
 
Citation Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 
Faghri & Yount152 N N N N N N Y N Y Y Y Y N 
Fan et al153 U U Y N U U Y N Y Y Y Y N 
Fanciulli et al154 U N Y U N N Y Y U Y Y Y Y 
Figueroa et al155 U U Y N N U Y Y N Y Y Y Y 
Kanegusuku156 Y Y Y N N N Y Y Y Y Y Y Y 
Gorelik et al157 U U Y N N U Y Y U Y Y Y Y 
Luther et al158 Y N Y N N N Y N Y Y Y Y Y 
Phillips et al159 Y Y U Y Y Y Y Y Y Y Y Y Y 
Podoleanu et al160 Y Y Y Y N N Y Y Y Y Y Y Y 
Rocca et al161 Y Y N N N U Y Y Y Y Y Y Y 
Takahagi et al162 U U Y N U U Y Y Y Y Y Y Y 
Taveggia et al163 Y N Y N N N Y Y Y Y Y Y Y 
Vijayakumar et al164 U Y Y U U U Y U U Y U Y Y 
Total % 46.2 38.5 76.9 15.4 7.7 7.7 100 69.2 69.2 100 92.3 100 84.6 
Y = Yes, N = No, U = Unclear; JBI critical appraisal checklist for randomised controlled trials: Q1 = Was true randomization used for assignment of 
participants to treatment groups?; Q2 = Was allocation to treatment groups concealed?; Q3 = Were treatment groups similar at baseline?; Q4 = Were 
participants blind to treatment assignment?; Q5 = Were those delivering treatment blind to treatment assignment?; Q6 = Were outcome assessors blind 
to treatment assignment?; Q7 = Were treatment groups treated identically other than the intervention of interest?; Q8 =  Was follow-up complete, and 
if not, were strategies to address incomplete follow-up utilized?; Q9 = Were participants analysed in the groups to which they were randomised?; Q10 = 
Were outcomes measured in the same way for treatment groups?; Q11 = Were outcomes measured in a reliable way?; Q12 = Was appropriate 
statistical analysis used?; Q13 = Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel 
groups) accounted for in the conduct and analysis of the trial? 
Table 2.1 Critical appraisal of methodological quality results of eligible randomised controlled trials 
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Table 2.2 presents the results of the critical appraisal of methodological quality 
of eligible quasi-experimental studies. Cause and effect was clear in all but two 
studies. In five studies, Q2 and Q3 were not applicable because there were no 
comparisons made. There was no control group in 13 of the 34 studies. In two 
studies, Q6 was not applicable because one was not an intervention study and 
subsequently excluded (Sasaki), in the other study all tests were completed on 
the same day and therefore there was no follow-up period. Q7 was deemed not 
applicable to one study because no comparisons were made. 
Citation Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 
Bouvette et 
al165 
N N N N Y Y U U Y 
Brilla et al166 Y N/A N/A N Y Y Y Y Y 
Chao & 
Cheing*167 
Y Y Y N Y Y Y Y Y 
Denq et al168 Y Y Y Y Y Y Y Y Y 
Elokda et 
al169 
Y Y Y Y Y N Y Y Y 
Faghri & 
Yount170 
Y Y Y Y Y N Y Y Y 
Gorelik et 
al171 
Y U U Y Y Y Y Y Y 
Gorelik et 
al172 
Y Y Y Y Y Y Y Y Y 
Hamzaid et 
al173 
Y N/A N/A N Y Y Y Y Y 
Henry et 
al174 
Y N/A N/A N N U Y Y U 
Hilz et al*175 Y Y U Y Y Y Y Y Y 
Hohler et 
al*176 
N Y N N Y N Y U Y 
Huang et 
al*177 
Y Y Y N Y U Y Y Y 
Humm et 
al178 
Y Y Y Y Y Y Y Y Y 
Kuznetsov et 
al179 
Y Y Y Y Y Y Y Y Y 
Loew et al180 Y Y Y Y Y Y Y Y Y 
Lopes et 
al181 
Y Y U Y Y Y Y Y Y 
Lucas et 
al182 
Y Y Y Y Y Y Y Y Y 
Mader183 Y Y Y Y Y Y Y Y Y 
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Puvi-
Rajasingham 
& Mathias184 
Y Y Y Y Y Y Y Y Y 
Rimaud et 
al185 
Y Y Y Y Y Y Y Y Y 
Sampson*186 Y Y Y Y Y Y Y Y Y 
Sasaki et 
al*187  
Y Y Y N Y N/A Y Y Y 
Shannon et 
al188 
Y Y Y N Y Y Y Y Y 
Smit189 Y Y Y N Y N/A Y Y Y 
Smit190 Y Y Y Y Y Y Y Y Y 
Ten Harkel 
et al191 
Y Y Y Y Y Y Y N Y 
Ten Harkel 
et al192 
Y Y U N Y Y Y Y Y 
Tutaj et al193 Y N/A N/A N N Y Y Y Y 
van Lieshout 
et al194 
Y Y N Y Y Y Y U Y 
Wadsworth 
et al195 
Y Y Y Y Y Y Y Y Y 
Yoshida et 
al196 
Y Y Y Y Y Y Y Y Y 
Young & 
Mathias197 
Y Y Y Y Y Y Y Y Y 
Zion et al198 Y N/A N/A N Y Y N/A Y Y 
Total % 94.1 79.4 64.7 61.8 94.1 79.4 94.1 88.2 97.1 
Y = Yes, N = No, U = Unclear, N/A – not applicable; JBI critical appraisal checklist for quasi-experimental 
studies; Q1 = Is it clear in the study what is the 'cause' and what is the 'effect' (i.e., there is no confusion 
about which variable comes first)?; Q2 = Were the participants included in any comparisons similar?; Q3 = 
Were the participants included in any comparisons receiving similar treatment/care, other than the 
exposure or intervention of interest?; Q4 = Was there a control group?; Q5 = Were there multiple 
measurements of the outcome both pre and post the intervention/exposure?; Q6 = Was follow up complete 
and if not, were differences between groups in terms of their follow up adequately described and 
analysed?; Q7 = Were the outcomes of participants included in any comparisons measured in the same 
way?; Q8 = Were outcomes measured in a reliable way?; Q9 = Was appropriate statistical analysis used? 
*studies excluded during critical appraisal process 
Table 2.2 Critical appraisal of methodological quality results of eligible quasi-
experimental studies 
 
Table 2.3 presents the critical appraisal results for eligible case report studies. 
The patient’s history was not clearly described or presented as a timeline for 
two of the three studies. Diagnostic tests or assessments, and the interventions 
or procedures were described in two of the three studies. Adverse events were 
reported in two of the three studies. 
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Citation Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 
Helmi199 Y Y Y Y N Y Y Y 
Mikula et al*200 Y N Y N Y Y N Y 
Taylor et al*201 Y N Y Y Y Y Y Y 
Total % 100 33.3 100 66.7 66.7 100 66.7 100 
Y = Yes, N = No, U = Unclear; JBI critical appraisal checklist for case report studies; Q1 = Were patient's 
demographic characteristics clearly described?; Q2 = Was the patient's history clearly described and 
presented as a timeline?’ Q3 = Was the current clinical condition of the patient on presentation clearly 
described?; Q4 = Were diagnostic tests or assessment methods and the results clearly described?; Q5 = 
Was the intervention(s) or treatment procedure(s) clearly described?; Q6 = Was the post-intervention 
clinical condition clearly described?; Q7 = Were adverse events (harms) or unanticipated events identified 
and described?; Q8 = Does the case report provide takeaway lessons? 
*studies excluded during critical appraisal process 
Table 2.3 Critical appraisal of methodological quality results of eligible case 
report studies 
 
Confounding factors were not identified in the case control study. All other 
aspects of methodological quality were met as presented in Table 2.4. 
Study Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 
Galizia 
et al202 
Y Y Y Y Y N N Y Y Y 
Total % 100 100 100 100 100 0.0 0.0 100 100 100 
Y = Yes, N = No, U = Unclear; JBI critical appraisal checklist for case control study; Q1 = Were the groups 
comparable other than the presence of disease in cases or the absence of disease in controls?; Q2 =Were 
cases and controls matched appropriately?; Q3 = Were the same criteria used for identification of cases 
and controls?; Q4 = Was exposure measured in a standard, valid and reliable way?; Q5 = Was exposure 
measured in the same way for cases and controls?; Q6 = Were confounding factors identified?; Q7 = 
Were strategies to deal with confounding factors stated?; Q8 = Were outcomes assessed in a standard, 
valid and reliable way for cases and controls?; Q9 = Was the exposure period of interest long enough to 
be meaningful?; Q10 = Was appropriate statistical analysis used? 
Table 2.4 Critical appraisal results of eligible case control study 
2.13.3 Characteristics of included studies 
Date of publication ranged from 1984 to 2018, and all were published in 
English. In the sections below the main features of these studies are 
summarized. Detailed information about the setting, participants, methods, 
interventions, outcomes and results are provided in Appendix 4. 
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2.14 Review findings 
2.14.1 Study settings 
Nineteen of the included studies were undertaken in Europe (four in the 
UK,174,184,178,197, six in the Netherlands203,204,192,189,191,194,, three in Italy205,206,160, 
two in Germany158,188, one in Austria154, one in France185, two in 
Switzerland161,180). Of the remaining 24 studies, 10 were undertaken in the 
USA152,155,165,166,169,170,181,183,198,207, three in Israel157,171,172, two in Canada159,196, 
two in Brazil162,208, one in India164, one in Malaysia173, one in Russia179, one in 
New Zealand182, one in Australia195 and it was unclear in which country two 
studies were undertaken.193,209. 
The interventions described were undertaken in: hospital inpatient 
settings157,171,172,180,184,195,197,204,210, rehabilitation facilities152,164,169,170,173,185,206, 
outpatient clinics or centers162,174,196,211,212, laboratories154,155,165,178,182,203,213, 
medical centers175,181,191,214, neuro rehabilitation units158,205, a stroke 
rehabilitation unit179, an autonomic dysfunction center188, a hospital clinic160, a 
research center183, or community settings.156,166,173,209 Two studies did not report 
where they were undertaken193,207. 
2.14.2 Participants 
The 43 studies analysed included a total of 1,084 participants, ranging in 
sample size from one (case report study204) to 128 (quasi-experimental 
study179). The age range of participants was reported in 20 
studies154,155,169,173,174,183-185,191,195,196,203,204,207,210-215, and was from 18 to 89 
years. Twenty-four studies152,157,158,160,162,164-166,170-172,178-182,193,195,197,205,206,208-210 
reported mean age. One study reported the age range for participants with 
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autonomic failure, and mean age for nine participants with idiopathic OH188. 
There was a total of 440 elderly (≥50 years) participants. 
Gender was reported for the intervention group in all studies. In total, there were 
525 male participants (48%). Six studies included only male169,173,181,182,185,204, 
16 studies included more males than females, two studies had an equal number 
of males and females182,191, three studies did not report gender for 
controls152,170,211. 
Studies included participants with OH (n=484), stroke (n=170), spinal cord injury 
(n=86), Parkinson’s disease (n=55), brain injury (n=28), brain haemorrhage 
(n=18), syncope (n=21), familial dysautonomia (n=17), cardiac arrhythmias 
(n=10), dizziness/palpitations (n=27), infectious diseases (n=21), pulmonary 
oedema (n=10), acute coronary syndrome (n=11), decompensated heart failure 
(n=18), other (n=8) and healthy controls (n=100); with four of the 1,084 
participants having both spinal cord injury and OH, and others having multiple 
conditions. 
Inclusion criteria for studies varied. Fourteen studies had OH as an inclusion 
criterion. Nine studies defined OH as a decrease in sBP of >20mmHg or 
decrease in dBP >10mmHg after a change in posture154,157,164,166,171-173,206,209,213. 
Other definitions were decrease in sBP >30mmHg or decrease in dBP 
>15mmHg155; sBP fall by at least 40mmHg or dBP fall by at least 30mmHg193; a 
decrease in sBP of >30mmHg or decrease in dBP >20mmHg207, and 
progressive decrease in BP below a value of 90mmHg160. Eleven studies had 
OH as an inclusion criterion but did not provide a definition of 
OH165,174,178,184,188,191,197,203,211,212,214. Twelve studies had inclusion criteria of 
elderly people: ≥50208, ≥60171,172,209,213 or ≥65157,180,206 years or specified an age 
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range166(60-85 years). Three did not specify age174,180,183. Eleven studies had 
neurological conditions as an inclusion criterion154,155,158,164,169,170,179,195,196,205,208. 
Seven studies did not provide any inclusion criteria152,162,181,182,185,204,215. 
2.14.3 Interventions/comparators 
Eight non-pharmacological interventions for OH were identified under two 
general categories: physical modalities (exercise, electrical stimulation, 
compression, compression and physical counter-manoeuvres, physical counter-
manoeuvres, sleeping with head up) and dietary measures (food and fluid 
intake) which aim to treat OH by raising standing blood pressure without raising 
supine blood pressure to increase the time people can stand, and improve their 
ability to perform activities of daily living. 
Physical modalities 
Exercise 
Exercise included aerobic training using a cycle ergometer, resistance/strength 
training using resistance bands or weights, passive stepping using robotic tilt 
tables, and upper limb exercises. Seven studies included in this systematic 
review evaluated the effects of exercise on OH. Participants included in these 
studies had spinal cord injury181, brain injury158,205,210, brain haemorrhage210, 
stroke210, neuro cardiogenic syncope162, Parkinson’s disease208, and 
OH166,206,213. 
Three studies158,181,205 used tilt tables, two of which158,205 used robotic tilt tables, 
where participants with brain injury undertook passive stepping whilst being 
tilted up to 65158 and 70205 degrees. Duration of intervention periods were 
different; two sessions of sequential testing158 (intended duration of testing in 
minutes not reported), and 24 sessions, each 30 minutes, three times per 
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week205. The third study181 used a tilt table and included participants with spinal 
cord injury who performed upper limb exercises whilst being tilted up to 70 
degrees. 
The effect of aerobic physical training was used in one study162 for participants 
with neuro cardiogenic syncope. Participants undertook a 12-week supervised 
program of moderate aerobic intensity training using a cycle ergometer. 
Training took place twice a week and lasted for 35 minutes, and patients were 
instructed to perform two additional unsupervised sessions. 
One study210 examined the effect of passive stepping at 30, 50 and 70 degrees 
using a robotic tilt table, automated cycling in supine versus standard care 
(defined as mobilization with physiotherapist), for patients with severe brain 
injury.  
Four studies166,206,208,213 examined the effects of resistance training on elderly 
people with OH. In one study206 participants performed 10 full extensions of the 
ankle, knee, and hip joints of both limbs starting from 60 degrees flexion of hips 
and 90 degrees flexion of knee and ankle joints against a resistance band (6kg 
load) that the participant positioned under the soles of their forefeet and firmly 
held at both ends whilst supine in bed prior to standing up. Participants in the 
three remaining studies166,208,213 undertook a home-based resistance program, 
which incorporated exercises for both upper and lower limbs. These three 
studies were included in a meta-analysis. 
Six studies162,181,205,206,208,210 in the exercise category had a control group, which 
consisted of tilting only181,205,206, standard care208,210, and stretching and light 
walking162. In one study, participants acted as their own controls158, and two 
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studies included in the meta-analysis (Section 2.14.5 Outcomes) did not include 
a control group166,213. 
Electrical stimulation 
Electrical stimulation is a technique that uses low energy electrical pulses to 
artificially generate a muscle contraction of paralyzed muscles. When used in a 
functional context to elicit patterns of movement it is also referred to as 
functional electrical stimulation. The studies included in this review used 
electrical stimulation of upper limbs, lower limbs and abdomen.  
Seven studies152,169,170,173,179,196,215 examined the effects of electrical stimulation 
on OH. Participants in one study179 had a stroke, the other six studies included 
people with spinal cord injury. Two studies152,170 included the same sample and 
examined the same experimental interventions, differing slightly in the 
measured outcomes. They compared upright stationary standing versus upright 
dynamic standing using functional electrical stimulation, both using standing 
apparatus for 30 minutes on the same day. Another repeated measures 
study169 positioned participants in multiple tilt angles (0, 15, 30, 45 and 60 
degrees), four minutes at each angle followed by four minutes recovery, 
repeated with and without electrical stimulation to lower limb (bilateral knee 
extensors and ankle plantar flexor) muscles. One study173 included two 
participants who underwent four weeks of electrical stimulation to trunk and 
lower-limb muscles (rectus abdominus, quadriceps, hamstrings and 
gastrocnemius muscles), four times per week for one hour per day. One 
study215 tested the capacity of electrical stimulation, applied transcutaneously 
over the spinal cord (approximately corresponding to the T8 spinal segment) to 
manage OH in participants with spinal cord injury. Two studies179,196 used a 
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robotic tilt table and electrical stimulation to compare passive stepping and 
passive stepping combined with electrical stimulation. These were included in a 
meta-analysis (Section 2.14.5 Outcomes). 
Four studies included a control group152,170,179,196, one study173 had no control 
group, and participants acted as their own controls in one study.169 
Compression 
Compression involves using various types of bandages and garments on 
different body parts, commonly the lower limbs and abdomen. Thirteen 
studies154,155,157,160,164,171,172,174,182,185,195,204,207 examined the effect of 
compression on OH. Participants in these studies were elderly with 
OH157,160,171,172,174, had acute stroke164, Parkinson’s disease154, neurogenic 
OH155,207, or spinal cord injury185,195,204. 
Two studies160,164, both RCTs, examined the effect of compression to both the 
abdomen and lower limbs. In one study160 elderly participants with OH wore 
ankle to thigh bandages for 10 minutes, then an abdominal bandage was added 
for a further 10 minutes. Participants then wore leggings from the mid foot to the 
abdomen for one month at home. Authors report these were worn daily but did 
not report any recommendations or report usage from follow-up data. In the 
other study164 participants with acute stroke wore a pneumatic abdominal binder 
(PAB) and pneumatic calf compression (PCC) for six consecutive sessions for 
approximately 15 minutes during progressive incline on a tilt table. 
Three studies154,155,195 examined the effect of abdominal compression on OH. 
Participants with Parkinson’s disease154 were enrolled into a randomised 
crossover trial. They wore an abdominal binder or placebo binder. Participants 
74 
 
then wore an abdominal binder every day (time not specified) for four weeks. 
The second study155, a randomised crossover trial, assessed the effects of a 
conventional or patient-controlled adjustable abdominal binder on OH. Binders 
were worn for approximately 10 minutes during the testing period. The third 
study195, enrolled participants with spinal cord injury into a randomised 
crossover trial. Participants wore an abdominal binder (pressure not reported) 
daily (time not specified) for six months. 
Three studies examined the effect of lower limb compression during tilt 
tabling174,204,207, all of which used different compression garments, different 
pressures, on different body parts. In one study207 participants with neurogenic 
OH underwent tilt testing without and with compression applied to calves, thighs 
and abdomen using an inflatable G-suit to evaluate the impact of compression 
of different body parts on orthostatic BP and tolerance. Another study204, a case 
report, tested one spinal cord injured participant on a tilt table without and then 
with inflatable external leg compression to bilateral lower limbs. The last 
study174 tested elastic compression hosiery (tights covering the legs and 
abdomen) fitted to bilateral lower limbs in elderly participants. 
One study185 examined the effects of a wheelchair ergometer with and without 
graduated compression stockings. Spinal cord injured participants used the 
wheelchair ergometer twice; once with garment compression stockings and 
once without a week later. Further details presented in Appendix 4 
(Characteristics of included studies). 
One study182 examined the effects of compression leggings at normal body 
temperature and a long-sleeved and legged, two-pieced, tube-lined perfusion 
suit at elevated body temperature in healthy older and younger adults. 
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Three studies157,171,172 examined the effect of lower limb compression bandages 
from ankle to thigh on OH. All three studies included elderly participants who 
were hospitalized due to acute medical conditions157, decompensated heart 
failure171 and OH.172 In all three studies, compression bandages were applied 
along both legs from ankle to thigh before sitting without compression and 
repeated with compression. In one study157, compression was approximately 
30mmHg compression at the ankle. The remaining two studies used 40mmHg 
compression171 and 30-40mmHg compression172 at the ankle. Both latter two 
studies have been included in a meta-analysis (Section 2.14.5 Outcomes). 
In 10 studies participants acted as their own controls 
154,155,157,160,171,172,174,182,185,203, two studies had a control group164,207, and one 
study had no control group.204 
Physical counter-manoeuvres 
Physical counter-manoeuvres are specific movements or exercises such as 
squatting, leg crossing, tensing specific muscles with the aim of increasing 
standing BP and reducing OH. Four studies165,211,212,214 were identified in the 
literature search which examined the effect of physical counter-manoeuvres on 
OH, varying in the number and type of manoeuvres performed. Participants in 
these studies had OH211,212,214, neurogenic OH165 and familial dyautomonia193. 
One study165 examined the use of multiple physical counter-manoeuvres for 3-4 
months following a training period. Training consisted of four training sessions 
in the laboratory performing the physical counter-manoeuvres. Participants 
were then asked to perform the three selected manoeuvres at home for 3-4 
months when symptomatic. 
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In one study211 all participants performed leg-crossing and squatting in a fixed 
order. Participants stood for 10 minutes maximum or until symptoms occurred, 
then performed leg-crossing in standing for 30 seconds then resumed normal 
standing. When BP dropped again, participants squatted for 30 seconds then 
resumed the normal standing position. 
In one study212, participants performed nine different manoeuvres, each for one 
minute serially, separated by 30-60 seconds of standing. Participants were 
asked to sit on seats of varying heights (48cm, 38cm, 20cm), with or without 
leg-crossing, squatting and standing in a crossed-leg position with or without 
additional contraction of the lower limb muscles. All manoeuvres were repeated 
twice and performed in a random order. 
One randomised crossover trial214 compared leg muscle pumping or tensing for 
one minute, commencing after two minutes of active standing, compared to 
active standing only.  
Three studies did not include a control group165,193,212 and two studies included 
a control group211,214. 
Physical counter-manoeuvres and compression 
Two studies used a combination of physical counter-manoeuvres and 
compression. One study203 examined the effects of abdominal compression and 
physical manoeuvres in participants with neurogenic hypotension. Participants 
maintained a standing position with the abdominal binder, and then performed 
physical manoeuvres in standing whilst wearing an anti-gravity suit. For nine 
participants the duration of standing was extended (duration not specified) by 
standing without crossed legs or abdominal compression. As soon as a stable 
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low BP was obtained for 30 seconds, the counter-manoeuvres were repeated 
for 90 seconds, followed by a short period of normal standing. Nine participants 
(unclear if it was the same nine who undertook extended standing) performed 
two active standing manoeuvres; external abdominal compression applied by 
elastic binder. 
One study193 compared the effect of physical counter-manoeuvres, one of which 
was abdominal compression. Participants performed four counter-manoeuvres 
in a randomised order and abdominal compression using an inflatable belt. 
Sleeping head up tilt 
One study209 examined the effect of sleeping with the head of the bed elevated 
by six inches for six weeks. The control group received no intervention. One 
study191 examined the effect of sleeping with the head of bed elevated with and 
without pharmacological intervention and 2,000ml water per day. There was no 
control group, but there was a control period during the first week. 
Dietary measures 
Food intake 
Studies in this category examined the size and frequency of meals and their 
effect on OH. Three studies180,183,184 examined the effect of food intake on OH. 
One study180 tested participants with Parkinson’s disease and 10 age-matched 
controls over two consecutive days to examine the change in sBP induced by 
meals. They also compared the impact of orthostatic sBP response in 
participants with Parkinson’s disease with that of control participants. 
One study183 examined the effect of meal size and the time of day on OH in 
elderly and young healthy participants. 
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The final study184 examined the effect of meal size and number of meals in 
people with autonomic failure. All participants underwent the same conditions: 
the first day participants ate three meals, versus the second day (at least one 
day apart) when participants ate six meals. Total calorie intake was the same 
over both days. 
Participants acted as their own controls in two studies180,184 and one study did 
not include a control group183. 
Fluid intake 
Ingesting water to increase BP and attenuate OH was examined in three 
studies178,188,197. Participants in all three studies drank 480ml fluid, however, 
additional variables such as food intake and exercise were also studied. 
One study178 examined the effect of ingesting water before exercise on OH. All 
participants had severe pre-exercise OH and underwent the same testing using 
a cycle ergometer. Testing was undertaken on two separate occasions; one in 
which participants drank 480ml distilled water. 
One study188 examined the effect of water ingestion and food intake. All 
participants underwent two protocols. Protocol one: participants drank 480mL of 
tap water; Protocol 2 participants drank 480mL of tap water immediately before 
eating the test meal. 
The final study197 in the category examined the effects of drinking 480ml 
distilled water. All participants had autonomic failure and underwent the same 
testing: standing BP was measured before, and 15 and 35 minutes after 
ingesting of 480ml distilled water. 
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Two studies178,188 did not include a control group and in one study participants 
acted as their own controls197. 
2.14.4 Follow-up and measurement intervals 
Follow-up periods varied: thirty days179, one month160, four weeks154,173, eight 
weeks166,205,213, twelve weeks162,208, three to four months165 and fourteen 
months.191 Due to the wide heterogeneity in outcomes of interest, follow-up and 
measurement intervals are described for BP and HR only. In all other studies 
there was no follow-up. 
Exercise 
Four studies158,181,205,206 measured outcomes of interest over one day, but all 
measured outcomes in various positions and at various time points. One 
study181 measured from 0 to 70 degrees verticalization in 10 degree intervals, 
every 30 seconds at 1.5, 2.5, three, four and five-minute intervals. One study158 
measured in supine and at 30, 50 and 70 degrees verticalization every five 
minutes. One study205 measured in 0, 30 and 65 degrees of verticalization for 
the first four minutes of every position. The fourth study206 measured in supine, 
immediately upon standing, and at one, three and five minutes into standing. 
In four studies, the outcomes of interest were measured pre- and post-training 
with follow-up at eight weeks166,213 and 12 weeks.162,208 One study undertook 
measurements in supine and at 70 degrees of verticalization.162 The remaining 
three studies213, 166,208 undertook measurements in supine, when seated and 
one and two minutes into standing. 
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Electrical stimulation 
Three studies152,170,215 tested participants on two separate days at least 24 
hours apart. Two measured in supine, sitting and standing, but one152 measured 
at five and 30 minutes in standing and the other170 measured at five, 10, 20 and 
30 minutes in standing. The third study215 measured for 15 minutes in supine 
and sitting. Two studies169,196 undertook measurements throughout one day. 
Measurements were taken at 0, 15, 30, 45 and 60 degrees verticalization at 
one-minute intervals169, and every minute in supine to 80 degrees verticalization. 
One study173 measured pre- and post- four weeks of electrical stimulation, every 
minute at 0 to 65 degrees verticalization. The final study179 measured every 
minute for 10 minutes in supine to 70 degrees before and after a 30-day training 
period. 
Compression 
Nine studies155,160,171,172,174,182,203,204,207 measured participants at one single visit. 
Three studies154,157,185 measured participants over two separate days, one 
study164 measured participants over six consecutive days, and one study 
measured participants on four separate occasions over six months.195 Each 
study measured outcomes of interest at multiple time-points and in multiple 
positions: one155,157,164,171,172,174, two174, three154,157,164,171,172,174, 
five154,155,157,164,171,172, 10154 minutes and the first and last 15 seconds of 
compression and deflation203; sitting157,171,172,185,195, standing154,155,182,203, 
supine154,160,164,174,182,195,203,207, and at 30164, 40203, 45164, 60154,160,164, 80207 and 
90174 degrees tilt. 
Physical counter-manoeuvres 
Four studies193,211,212,214 measured participants at one single visit. Three of 
these measured participants in supine and standing but measured two214, 
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four193 and eighteen212 different time-points. One study measured standing six 
times.211 The final study165 measured participants in supine, 80 degrees 
verticalization and standing; measures were performed 10 times over four 
sessions, but it was unclear whether each session was on a separate day and 
how many days apart. Follow-up was performed 3-4 months after session four. 
Sleeping with head up 
One study191 in this category measured participants in supine and standing at 
four different intervals including at 14-month follow-up. The second study209 
were followed-up at the end of the six-week intervention. 
Dietary measures 
Food intake 
All three studies measured outcomes in multiple positions at multiple time 
points. One study183 measured participants over two days with an overnight stay 
at 12 different intervals in supine (three times) and once after one minute of 
standing. One study180 measured over two consecutive days, 21 times over 10 
hours in supine, sitting and standing, plus four times in supine, standing and 70 
degrees verticalization. The final study184 in this category measured participants 
for two days at least one day apart. Automatic ambulatory BP was measured 60 
times (every 30 minutes from 0630 to 2100 hours on both days). In addition, 
participants initiated BP readings 11 times in lying, sitting and standing (pre-
breakfast and 30 minutes following three meals; pre-breakfast and 30 minutes 
following six meals). 
Fluid intake 
Two studies178,197 measured participants during a single visit, and one study188 
measured them on separate days (unclear if consecutive or separated). All 
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studies measured participants in various positions at different time intervals. 
One study188 measured participants in seated (13 times protocol one and 24 
times protocol two) and standing (twice protocol one) positions. One study197 
measured outcomes of interest a total of 26 times; 20 times seated and six 
times in standing (three times at three and five minutes of standing). The final 
study178 measured participants 16 times; four times in supine and four times in 
standing (two and five minutes), repeated twice. 
2.14.5 Outcomes 
A wide variety of outcome measures were used in the included studies. The 
most common objective outcomes were sBP and/or dBP152,154,155,157,158,160,164-
166,169,171-174,178-185,188,191,193,195-197,203-215, HR152,155,157,158,160,162,164-166,169-173,178-
185,188,191,193,195-197,203-210,212-215, cardiac output152,170,178,185,193,197,203,209,212,214, and 
stroke volume.152,170,178,179,182,185,193,196,197,203,204,209,212,214,215 Other objective 
outcomes included: total peripheral resistance152,170,178,182,193,197,203,209,212, mean 
arterial pressure152,170,173,182,193,195,209,215, mean BP154,165,191,193,196,210-212,214, 
oxygen saturations157,172,204, respiratory rate210, resistance index165,179, HR 
variability185, stroke index165, cardiac index165,204,207, maximum power output185, 
maximum systolic velocity179, minimum diastolic velocity179, end diastolic 
index165, peripheral resistance index207, end diastolic volume index207, pulsatility 
index179, systemic vascular resistence214, inferior caval vein diameter203, femoral 
vein diameter203, rate pressure product170, perfusion index204, cerebral blood 
flow179,210, blood velocity of middle and posterior cerebral artery215, cerebral 
vascular resistence182, calf impedence193, electrocardiographic RR-
intervals193,208, Valsalva manouvers188,208, hyperventilation test188, cold pressor 
test178,188, oxygen uptake185, end-tidal partial pressure of carbon dioxide182, 
peak expiratory flow195, forced expiratory flow195, forced vital capacity195, voice 
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measures195, interruption of verticalization158, maximal cardiopulmonary 
exercise test162, fluid balance191,209, oesophageal temperature182, venous blood 
and plasma samples,210, oedema209. 
Orthostatic symptoms were measured using a variety of methods. The most 
common method was self-report157,169,171-173,178,184,191,196,197,204,209,211,212 where 
participants described their symptoms. One study215 asked participants to rank 
their symptoms from one to 10. Other studies used formal outcome measures: 
Specific Symptom Scale Questionnaire for Orthostatic Intolerance160, Global 
Symptomatic Improvement Score165, Orthostatic Symptom Scale155, Severity of 
OH Symptoms207, Orthostatic tolerance191, Symptom Change Scale155, 
Orthostatic Hypotension Questionnaire154, OH Daily Activity Scale154, and OH 
Symptom Assessment154. 
Other studies included measures of muscle strength178,179,188,208,213, one 
repetition maximum166,208 and electromyography (EMG) of leg muscles196. Two 
studies measured maximum standing time178,191. Three studies used measures 
of disability and function: Timed Up and Go213, Barthel Index179 and modified 
Rankin Scale164. 
Physical modalities 
Exercise interventions delivered during tilt tabling demonstrated mixed results. 
Greater tolerance of verticality and reduced occurrence of OH was observed in 
three studies158,181,205. Passive stepping using robotic tilt tables was effective at 
reducing the number of OH symptoms158,205 and this was also observed when 
performing upper limb exercises during verticalization181. A twelve-week aerobic 
training programme162 resulted in an increase in orthostatic tolerance and 
reduction of positive head up tilt tests. Lower limb resistance exercises206 were 
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the least effective, resulting in minimal reduction in an initial fall in sBP when 
moving from supine to standing. No significant absolute or relative difference 
was observed in any of the BP components with passive cycling or passive 
stepping210. However, there was a higher difference in arterial BP in both the 
intervention groups compared with standard physiotherapy. Three studies213, 
166,208 investigating the effects of resistance exercise training were included in a 
meta-analysis (Figure 2.2), which concluded that resistance exercise training 
was favourable compared to no intervention, however the 95% confidence 
intervals for the standardized mean difference crossed zero and were wide. 
 
Figure 2.2 Resistance exercise compared with no intervention 
 
Conclusion of effectiveness of exercise interventions: exercise interventions 
may improve orthostatic tolerance, but there were no statistically significant 
results with any of the exercise interventions. 
Electrical stimulation was favourable in the five studies not included in the 
meta-analysis, wherein participants using electrical stimulation could stand for 
longer and had reductions in OH152,170, demonstrated a longer tolerance time 
during head-up tilt173, and normalized BP169,215. Passive stepping on a robotic tilt 
table and functional electrical stimulation was the most favourable intervention. 
The overall outcome of the two studies196, 179 included in the meta-analysis 
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(Figure 2.3) was that electrical stimulation was favourable in treating OH, 
however the 95% confidence intervals for the standardized mean difference 
crossed zero. 
 
ROBO: Passive stepping on robotic tilt table; ROBO-FES: passive stepping on robotic tilt table and functional electrical 
stimulation of lower limb muscles; Control: no intervention (Yoshida et al196) or tilt tabling only (Kuznetsov179) 
Figure 2.3 Electrical stimulation compared with no intervention, robotic 
stepping, and electrical stimulation combined with robotic stepping 
compared with no intervention 
 
Conclusion of effectiveness of electrical stimulation: electrical stimulation for the 
studies not included in the meta-analysis was favourable, but not statistically 
significant. The meta-analysis concluded that electrical stimulation was 
favourable when comparing electrical stimulation with passive stepping, tilt 
tabling only, or no intervention. However, the 95% confidence interval crossed 
zero in two out of three of the training conditions. 
Compression demonstrated positive results for elderly people with OH and 
people with neurogenic OH. Two studies160,164 concluded that combined lower 
limb and abdominal compression improved orthostatic stability in older people 
and people with stroke.  
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Abdominal compression154,155 was shown to reduce OH in older adults with 
neurogenic OH. Abdominal compression significantly reduced BP fall upon 
tilting154, compared to placebo. Symptoms of OH decreased significantly at the 
four-week follow-up. Abdominal compression was effective at attenuating OH 
compared with no abdominal compression155, and symptoms were not affected 
by type of binder. There was no statistically significant difference with or without 
abdominal binder195, however, mean arterial BP was higher with the abdominal 
binder at six weeks and six months. 
All three lower limb compression studies reported positive results. Maximum 
improvement was observed with all three combinations of compression (calves, 
thighs and abdomen)207, and abdominal compression alone significantly 
reduced OH (p<0.005). Similarly, a significant improvement was observed in 
elderly people with OH wearing elastic hosiery tights174, with reduction of OH at 
one minute (p<0.01) and two minutes (p<0.005). The spinal cord injury case 
report204 demonstrated that the individual was able to remain in the upright 
position for longer, allowing improved mobilization during physiotherapy whilst 
wearing the inflatable external leg compression. The inflatable external leg 
compression succeeded in improving pre-syncope symptoms and preventing 
OH for several hours. 
Participants with spinal cord injury demonstrated an increase in sympathetic 
activity and a decrease in parasympathetic activity after maximal exercise whilst 
wearing graduated compression stockings using the wheelchair cycle 
ergometer185. 
Lower limb compression stockings182 caused a passive physical resistance that, 
upon standing, delayed the maximal drop in mean arterial pressure in both 
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younger and older adults. The authors of the study concluded that compression 
stockings appeared to reduce venous pooling, however, the total peripheral 
resistance increased in older participants in minute six. There were no 
differences between groups when heat and orthostatic stress were combined.  
Lower limb compression bandages157 decreased OH symptoms in participants 
who were medically unwell including 14 with stroke. Approximately 55% of 
participants experienced symptoms in the un-bandaged group. Significant 
changes were observed in the un-bandaged group compared to the bandaged 
group with significantly greater incidence of palpitations, tachycardia and 
decline of oxygen saturation over time (p < 0.04, <0.03, <0.03 respectively). 
Authors did not report results for sBP or dBP. Results from the two studies171, 
172 included in the meta-analysis favour compression bandaging (Figure 2.4), 
however the 95% confidence intervals for the standardized mean difference 
crossed zero. 
 
Figure 2.4 Compression bandaging compared with no intervention 
 
Conclusion of the effectiveness of compression interventions: lower limb and 
abdominal compression160,164,207, lower limb compression157,171,172,174,182,185,204 
and abdominal compression154,155,207 are effective in improving OH. However, 
not all studies were statistically significant, hence, the benefit of undertaking a 
meta-analysis. 
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Physical countermanouvers165 were deemed effective in reducing OH in 
people with neurogenic OH, if performed correctly. Squatting produced the most 
dramatic change in arterial BP, resulting in longer standing time improved. The 
follow-up survey identified that the use of the manoeuvres varied from once to 
11 times per day (3.83(±3.1) manoeuvres per day). However, the follow-up 
survey was conducted via telephone, therefore it was unknown whether 
participants were performing manoeuvres correctly. 
Leg crossing and squatting211 improved standing BP in people with autonomic 
failure. After leg crossing, all participants stood for 10 minutes or more (pre-
intervention standing times not provided). Time in standing after squatting was 
not reported. 
Leg crossing and leg muscle contractions212 resulted in higher standing BP than 
without leg muscle contraction. Leg crossing whilst sitting on 48cm and 38cm 
chairs demonstrated an increase in sitting BP in people with pure autonomic 
failure. 
Leg muscle pumping (tiptoeing and leg crossing)214 had different effects on OH 
in people with autonomic failure. Tiptoeing did not change BP after one minute 
in the patient group, but the normative group showed an increase in BP. Leg-
crossing increased BP in both groups initially, which was more pronounced in 
the normative group. 
Physical manouvres193 that significantly increased mean BP included bending 
forward (p<0.005), squatting (p<0.002) and abdominal compression (p<0.04) 
but not leg crossing. Squatting and abdominal compression also induced a 
significant increase in cardiac output during squatting (p<0.02) and during 
abdominal compression (p<0.014). 
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Conclusion of effectiveness of physical countermanouvers165,193,211, leg 
crossing211,212,214, leg muscle pumping/contractions212 and bending forward193 
improved OH, whilst tiptoeing did not214. 
A combination of abdominal compression and physical counter-
manouvres203 had a significant effect on standing BP (p<0.05). However, there 
were no significant differences in the effect of abdominal compression on the 
diameter of caval or femoral veins, or compression and arterial pressure 
response. 
Conclusion of the effectiveness of a combination of abdominal compression and 
physical counter-manoeuvres: A combination of abdominal compression and 
physical counter-manoeuvres is effective in treating OH. 
Sleeping with head up191 reduced the drop in BP after one minute of standing 
(p<0.01 for sBP). Four of the six participants received sleeping with head up 
alone, and five participants received combined treatment (sleeping with head up 
and pharmacological treatment using Fludrocortisone). Combined treatment 
was most effective, significantly reducing OH symptoms in all patients (p< 
0.001), increasing the maximal standing period to at least 10 minutes compared 
to 35 to 170 seconds pre-treatment. Sleeping with head-up at six inches for six 
weeks209 had no effect on OH symptoms and BP. 
Conclusion of the effectiveness of sleeping with head: Sleeping with head up in 
combination with Fludrocortisone is more effective than sleeping with head up 
alone. 
Dietary measures 
Food intake had a negative effect on BP in elderly people and people with 
neurogenic OH. Participants with Parkinson’s disease had a significant (p<0.01) 
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postprandial sBP drop in supine position compared to healthy controls180. There 
was a greater fall of sBP with passive versus active standing in both groups, 
with a greater postprandial fall in the group with Parkinson’s disease. The 
authors reviewed one meal (lunch) and did not look at all meals throughout a 
whole day, nor collect data on the size of meals participants usually ate with 
those provided in the study. 
Post-meal BP was lower in all positions184 (lying sBP p<0.005, lying dBP 
p<0.02; sitting dBP p<0.07; standing dBP p<0.06) after three large meals. 
Compared to six meals, sBP and dBP between meals reached lower levels on 
the three-meal study day. Fewer symptoms were reported during the six-meal 
study day.  
Post-meal supine BP was significantly lower (p<0.02) in older participants183. 
Supine sBP and dBP was significantly higher (p<0.15 and p<0.001) in the 
elderly group but standing sBP and dBP was similar between groups. 
Conclusion of effectiveness of food intake interventions: Eating smaller, more 
frequent meals as opposed to larger, less frequent meals resulted in 
significantly higher supine, sitting and standing BP and improved OH symptoms 
in people with autonomic failure, neurogenic OH, elderly people and people with 
Parkinson’s disease'. 
Fluid intake prior to standing had a positive effect on OH in various positions. 
Five minutes after drinking water, there was a significant rise in BP in the supine 
position (p<0.05)178. With exercise there was a clear fall in BP, this occurred 
even after water ingestion. Blood pressure remained low after exercise but was 
significantly higher (p<0.05) after water intake, resulting in better tolerance of 
post-exercise standing. Water drinking improved orthostatic tolerance post-
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exercise. Standing prior to water ingestion caused a significant fall (p<0.01) in 
BP in all participants188. After water ingestion there was a rise in seated BP. 
Seated and standing BP at 15 and 35 minutes after water ingestion was 
significantly higher (p<0.01, p<0.001) than before water, with an improvement in 
orthostatic symptoms. 
Drinking 480mls of water at room temperature in less than five minutes 
improved standing BP and orthostatic tolerance in people with autonomic 
failure197. The response was similar in patients with multiple system atrophy and 
those with pure autonomic failure. Water ingested before a meal attenuated 
postprandial hypotension in these patients. Drinking water also attenuated 
orthostatic tachycardia in people with idiopathic orthostatic intolerance. 
Conclusion of effectiveness of fluid intake interventions: Ingestion of water 
increases BP in supine178, sitting188 and standing188,197. Water ingested prior to 
a meal also attenuates postprandial hypotension197. 
2.15 Discussion 
This review set out to examine the effectiveness of non-pharmacological 
interventions to treat OH in elderly people and people with a neurological 
condition. 
Whilst the literature contained many non-pharmacological interventions to treat 
OH in these populations, the review highlighted a heterogeneity of methods. 
The inclusion criteria included some participants who did not have a formal 
diagnosis of OH prior to entering a study. Many studies included participants 
with neurological conditions such as Parkinson’s disease, brain injury, stroke 
and spinal cord injury, but did not specify OH as an inclusion criterion. This may 
be because OH in neurological conditions is associated with central autonomic 
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dysfunction and/or the absence of vein blood pump related to lower limb 
paralysis. Further, periods of immobility or prolonged bed rest, which can cause 
physiological changes such as diminished sympathetic activity216, in 
combination with hypovolemia, may also predispose some individuals with 
neurological conditions to OH. However, authors did not explicitly provide this 
as a rationale for their chosen sample. 
Thirty-one percent of studies specified OH in their inclusion criteria, but there 
was heterogeneity in the definitions used, and only 26% provided a definition, 
which makes meaningful comparison difficult. The most commonly used 
definition was a sustained drop in sBP of at least 20 mmHg and/or dBP of at 
least 10 mmHg following a change of posture, which was applied to various 
postures (standing, tilting (ranging from 15-90 degrees tilt angles) or sitting). 
Other variations used a higher threshold155,193,207. Using higher thresholds could 
result in participants being missed during screening. It also raises the question 
as to whether the lack of standardization observed in these studies, is mirrored 
in clinical practice. The time points at which BP was measured also varied from 
immediately160,206 to up to 10 minutes166,179 of being upright. Further, the 
definition of “being upright” varied from 60-90 degrees on a tilt table or self-
initiated standing, and authors did not acknowledge or discuss the differences 
of active and passive standing. Verticalization using a tilt table does not fully 
replicate the physiology of active standing because the exercise reflex and the 
mechanical squeeze on the venous capacitance and arterial resistance vessels 
are less217. Therefore, OH may occur more frequently with tilt table testing218. 
Cerebral hypoperfusion is acknowledged in clinical guidelines105,136 as a very 
common cause of syncope or transient loss of consciousness219, which is likely 
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to impact on standing time and symptoms experienced. Monitoring cerebral 
blood flow is important in people with acute or sub-acute stroke, because 
autoregulation is impaired following stroke130. Two recent meta-analyses220,221, 
for example, concluded that OH was independently associated with a 
significantly higher risk of developing coronary heart disease, cardiovascular 
disease and heart failure. Despite the relative importance of maintaining 
cerebral blood flow when standing upright, it was measured in only two studies. 
One study210 monitored cerebral blood flow, but only in participants with sub-
arachnoid haemorrhage and not in participants with ischemic stroke or severe 
brain trauma. The authors acknowledged the potential risk of impairing cerebral 
blood flow during mobilization but did not provide a rationale for only monitoring 
participants with sub-arachnoid haemorrhage. Additionally, they did not provide 
any data on cerebral blood flow. The second study179 included 104 participants 
with stroke, all of whom had cerebral blood flow measured pre- and post-
training. Cerebral blood flow was reduced ≤10%, but participants were 
asymptomatic. Asymptomatic OH is more common than symptomatic OH222, 
which means clinicians may be unaware of the potential risk of further brain 
damage when these patients are being mobilised and/or undergoing therapy. 
As well as measuring cerebral blood flow, future work should also investigate 
what is a clinically important drop in cerebral blood flow. 
2.15.1 What type of interventions worked? 
Overall, the results were mixed. Although effect sizes often favoured the 
intervention in individual studies, meta-analysis of three interventions were non-
significant, as highlighted in the forest plots in Figures 2.2, 2.3 and 2.4. Of the 
additional interventions reviewed, physical counter-manoeuvres and fluid intake 
produced favourable results. It is important to consider the feasibility and 
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practicality of these interventions if they are to be implemented into clinical 
practice. 
Physical counter-manoeuvres were favourable in reducing OH, for example, but 
people with balance and mobility problems may find many of the physical 
manoeuvres challenging, and their risk of falling increased. Additionally, 
performing these physical manoeuvres requires the ability to stand and move 
between sitting and standing, and people with moderate and severe disability 
would often not be able to perform these movements without 
mechanical/physical assistance. Exercise was favourable, but the changes 
measured were not statistically significant. The resistance training programs 
may also be unsuitable for people with moderate to severe disability. Several 
studies used robotic tilt tables and automated cycle ergometers to passively 
move lower limbs during verticalization, which may be more suitable for people 
with neurological conditions who have moderate to severe disability. When 
considering implementation into practice it is important to consider how 
accessible this equipment is; robotic tilt tables, for instance, are not routinely 
available in clinical practice. 
Other interventions that may be suitable for people with moderate to severe 
disability are compression and electrical stimulation. Compression garments, 
such as compression stockings, may allow repeated safe standing and/or sitting 
out. They can be used in conjunction with tilt tabling and standing frames to 
facilitate orthostatic tolerance, and are frequently used in spinal cord 
rehabilitation223. In stroke, current clinical guidelines recommend intermittent 
pneumatic compression or graded compression stockings of lower limbs as 
thromboembolism prophylaxis224. Therefore, abdominal binders may be more 
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appropriate as they would not interfere with this. Furthermore, abdominal 
binders may be easier for healthcare providers to monitor skin integrity, and 
provide less risk of skin damage, although they would be contraindicated for 
people receiving nutritional support via a gastrostomy tube, because the binder 
would compress the gastrostomy tube and may cause pain and skin damage. 
Additionally, people with moderate to severe disability may need assistance to 
don and doff compression garments. 
Electrical stimulation is an adjunctive intervention commonly used in clinical 
practice to treat muscle impairment225. Contraindications for electrical 
stimulation include poor skin integrity, significant autonomic dysreflexia in 
incomplete spinal cord injury above T6, and uncontrolled epilepsy226. Only one 
study173 provided this information. None of the studies discussed the 
implications of contraindications of using electrical stimulation in clinical 
practice. However, contractions induced by electrical stimulation of lower limb 
muscles may activate the skeletal muscle pump as effectively as voluntary 
contractions of these muscles in people without weakness or disability as a 
result of stroke or neurological impairment. This may allow patients to stand 
earlier or for longer during rehabilitation sessions or performing activities of daily 
living. 
Water ingestion had a positive effect on OH and would be suitable for many 
people. However, stroke and degenerative neurological conditions can cause 
swallow impairments227, therefore, ingesting water quickly may be unsafe 
and/or challenging for these people due to risk of aspiration and aspiration 
pneumonia. Further, people who have incontinence, and/or reduced mobility 
that affects their ability to get to the toilet, may be reluctant to undertake this 
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intervention. This intervention would also be unsuitable for people who have 
fluid restriction due to other medical conditions. All three studies tested water 
ingestion on a one-off basis, thus, the accumulative effects are unknown. 
Long-term follow-up and prolonged intervention regimes were lacking in most 
studies. Therefore, it is unknown whether OH improves over time with repeated 
application of a specific non-pharmacological intervention, and whether any 
improvements are sustained, thereby alleviating the need for further intervention 
over the longer term. None of the studies evaluated the instantaneous versus 
training effects (e.g. repeated interventions) of the different OH interventions. 
For example, an abdominal binder improved OH when it was worn for four 
weeks154, but there was no follow-up beyond this point, so it was not known if 
symptoms returned once it was no longer worn. This warrants different trial 
designs with longer follow-up periods.  
Determining long-term effect is important because studies suggest the 
cardiovascular system can adapt over time to develop orthostatic tolerance. In 
spinal cord injury, for example, these adaptations may be due to changes in 
Rennin–angiotensin–aldosterone activity228,229. Further, adaptations in the 
central control of autonomic functions have been identified in healthy animals 
with prolonged exercise training and may occur over time and with training in 
people with OH230. 
There may be a difference in the short and long-term effects of the interventions 
between conditions. Where there is direct damage to autonomic centres such 
as seen in multiple system atrophy231 and Parkinson’s disease232, the potential 
for adaptive changes may be limited. In contrast, there may be greater potential 
for central and neuro-hormonal adaptive changes in the elderly and after stroke, 
97 
 
where causes may be more linked to paralysis and long-term immobility. This 
highlights the need for future studies to stratify participants according to both 
their condition and stage or severity of disease. Different conditions have 
different pathophysiological mechanisms underlying OH233-235, and thus 
potentially different short and long-term effects of an intervention. 
2.15.2 Implications for practice 
The findings of this systematic review have several implications for clinicians 
working with people with neurological conditions and elderly people in both 
inpatient and community settings. The meta-analysis concluded that electrical 
stimulation, lower limb compression and resistance exercise training were 
favourable in reducing or abolishing OH, although the GRADE certainty of 
evidence was very low for all three physical modalities. These modalities could 
be implemented into rehabilitation sessions for people with stroke, neurological 
conditions and elderly people.  
Many rehabilitation units have cycle ergometers (e.g. MotoMED or 
TheraTrainer) which patients could use whilst sitting out, even in specialist 
wheelchairs. However, depending on the severity of disability some patients 
may need supervision to optimize safety. Additionally, many rehabilitation units 
also have access to functional electrical stimulation (e.g. MicroStim) which 
could be incorporated into standing practice to increase the duration of standing 
and optimise physical activity during rehabilitation sessions. However, clinicians 
need to check whether patients have any contraindications, for example, people 
with spinal cord injury above T6, uncontrolled epilepsy, poor skin integrity or 
cognitive problems.  
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When OH is problematic, lower limb compression and abdominal binders could 
be used, both within and outside of rehabilitation sessions, to optimise physical 
activity. Abdominal binders are easier to don and doff than lower limb 
compression stockings and this may enable patients to carry this out 
independently. For those who require assistance, education of clinicians, carers 
and family members would be required to enable this to be undertaken both 
within and outside of rehabilitation sessions, and in the community setting. 
The applicability of water ingestion for people with neurological conditions has 
been acknowledged in the discussion. However, if patients have been screened 
by Speech and Language Therapists and deemed to have no swallow 
impairment, sipping water may be a useful way of managing OH during 
standing practice. 
This review suggests a range of non-pharmacological interventions may be 
effective in managing OH. Most do not require specialist equipment and training 
therefore the cost of implementation is likely to be minimal. Importantly, from a 
practical perspective, it is apparent that many of these interventions can be 
incorporated into and/or outside of rehabilitation sessions. However, patient’s 
physical abilities and impairments should be considered when selecting which 
non-pharmacological interventions to implement e.g. cognitive impairment, 
severity of disability, swallow impairment and other medical conditions. 
2.15.3 Conclusion 
The review found mixed results for the effectiveness of non-pharmacological 
interventions to treat OH in people aged 50 years and over and people with a 
neurological condition. Setting, participants, outcomes, study designs and 
intervention types were heterogeneous, resulting in an inability to include all 
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studies into a meta-analysis. There are several non-pharmacological 
interventions effective in treating OH (electrical stimulation, lower limb and 
abdominal compression, physical manoeuvres, resistance exercise training, 
eating smaller more frequent meals and drinking 480ml water), but not all have 
resulted in clinically meaningful changes in outcome. Some may not be suitable 
for people with moderate to severe disability, for example, they may be unable 
to stand to perform physical manoeuvres or perform resistance training due to 
weakness. Thus, it is important for clinicians to consider the patient’s abilities 
and impairments when clinically reasoning which non-pharmacological 
interventions to implement. Participants in this feasibility trial have severe stroke 
and will be unable to perform physical manoeuvres, or resistance exercises. 
They may have impaired swallow and likely wear pneumatic compression 
stockings therefore abdominal binders will be used in the OH protocol. 
2.15.4 Limitations 
The primary limitation of this review is the heterogeneity of methods of the 
studies included. Most studies had small sample sizes which limits 
generalizability of the results. The methodological quality of the included studies 
varied. For RCTs randomization not used or unclear, blinding in most RCTs was 
low. Some quasi-experimental studies did not include a comparator or control 
group. The number of participants in each experimental group varied in the 
different studies included in the meta-analyses varied. The certainty of the 
evidence was very low for all studies included in the meta-analysis, thus any 
translation into practice must be tentative. Subgroup analysis was not possible 
due to insufficient studies included in the meta-analysis, as well as 
inconsistency of reported demographics, medications, and severity of 
neurological condition using disease specific validated outcome measures. The 
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meta-analysis supports the adoption of abdominal binders in the OH protocol 
used in the feasibility RCT. This aligns with recommendations that non-
pharmacological treatments for OH should be considered first before 
progressing to pharmacological treatments23,136. 
This review was further limited by the inclusion of only English language 
studies. 
2.15.5 Recommendations for future research 
This systematic review highlighted heterogeneity in measurement of non-
pharmacological interventions to treat OH. Lack of a standardized approach to 
measurement in OH trials makes consolidation of the body of knowledge 
difficult, which may negatively impact on effective interventions being 
implemented into clinical practice. A consensus is required when measuring BP 
at specific time-points during standing or verticalization. Further, a consensus is 
required for measuring OH in people with neurological conditions who have 
impaired mobility and reduced standing times. Additionally, a core set of 
outcome measures and standardized time points would facilitate pooling of 
results in meta-analyses, to enable more accurate conclusions to drawn. 
Standardization of inclusion criteria is required to ensure all participants enrolled 
in OH intervention studies have OH, either by testing during screening or from a 
formal diagnosis. Improved consistency of reporting of methodology, as 
recommended by the Consolidated Standards of Reporting Trials guidelines236 
is also recommended. Consistency of reporting demographics, medications, 
and severity of neurological condition using disease specific validated outcome 
measures would allow sub-group analysis. 
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2.16 Summary 
Chapter 2 has presented the results of the systematic review, which suggest 
several non-pharmacological interventions are effective in treating OH in people 
with a neurological condition. However, due to time constraints, the review was 
completed after recruited closed. Thus, the OH protocol used in the feasibility 
RCT only included abdominal binders, which were deemed favourable in 
treating OH. The OH protocol will need to be developed further prior to 
progressing to a definitive trial. 
Chapter 3 presents the feasibility trial methodology. 
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Chapter 3 Feasibility trial methodology 
3.1 Research problem and uncertainties 
Standing up early after stroke has the potential to prevent or minimise 
secondary complications in the musculoskeletal and cardiorespiratory systems 
which can be detrimental to recovery of independence in ADL. Performing 
functional tasks such as standing and sit to stand early after stroke may result in 
adaptive neuroplasticity and improve functional outcome. Standing and sit to 
stand are functionally linked tasks but this novel combination has not been 
tested in people with severe stroke, therefore its efficacy in this patient 
population is unknown. Due to the profound disability caused by a severe 
stroke, individuals require physical and mechanical assistance to perform these 
activities. A standing frame would enable people with severe stroke to practise 
prolonged standing and task-specific training (repeated sit to stand); combining 
these two interventions will create a functional standing frame programme. The 
functional standing frame programme will address a key priority for people who 
have suffered a severe stroke who have identified that standing up soon after 
their stroke was an “important milestone” in their recovery. However, several 
uncertainties exist which need to be understood prior to progressing to a full-
scale trial. 
3.2 Uncertainties to be addressed 
It is not known if it is feasible to undertake a RCT of a functional standing frame 
programme for people with severe stroke. Therefore, prior to progressing to a 
main trial, a feasibility trial is indicated to inform the design the main trial238. This 
chapter presents the research methodology and rationale for the feasibility trial. 
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3.3 Trial aims, objectives and research question 
3.3.1 Trial aims 
The primary aim was to establish whether a RCT of a functional standing 
frame programme (intervention) versus usual physiotherapy (control) in people 
with severe stroke in an inpatient sub-acute stroke rehabilitation setting is 
feasible. 
The secondary aim was to explore experience of the intervention and 
associated procedures from the perspective of participants, their relatives and 
physiotherapists delivering the trial, using qualitative methods. 
3.3.2 Trial objectives 
Feasibility trial objectives were set according to the following indicators to 
assess : 
Process 
Eligibility criteria, ability to consent, consent rate, recruitment rate, 
willingness/ability of physiotherapists to recruit, willingness of participants to be 
randomised, retention rate, acceptability of the intervention, determining usual 
physiotherapy, sample size estimates, primary outcome, end point. 
Resource 
Burden (participants and treating research physiotherapists/assessors). 
Management 
Participant adherence, acceptability of outcome measures to participants and 
physiotherapists, fidelity, OH protocol. 
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Safety 
Safety was assessed by comparing the number and nature of serious adverse 
events (SAEs) and adverse events (AEs) in both the intervention and control 
group. 
Further details on these indicators are contained in the Statistical Analysis Plan 
(Appendix 5). 
Objectives related to the qualitative component were to explore: 
• How trial procedures (timing and mode of participant recruitment, 
information provision, methods of data collection for example timing and 
content of outcome measures) can be refined to maximise recruitment, 
retention and acceptability in the definitive trial 
• Participants’ experience of the intervention 
• Participants’ experience of being randomised 
• Participants’ reasons for, and experience of, withdrawing from the trial 
• Relatives’ influence of participants’ decision to consent to participate, 
remain in the trial or provide assent for their relative 
• Physiotherapists’ attitudes, thoughts and feelings of implementing the 
intervention and whether they perceive a subsequent RCT to be 
achievable 
• Physiotherapists’ attitudes, thoughts and feelings of the trial 
documentation and trial procedures. 
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3.3.3 Research question 
Does early standing and sit to stand practice, using a standing frame in people 
with severe sub-acute stroke lead to an improvement in functional ability and 
quality of life and a reduction in neuromuscular impairment? 
However, this question will not be answered in this feasibility trial. The aim is to 
determine if this trial is feasible prior to progressing to a main trial to test 
effectiveness. 
3.4 Trial design and justification 
A pragmatic, multi-centre, parallel single-blinded two-armed feasibility RCT was 
deemed appropriate to determine the feasibility of a functional standing frame 
programme for people with severe stroke versus usual physiotherapy during 
their inpatient sub-acute rehabilitation. A feasibility RCT with a nested 
qualitative component (semi-structured face-to-face interviews and focus group) 
was chosen to determine, in the first instance, whether the implementation of a 
definitive RCT would be feasible in the future. 
A cluster RCT was initially considered, where each SRU would be randomised 
as opposed to individual participants239. However, this would have prevented 
the intervention and associated trial procedures to be tested and evaluated 
across all four SRUs. Additionally, usual physiotherapy practices would have 
been limited to only two SRUs, which would have limited the ability to describe 
physiotherapists’ current clinical practices for people with severe stroke during 
sub-acute inpatient rehabilitation. The RCT was chosen as the most appropriate 
method to answer the research question in a future definitive trial, as it is 
considered the ‘gold standard’ due to its rigorous and robust method of 
determining whether a cause-effect relationship exists between the intervention 
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and outcome240,241. The RCT is a fundamental part of clinical research, and 
highly regarded because it has the potential to reduce bias related to 
confounding variables through a control group and selection bias through 
randomisation242. In this feasibility RCT participants were randomly allocated to 
one of two groups: the functional standing frame group (intervention) or the 
control group (usual physiotherapy). 
Qualitative research was embedded in this feasibility trial to provide insights into 
the intervention and trial procedures. The use of qualitative research within 
feasibility RCTs is becoming increasingly common243. It has been identified as 
useful to examine and address key uncertainties concerning intervention 
content and delivery (acceptability, feasibility and fidelity etc.); trial design, 
conduct and processes (impact of trial on participants and staff, recruitment and 
retention, acceptability of the trial in principle and practice etc.); outcome 
measures (breadth, selection, accuracy and completion)243. This is discussed 
further in Section 3.19. 
The intervention combined two physiotherapy interventions that have been 
separately evaluated and reported in the literature; prolonged standing and 
task-specific strength training. Currently, it is not known whether this novel 
combination of physiotherapy for people with severe stroke is effective. 
The functional standing frame programme is a complex intervention and the 
United Kingdom Medical Research Council (MRC)244 provides guidance on 
developing and evaluating complex interventions. A key component of the 
evaluation is the acceptability among people engaged in the feasibility trial, e.g. 
people with severe stroke, their relatives, treating physiotherapists and research 
assessors. Acceptability has been defined as “a multi-faceted construct that 
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reflects the extent to which people delivering or receiving a healthcare 
intervention consider it to be appropriate, based on anticipated or experiential 
and emotional responses to the intervention”245. Currently it is unknown whether 
the intervention would be acceptable to, or tolerated by, people with severe 
stroke, at this early stage of their rehabilitation continuum. Thus, this feasibility 
trial was used to determine whether the intervention was appropriate for further 
testing; enabling assessment of whether a main trial is feasible246. 
This feasibility RCT was a multi-centred using three healthcare sites (four 
SRUs) based in two counties in the South West Peninsula, England. The 
rationale for a multi-centre trial was to include a broader range of SRUs that 
may improve subsequent generalisation of findings, as well as increase the 
number of clinical judgements concerning the acceptability and feasibility of the 
intervention. It reduces the possibility of local phenomenon for trial processes 
and procedures and is more reflective of a subsequent national main trial. This 
design provides the opportunity to determine and describe what usual 
physiotherapy practices are in sub-acute inpatient stroke rehabilitation for 
people with severe stroke that has been identified as an important factor in the 
success of stroke rehabilitation trials247. Furthermore, there is access to a larger 
number of potential participants as well as ability to compare results among 
SRUs. 
Details of what treatments physiotherapists are implementing as usual 
physiotherapy during rehabilitation sessions with people with severe stroke 
were gathered using a Physiotherapy Content Recording Tool (Appendix 6: 
Treating Therapist Control Group CRF). This will enable current practices to be 
described and highlight whether current practices align with current evidence-
based recommendations. National clinical guidelines3 recommend physical 
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rehabilitation post-stroke should focus on mobility, balance and walking to 
facilitate independence in ADL. Evidence for task-specific strength training and 
early mobilisation is provided in these guidelines, however, it is not known if or 
how physiotherapists are routinely implementing these evidence-based 
interventions with people with severe stroke. Various approaches to physical 
rehabilitation are used after stroke248, yet there is no standard treatment 
protocol which enables physiotherapists to implement multiple approaches. 
Additionally, there is potential for physiotherapists to follow a single approach to 
the exclusion of others, and for their practice to be based on personal 
preference as opposed to scientific rationale248. 
Risk of contamination was identified as a potential problem in the current 
feasibility RCT where individuals allocated to the control group may 
inadvertently receive some aspects of the standing frame intervention as 
physiotherapists at each of the sites were treating participants in both groups. 
The trial protocol explicitly states that treating physiotherapists should not alter 
their usual physiotherapy practice during the trial, and this was emphasised in 
face-to-face training. However, it was acknowledged that physiotherapists may 
perceive the intervention to be effective and this could ‘unconsciously’ influence 
their usual physiotherapy practice over time249. Treating physiotherapists 
documented the content of their usual physiotherapy sessions. This enabled 
treatment activities implemented to participants in this group to be reviewed to 
determine any deviations from the protocol during the recruitment period. 
Additionally, fidelity checking was conducted to establish physiotherapists’ 
adherence to the trial protocol and whether the intervention and control was 
delivered as specified in the protocol250. See Process Evaluation (Section 3.13). 
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The current feasibility RCT design reduces bias. Recruitment bias was 
eliminated as physiotherapists were unaware of group allocation until informed 
consent/assent was received and baseline blinded assessments were 
undertaken by an independent blinded assessor. Additionally, the current RCT 
design ensured the assessor was blinded to group allocation. 
Blinding is a key methodological procedure in RCTs251. The ideal is for both 
participants and assessors to be blinded to treatment allocation252. However, for 
pragmatic RCTs in areas such as physiotherapy rehabilitation, double-blind 
trials are often impossible to achieve253,254. Thus, blinded outcome assessment 
was used in this feasibility RCT to limit bias254. Blinded outcome assessment 
refers to the process of concealing treatment group identity from outcome 
assessors, after their treatment assignment through randomisation, to minimise 
the occurrence of biased assessments influencing research findings255. 
All blinded assessments were undertaken in separate visits independently of 
delivery of the trial intervention or usual care sessions. The baseline 
assessment was undertaken by a blinded assessor, after written informed 
consent was obtained by the research physiotherapist, prior to randomisation. 
Every effort was made throughout the trial to ensure assessments were blinded. 
Treating physiotherapists and/or participants were reminded not to discuss their 
allocated group with the assessor during any interaction. The success of 
blinding in this trial was formally tested by asking blinded assessors to guess 
group allocation during each assessment visit and comparing these responses 
to what would be expected by chance256,257. 
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3.5 Participants 
In keeping with the pragmatic trial design, eligibility criteria were kept broad. 
Inclusion criteria were: 
1. A confirmed clinical diagnosis of new (first/recurrent) severe stroke, 
cerebral haemorrhage or infarct confirmed by consultant or CT scan 
leading to admission to the SRU 
2. Aged ≥18 years 
3. Graded as mRS 4 or 5 and/or National Institutes of Health Stroke Scale 
(NIHSS)258 ≥16 (severe or very severe stroke and unable to stand 
without support/mechanical aid and assistance of two people) 
4. Able to give informed consent, or assent received from a consultee (see 
recruitment section) 
5. Conscious and responsive to verbal commands. 
Exclusion Criteria were: 
1. Systolic blood pressure ≤100mmHg or ≥220mmHg at rest, lying or sitting 
2. Oxygen saturation ≤87% with or without supplementary 
oxygen (e.g. severe acute/chronic cardiorespiratory 
disease) 
3. Resting heart rate of ≤40 or ≥110 beats per minute (e.g. cardiovascular 
instability) 
4. Temperature ≥38.5 degrees centigrade or ≤35 degrees centigrade 
5. Orthopaedic impairments which prevent full weight bearing in standing 
6. Malnutrition Universal Screening Tool score of ≥2, or deemed 
to be not meeting nutritional demands for therapeutic 
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interventions by dietician 
7. Documented clinical decision for receiving end of life care 
8. Unstable coronary or other medical condition that is judged by the 
Principal/Chief Investigator (PI/CI) or clinical team to impose a 
medical risk to the patient by involvement in the trial 
9. Assessed functionally by specialist physiotherapists as being a risk 
to themselves or others due to their inability to follow non-verbal 
prompts or are behaving erratically 
10. Immobile and not weight bearing pre-stroke 
11. Additional neurological deficits unrelated to the current or past 
stroke (e.g. peripheral neuropathy or Multiple Sclerosis, because 
these impairments are not related to the condition of interest) 
12. Weight of 115kg or more (weight limit on the standing frames) 
13. Being discharged out of county, e.g. admitted during holiday/visit to 
Cornwall or Devon because they would be unable to participate in 
follow-up assessments 
14. If people are registered in another trial the CI was contacted to 
ensure there was no conflict between trials 
15. Non-English speaking. 
Eligibility criteria for clinical trials can affect recruitment and retention259. To 
optimise potentially beneficial treatments being used in clinical practice, it is 
important to ensure eligibility criteria is representative of the overall population 
to whom the intervention is intended for260. Eligibility criteria for this trial were 
selected using literature from relevant research trials and discussions with 
specialist physiotherapists in inpatient sub-acute stroke rehabilitation. This was 
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to ensure the participants included in the trial were representative of the patient 
population physiotherapists routinely see in their clinical practice in SRUs. 
Stroke is predominantly, although not exclusively, prevalent in older people261 
who are highly likely to have co-morbidities in conjunction with their stroke262. 
To facilitate a representative sample, comorbidities were not excluded. 
People with cognitive and communication impairments are frequently excluded 
from clinical trials248,263. Exclusion of such impairments may be due to 
interventions requiring a specific level of ability, or challenges around informed 
consent. Given that 75% of people post-stroke experience significant cognitive 
impairment264 and over a third of people experience speech and language 
impairments (aphasia) post-stroke265 arguably these people should be included 
in an evaluation of the functional standing programme as they constitute those 
to whom these trial results would be especially applicable. Thus, people with 
cognitive and communication impairments were not excluded. 
3.6 Recruitment 
Identification and recruitment of potential participants was conducted on 
admission to participating inpatient SRUs by physiotherapists. This was 
supported by the local National Institute for Health Research (NIHR) Clinical 
Research Network (CRN). Physiotherapists logged all admissions and screened 
patients for stroke severity. All patients classified as a severe stroke (mRS 4 or 
5) were screened for eligibility (see Appendix 7: Screening CRF and Appendix 
8: Post-Screening CRF) and eligible participants were approached within 48 
hours of them being deemed medically fit for rehabilitation, or as soon as 
practicable. Potential participants were given a Participant Information Sheet 
(PIS) (Appendices 9-11 Participant Information Sheets). There were three 
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different versions of the PIS to accommodate different levels of communication 
and cognition. 
3.7 Randomisation 
Eligible consented participants were randomly allocated to either the 
intervention or control group using a secure centralised web-based system. 
Randomisation took place after the baseline assessment. Randomised 
allocations were computer-generated by the Peninsula Clinical Trials Unit 
(PenCTU) in conjunction with an independent statistician, in accordance with 
the PenCTU’s standard operating procedure. The randomisation list and the 
program were stored in a secure network location within the PenCTU, 
accessible only to those responsible for provision of the randomisation system. 
This ensured concealment of allocation for the physiotherapists undertaking 
recruitment and the blinded assessors. 
A minimisation procedure (which has a random element) during the 
randomisation process was used to reduce possible imbalance between the two 
groups. Minimisation factors were: 
1. Fatigue at baseline assessment, scored by the participant and measured 
using a Visual Analogue Scale (VAS) (fatigue (VAS: 4-10) vs. no/minimal 
fatigue (VAS: 0-3)) 
2. Presence of OH at baseline, tested using manual sphygmomanometer and 
a standardised protocol (a decrease in systolic blood pressure of 20mmHg 
or more, or a reduction in diastolic blood pressure of 10mmHg or more, 
upon changing body position from supine to an upright posture in sitting or 
standing)126. 
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After randomisation, an automatic email was sent by the PenCTU to the 
relevant treating physiotherapist to notify them of each participant’s allocated 
group. Notification of randomisation (but no details regarding group allocation) 
was emailed to the CI/blinded assessor.  
3.8 Intervention group 
The intervention was protocolised to be delivered once a day over three weeks. 
It aimed to start as early as possible after randomisation to ensure treatment 
was completed during participants’ inpatient admission. A detailed description of 
the intervention can be found in the Work Instruction (Appendix 12). The Work 
Instruction required physiotherapists to check participants’ BP for the first three 
sessions, or until BP was within the participants’ normal range on three 
consecutive sessions. If a participant had a drop in sBP of at least 20mmHg 
and/or dBP of at least 10mmHg within three minutes of moving from supine or 
sitting into standing, physiotherapists were directed to the OH protocol 
(Appendix 13). 
The programme consisted of 5-7 sessions per week for three weeks. Each 
session was protocolised to last for 45 minutes: 30 minutes (or as long as 
tolerated) using the standing frame which included standing and repeated sit to 
stand (up to 8-12 repetitions). Eight to 12 repetitions was based on exercise 
recommendations for people with stroke266 and discussions with 
physiotherapists and occupational therapists working with people with severe 
stroke during the design of the trial. There was an additional 15 minutes (or as 
long as tolerated) to provide time for usual physiotherapy where participants 
could practise transfers, upper limb activities or activities chosen by participants 
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or guided by physiotherapists. The target number and duration of sessions is 
aligned with current RCP Guidelines3. 
The initial frequency and duration of standing was anticipated to vary according 
to physical capability as assessed by the treating physiotherapist. The aim was 
to progress standing time and sit to stand repetitions by 30% in each session up 
to the maximum of 30 minutes and 8-12 repetitions per session. Each treating 
physiotherapist used their individual clinical reasoning when evaluating 
participants’ tolerance to standing and ability to tolerate incremental increases 
in standing duration. 
Should participants improve to the extent where support from the standing 
frame was not required, participants could progress to unsupported standing 
outside of the frame or walking to optimise physical recovery for the remainder 
of the 3-week intervention. However, the protocol stipulated participants needed 
to continue with sit to stand repetitions within each 30-minute session. 
Physiotherapists were required to record activities undertaken during every 
session using a Physiotherapy Content Recording Tool (Appendix 14: Treating 
Therapist Intervention CRF). This standardised checklist is based on the Stroke 
Physical Therapy Intervention Tool267, which provides a system for recording 
physiotherapy treatment for stroke patients. This Recording Tool was modified 
to reflect current clinical practice in a sub-acute rehabilitation setting. Recording 
physiotherapy interventions during sub-acute stroke rehabilitation enabled usual 
physiotherapy management to be described.  
For the first three sessions (or longer if deemed appropriate by therapists), 
blood pressure was assessed both prior to and during standing. This was based 
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on the protocol used in the feasibility and safety testing of a very early 
rehabilitation trial82. 
3.8.1 Standardisation of the intervention 
Use of standing frames is incorporated within undergraduate physiotherapy 
training in the UK and is a recognised core skill for neurological 
physiotherapists. To standardise and optimise implementation of the 
intervention, treating physiotherapists received face-to-face training and an 
information pack. 
Treating physiotherapists were required to record any deviations from the 
protocol on a Protocol Deviation form. 
3.9 Control group 
This was defined as usual physiotherapy delivered during stroke rehabilitation 
for 45 minutes once a day (or as long as a tolerated) for a target of 5-7 sessions 
per week which aligned with RCP Guidelines3. Physiotherapists recorded 
activities undertaken during every session using the Physiotherapy Content 
Recording Tool contained in the Control Group CRF (Appendix 6). 
3.10 Assessment 
Participants were assessed at baseline (prior to randomisation), three weeks (at 
the end of the intervention period) and 3, 6 and 12 months (Appendix 15: 
Assessor CRF). Assessments aimed to be completed within ±seven days of the 
assessment due date provided by the PenCTU’s centralised website. 
3.11 Outcome measures 
Standardised, validated clinician-rated and patient self-reported clinical 
outcomes were measured in both groups. There is no core set of standardised 
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outcome measures for stroke and no agreed upon time-points when outcomes 
should be measured. Physiologically, the biggest changes post-stroke occur 
within the first three months as discussed in Chapter 1, Section 1.3, and the 
Stroke Recovery and Rehabilitation Roundtable taskforce11 have developed a 
framework defining critical time-points post-stroke that link to the currently 
known biology of recovery: baseline, post-intervention, 3-6 and >6 months. 
They do not explicitly suggest 12-month follow-up; however, a scoping review 
suggests that improvements in participation occur up to 12 months post-
stroke268. Thus, outcomes in this feasibility trial were measured at baseline, 
post-intervention, 3-, 6- and 12-months post-intervention. All the outcome 
measures listed below were undertaken at each of the follow-up trial visits. 
3.11.1 Proposed primary outcome measures for the anticipated main trial 
To facilitate comparison between the intervention and control groups in the 
anticipated main trial, an outcome measure relevant to the clinical question and 
valid for the population studied was required269. The proposed primary outcome 
measure assessed functional ability in performing ADL. Functional ability was 
identified as being important and a priority for people with severe stroke and 
their relatives during discussions in the development of this trial. People 
associated functional status with being independent in undertaking ADL which 
was a priority and meaningful for them. 
The Barthel Index of Activities of Daily Living (BI)270 is frequently used in stroke 
clinical trials, although was not designed specifically for this purpose. The BI 
rates a person’s degree of independence performing functional self-care 
(feeding, grooming, bathing etc.) and mobility activities (transferring in/out of 
bed/chair, walking etc.). Advantages of the BI are its simplicity and ease of 
administration and its convenience and low cost in longitudinal assessment271. 
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A major limitation of the BI is its floor effect272 with its limited ability to detect 
change at extremes of ability, making it less discriminating in severe stroke273. 
This feasibility trial provided the opportunity to investigate whether an 
alternative functional outcome measure is more responsive to detecting change 
in people with severe stroke and can be used in both inpatient and community 
settings for both the acute and chronic stages of stroke. Therefore, the Edmans 
Activities of Daily Living Index for Stroke Patients274 (Edmans) was also used. 
This measure covers all the categories included in the BI; however, the degree 
of independence is more detailed than dependent/independent for each item 
assessed. It was developed specifically for people with stroke, both as an 
inpatient in the sub-acute phase as well as in the community setting in the 
chronic phase. Collecting both these outcomes enabled investigation of the 
clinical utility and responsiveness of two functional outcome measures, to 
determine which measure will be used in the anticipated main trial. 
Both the BI (self-report version) and the Edmans are self-report. However, given 
the prevalence of communication and cognitive impairments, participants may 
be unable to report this information or may have reduced insight into their actual 
versus perceived abilities. In cases where it was not possible to obtain all the 
outcome measurement data from the participant, the researcher obtained proxy 
data from the treating physiotherapist during inpatient admission or next of 
kin/carer once discharged from hospital. 
3.11.2 Proposed secondary outcome measures for the anticipated main trial 
Proposed secondary outcome measures are listed in Table 3.1 
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Outcome measure Measurement 
domain 
Description 
Hand held 
dynamometer275,276 
Knee muscle 
strength 
Knee extensor strength is strongly correlated to common daily functional 
activities such as the ability to sit to stand, stand and walk in people with sub-
acute stroke275,276. Quadriceps strength on both lower limbs was explored 
using a portable hand held dynamometer. This involved measuring the 
maximal isometric strength with participants in standardised position of side 
lying with knee at 90-degree flexion. It is reliable in measuring lower limb 
strength in people with stroke (ICC=0.88-0.98)277. 
Manual universal 
goniometer278 
Length of hip flexors, 
hamstrings and 
ankle plantarflexors 
Hip flexors, hamstrings and ankle plantarflexors are all muscles that cross two 
joints and hence are at higher risk of contracture (especially within the first six 
weeks post-stroke279) which can directly impact negatively on function and 
societal participation. 
Goniometry is the most commonly used instrument by physiotherapists in both 
clinical and research practice and is a simple and quick method of assessing 
the degree of contracture at any joint280. Passive range of movement of these 
muscles was measured on both lower limbs. 
Intra-rater reliability using goniometry to measure ankle plantarflexor length is 
moderate to good (ICC: 0.719-0.892) and inter-rater reliability is moderate 
(ICC: 0.725-0.741) in people with stroke. 
Modified Ashworth 
Scale281 
 
Muscle tone in hip 
adductors, 
hamstrings and 
ankle 
Increased muscle tone was measured in the hip adductors, hamstrings and 
ankle plantarflexors. Spasticity is common post-stroke and may interfere with 
functional activities and cause pain and further complications such as loss of 
range of joint movement282. The Modified Ashworth scale was used. This rates 
tone on a 4-point ordinal scale (0=no increase in muscle resistance, 
4=affected part(s) rigid in flexion or extension). This shows: good inter-rater 
reliability hip and knee (weighted kappa=0.82) and ankle (weighted kappa = 
0.74); moderate intra-rater hip (weighted kappa = 0.45), good intra-rater 
reliability for knee (weighted kappa = 0.62) and very good for the ankle 
plantarflexors (weighted kappa = 0.85) people with stroke283. 
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Trunk Control 
Test284,285 
Control of trunk Trunk control is strongly correlated to common daily functional activities such 
as the ability to sit, sit to stand and walk286,287. The Trunk Control Test 
measures four simple aspects of trunk movement. The patient lies supine on 
the bed and is asked to roll to the weak side, roll to the strong side, sit up from 
lying down and sit in a balanced position on the edge of the bed, with feet off 
the ground for a minimum of 30 seconds. Movements are rated using a 3-
point ordinal scale (0= unable to do without assistance; 12= able to do so 
using non-muscular help or in abnormal style; uses arms to steady self when 
sitting; 25= able to complete task normally)285,286. These are very low-level 
activities that reflect the abilities of people with severe stroke in the acute/sub-
acute phase of stroke285, although it is acknowledged that this measure of low-
level activity has the potential for a ceiling effect for people who improve at 
various stages of their rehabilitation continuum.  
An alternative is the Trunk Impairment Scale which is reported to have no 
ceiling effect286. The Trunk Impairment Scale evaluates static and dynamic 
sitting balance as well as co-ordination of trunk movement. However, this 
measure would be too challenging and subsequently has a floor effect with 
people with severe impairments post-stroke288. 
Patient Health 
Questionnaire 
(PHQ-9)289 or 
Stroke Aphasia 
Depression 
Questionnaire-10 
(SADQ-10) for 
participants who 
have aphasia290 
Mood Psychological mood disturbance is associated with higher rates of mortality, 
long term disability, hospital readmission, suicide and higher utilisation of 
outpatient services if untreated291-293. The National Institute for Health and 
Clinical Excellence (NICE)294 and RCP Guidelines3 recommend routine 
assessment and management of mood after stroke. Mood was assessed 
using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a 9-item 
summed scale with scores ranging from 0 (no depressive symptoms) to 27 (all 
symptoms occurring daily). It shows good sensitivity (78%) and specificity 
(96%) for any depression diagnosis regardless of age, gender or ethnicity289. It 
was administered by the assessor and reported by the participant. 
Some participants with significant aphasia required assessment with the 
Stroke Aphasia Depression Questionnaire-10 (SADQ-10). This is scored out 
of 30 with ≥14 = depression. This is an observer rating of observed behaviour 
on a 4-point scale and has good internal consistency (Cronbach’s alpha =0.80 
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and a split-half reliability of r =0.81)290. The SADQ-10 hospital version was 
used whilst an inpatient and the SADQ-10 community version was used once 
discharged from hospital. The clinical care team completed the SADQ-10 
during inpatient stay and relatives or caregivers were asked to complete in the 
participants’ place of residence. The blinded assessor then reviewed this as it 
is an observational measure over the proceeding seven days. 
Stroke and Aphasia 
Quality of Life 
Scale-39295 and the 
EQ-5D 5L296 
Health related quality 
of life 
Health related quality of life (HRQoL) measures are relevant in stroke because 
the key aims of rehabilitation are to maximise functional independence as well 
as facilitate adaption to disability, promote social and community integration 
and maximise well-being and quality of life295. 
The Stroke and Aphasia Quality of Life Scale-39 item (SAQOL-39) is a stroke 
specific HRQoL instrument. The 12 domains (energy, family roles, language, 
mobility, mood, personality, self-care, social roles, thinking, upper extremity 
function, vision, work/productivity) were obtained from interviews with stroke 
survivors and subsequently modified by stroke and rehabilitation experts. 
Each domain is scored 1 = couldn’t do at all, 5 = no problem with a total score 
out of 195 (all four subgroups combined). Lower scores = more trouble with 
activity. 
Internal reliability of the domains are high (alpha = 0.74-0.94) and test re-test 
reliability is also good (ICC =0.89)295. However, it is unknown whether it is 
feasible for people with severe stroke to use this outcome measure, given the 
high incidence of cognitive and communication impairments post stroke264,265. 
Ceiling effects have been reported in the language domains in people with nil, 
mild or moderate aphasia295. There is no evidence on the responsiveness of 
this measure. 
 
The feasibility of a health economic evaluation using HRQoL was evaluated 
by using the EQ-5D (5L)29. The EQ-5D (5L) is a valid and reliable simple 
questionnaire in health-related research and provides a simple descriptive 
profile and a value for health status and takes five minutes to complete. 
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However, this is a generic measure and uncertainties exist regarding the 
appropriateness of the EQ-5D (5L) for people with severe stroke. Proxies 
were used if participants were unable to complete the questionnaire. Each of 
the five questions are scored 1 = no problem to 5 = unable. The Health State 
is scored out of 100. 100 = best health. 
Visual Analogue 
Scale to enable 
people with aphasia 
to also rate their 
level of fatigue297 
Fatigue Fatigue is one of the most distressing symptoms after stroke and can 
adversely affect ability to carry out ADL, return to work, participation in 
rehabilitation programmes and quality of life298,299. Prevalence of post-stroke 
fatigue stroke spans from 29% to 77%299, ranges from mild to severe300 and is 
reported by stroke survivors to persist two years post-stroke301. 
Several assessment scales exist to measure fatigue, many of which are stroke 
trials302,303. The most commonly used is the Fatigue Severity Scale304 which is 
a 9-item self-report questionnaire designed to assess fatigue over the past two 
weeks. The high incidence of communication and cognitive impairments 
suggests many participants would not be able to complete this questionnaire. 
However, given the significant adverse effect of fatigue it was essential to 
optimise inclusion of people with severe cognitive and communication 
impairments. Therefore, a visual analogue scale was used. This enabled 
people with or without aphasia to objectively score their fatigue: where 0 
indicates “Not tired at all” and 10 indicates “So tired I can’t do any more” 
(Figure 3.1). Fatigue was categorised as mild (1-3), moderate (4-6) and 
severe (7-10) based on a previous study of post-stroke fatigue304. A highly 
significant correlation (r = 0.69, P < 0.01) was observed between Fatigue 
Severity Scale scores and fatigue as indicated on a VAS306.  
Table 3.1 Proposed secondary outcome measures for the anticipated main trial 
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Figure 3.1 Fatigue Visual Analogue Scale 
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3.12 Economic evaluation 
As this is a feasibility trial an economic evaluation was not carried out. However, 
the data set for the EQ-5D (5L) were collected to determine the feasibility of 
people with severe stroke being able to complete this given the high prevalence 
of communication and cognitive impairment. 
3.13 Process Evaluation 
This feasibility trial is considered as the modelling phase of the MRC guidelines 
for developing complex interventions115. As a feasibility trial, the purpose is not 
to make a formal analysis of the primary outcome, but to evaluate trial 
processes to determine whether to progress to an effectiveness trial and to 
estimate unknown parameters needed to design this trial. 
Process evaluation is a key part of the intervention development process to 
enable conclusions to be made about the strengths and weaknesses of a trial. 
This will facilitate decision-making for the anticipated main trial. The MRC 
guidance115 recommends process evaluation and highlights the importance of 
capturing fidelity (whether the intervention was delivered as intended); dose (the 
quantity of intervention implemented) and reach (whether the intended audience 
comes into contact with the intervention, and how). 
Fidelity was measured using several mechanisms: treating therapists recorded 
the content of their physiotherapy sessions in the CRFs; an independent 
assessor observed 10% of sessions in both the functional standing frame 
intervention and the usual physiotherapy groups across all four healthcare sites 
and completed a fidelity checklist (Appendix 16), and during qualitative 
interviews with treating therapists. 
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3.14 Safety monitoring 
Throughout the trial, all possible precautions were taken to ensure participant 
and physiotherapist safety and wellbeing. Participants in both groups were 
monitored for AEs via completion of the brief interview after every therapy 
session during the three-week intervention period. 
Treating physiotherapists were asked to report AEs related to the intervention 
(e.g. falls, musculoskeletal aches and pains, fatigue) and all SAEs to the 
research team, regardless as to whether they were thought to be related to the 
intervention or not; and whether they believed these AEs/SAEs were related to 
the intervention or not. Additionally, participants were monitored during their 
scheduled follow-up visits for AEs and SAEs. AEs were reviewed regularly by 
the Trial Management Group (TMG) to determine the relatedness of these 
events to the intervention. SAEs were reviewed by the Trial Steering Committee 
(TSC). 
Physiotherapists followed local policy with regards to documenting AEs and 
SAEs in patients’ medical notes or other monitoring systems. 
3.15 Retention rates and withdrawal 
Each participant had the right to voluntarily withdraw from the trial at any time, 
without any effect on their current or future care. 
Any participant could at any time after they consented decide that they no 
longer wished to be part of the trial. Withdrawal may have been through 
personal choice (i.e. they withdrew their consent), in consultation with a health 
professional, for example where it became impossible to provide outcome data 
or comply with any other trial procedures for whatever reason, or on the 
recommendation of a health professional following an AE or SAE. In addition, 
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the treating physiotherapist, doctor or other health professional responsible for 
the participant could have suggested withdrawal following a significant protocol 
deviation, such as a participant being found to be ineligible post-randomisation. 
Ineligible participants would have been withdrawn from the trial. Number and 
reasons for withdrawals were recorded and reported by the treating 
physiotherapist using a standardised proforma. Participants who were 
withdrawn (except any who were deemed ineligible post-randomisation) were 
asked to remain in the trial for follow-up assessments as per protocol, although 
it was acknowledged that if a participant was receiving end of life care this 
would not be appropriate. 
To ensure the CI remained blinded, treating therapists could discuss any 
potential withdrawals with a member of the research team to ensure the treating 
therapists were supported in this process. 
3.16 Statistical analysis 
3.16.1 Sample size 
As a feasibility trial, a formal sample size calculation based on considerations of 
power was not appropriate and hence this trial was not powered to detect 
between-group clinically meaningful differences in a primary outcome. One of 
the aims of this trial was to provide robust estimates of the likely rates of 
recruitment and follow-up, as well as estimates of the variability of the proposed 
primary and secondary outcomes to inform sample size calculations for the 
anticipated trial. There is no consensus on the recommended number of 
participants required for a feasibility trial, with published “rules of thumb” ranging 
from 20 to 70 or more participants, when the planned primary outcome is of a 
continuous nature. For example, a recent paper recommended a feasibility trial 
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sample size should recruit 25 participants per allocated group, if the anticipated 
trial has a two-arm parallel group design, with 90% power and two-sided 5% 
significance level, to detect a “small” standardised effect size307. Therefore, this 
feasibility trial aimed to recruit 50 participants in total. 
It was anticipated that 60% of participants randomised would complete their 29- 
and 55-weeks post-randomisation follow-up assessment. This included an 
estimated 40% drop out rate due to mortality308,309. 
3.16.2 Statistical analysis plan 
In keeping with the aims of a feasibility trial, a detailed statistical analysis plan 
was developed by the CI and approved by statisticians and the TSC, prior to the 
final database lock and analyses (Appendix 5 Statistical Analysis Plan). 
3.17 Protocol compliance 
Any protocol deviations, non-compliances, or breaches of the approved protocol 
were documented on the relevant form by a relevant member of the research 
team, or the CI or blinded assessor, and reviewed by the CI. Significant or 
repeat episodes of non-compliance were reported by the CI to the TMG 
(including the Sponsor) and every effort made to prevent further occurrences. 
Frequently recurring protocol deviations were not acceptable and would have 
required immediate action and potentially classified as a serious breach. 
3.17.1 Notification of serious breaches to Good Clinical Practice and/or the protocol 
A serious breach to the Good Clinical Practice (GCP) and/or the protocol was a 
breach that was likely to affect to a significant degree: 
1. the safety or physical or mental integrity of the trial participants 
2. the scientific value of the trial 
3. the conditions and principles of GCP in connection with the trial 
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3.18 Determining progression to the full trial 
This research will progress to a full trial application if minimum success criteria 
are achieved in key feasibility aims and objectives, and/or if solutions to 
overcome any issues can be identified. These criteria are listed in Table 3.2. 
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 Criteria 
Scenario 1 Scenario 2 Scenario 3 
1 % of recruitment target achieved (50 participants) ≥70% of the 
target figure 
51-69% of the 
target figure 
≤50% of the 
target figure 
2 Target figure = 75% of the percentage of participants 
randomised to the intervention group who participated in at 
least five sessions per week of the intervention (e.g. 30 
minutes of standing, or a 30% increase in standing time 
every session, and 8-12 sit to stand repetitions). This 
includes an estimated dropout rate of 25% due to 
mortality308,309 
≥70% of the 
target figure 
51-69% of the 
target figure 
≤50% of the 
target figure 
3 Target figure = 60% of the percentage of participants 
randomised who completed their 29- and 55-weeks post-
randomisation follow-up assessment. This includes an 
estimated 40% drop out rate due to mortality308,309. 
≥70% of the 
target figure 
51-69% of the 
target figure 
≤50% of the 
target figure 
 
        Proposed action 
Proceed to 
submitting plan 
to funder for 
full trial 
Discuss with 
TSC and funder 
about 
progression and 
resources 
needed to 
achieve target 
No progression 
to plan a full trial 
in the current 
design 
Table 3.2 Criteria for progression to a full trial 
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3.19 Qualitative component 
Qualitative methods were used alongside quantitative methods to provide the 
opportunity to explore, examine and address key uncertainties prior to the 
anticipated main trial243. The combination of both qualitative and quantitative 
research is recommended for complex interventions to understand barriers to 
participation and provide insights into important processes and experiences of 
the intervention and trial processes114,115. An embedded design was considered 
important to facilitate meeting the aims and objectives of this feasibility trial. 
Qualitative data were collected using semi-structured interviews and a focus 
group. This methodology is ideally suited to a feasibility trial where uncertainties 
exist and offers the opportunity to explore people’s experience of being involved 
in the trial, identifying and overcoming barriers to recruitment240. Interviews and 
focus groups were conducted by the author. 
A topic guide (Appendix 17), with suggested questions and prompts helped 
guide interviews using open-ended questions, while enabling me to respond 
flexibly to the flow and direction of the interviewee’s responses311. This was 
developed in collaboration with people with stroke, relatives, physiotherapists 
and supervisory team. I used an iterative and reflexive approach to interviews, 
the notion that data from interviews and data analysis and reflection shaped 
subsequent interview topics guide. 
3.20 Participants (qualitative component) 
Participants were eligible for interview if they were: 
1) Able to use a range of communication methods including speech, 
gesture and/or writing as determined by the Consent Support 
Tool as well as other assessments determined appropriate by the 
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Speech and Language Therapist based on the SRU. 
2) Able to recall involvement in the trial or trial processes with or 
without prompts or aids (e.g. trial documentation) as required. 
Eligible relatives were given a PIS (Appendix 18 Relative Participant Information 
Sheet). Relatives were eligible for interview if they were: 
1. Aged ≥18 years 
2. A family member/close friend of a participant enrolled in the trial 
3. Able to provide written informed consent for a semi-structured 
interview related to their family member/close friend’s participation in 
the trial. 
Eligible physiotherapists were given a PIS (Appendix 19: Physiotherapist 
Participant Information Sheet). Physiotherapists were eligible for interview 
and/or focus group if they were: 
1) A registered physiotherapist working on the SRU for three or more 
days in each week 
2) Willing to provide written informed consent for a semi-
structured interview and subsequent focus group at the end of 
the recruitment period related to the feasibility of implementing 
the intervention and associated trial procedures. 
Exclusion criteria for participants were severely impaired communication and/or 
deficits in cognitive skills or hearing which impacted on their ability to participate 
in an interview. 
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3.20.1 Sampling 
Stratified purposive maximum-variation sampling was used to best inform the 
qualitative component aims and objectives and ensure that participants selected 
were relevant to the topic being explored312 and had the cognitive and/or 
communication ability to participate. 
The aim was to interview up to one third of participants (n=16) which included 
participants who participated in the intervention group (n=6) and control group 
(n=6) sessions as well as those who declined to participate or withdrew (n=4). 
Additional interviews involved up to eight relatives and eight treating therapists 
(including PIs) which was proportionate to each SRU. This was to gather a 
broad representation of views and experiences within the time limits of this 
three-year fellowship313. However, I acknowledge that due to the severity 
impairments in this patient population, the prevalence of severe cognition and 
communication impairments may have potentially limited the number of 
participant interviews. I aimed to interview people with mild to moderate aphasia 
because it was important to seek the perspectives and experiences of people 
with aphasia due to its high prevalence post-stroke. A member of the research 
team who did not require blinding undertook the sampling in discussion with me 
because I was aware of participants’ communication and cognitive impairment 
thus their ability to participate in an interview. 
3.21 Data collection 
A combination of data collection methods were offered for the qualitative 
interviews: semi-structured face-to-face, telephone or Skype based on 
suggestions from patient and relatives during trial design. All participants were 
offered a date, time and venue (when face-to-face) convenient for them. 
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Interviews and the focus group were digitally audio recorded, transcribed 
verbatim and anonymised. 
Participants’ may experience recall bias314 (e.g. memory impairment post-stroke 
or pre-existing). To address this and maintain blinding during the three-week 
intervention, a brief interview was used with each participant following each 
intervention session. A visual analogue scale was used to allow participants to 
rate their fatigue, enjoyment and effort and body aches and pains (Figure 3.2), 
responses to which were documented in the intervention CRF. 
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Figure 3.2 Brief interview questionnaire 
  
Please mark on the body chart where 
the participant reports or indicates any 
aches or pains. 
Unbearable None Mild Moderate Severe 
0 1-3 4-6 7-9 10 
None Mild Moderate Severe Worst pain  
0 1-3 4-6 7-9 10 
EFFORT 
ENJOYMENT 
Not tired at all A little tired Tired Really tired 
0 1-3 4-6 7-9 10 
FATIGUE 
ACHES & PAINS 
So tired, I can’t 
do any more 
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Physiotherapist interviews were conducted approximately three months after 
recruitment commenced and at various times throughout the trial depending on 
opening of sites and staff availability, and a focus group approximately one 
month after recruitment closed. 
Interviews with two people with stroke from each site who declined to participate 
or withdrew from the trial were planned to provide insights into trial procedures 
that could be addressed prior to a subsequent main trial to optimise recruitment 
and retention. 
I transcribed all interviews and focus group recordings which were digitally 
recorded. Where possible, I transcribed the interviews the same day as the 
interview, and in advance of subsequent interviews. This enabled me to reflect 
and take an iterative approach to the topic guide and note where prompts or 
change of wording were required for future interviews. 
3.21.1 Safeguarding of adults 
If participants disclosed information to me or any other member of staff involved 
in the trial, or the staff had concerns about participants experiencing, or being at 
risk of abuse at any point during the trial, they were advised to follow relevant 
local and national safeguarding procedures. 
3.22 Data analysis 
All transcribed data were transferred into NVivo software315 and all transcripts 
were analysed using thematic analysis316,317. 
Thematic analysis is an approach informed by Braun and Clarke316,317 who 
identified six phases of analysis: a) familiarisation with the data, bi) generating 
initial codes, c) searching for themes, d) reviewing themes, e) defining and 
naming themes, and f) producing a report. Thematic analysis was chosen as 
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the method of analysis for several reasons. First, it can be considered a 
foundation method of analysis, suitable for novice qualitative researchers317. 
Second, thematic analysis is flexible, in that it is not aligned with a particular 
epistemological, philosophical or theoretical approach316-318. Finally, I wanted to 
perform an inductive analysis, whereby themes (patterns of meaning) are 
derived directly from the data, rather than from interview questions or my 
preconceptions316-318. 
Transcripts were coded using extracts from the data, to remain close to the 
data. Each unit of analysis was analysed in groups (e.g. all patient participants 
were analysed together).  
Some transcripts were reviewed by supervisors to provide opportunity to 
discuss codes. Once all transcripts had been reviewed and coded in NVivo, all 
codes were printed out and cut into separate pieces and stuck to a wall. I had 
intended to use NVivo to combine codes, but I found this restrictive, and tacking 
codes to a wall enabled me to see all the codes and organise into groups, 
considering how different codes may form an overarching theme. Group codes 
were typed up and I used supervision sessions to identify relationships between 
codes, between overarching themes and subthemes to develop themes. Cross-
cutting of data enabled me to review any physiotherapist-participant dyad, e.g. 
any differences between what physiotherapists and participants said. 
Original transcripts were then reviewed to ensure the themes were an authentic 
representation of the data. Interview and focus group participants were invited 
to review an initial draft of the themes, to ensure the analysis represented an 
accurate overview of participants’ views and experiences. Data was also 
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presented to physiotherapists and fellow PhD colleagues to facilitate develop of 
themes. 
3.23 Trial management and monitoring 
3.23.1 Data management 
The PenCTU were responsible for data management for the trial. Data were 
recorded on trial specific CRFs by the treating physiotherapists and blinded 
assessors. Completed forms were sent to the PenCTU and entered onto a 
secure web-based database. All data were double entered and compared for 
discrepancies. Discrepant data were verified using the original paper data 
sheets. Data were collected and stored in accordance with the Data Protection 
Act 1998 and General Data Protection Regulations 2018 and are accessible for 
the purposes of monitoring or auditing. 
3.23.2 Trial oversight 
Two committees were involved in the set-up, management and oversight of this 
trial: the TMG and TSC. The TMG comprised individuals involved in the 
development of the protocol and the day-to-day running of the trial. They were 
responsible for all practical details of the trial, ensuring it was progressing to 
time, monitoring AEs and recruitment and attrition. 
The TSC was responsible for overseeing the conduct of the trial on behalf of the 
Sponsor and funder and comprised a group of experienced trialists with majority 
independent representation including patients and members of the public. The 
TSC monitored the scientific integrity of the trial including trial progress, 
adherence to the protocol, reviewing accumulating safety data to monitor 
participant safety. 
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3.24 Ethical issues 
Ethical approval for the trial was granted by the National Research Ethics 
Scheme (NRES) Committee Wales (Reference number: 16/WA/0229) and the 
Health Research Authority (HRA) (Reference number: 201646). The 
International Standard Randomised Controlled Trials Number is 15412695. 
Royal Cornwall Hospitals NHS Trust were the trial sponsors (Reference 
number: 2016.RCHT.009). The trial was funded by NIHR as part of a Clinical 
Doctoral Research Fellowship Award (Reference Number: ICA-CDRF- 2015-01-
044). 
The trial was conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki principles of Good Clinical Practice319, and 
the Department of Health Research Governance Framework for Health and 
Social Care320. 
3.24.1 Consent 
In line with GCP, PIs at each site had overall responsibility for informed consent 
of participants at their site. PI’s took responsibility for ensuring all vulnerable 
people were protected and participated voluntarily, free from coercion or undue 
influence. 
To make the decision to participate in the trial, written informed consent was 
received if the person was deemed to have capacity or capacity was not 
doubted under the Mental Capacity Act 2005321 (See Appendix 20 Patient 
Consent form). Participants had the right to withdraw from the trial at any time 
for any reason without adversely affecting their ongoing care and their decisions 
respected. 
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Aphasia, cognitive and/or visual impairments can impact on the ability to read 
and understand participant information sheets and provide consent. If capacity 
was doubted due to aphasia, Speech and Language Therapists used the 
Frenchay Aphasia Screening Test322 (FAST) (recommended in the Royal 
College of Physicians Guidelines for Stroke3 to confirm the presence of 
aphasia. They used the Consent Support Tool323 to identify the optimum format 
in which to present the research information during their subsequent capacity 
assessment. If capacity was doubted due to cognitive and/or visual impairment 
the OT undertook their routine assessments and utilised this information to 
indicate the style of information participants were most likely to understanding 
during their capacity assessment to consent for trial enrolment.  
Capacity assessments were carried out by one or two members of the patient’s 
usual clinical care team (depending on local policy) and included an OT or 
Speech and Language Therapist to ensure their cognitive and/or 
communication needs were supported appropriately. The outcome of the 
capacity assessment was communicated to the PI or authorised delegate to 
enable them to undertake the consent process if the participant was deemed to 
have capacity. 
For participants who were unable to provide written consent (e.g. unable to 
write due to aphasia or apraxia) but could verbally consent or point to an 
appropriate tick or yes diagram, a witness was permitted to sign and date on the 
participant’s behalf. A consultee was approached when participants were 
deemed to lack capacity (see Section 3.24.2). 
Ethical approval was granted to gain immediate consent due to the nature of the 
research (dealing with new disability, potential for impaired recall of details and 
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the need to instigate the trial in a sub-acute setting and not delay the onset of 
the intervention). However, potential participants and consultees had the 
opportunity to speak to any member of the clinical care team, research team or 
family about the trial and have time to consider providing consent/assent, if 
requested. 
3.24.2 Assent by consultee 
Potential participants lacking capacity were included in the trial if a consultee 
provided written assent (See Appendix 21 Consultee declaration form). A 
“personal consultee” is someone engaged in caring for the participant (not 
professionally or for payment) or is interested in his/her welfare and is prepared 
to be consulted. If a personal consultee was not identified or willing to act as 
consultee, the PI could consult a “nominated consultee”, e.g. a person 
independent of the projected appointee in accordance with the Department of 
Health’s Guidance on nominating a consultee for research involving adults who 
lack capacity to consent324. Consultees were given information about the trial 
and advised what the participant’s wishes and feelings would be about taking 
part in the trial. The consultee gave advice rather than consent. The advice of 
the consultee was respected. 
Trial documentation accessible for people with aphasia was produced using 
resources from the NIHR325, in collaboration with stroke specialist Speech and 
Language Therapists. Appropriate time was allowed for questions/responses 
and environmental aspects also considered (choice of environment, relative 
present or alone etc.). 
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3.24.3 Burden 
Given the sudden onset of disability as a result of a severe stroke, participants 
may be vulnerable and adjusting to life after stroke. People with stroke admitted 
to the SRU participate in active therapy and rehabilitation practice for a 
minimum of 45 minutes’ duration (or as long as tolerated) once a day, a 
minimum of five days per week as part of their inpatient stay, therefore, 
participating in the functional standing frame or usual physiotherapy 
interventions should not have caused any additional burden. However, 
interviews and outcome assessments with participants are not part of usual 
stroke care and required additional time. Furthermore, interviews may cover 
topics that the interviewee may have found distressing or upsetting. They were 
made aware of this prior to consenting to the interview. At the time of the 
interview participants were reminded they could pause and/or terminate the 
interview at any time. Participants were directed to a healthcare professional or a 
relative for support, if needed, either during or after the interview if required. 
For participants who were interviewed in the SRU, members of the research 
team and clinical care staff were available to support participants, in addition to 
any relative support, as required. Relatives were informed of the date and time 
of the interview by the PI for those participants who consented/requested this. 
For participants who were interviewed at home, the CI informed carer/relatives 
of the date and time of the interview if the participant consented/requested this. 
If the participant gave the CI reason to be concerned about their safety during 
their interview and they lived alone, the CI contacted their General Practitioner. 
The sudden change in physical and/or cognitive ability may also impact on the 
relatives. Relatives may have been obliged to be continually present to support 
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and assist their loved one during the physiotherapy interventions, increasing 
their feelings of responsibility and burden. The relative may have wondered if 
their significant other was being taken care of in their absence and during the 
trial interventions, which may have created unnecessary/unwanted anxiety. 
Additionally, the relative may have found the interview upsetting as they too 
were coming to terms with a sudden change in their significant other. 
Other than making available the time required to participate in the interview and 
focus group, it was not anticipated that physiotherapists would find participating 
in the trial a burden. 
3.24.4 Data protection and patient confidentiality 
All investigators and trial site staff were required to comply with the Data 
Protection Act 1998326 and the subsequent 2018 Data Protection Act327 with 
regards to the collection, storage, processing and disclosure of personal 
information and to uphold the Act’s core principles. The Sponsor is the data 
custodian and they will store the data for a minimum of five years in a secure 
location managed by Royal Cornwall Hospitals NHS Trust. 
3.24.5 Confidentiality 
Individual participant medical information obtained as a result of this trial was 
and continues to be considered confidential and disclosure to third parties was 
prohibited with the exceptions noted below. 
Participant confidentiality was ensured by using unique trial numbers on all 
documentation. If information was disclosed during the trial (e.g. during the 
intervention or control group sessions, trial assessments or interviews) that 
could pose a risk of harm to the participant or others, the researcher discussed 
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this with the CI and where appropriate reported accordingly adhering to local 
policies/procedures. 
Identifiable participant details such as name, address and telephone number 
were stored at each of the four SRUs in line with local data protection and 
confidentiality guidelines. Additionally, identifiable participant details such as 
name, address and telephone number were stored securely in the Faculty of 
Health and Human Sciences, Knowledge Spa, Truro for the purposes of 
contacting the participants for trial follow-up visits. This data was securely 
stored in a separate secure cabinet from non-identifiable data such as the 
CRFs. 
Direct quotes will be published in research journals, but they will be anonymised 
to maintain confidentiality. 
3.25 Patient and public involvement 
Involving patients and the public in research is intended to benefit the research 
process by ensuring research is relevant, conducted ethically, participant 
friendly, and the results made accessible and provided with sensitivity to trial 
participants and the wider public once the trial is complete328. 
People with severe stroke (weeks, months and years post-stroke), their 
relatives and clinicians (physiotherapists, OTs, Speech and Language 
Therapists, doctors) were involved in the development of the trial from the 
outset through focus groups and one-to-one interviews. The research topic was 
strongly endorsed as meaningful and relevant by patients, relatives and 
clinicians. Key priorities of patients were “get up and move straight away” and to 
“stand and walk as soon as possible” post-stroke. Patients believed it would 
help them “get back to normal” and “get back to work”. 
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PPI identified potential difficulties with fatigue and being physically and 
psychologically overwhelmed in the early stages post-stroke. They suggested 
trial assessments should be split into two sessions for those that needed it, and 
that standing time should be slowly built-up because they may get tired. These 
changes were incorporated into the trial design. PPI also highlighted that those 
randomly assigned to the control group may be “devastated” about not receiving 
the intervention, potentially influencing their willingness to participate in the trial. 
Qualitative interviews explored this to address any impact of this on recruitment 
and retention. Stroke consultants reviewed eligibility criteria and the trial 
protocol were reviewed by stroke consultants and local Research and 
Development teams. 
Physiotherapists and OTs working in SRUs highlighted the challenge of 
identifying a suitable measure of function for people with severe stroke; they 
were particularly concerned with the ability of outcome measures to identify 
change from the sub-acute (seven days to six months) to chronic phase (seven 
months onwards)3. They reviewed and discussed the range of available 
measures, including their psychometric properties. Based on this process, 
together with a review of the literature, the BI and the Edmans were selected for 
this feasibility trial. 
The development of trial documentation involved significant PPI representation 
to optimise comprehension and facilitate inclusion of people with varying 
communication abilities being involved in the trial. Trial documentation was 
developed using the NIHR resources for stroke researchers which were 
specifically developed with and for people with aphasia. Two Participant 
Information Sheets were developed specifically for people with aphasia: an A4 
double sided information sheet with pictures only and a multiple paged 
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information sheet with single line text to accompany pictures. These Participant 
Information Sheets were reviewed and scrutinised for their suitability for people 
with aphasia from multiple sources: five people who had a severe stroke (1 
month, 9 months, 12 months, 3 and 5 years’ post-stroke), all of whom had 
aphasia; three stroke specialist Speech and Language Therapists; a local 
communication group for people with aphasia run by a Speech and Language 
Therapist and a Consumer Group attended by people who have had a stroke 
based in Bradford run by the Bradford Institute for Health Research. 
Participant Information Sheets for relative interviews were reviewed by six 
relatives. Participant Information Sheets for physiotherapist interview and focus 
group were reviewed by five physiotherapists. The standard Participant 
Information Sheet and the multiple page aphasia friendly Participant Information 
Sheet were reviewed by the Making Reasonable Adjustments Team in Cornwall 
for readability to ensure trial documentation was aligned with Accessibility 
Standards for NHS and Social Care providers329 which came into effect in July 
2016. 
Two people who had a severe stroke and their relatives were members of the 
TSC that had overall responsibility for the research. The TSC met regularly 
throughout the trial to optimise the participants’ experience and ensure all 
aspects of PPI are addressed. They were involved in analysing and interpreting 
findings of both the systematic review and feasibility trial and commenting on 
drafts of papers/reports. This optimised the validity of the conclusions from a lay 
perspective and was intended to highlight findings most relevant to the public. 
Patients and their relatives were invited to share their perspectives of the 
interview data to refine the analyses and future interview topic guides. They 
were involved in formulating the dissemination plan, and disseminating research 
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findings through links with relevant organisations, joint presentations, and a 
range of media formats. 
PPI who were members of the TSC have and, continue to be supported in 
several ways. Initial conversations during trial development and funding 
applications involved information provision as to the purpose and relevance of 
the research to people who have had a severe stroke. Once funding was in 
place further discussions were held highlighting the importance of PPI 
involvement throughout the whole trial and what their role would be (attending 
meetings, reading/reviewing trial documentation, minutes as well as sharing 
their thoughts and perspectives on trial design, content and delivery). Recent 
research suggests that PPI works well if its goals are clear and there are well 
developed plans for PPI in a trial (for example, membership of a TMG) rather 
than restricted to general oversight (for example, membership of a TSC)328. 
However, this may be reflective of how much PPI members of the TSC are 
encouraged and want to be actively involved outside of committee meetings as 
well as their motivation for being involved in research. I had regular contact with 
PPI members, providing updates about recruitment and sites opening, changes 
to the trial protocol or documentations. I acknowledge that the PPI members are 
supportive of my research as well as me personally which may impact on how 
successful PPI is in this trial. I do however remain cognisant of the potential 
burden that their involvement may have in terms of time spent preparing for 
meetings, travelling to meetings (all PPI members travel from Cornwall to 
Devon for meetings) and time spent at meetings (approximately two hours). 
I have had several discussions with the Peninsula Collaboration for Leadership 
in Applied Health Research and Care (PenCLAHRC) who have provided access 
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to online training and Advice Clinics, as well as the INVOLVE booklets which 
were utilised by our PPI representatives. 
From the outset PPI informed the development of this trial, ensuring it reflects 
the opinions and needs of people with sub-acute severe stroke. The 
intervention specifically aims to address their stated key priorities of optimising 
general function, standing and walking. Potential barriers of participation (e.g. 
fatigue, exercise tolerance, communication difficulties) were carefully 
considered. 
3.26 Philosophical underpinnings 
Philosophy is a lens through which we view the world, and which allows 
researchers to identify knowledge gaps upon which to base research and the 
method with which the gaps are filled330. It is important to declare my 
philosophical assumptions because they have influenced the development, 
execution, interpretation, and reporting of this research. Philosophy comprises 
both ontological and epistemological components. 
Ontology aims to understand the nature of the social world and what there is to 
know about it, of being, of becoming, of existence, and of reality331. This has 
been broadly categorised into realism or idealism. Realism accepts that an 
external reality exists independent of our beliefs or understanding, whereas 
idealism assumes that no independent external reality exists332. My ontological 
position of realism was adopted throughout the thesis, due to my consideration 
that a distinction exists between the way the world is and the interpretation of 
that world. 
Epistemology is concerned with what it means to know; how knowledge can be 
created, acquired and communicated and the relationship between knowledge 
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and truth332. I adopted the epistemological position of correspondence theory of 
truth, believing a statement to be true if it matches independent reality. Overall, I 
aspired to ‘empathic neutrality’, recognising that although truly value free 
judgements may not be achieved, assumptions, biases, and values were 
transparent332. 
This feasibility trial used both quantitative and qualitative methods, thus, subtle 
changes were occasionally employed to the philosophical assumptions of 
realism, post-positivism, and pragmatism influencing the ‘world view’ of this 
thesis. The qualitative component required an open approach to achieve its aim 
of capturing experiences of participants, relatives and physiotherapists. Thus, 
an ontological perspective based on subtle realism was utilised, which 
recognises the critical importance of participants’ own interpretations of the 
issues researched333. Epistemologically the more inductive approach of 
constructionism was adopted317. 
The RCT was based on pragmatism and post-positivism. The pragmatic 
paradigm; not committed to any one philosophy or reality, places the “research 
problem" as central and applies all approaches to understanding the problem334. 
Post-positivism has similar ontological and epistemological beliefs as positivism 
(objectivism, being impartial, discovering absolute knowledge about and 
objective reality), post-positivists seek to understand causal relationships and a 
hypothesis is not proven but simply rejected333,334. The systematic review 
(Chapter 2) was influenced by critical realism and post-positivism, thereby 
assuming that phenomena are measurable using deductive principles and the 
scientific model336. Both the feasibility RCT and the systematic review were 
based on the assumption that objective measurements can be used to make 
inferences about the population of interest337,338. The results will not be 
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considered as objective ‘truths’, however, rather supporting evidence subject to 
review and consideration339. 
Collectively, the epistemological position adopted in this thesis combined 
pragmatism and post-positivism. 
3.27 Clinician-researcher role 
I have been a physiotherapist for 12 years, but leading my research created a 
new role: clinician-researcher. A clinician-researcher is an individual who 
conducts research and provides direct patient care340 although not at the same 
time and not necessarily for the same organisations. 
Several benefits have been identified when clinicians are involved in research: 
increased clinical relevance of research questions, gaining access to clinical 
settings to undertake the research, bringing clinical expertise and insider 
perspectives, having researchers who are trusted by participants that may 
encourage their participation, and having researchers who are motivated to 
disseminate applicable findings, continue their commitment to the research341. It 
has been suggested that the clinician role can increase rapport which may 
result in rich and detailed data342. Additionally, clinicians interviewing other 
clinicians are insider researchers in that they may share at least some 
understanding of the clinical environment. However, I acknowledge that I do not 
have experience of delivering the intervention in clinical practice. Thus, I may 
have understood their language but did not fill in the blanks or make 
assumptions as this may have led to misinterpretation and consequently lack of 
exploration of specific issues during interviews. 
Several challenges have been identified managing dual perspectives of 
clinician-researchers: expectations from patient-participants about their clinical 
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care and the clinician-researcher’s natural desire to adopt the role of clinician 
and respond to the queries of the patient-participant or relatives during 
assessments/interviews342. One of the most pertinent issues was the ethical 
considerations that included the risk of coercion of participants and the potential 
blurring of role boundaries between clinician-researcher and participants342,343. 
There was also potential for role confusion which can be external (clarifying my 
role to others) and internal (feeling conflict and/or tension)343. 
A framework has been developed for dealing with the ethical and practical 
implications and demands of dual role throughout the research process343. I 
utilised this framework in conjunction with reflexivity and discussions in my 
supervision sessions to raise ethical and practical issues, grapple with the 
unavoidability and implications of dual-role and recognise and review both 
clinical and research obligations and boundaries342. This facilitated the balance 
between privileged access to patients and colleagues with a responsibility for 
rigorous research methods344. 
Reflexivity was used to place myself and my practice under scrutiny, 
acknowledging the ethical dilemmas that permeate the research process and 
impinge on the creation of knowledge345. Reflexivity acknowledged how my 
background and position affected what I chose to investigate, the design and 
methods, and interpretations346. Adopting a reflexive approach throughout my 
fellowship facilitated creation of a heightened self-awareness facilitating 
impartiality and rigour in my research. 
3.28 Summary 
Chapter 3 has presented the research methodology with justification of the 
design for the trial in relation to the research problem and uncertainties 
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identified in Chapter 1. Justification of the multi-centre feasibility RCT was 
presented in terms of why and how this methodology can best answer the trial 
aims, objectives and research question. Rationale was provided for the 
qualitative component to ensure the complexity of the intervention was fully 
evaluated. This chapter acknowledges the pragmatic approach that was 
adopted and the barriers and facilitators of my new clinician-researcher role. 
Chapter 4 presents the quantitative and qualitative results. 
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Chapter 4 Quantitative results 
4.1 Introduction 
This chapter presents the quantitative  data arising from the physiotherapy 
sessions for both the intervention (functional standing frame programme) and 
control (usual physiotherapy) groups during the 3-week intervention period, and 
the follow-up assessments.  
Data presented in this chapter focuses on feasibility objectives: eligibility, 
consent, recruitment, randomisation and minimisation, acceptability of the 
intervention, adherence, safety, baseline and demographics of the participants, 
summary of missing data and blinding. Data from the proposed primary and 
secondary outcomes will be presented, but the focus of the trial was testing trial 
procedures and determining acceptability, and not focusing on the outcome of 
interest. 
As stated in the Statistical Analysis plan, analyses are descriptive only. 
4.2 Eligibility 
Patients admitted to any of the four sites were initially screened for their stroke 
severity. If patients had been diagnosed with either moderately severe or 
severe disability post-stroke using the modified Rankin Scale (mRS)347 the 
physiotherapists completed a Screening CRF to determine eligibility. A total of 
586 patients were admitted across the four SRUs between 1st January 2017 
and 30th September 2017 (9 months), n=462 (78.8%) were not eligible and the 
number and reasons for ineligibility are listed in Tables 4.1a and 4.1b below, 
and the CONSORT (Figure 4.1). 
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Reasons not eligible Number of 
participants % (n) 
Non-stroke 29.43 (136) 
Mild stroke 45.67 (211) 
Moderate stroke 9.74 (45) 
Medically unwell 4.76 (22) 
End of life care 4.55 (21) 
Erratic behaviour 1.52 (7) 
Being transferred out of county 1.30 (6) 
Not a new stroke 0.87 (4) 
Non-English speaking 0.65 (3) 
Additional neurological condition 0.65 (3) 
Not meeting nutritional requirements 0.43 (2) 
Exceeded weight limit of standing frame 0.43 (2) 
Table 4.1a Eligibility on admission 
 
Reasons not eligible Number of 
participants % (n) 
End of life care 14.29 (2) 
Medically unwell 21.42 (3) 
Walking independently at baseline 14.29 (2) 
Not meeting nutritional requirements 14.29 (2) 
Unable to stand due to poor tissue viability 14.29 (2) 
Neurological condition 7.14 (1) 
Orthopaedic impairment 7.14 (1) 
Being discharged out of county 7.14 (1) 
Table 4.1b Eligibility post-screening 
 
Seventy-three potential participants were screened but n=14 (19.2%) were 
deemed not eligible and n=13 potential (17.8%) participants were deemed 
eligible but were not consented (n=2 died, n=7 declined, n=4 staff shortage). A 
total of 46 participants subsequently provided consent; a consent rate of 78%. 
Reasons why seven eligible potential participants did not want to participate in 
the trial were not captured in the CRFs. 
4.3 Consent 
Ability to provide consent was 63.0% based on 29 participants providing 
informed consent. Seventeen (37.0%) consultees declared informed consent. 
154 
 
Two participants provided consent themselves, and their consultee also 
declared consent. Reasons for this were not captured on the Screening CRF.  
4.4 Recruitment 
A CONSORT348 flow diagram (Figure 4.1) has been used to present a summary 
of the trial recruitment and retention pathway. It displays the number of potential 
participants admitted to the four SRUs, number eligible and ineligible patients, 
number of participants who provided consent and completed baseline 
assessments, number randomised to each of the two groups, number of 
participants who completed the 3-week intervention period and the follow-up 
assessments, and number of withdrawals. 
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Figure 4.1 CONSORT flow diagram 
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4.4.1 Recruitment rate 
The recruitment target was 50 participants in 12 months. Due to delays with 
Health Research Authority approvals and subsequent approval for capacity and 
capability, the recruitment period was 10 months with staggered opening of 
sites. The first two sites opened 5th December 2016 but due to staff shortages 
over the Christmas holidays they did not commence logging admissions and 
actively recruiting until 2nd January 2017, thus data for the recruitment period 
was captured for nine months only. The third site opened 10th February 2017 
and the fourth site opened 26th June 2017 due to organisational restructuring of 
stroke services. A total of 45 participants over 10 months were recruited, 90% of 
the target.  
The first participant was recruited on 9th January 2017. An average 4.2 
participants per month for 12 months across all four sites was predicted, and 
the actual number of participants recruited in 10 months was 4.5 participants 
per month (Figure 4.2). If recruitment had continued for the planned 12 months, 
the target of 50 would have been reached at 11.2 months. The percentage 
recruitment rate was 7.6% per month, calculated by dividing the number of 
participants recruited per month (4.5) by the number of participants who met the 
inclusion criteria (n=59) multiplied by 100. 
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Figure 4.2 Recruitment for all four sites 
 
The number of beds and staffing affected recruitment. The number of beds 
varied among sites: site 1: 21 beds; site 2: 9 beds; site 3: 15 beds; site 4: 18 
beds, which resulted in different staff:patient ratios but broadly aligned with 
recommendations3,349. However, sites with smaller number of beds had less 
ability to manage staff absences/vacancies. This was evident at site 2, which 
stopped recruiting in March due to significant staffing issues. Clinical Research 
Network staff were involved in recruiting at site 4, but this did not appear to 
have a significant impact on numbers recruited at this site.  
Of the n=46 participants who consented, one was not randomised because they 
were walking independently at their baseline visit. The numbers recruited per 
site/month is shown in Figure 4.2 This highlights that total recruitment varied 
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with site (site 1 n=27, site two n=3, site three n=14 (only n=13 randomised), site 
four n=2)). The highest recruiter was the site that was local and most known to 
the CI. The percentage of participants screened who provided consent varied 
among sites (site 1 50.9%, site 2 100%, site 3 9.3% and site 4 100%). However, 
51 were not enrolled in the trial as highlighted in the CONSORT diagram and 
this also varied among sites with sites 1 and 3 (the largest recruiters) showing 
lower numbers of non-enrolment than site 2 (site 1 11.76%, (n=6), site 2 70.6%, 
(n=36), site 3 17.6%, (n=9), site 4 0% (n=0)).  
4.5 Randomisation and minimisation 
A total of 45 participants were randomised; n=22 into the intervention group 
(intervention) and n=23 into the control group (control). Table 4.2 provides 
details on the minimisation characteristics in both groups. Both groups were 
similar for fatigue and orthostatic hypotension. 
Characteristic Intervention 
% (n) 
[within allocation 
n=22] 
Control 
% (n) 
[within allocation 
n=23] 
Fatigue 
0-3 (no or minimal fatigue) 
4-10 (fatigue) 
 
18.2 (4) 
81.8 (18) 
 
17.4 (4) 
82.6 (19) 
 
Orthostatic Hypotension 
% with orthostatic 
hypotension at randomisation 
% without orthostatic 
hypotension at randomisation 
 
18.2. (4) 
 
81.8 (18) 
 
 
13.0 (3) 
 
87.0 (20) 
Table 4.2 Minimisation characteristics in allocated groups 
4.6 Baseline and demographic data 
Baseline and demographic data is summarised in Tables 4.3a (Demographic 
data), 4.3b (Pre-stroke disability status and medical and surgical conditions). 
4.3c (Pre-stroke medical and surgical conditions for the intervention group) and 
4.3d (Disability status post-stroke). Forty-five participants were recruited to the 
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trial with an overall mean age of 80.3 years (age range 51-96 years), n=1 in 
their 50s, n=7 in their 60s, n=10 in their 70s, n=17 in their 80s and n=10 in their 
90s. Both groups were similar in age range. The age range in the control group 
was 60-94 years (mean age 78.9 years). The age range in the intervention 
group was 51-96 years (mean age 81.7 years). 
There were more females (57.8%) in the trial than males (42.2%), but both 
groups were similar in this respect with 39.1% (n=10) males in the control group 
and 45.5% (n=9) in the intervention group (Table 4.3a).  
 Intervention 
[n=22] 
Control 
[n=23] 
All 
[n=45=] 
Age in years, Mean (SD) 
[range]  
81.7 (11.7) 
[51-96] 
78.9 (10.5) 
[60-94] 
80.3 (11.1) 
[51-96] 
Gender % (n) 
 Male 45.5 (10) 39.1 (9) 42.2 (19) 
 Female 54.5 (12) 60.9 (14) 57.8 (26) 
 
Weight in kg, mean (SD) 
[range] 
69.3 (13.9) 
[38.0-94.8] 
77.3 (17.3)  
[43.0-112.0] 
73.6 (16.0)  
[38.0-112.0] 
Marital Status % (n) 
Single 0 (0) 13.0 (3) 6.7 (3) 
Married or in a civil 
partnership 
50.0 (11) 21.7 (5) 35.6 (16) 
Separated 0.0 (0) 0.0 (0) 0.0 (0) 
Divorced 4.5 (1) 4.3 (1) 4.4 (2) 
Widowed 31.8 (7) 60.9 (14) 46.7 (21) 
Missing 13.6 (3) 0.00 (0) 6.7 (3) 
 
Place of Residence % (n) 
Lives at home 86.4 (19) 91.3 (21) 88.9 (40) 
Lives in residential care 9.1 (2) 4.3 (1) 6.7 (3) 
Other 4.5 (1) 4.3 (1) 4.4 (2) 
 
Living Arrangements % (n) (not mutually exclusive, more than one option could be ticked) 
Alone 22.7 (5) 65.2 (15) 44.4 (20) 
Spouse/Partner 50.0 (11) 21.7 (5) 35.6 (16) 
Warden controlled flat 4.5 (1) 0.0 (0) 2.2 (1) 
Parent(s) 4.5 (1) 0.0 (0) 2.2 (1) 
Children under 18 4.5 (1) 0.0 (0) 2.2 (1) 
Children over 18 18.2 (4) 8.7 (2) 13.3 (6) 
Other family 0.0 (0) 8.7 (2) 4.4 (2) 
Non-family 9.1 (2) 0.0 (0) 4.4 (2) 
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Employment Status % (n) 
In employment or self-
employed 
4.5 (1) 4.3 (1) 4.4 (2) 
Retired 90.9 (20) 91.3 (21) 91.1 (41) 
Unemployed 4.5 (1) 4.3 (1) 4.4 (2) 
Table 4.3a Demographic data 
 
Pre-stroke disability (modified Rankin Scale (mRS)) and mobility varied 
between groups (Table 4.3b). The control group had higher (30.4%) percentage 
of participants with slight disability (mRS 1) versus 9.1% in the intervention 
group, and there were more participants with pre-stroke moderate disability 
(mRS4) in the intervention group (22.7%) compared to the control group 
(13.0%). In contrast, pre-stroke, more participants in the intervention group 
walked without an aid (54.5% n=12 equivalent to mRS 1-3). In the control group 
(26.1% n=6) walked without an aid. More participants in the control group 
walked with an aid or physical assistance (73.9%, n=17) versus 45.5% (n=10) in 
the intervention group; equivalent to mRS4-5. 
The incidence of medical and surgical conditions (Table 4.3b) were mostly 
similar between groups, with a high number of people across both groups with 
coronary heart disease, hypertension/hypotension and COPD/asthma. More 
participants in the control group had diabetes and depression/anxiety. Five 
participants had dementia or Alzheimer’s listed as “other” medical conditions; 
n=3 in the control group and n=2 in the intervention group.  
Stroke classification differed between groups with more TACS in the 
intervention group (72.7%) and more PACS and LACS in the control group 
(65.2%). Middle cerebral artery stroke was the most common stroke (17%), 
nearly twice the number of which were in the control group. Days since stroke 
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were similar in both groups, ranging from 0-36 days. Aphasia was more 
prevalent in the intervention group (59.1 %). The prevalence of orthostatic 
hypotension was similar in both groups (17.4% in the control group and 13.6% 
in the intervention group) and the prevalence of fatigue was high but similar in 
both groups (43.5% tired and 34.8% really tired in the control group versus 
50.0% and 27.3% in the intervention group). 
 Intervention 
[n=22] 
Control 
[n=23] 
All 
[n=45] 
Pre-stroke modified Rankin Scale % (n) 
0 (no symptoms) 40.9 (9) 13.04 (3) 26.7 (12) 
1 (no significant disability) 9.1 (2) 34.80 (8) 22.2 (10) 
2 (slight disability) 13.6 (3) 30.43 (7) 22.2 (10) 
3 (moderate disability) 9.1 (2) 8.69 (2) 8.9 (4) 
4 (moderately severe disability) 22.7 (5) 13.04 (3) 17.8 (8) 
5 (severe disability) 4.5 (1) 0.0 (0) 2.2 (1) 
6 (dead) 0.0 (0) 0.0 (0) 0.0 (0) 
 
Pre-stroke mobility status % (n) 
Walking without an aid 54.5 (12) 26.1 (6) 40.0 (18) 
Walking with an aid 41.0 (9) 73.9 (17) 57.8 (26) 
Walking with physical assistance 4.5 (1) 0.0 (0) 2.2 (1) 
Mechanical aid with assistance 0.0 (0) 0.0 (0) 0.0 (0) 
 
Medical and surgical conditions % (n) (not mutually exclusive, more than one option 
could be ticked) 
Osteoarthritis – has/had this 
condition 
19.0 (8) 13.6 (6) 16.3 (14) 
Osteoarthritis – ongoing at study 
entry 
20.0 (8) 11.3 (6) 15.1 (14) 
Joint replacement – has/had this 
condition 
11.9 (5) 4.5 (2) 8.1 (7) 
Joint replacement – ongoing at 
trial entry 
0.0 (0) 0.0 (0) 0.0 (0) 
Osteoporosis – has/had this 
condition 
2.4 (1) 2.3 (1) 2.3 (2) 
Osteoporosis – ongoing at trial 
entry 
2.5 (1) 1.9 (0) 2.2 (2) 
Coronary heart 
disease/Hypertension/ 
Hypotension – has/had this 
condition 
35.7 (15) 36.4 (16) 36.0 (31) 
Coronary heart 
disease/Hypertension/ 
35.0 (14) 30.2 (16) 32.3 (30) 
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Hypotension – ongoing at trial 
entry 
COPD/Asthma – has/had this 
condition 
4.8 (2) 6.8 (3) 5.8 (5) 
COPD/Asthma – ongoing at trial 
entry 
5.0 (2) 5.7 (3) 5.4 (5) 
Diabetes – has/had this condition 4.8 (2) 13.6 (6) 9.3 (8) 
Diabetes – ongoing at trial entry 4.8 (2) 13.6 (6) 9.3 (8) 
Depression/anxiety – has/had this 
condition 
4.8 (2) 11.4 (5) 8.1 (7) 
Depression/anxiety – ongoing at 
trial entry 
2.5 (1) 9.4 (5) 6.5 (6) 
TIA – has/had this condition 9.5 (4) 6.8 (3) 8.1 (7) 
TIA – ongoing at trial entry 0.0 (0) 0.0 (0) 0.0 (0) 
Epilepsy/seizure – has/had this 
condition 
2.4 (1) 2.3 (1) 2.3 (2) 
Epilepsy/seizure – ongoing at trial 
entry 
2.5 (1) 1.9 (1) 2.2 (1) 
Neurological condition – has/had 
this condition 
4.8 (2) 2.3 (1) 3.5 (3) 
Neurological condition – ongoing 
at trial entry 
5.0 (2) 0.0 (0) 2.2 (2) 
Other* – ongoing at trial entry 22.5 (9) 28.3 (15) 25.8 (24) 
Had previous strokes (%) 18.2 (4) 21.7 (5) 20.0 (9) 
For those with previous stroke, 
median (IQR) number of strokes 
1.0 (2) 0.0 (0)  
*Polymyalgia rheumatica, leg ulcers, bowel cancer, malignant melanoma, iron deficient anaemia, 
necrotising scleritis, giant cell arteritis, diverticulitis, atrial fibrillation, hypercholesterolemia, 
hypothyroidism, Crohn's disease, dementia, Korsakoff dementia, Alzheimer’s, ankylosing spondylitis, 
peripheral neuropathy, carpal tunnel syndrome, gall stones, chronic kidney disease, migraines, 
bronchiectasis, mediastinal lymphadenopathy, rheumatoid arthritis, macular degeneration, cataracts, 
Fuchs dystrophy, glaucoma. 
Table 4.3b Pre-stroke disability status and medical and surgical conditions 
 
Most participants in the intervention group had multiple morbidities (Table 4c). 
Four participants had one co-morbidity; 11 had two, three had three and two 
had four. 
163 
 
Participant 
number 
N and description of morbidity/multi-morbidities for 
intervention group participants 
01005 2 (osteoarthritis and previous stroke) 
01008 3 (osteoarthritis, joint replacement and coronary heart 
disease/hyper- or hypotension 
01009 4 (coronary heart disease/hyper- or hypotension, 
depression/anxiety, diabetes, joint replacement) 
01010 4 (COPD/Asthma, coronary heart disease/hyper- or 
hypotension, diabetes, osteoarthritis 
01013 1 (coronary heart disease/hyper- or hypotension) 
01014 3 (coronary heart disease/hyper- or hypotension, 
osteoarthritis, osteoporosis) 
01015 2 (coronary heart disease/hyper- or hypotension) 
01018 no data 
01019 2 (coronary heart disease/hyper- or hypotension, TIA) 
01020 2 (coronary heart disease/hyper- or hypotension, TIA) 
01024 2 (joint replacement, osteoarthritis) 
01042 3 (coronary heart disease/hyper- or hypotension, joint 
replacement, TIA) 
01043 2 (coronary heart disease/hyper- or hypotension, TIA) 
01051 no data 
01054 2 (coronary heart disease/hyper- or hypotension, 
COPD/Asthma) 
01055 1 (osteoarthritis) 
02003 2 (coronary heart disease/hyper- or hypotension, 
osteoarthritis) 
03007 1 (osteoarthritis) 
03011 2 (coronary heart disease/hyper- or hypotension, 
epilepsy/seizure) 
03012 1 (coronary heart disease/hyper- or hypotension) 
03014 2 (depression/anxiety, neurological condition) 
04002 2 (coronary heart disease/hyper- or hypotension, joint 
replacement) 
TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease 
Table 4.3c Pre-stroke medical and surgical conditions for the intervention 
group 
 
For post-stroke mobility status (Table 4.3d), over half of the participants 
required a hoist for transfers, with slightly more in the control group (60.9%) 
than in the intervention group (40.9%), but the severity of stroke (mRS) was 
similar in both groups. 
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 Intervention 
[n=22] 
Control 
[n=23] 
All 
[n=45] 
Current mobility status % (n) (mutually exclusive but n=1 in control group ticked hoist 
and electronic stand aid) 
Hoist 40.9 (9) 60.9 (14) 51.1 (23) 
Transfer board  0.0 (0) 0.0 (0) 0.0 (0) 
Handling belt  0.0 (0) 0.0 (0) 0.0 (0) 
Electronic standing aid  22.7 (5) 8.7 (2) 15.6 (7) 
Mechanical standing aid 36.4 (8) 30.4 (7) 33.3 (15) 
 
How many people required? 
One person 
Two people 
Two to three people (variable) 
 
0.0 (0) 
100.0 (22) 
0.0 (0) 
 
4.35 (1) 
91.30 (21) 
4.35 (1) 
 
2.2 (1) 
95.6 (43) 
2.2 (1) 
 
Stroke severity % (n) (option to complete NIHSS or mRS therefore, only 22 out of 45 
completed) 
NIHSS at time of screening 
0 (no stroke symptoms)  0.0 (0) 0.0 (0) 0.0 (0) 
1-4 (minor stroke) 4.54 (1) 0.0 (0) 2.2 (1) 
5-15 (moderate stroke) 13.63 (3) 21.7 (5) 17.8 (8) 
16-20 (moderate to severe 
stroke) 
22.73 (5) 17.4 (4) 20.0 (9) 
21-42 (severe stroke) 9.1 (2) 8.7 (2) 8.9 (4) 
 
mRS at time of screening 
0 (no symptoms) 0.0 (0) 0.0 (0) 0.0 (0) 
1 (no significant disability) 0.0 (0) 0.0 (0) 0.0 (0) 
2 (slight disability) 0.0 (0) 0.0 (0) 0.0 (0) 
3 (moderate disability) 0.0 (0) 0.0 (0) 0.0 (0) 
4 (moderately severe disability) 77.3 (17) 82.6 (19) 80.0 (36) 
5 (severe disability) 22.7 (5) 17.4 (4) 20.0 (9) 
6 (dead) 0.0 (0) 0.0 (0) 0.0 (0) 
 
Stroke classification 
(between groups) % (n) 
   
TACS (total anterior circulation 
stroke) 
72.7 (16) 30.4 (7) 51.1 (23) 
PACS (partial anterior 
circulation stroke) 
13.6 (3) 39.1 (9) 26.7 (12) 
POCS (posterior circulation 
stroke) 
9.1 (2) 4.3 (1) 6.7 (3) 
LACS (lacunar syndrome) 4.5 (1) 26.1 (6) 15.6 (7) 
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Lesion location (% and n within allocation)  
(not mutually exclusive n=2 in control group and n=3 in the intervention group had multiple lesion 
locations ticked) 
Cortical 
Middle cerebral artery 27.3 (6) 50.0 (11) 38.6 (17) 
Frontal 13.6 (3) 0.0 (0) 6.8 (3) 
Sub-cortical 
Thalamus 0.0 (0) 0.0 (0) 0.0 (0) 
Basal ganglia 4.5 (1) 13.6 (3) 9.1 (4) 
Midbrain 0.0 (0) 0.0 (0) 0.0 (0) 
Pons 0.0 (0) 0.0 (0) 0.0 (0) 
Medulla 0.0 (0) 0.0 (0) 0.0 (0) 
Cerebellum 4.5 (1) 4.5 (1) 4.5 (1) 
Brain stem 0.0 (0) 0.0 (0) 0.0 (0) 
Parietal 9.1 (2) 4.5 (1) 6.8 (3) 
Temporal 0.0 (0) 0.0 (0) 0.0 (0) 
Occipital 13.6 (3) 4.5 (1) 9.1 (4) 
Other* 13.6 (3) 18.2 (4) 15.9 (7) 
*(small vessel disease, haemorrhage or haemorrhagic transformation) 
 
 
Stroke sub-type % (n) (these options were linked with lesion location above and not 
mutually exclusive) 
Lacunar 0.0 (0) 13.6 (3) 6.8 (3) 
Anterior cerebral artery  0.0 (0) 9.1 (2) 4.5 (2) 
Posterior cerebral artery 0.0 (0) 0.0 (0) 0.0 (0) 
Basilar artery 0.0 (0) 0.0 (0) 0.0 (0) 
Cerebellar artery 4.5 (1) 4.3 (1) 4.5 (2) 
Carotid artery 0.0 (0) 0.0 (0) 0.0 (0) 
Other 0.0 (0) 0.0 (0) 0.0 (0) 
Missing 0.0 (0) 4.3 (1) 2.2 (1) 
 
Prevalence of aphasia % (n) 59.1 (13) 47.8 (11) 53.3 (24) 
 
Prevalence of orthostatic 
hypotension % (n) 
13.6 (4) 17.4 (3) 15.6 (7) 
 
Prevalence of fatigue % (n)    
0-3 (not tired, or a little tired) 
4-6 (tired) 
7-10 (really tired) 
22.7 (5) 
50.0 (11) 
27.3 (6) 
21.7 (5) 
43.5 (10) 
34.8 (8) 
22.2 (10) 
46.7 (21) 
31.1 (14) 
 
Days since stroke admitted 
to Stroke Rehabilitation Unit, 
median (range) [IQR] 
10.0 (0-31) 
[11] 
6.0 (0-36) [10] 7.0 (0-
36) [11.0] 
 
 
Days since stroke informed 
consent received, median 
(range) (IQR) 
11.0 (3-32) 
[10.0] 
15.0 (5-25) 
[13] 
13.50 (3-
32) [11.0] 
 
 
Days since admission to 
Stroke Rehab Unit consent 
received, median (range) 
[IQR] 
3.0 (1-9) 
[4.0] 
3.0 (1-22) [4.0] 3.0 (1-
22) [4.0] 
Table 4.3d Disability status post-stroke 
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4.7 Adherence 
4.7.1 Number of sessions 
Adherence for this feasibility trial was defined as completing the three-week 
intervention with a minimum of five and maximum of seven sessions per week 
(minimum total of 15 sessions and maximum total of 21 sessions). None of the 
participants completed all 21 sessions and only eight participants across the 
two groups completed 15 or more sessions over the three weeks: three (13.6%) 
in the intervention group and five (21.7%) in the control group. Thus, during this 
trial participants were not receiving the recommended number of sessions for 
their stroke rehabilitation3. The mean number of sessions overall for the 
intervention group was 8.14 (9.0 median), compared to 10.54 (12.00 median) in 
the control group, ranging from one to 16 for both groups during the 3-week 
physiotherapy period. The session number frequency distribution for both 
groups is summarised in Figure 4.3.  
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Figure 4.3 Number of sessions completed out of 21 sessions for both groups 
during the 3-week intervention period 
 
The number of sessions completed per week varied in both groups (Figure 4.4). 
In the intervention group, one of the three participants who completed 15 
sessions, consistently completed five sessions per week in each of the three 
weeks. Four participants in the control group consistently completed a minimum 
of five sessions per week over the three weeks. Number of sessions per week 
over the three weeks for the other three participants ranged from one to seven 
in the control group and three to six. 
Total number of sessions over the  
3-week intervention period 
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Figure 4.4 Mean number ± SD (error bars) of sessions completed per week 
for both groups during the 3-week physiotherapy period 
 
In summary, the mean total number of sessions across the three weeks per 
week in the intervention group was 8.2 (week one 3.1, week two 2.5, week 
three 2.6) and 10.5 in the control group (week one 4.2, week two 3.5, week 
three 2.8.0) (Figure 4.4). 
4.7.2 Session duration, standing time and sit to stand repetitions 
The mean duration of sessions in the intervention group was 36.6 minutes 
(±10.6 standard deviation (SD)), the median 40.0 minutes compared with 39.40 
minutes (± 18.8 SD), 45.0 minutes (median) in the control group. Figure 4.5 
summarises the session duration for both groups.  
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Figure 4.5 Median, quartiles and extreme values duration of session for both 
groups 
 
The target duration of standing was 30 minutes or to increase the duration of 
standing by 30% each session. The mean duration of standing when the 
participant completed a session was 12.52 minutes (±8.8 SD), median 11.00. 
Figure 4.6 shows the duration of stand for the intervention group across each 
week. Prevalence of standing (and other treatment activities) for the control 
group were captured, but not the duration for each activity. Therefore, the 
duration of standing for the control group is not known. 
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Figure 4.6 Median, quartiles and extreme values duration of stand for the 
intervention group 
 
The frequency distribution of standing duration is summarised in Figure 4.7. 
Two participants stood for longer than the 30 minutes (n=1, 32 minutes, n=1 36 
minutes), reasons for which were not captured in the CRF. A minimum of 30 
minutes standing was achieved in n=10 sessions (n=6 participants). Most 
participants stood for ≤20 minutes, with 15 and 20 minutes being the most 
common standing duration, 
Not all participants in the intervention group stood in their sessions. Five 
participants across eight sessions did not achieve any standing during their 
documented intervention session. Reasons for not standing during these eight 
sessions were not captured. Reasons for sessions not being completed are 
shown in Figure 4.13. 
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Figure 4.7 Duration of standing for the intervention group 
 
The target session time for the intervention group was 45 minutes during which 
time participants were aiming to stand for 30 minutes or increase the duration of 
standing by 30% each session up to the 30 minutes maximum standing time. As 
highlighted in Figure 4.8 the relationship between duration of standing and 
duration of session is skewed to the right; that is longer session durations 
tended to be associated with longer durations of standing. 
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Figure 4.8 Median, quartiles and extreme values for the duration of session 
and number of minutes in standing for the intervention group (not 
per participant) 
 
As stated above, the aim was for participants to stand for 30 minutes per day, 
five times per week, or increase the duration of standing by 30% each session 
up to the 30 minutes maximum standing time. Looking at a percentage change 
is difficult because many sessions had zero minutes of standing, thus 
calculations cannot be made with a denominator of zero. This is because 
participants were not aligned to start standing on the same day, therefore, some 
started on a Friday, and not all physiotherapists worked weekends/bank 
holidays, and some participants were unwell/unavailable and did not stand. 
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However, it was possible to calculate the change per week using 150 minutes 
(30 minutes, five times per week) as the minimum target duration of standing. 
Figure 4.9 shows the percentage change per week and highlights variability in 
the data with some participants increasing their duration of standing over time, 
however, some participants decreased their time in standing.
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Figure 4.9 Percentage change in standing time per week for the intervention group 
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The mean number of sit to stand repetitions within a session was 4.64 (±3.9 
SD), median 3.00, range 0-20. The number of sit to stand repetitions across 
sessions is summarised in Figure 4.10. The frequency distribution of the 
number of sit to stand repetitions across the three weeks is summarised in 
Figure 4.11 and the percentage change per week in Figure 4.12. 
 
Figure 4.10 Number of sit to stand repetitions within a session for the 
intervention group 
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Figure 4.11 Median, quartiles and extreme values of sit to stand repetitions per 
week for each of the 3 weeks for the intervention group 
 
The target number of sit to stand repetitions was 8-12 with a graded increase of 
30% in each session, as per standing duration. Unfortunately, it is not known 
whether the adherence of sit to stand repetitions was due to participant ability or 
adherence by physiotherapists to the protocol. Additionally, the work instruction 
did not prescribe a starting position, e.g., perched or normal chair height. 
100% represents the minimum target, 40 repetitions of sit stand per week for 
the three weeks. Three participants reached the target level.
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Figure 4.12 Percentage change of sit to stand repetitions per week for the intervention group 
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4.7.3 Reasons for non-adherence 
Out of the 945 potential sessions (45 participants x 21 sessions each), 429 
(45.4%) were completed, 503 (53.2%) were not completed and 13 (1.4%) were 
records missing. The most common reasons for incomplete sessions in total 
were staffing (n=264, 51.2%) and patients being unwell (n=97, 18.8%). A total 
of 22 participants declined n=53 sessions in total (n=32 sessions in the 
intervention group and n=21 in the control group). The percentage of the 
different reasons for not completing a session are summarised in Figures 4.13 
and 4.14. 
 
Figure 4.13 Reasons for non-adherence across both groups during the 3-week 
physiotherapy period 
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One participant discontinued the intervention following recommendation from a 
physiotherapist. This participant continued with their follow-up visits at all 
timepoints. 
 
Figure 4.14 Reasons for non-adherence by site during the 3-week 
physiotherapy period 
 
4.7.4 Relationship between age, stroke severity and duration in standing 
for the intervention group 
There were no clear trends between the duration of standing and stroke severity 
when controlling for age (Figure 4.15) or gender (Figure 4.16) in the intervention 
group. However, in both figures, except for one participant, participants with 
very severe stroke stood for less time than the majority of participants with a 
Site number & number 
recruited per site 
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moderately severe stroke. In Figure 4.15, as age increases the duration of 
standing decreases in participants with very severe stroke (mRS5). 
 
Figure 4.15 Relationship between age, stroke severity and duration in standing 
for the intervention group 
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Figure 4.16 Relationship between gender, stroke severity and duration in 
standing for the intervention group 
 
The CRF did not require physiotherapists to document the exact number of 
minutes participants in the intervention group spent undertaking usual 
physiotherapy activities after using the standing frame. The CRF captured the 
number of minutes in standing and the duration of session. Data in Figure 4.17 
was calculated by subtracting the minutes in standing from the duration of 
session (minutes). Reasons participants received more than 15 minutes of 
usual physiotherapy were not captured. The duration of usual physiotherapy in 
the intervention group varied: mean 35.8 minutes, ±SD 16.1 minutes, range 3-
100 minutes. 
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Figure 4.17 Adherence to 15 minutes of usual physiotherapy in the 
intervention group 
 
Participants in the intervention group were required to complete 30 minutes of 
prolonged standing, 8-12 repetitions of sit to stand, and 15 minutes of usual 
physiotherapy for each of their 21 sessions, or a minimum of 15 sessions. This 
was not achieved by any of the participants. Only six sessions (n=4 
participants) met the target of 30 minutes of standing, 15 minutes of usual 
physiotherapy and eight or more sit to stand repetitions.  
In summary, no participants achieved complete adherence (Table 4.4). 
However, overall adherence did not incorporate a graded increase of sit to 
stand repetitions or weekly adherence criteria allowing for progression of 
standing time and sit to stand repetitions over time, therefore, it is unsurprising 
complete adherence was not achieved by any participant. 
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Complete adherence* for intervention 
group 
% (n) 
Yes 
 
0.0 (0) 
No 100.0 (22) 
*minimum 5 sessions per week, 30 minutes of standing and 15 minutes of usual physiotherapy and 8-12 
sit to stand repetitions 
Table 4.4 Complete adherence for the intervention group 
 
Table 4.5 shows the breakdown of adherence by site. Two sites (2 and 3) had 
participants (n=3) complete 15 or more sessions during the 3-week intervention 
period. However, only one participant completed five sessions per week every 
week, the other two participants completed different number of sessions per 
week (n=1 week 1 five, week 2 four and week 3 six, and week 1 six, week 2 
three and week 3 six sessions). None of the participants adhered to the target 
duration of standing or sit to stand repetitions.
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 Stroke 
severity 
Site 1 
% (n) 
[this site recruited 
n=27] 
Site 2 
% (n) 
[this site recruited 
n=3] 
Site 3 
% (n) 
[this site recruited 
n=13] 
Site 4 
% (n) 
[this site recruited 
n=2] 
Number of participants at this site who 
completed minimum 15 or maximum 21 
sessions  
mRS 4 3.7 (1) 0.00 (0) 15.40 (2) 0.00 (0) 
mRS 5 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
 
Number of participants at this site who 
achieved 30 minutes in standing 
mRs 4 11.11 (3) 33.33 (1) 15.40 (2) 0.00 (0) 
mRS 5 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
 
Number of sessions at this site in which 
participants achieved 30 minutes in 
standing 
mRs 4 3.60 (4) [out of 
111 completed 
sessions] 
(1) [out of 11 
completed 
sessions] 
12.90 (5) [out of 
39 completed 
sessions] 
0.00 (0) 
mRS 5 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
 
Number of participants at this site who 
completed 8-12 (or more) sit to stand 
repetitions 
mRS 4 22.2 (6) 0.00 (0) 30.80 (4) 0.00 (0) 
mRS 5 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
 
Number of sessions at this site in which 
participants achieved 8-12 (or more) sit 
to stand repetitions 
 
mRs 4 17.1 (19) [out 
of 111 completed 
sessions] 
0.00 (0) 38.5 (15) [out of 
39 completed 
sessions] 
0.00 (0) 
mRS 5 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Table 4.5 Adherence by site for intervention group 
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It was anticipated that fatigue and OH may impact completion of intervention 
sessions. Figure 4.18 shows the relationship between fatigue and OH 
measured during their intervention sessions and the number of minutes 
participants were able to stand during these sessions. Most participants with 
fatigue and OH spent less time in standing.  
 
Figure 4.18 Relationship between adherence of standing time, orthostatic 
hypotension and fatigue measured during intervention sessions 
 
There was no significant relationship between OH and fatigue in participants in 
the intervention group, as shown by the Chi-Square test in Table 4.6. 
 Fatigue 0-3 Fatigue 4-6 Marginal Row 
Totals 
Has OH 3 3 6 
Does not have OH 9 7 16 
Marginal Column Totals 12 10 22 (Grand total) 
The Fisher exact test statistic value is 1. The result is not significant at p < .05 
Table 4.6  Chi square test for orthostatic hypotension and fatigue in the 
intervention group 
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It was anticipated that OH may affect participants’ ability to complete some 
intervention sessions (see Chapter 2). Orthostatic hypotension occurred in 21 
out of 426 sessions (Table 4.7). Nine participants experienced OH: three in the 
control group and six in the intervention group. The prevalence of OH is slightly 
higher in the intervention group (n=6) than is reported in the minimisation 
procedure data (n=4). This may likely be because the assessment for OH 
during the minimisation procedure is lying to upright sitting, whereas 
participants in the intervention group were moving from sitting to standing. 
Orthostatic hypotension affected completion of 13 sessions (7.2%) in the 
intervention group and 0.8% (n=2) in the control group. Participants required 
treatment for OH during 12 sessions (6.7%); six of which entailed 
pharmacological treatment. 
Parameter Intervention group 
% within allocation 
(n) 
[n=180 sessions] 
Control group % 
within allocation 
(n) 
[n=246 sessions] 
Number of sessions OH occurred 8.3 (15) 
 
2.4 (6) 
Number of times OH needed 
treatment 
6.7 (12) 0.0 (0) 
 
Treatment pharmacological 
 
3.3 (6*) 
 
0.0 (0) 
 
Treatment non-pharmacological 
 
2.8 (5*) 0.0 (0) 
Number of times OH affected 
completion of the session 
7.2 (13) 0.8 (2) 
*Spoiled CRF; OH, orthostatic hypotension 
Table 4.7 Prevalence, impact and treatment of orthostatic hypotension 
4.8 Content of usual physiotherapy across both groups 
Supported standing, supported sitting and unsupported sitting were the most 
commonly adopted postures during the control group rehabilitation sessions 
and during the 15 minutes of usual physiotherapy as part of the intervention 
(Table 4.8). Based on percentages, the groups were similar except supine was 
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more commonly used in treatment activities in the control group. Supported 
standing was the most commonly adopted position in the control group and 
used in 161 (63.63%) of sessions. Two sites used supported standing most 
frequently in the control group: site 1 n=59 sessions, site 3 n=85 sessions. 
Twenty-one participants (over 161 sessions) in the control group performed 
supported standing, ranging from one to 14 sessions per participant. However, 
the number of minutes participants spent in supported standing and equipment 
used were not captured in the CRFs. Additionally, there did not appear to be 
any pattern to this, e.g., practice changing over time throughout the trial. 
Participants’ positions during 
usual physiotherapy (number of 
sessions the positions were used out of 429 
completed sessions, not per participant and not 
mutually exclusive) 
Intervention 
group during 
usual physio 
component % (n) 
[n=176 sessions] 
Control % (n) 
[n=253 sessions] 
Supine 16.50 (29) 37.94 (96) 
Prone 0.00 (0) 0.00 (0) 
Side lying (affected side) 1.70 (3) 9.50 (24) 
Side lying (unaffected side) 2.84 (5) 8.30 (21) 
Supported sitting 51.13 (90) 50.20 (127) 
Supported standing 54.54 (96) 63.63 (161) 
Perch sitting 5.11 (9) 9.10 (23) 
Unsupported sitting 54.54 (96) 41.10 (104) 
Unsupported standing 9.10 (16) 6.77 (17) 
Prone standing 0.00 (0) 0.00 (0) 
4-point kneeling 0.00 (0) 0.00 (0) 
2-poing kneeling 0.00 (0) 0.00 (0) 
Crook lying 1.70 (3) 7.51 (19) 
Table 4.8 Gross position of participants during usual physiotherapy for both 
groups 
 
A total of 429 usual physiotherapy sessions were completed: n=253 in the 
control group and n=176 in the intervention group. More participants withdrew 
from the intervention group, contributing to the higher number of sessions 
completed in the control group. Treatment activities varied between groups 
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(Table 4.9), specifically in exercises to improve strength, upper limb tasks, 
facilitation of movement, sensory stimulation and functional tasks. 
Exercises to improve strength were low in both groups but used in more 
sessions in the intervention group. This may be due to standing and sit to stand 
repetitions being considered as strengthening exercises, thus double counted. 
Functional activities were high in the control group, but this included washing 
and dressing as well as sit to stand, therefore, the tasks specifically undertaken 
in this category are unknown. 
Treatments activities undertaken 
by participants during usual 
physiotherapy [number of sessions 
treatment activities were used out of 429 
completed sessions, not per participant and not 
mutually exclusive] 
Intervention 
group during 15 
minutes usual 
physiotherapy 
component % (n) 
[n=176 sessions] 
Control % (n) 
[n=253 sessions] 
Exercise to improve cardiovascular 
fitness 
2.84 (5) 3.47 (9) 
Exercise to improve strength 22.72 (40) 4.74 (12) 
Exercise to improve co-ordination 1.13 (2) 5.92 (15) 
Upper limb tasks 21.60 (38) 30.83 (78) 
Facilitation of movement/muscle 
activation 
26.13 (46) 40.71 (103) 
Soft tissue mobilisation 1.13 (2) 2.80 (7) 
Joint mobilisation 7.40 (13) 9.10 (23) 
Sensory stimulation 8.00 (14) 19.40 (49) 
Balance activities (static) 21.60 (38) 27.70 (70) 
Balance activities (dynamic) 13.10 (23) 25.30 (64) 
Functional tasks (e.g. sit to stand, 
wash/dress) 
22.72 (40) 53.80 (136) 
Practising transfers 48.90 (86) 49.01 (124) 
Stepping/walking/gait re-education 23.90 (42) 19.40 (49) 
Review/progress seating 5.70 (10) 9.10 (23) 
Positioning 15.34 (27) 20.20 (51) 
Tone management 6.25 (11) 10.70 (27) 
Oedema management 2.30 (4) 1.19 (3) 
Pain management 1.13 (2) 1.60 (4) 
Splinting 0.00 2.00 (5) 
Orthotics 1.13 (2) 0.00 
Education/training for patient and/or 
family/carers 
1.13 (2) 2.40 (6) 
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Other treatment activities   
Acupuncture 0.00 (0) 0.00 (0) 
Taping (e.g. ROCK or kinesiology tape) 7.95 (14) 3.20 (8) 
Ultrasound 0.00 (0) 0.00 (0) 
Compression 0.00 (0) 0.40 (1) 
Warm water bathing 0.00 (0) 0.00 (0) 
Body weight support treadmill training 0.00 (0) 0.00 (0) 
Functional electrical stimulation 1.13 (2) 4.34 (11) 
Microstim 0.00 (0) 0.00 (0) 
Hydrotherapy 0.00 (0) 0.00 (0) 
Theraband 0.00 (0) 0.00 (0) 
Nintendo Wii or other virtual reality games 0.00 (0) 0.00 (0) 
Lycra/compression garments 0.00 (0) 0.00 (0) 
Other*  8.52 (15) 18.60 (47) 
*motoMED (cycle ergometer), respiratory physiotherapy, neck exercises, cognitive assessment with 
Occupational Therapist 
Table 4.9 Treatment activities undertaken by participants during usual 
physiotherapy for both groups 
 
4.9 Experience of the intervention 
Brief interviews were conducted at the end of 167 intervention sessions. Brief 
interviews were not conducted or completed for n=9 sessions (n=5 participants). 
Reasons were not captured but all five participants had aphasia and/or 
cognitive impairment. Table 4.10 shows that most sessions (91.0%) were 
reported to being enjoyed by participants. Most sessions required moderate 
(46.1%) or severe (32.3%) effort, and at the end of 33.5% sessions participants 
were tired, 31.7% really tired and 22.8% a little tired. Participants did not report 
experiencing aches or pains in most sessions (66.5%). 
Enjoyment of each completed 
session % 
Yes (enjoyed) No (did not enjoy) 
91.0 (152) 9.0 (15) 
Effort % (n) per completed session 
None (0) 
Mild (1-3) 
Moderate (4-6) 
Severe (7-9) 
Unbearable (10) 
Missing 
1.2 (2) 
12.6 (21) 
46.1 (77) 
32.3 (54) 
0.0 (0) 
7.8 (13) 
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Fatigue % (n) per completed session 
Not at all (0) 
A little tired (1-3) 
Tired (4-6) 
Really tired (7-9) 
So tired I can’t do anything (10) 
Missing 
3.0 (5) 
22.8 (38) 
33.5 (56) 
31.7 (53) 
5.4 (9) 
3.6 (6) 
 
Aches and pains % (n) per completed session 
None (0) 
Mild (1-3) 
Moderate (4-6) 
Severe (7-9) 
Worst pain possible (10) 
Missing 
66.5 (111) 
10.2 (17) 
9.6 (16) 
9.6 (16) 
0.6 (1) 
3.6 (6) 
Table 4.10 Experience of the intervention (enjoyment, effort, fatigue, aches and 
pains) 
 
The work instruction stipulated brief interviews were conducted at the end of the 
intervention session. Therefore, it is not known whether responses to the 
assessed domains in Table 4.10 were related specifically to the standing frame 
or the whole session which included 15 minutes usual physiotherapy activities. 
Participants reported fatigue for 93.4% (n=156) of sessions that the brief 
interviews were conducted. Figure 4.19 shows that their fatigue fluctuated over 
the 21 sessions and participants did not appear to be experiencing more fatigue 
at the start of the 21 days, e.g. soon after their stroke, or at the end of the trial. 
191 
 
 
Figure 4.19 Fatigue scores over the 3-week trial period 
4.10 Adverse and serious adverse events 
4.10.1 Adverse events 
A total of 118 AEs were reported during the whole trial (3-week treatment and 
follow-up period): 59 in each group (Table 4.11). Thirty-eight participants had 
AEs: 20 in the intervention group and 18 in the control group. During the 3-week 
treatment period 10 AEs were reported in the control group and 16 in the 
intervention group. The most common AEs were falls, respiratory, thoracic and 
mediastinal disorders and renal disorders, all slightly higher in the control group. 
Proportion of AEs: six participants had one, 12 had two, seven had three, five 
had four, three had five, four had six and one had eight. Therefore, the count of 
participants with AEs and percentage in the right column of each group in Table 
4.11 is not equal to the number of participants allocated to each group. AEs 
were similar in both groups.
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Organ system  
Intervention Control 
Count (n) and % 
of AEs within 
allocation* n=22 
Count (n) and % 
of participants 
with AEs** n=45 
Count and % of 
AEs within 
allocation* n=23 
Count and % of 
participants with 
AEs** n=45 
Blood and the lymphatic system disorders 13.6 (3) 4.44 (2) 4.34 (1) 2.22 (1) 
Cardiac disorders 9.10 (2) 4.44 (2) 0.00 (0) 0.00 (0) 
Congenital and familial and genetic 
disorders 
0.00 (0) 0.00 (0) 4.34 (1) 2.22 (1) 
Ear and labyrinth disorders 0.00 (0) 0.00 (0) 4.34 (1) 2.22 (1) 
Endocrine system 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
End of life care 4.54 (1) 2.22 (1) 0.00 (0) 0.00 (0) 
Fall 68.18 (15) 15.56 (7) 82.6 (19) 20.00 (9) 
Gastrointestinal disorders 18.18 (4) 6.67 (3) 8.70 (2) 4.44 (2) 
General disorders and admin site conditions 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Hepatobiliary disorders 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Infections and infestations 22.73 (5) 8.89 (4) 26.10 (6) 11.11 (5) 
Injury, poisoning and procedural 
complications 
4.54 (1) 2.22 (1) 4.34 (1) 2.22 (1) 
Metabolism and nutrition disorders 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Musculoskeletal and connective tissue 
disorders 
4.54 (1) 2.22 (1) 4.32 (1) 2.22 (1) 
Nervous system disorders 18.18 (4) 8.9 (4) 13.04 (3) 4.44 (2) 
Orthostatic hypotension 18.18 (4) 6.67 (3) 0.00 (0) 0.00 (0) 
Psychiatric disorders 4.54 (1) 2.22 (1) 0.00 (0) 0.00 (0) 
Renal and urinary disorders 27.27 (6) 11.11 (5) 30.43 (7) 8.89 (4) 
Respiratory, thoracic and mediastinal 
disorders 
40.91 (9) 13.33 (6) 60.90 (14) 13.33 (6) 
Skin and subcutaneous tissue disorders 9.10 (2) 4.44 (2) 13.04 (3) 6.67 (3) 
Surgical and medical procedures 4.54 (1) 22.22 (1) 0.00 (0) 0.00 (0) 
Total (n) 59 AEs 20* participants 59 AEs 18* participants 
Most participants had more than one AE reported in the same or different organ system therefore this number does not equal the total number in this column 
*Calculated by number of AEs divided by total number of participants in this group **Calculated by number of people with AEs divided by total number of participants 
Table 4.11 Adverse events in both groups 
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4.10.2 Serious adverse events 
Twenty AEs listed in Table 4.10 above were classified as serious and 10 additional serious adverse events (SAEs) were 
reported separately, thus a total of 30 SAEs (Table 4.12) were reported during the trial: 17 in the intervention group and 13 in 
the control group. Twenty-five participants had SAEs: 12 in the intervention group and 13 in the control group. During the 3-
week treatment period two SAEs were recorded for two participants, both in the intervention group. The remaining n=28 were 
recorded during the follow-up period. SAEs were similar in both groups. The most common SAEs were infections (slightly 
higher in the intervention group). Proportion of SAEs: n=15 participants had one, n=6 had two and n=1 had three. 
 
 
Organ system  
Intervention Control 
Count (n) and % 
of SAEs within 
allocation* n=22 
Count (n) and % 
of participants 
with SAEs** n=45] 
Count and % of 
SAEs within 
allocation* n=23 
Count and % of 
participants with 
SAEs** n=45 
Blood and the lymphatic system disorders 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Cardiac disorders 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Congenital and familial and genetic disorders 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Ear and labyrinth disorders 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Endocrine system 0.00 (0) 0.00 (0) 4.34 (1) 2.22 (1) 
End of life care 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Fall 4.54 (1) 2.22 (1) 0.00 (0) 0.00 (0) 
Gastrointestinal disorders 9.09 (2) 4.44 (2) 0.00 (0) 0.00 (0) 
General disorders and admin site conditions 4.54 (1) 2.22 (1) 4.34 (1) 2.22 (1) 
Hepatobiliary disorders 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Infections and infestations 31.82 (7) 11.11 (5) 21.7 (5) 11.11 (5) 
Injury, poisoning and procedural 
complications 
9.09 (2) 4.44 (2) 8.70 (2) 4.44 (2) 
Metabolism and nutrition disorders 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Musculoskeletal and connective tissue 
disorders 
0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
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Nervous system disorders 9.09 (2) 4.44 (2) 8.70 (2) 6.67 (3) 
Orthostatic hypotension 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Psychiatric disorders 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Renal and urinary disorders 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Respiratory, thoracic and mediastinal 
disorders 
4.54 (1) 2.22 (1) 4.34 (1) 2.22 (1) 
Skin and subcutaneous tissue disorders 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Surgical and medical procedures 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 
Unknown 4.54 (1) 2.22 (1) 0.00 (0) 0.00 (0) 
Total (n) 17 AEs 12† participants 13 AEs 13† participants 
†Seven participants had more than one SAE reported in the same or different organ system therefore this number does not equal the total number in this column 
*Calculated by number of AEs divided by total number of participants in this group **Calculated by number of people with AEs divided by total number of participants 
Table 4.12 Serious adverse events in both groups 
 
Table 4.13 presents the AEs and SAEs by site. Site 1 had the highest number of AEs, which was unsurprising given they 
recruited the highest number of participants. Sites 1 and 3 had the highest number of SAEs and when reviewing the proportion 
of participants recruited to the number of SAEs, site 3 had the highest number of SAEs. 
 Site 1 
% (n of AE or SAE) 
Site 2 
% (n of AE or SAE) 
Site 3 
% (n of AE or SAE) 
Site 4 
% (n of AE or SAE) 
AE % within site total Intervention Control Intervention Control Intervention Control Intervention Control 
39.0 (46) 21.2 (25) 1.7 (2) 5.9 (7) 6.8 (8) 22.9 (27) 2.5 (3) 0.0 (0) 
AE total % across 4 sites 60.2 (71) 7.6 (9) 29.7 (35) 2.5 (3) 
SAE% within site total 33.3 (10) 10.0 (3) 0.0 (0) 10.0 (3) 13.3 (4) 23.3 (7) (3) 0.0 (0) 
SAE total % across four sites 43.3 (13) 10.0 (3) 36.6 (11) 10.0 (3) 
Table 4.13 Adverse Events and Serious Adverse Events by site 
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Twelve participants (26.7%) died during the trial, seven (15.6%) in the 
intervention group and five (11.1%) in the control group (Table 4.14). Two 
participants (4.4%) in the intervention group died during the 3-week treatment 
period and five (11.1%) died in the follow-up period compared to five 
participants (11.1%) in the control group who all died during the follow-up 
period. The highest number of deaths occurred between 29 and 55 weeks. 
Details of which time-points deaths occurred are shown in Figure 4.1 
(CONSORT). 
 
Organ system 
Deaths in group 
allocation % (n) 
Intervention  Control 
Infections and infestations 0.0 (0) 4.3 (1) 
Nervous system disorders 0.0 (0) 8.7 (2) 
Respiratory, thoracic and mediastinal 
disorders 
0.0 (0) 4.3 (1) 
General disorders and administration 
site conditions 
0.0 (0) 4.3 (1) 
Infections and infestations 18.2 (4) 0.0 (0) 
Nervous system disorders 4.5 (1) 0.0 (0) 
General disorders and administration 
site conditions 
4.5 (1) 0.0 (0) 
Unknown 4.5 (1) 0.0 (0) 
Table 4.14 Total number and causes of death in both groups 
Eleven of the 12 participants who died were aged ≥80 years: n=8 in their 80s, 
n=3 in their 90s. One participant was 72 years of age. Eight of the participants 
(66.7%) who died were from site 1. Deaths at other sites were: one (8.3%) from 
site 2, two (16.7%) from site 3 and one (8.3%) from site 4. 
4.10.3 Relationship of adverse and serious adverse events and stroke 
severity 
The relationship between AEs and SAEs are shown in Tables 4.15a and 4.15b. 
Most AEs were recorded in participants with moderately severe stroke (mRS 4) 
(86.4% in the intervention group and 91.5% in the control group) (Table 4.15a). 
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There were slightly more AEs in the intervention group (13.6%) compared to the 
control group (8.5%) for participants with very severe stroke (mRS 5). 
Relatedness of AEs was not recorded. 
Stroke severity 
 
Adverse Events 
% (n) 
Total number (n) 
of AEs 
Intervention 
Group 
Control 
group 
 
Moderately severe stroke 
(mRS 4) 
86.4 (51) 91.5 (54) (105) 
Very severe stroke (mRS 5) 13.6 (8) 8.5 (5) (13) 
Table 4.15a Relationships between Adverse Event and stroke severity in both 
groups 
 
Table 4.15b shows the relationship between SAEs and stroke severity and 
relatedness of SAEs to the trial. In total there were 30 SAEs, (n=17 (56.7%) in 
the intervention group and n=13 (43.3%) in the control group and) none which 
were considered related to the trial. 
Stroke severity SAEs 
Intervention % 
(n) within group 
Control % (n) 
within group 
mRS 4 Unlikely 23.52 (4) 38.50 (5) 
mRS 4 Not related 52.94 (9) 38.50 (5) 
mRS 5 Unlikely 0.00 (0) 0.00 (0) 
mRS 5 Not related 23.52 (4) 23.10 (3) 
Table 4.15b Relationships between Serious Adverse Events (SAEs) and stroke 
severity and relatedness of SAEs to the trial in both groups 
 
4.11 Outcomes 
4.11.1 Primary outcome measures 
The BI has a maximum score of 20, and the Edmans has maximum subgroup 
scores of 9. In both measures a lower score indicates increased 
dependency/disability. BI scores increased over time (Table 4.16a). For both 
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groups, initially this was more marked between baseline to 3 weeks, then a 
slower increase between 3-29 weeks, before it plateaued between 29-55 weeks 
for the intervention group, and a slight decrease for the control group. Scores 
varied for the Edmans subgroups, with mean scores in washing, meal times, 
bed mobility and advanced mobility scores increasing at each time point in the 
intervention group, but scores in all subgroups improved from baseline to 55 
weeks in both groups. Both measures were able to detect change in people with 
severe stroke, but the Edmans shows changes in scores in individual 
subgroups. This will be expanded upon in Section 4.15 (Responsiveness of 
proposed outcome measures).
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Outcome variable 
 
Treatment 
Group 
Time point 
Baseline 3 (+/-1) 
weeks 
15 weeks  
(+/-1 week) 
29 weeks  
(+/-1 week) 
55 weeks  
(+/-1 week) 
Barthel Index total   
Mean (SD) [range] 
 
Intervention 2.32 (2.056) 
[0-8] 
5.53 (5.293)  
[1-20] 
7.0 (6.066)  
[0-20] 
7.88 (6.888)  
[1-20] 
8.33 (7.762)  
[1-20] 
Control 
 
2.57 (2.573)  
[0-10] 
5.05 (4.675)  
[0-16] 
6.82 (5.992)  
[1-19] 
7.69 (6.085)  
[1-19] 
7.47 (6.446)  
[0-16] 
 
Median (IQR) 
 
Intervention 1.50 (3) 2.00 (7) 5.50 (9) 4.00 (12) 4.50 (16) 
Control 
 
1.00 (4) 3.0 (8) 3.0 [10] 6.50 (12) 7.00 (14) 
Edmans Activities of Daily Living Index for Stroke subgroup totals Mean (SD) [range] 
Washing  
Mean (SD) [range] 
Intervention 0.73 (0.50) 
[0-2] 
2.18 (6.40) 
[0-9] 
2.63 (2.90) 
[0-9] 
2.63 (3.40) 
[0-9] 
3.25 (3.77) 
[0-9] 
 
Control  
 
0.57 (0.66) 
[0-2] 
1.77 (2.12) 
[0-9] 
2.235 (2.26) 
[0-9] 
2.63 (2.39) 
[0-7] 
2.33 (2.29) 
[0-7] 
 
Grooming 
Mean (SD) [range] 
Intervention 2.18 (2.99) 
[0-9] 
4.41 (2.81) 
[0-9] 
5.00 (3.16) 
[0-9] 
4.50 (3.78) 
[0-9] 
4.83 (3.81) 
[0-9] 
 
Control  
 
2.57 (3.10) 
[0-9] 
4.23 (3.68) 
[0-9] 
5.06 (3.78) 
[0-9] 
5.63 (3.14) 
[0-9] 
4.93 (3.69) 
[0-9] 
 
Dressing 
Mean (SD) [range] 
Intervention 0.32 (0.72) 
[0-3] 
1.82 (2.74) 
[0-9] 
1.81 (3.02) 
[0-9] 
2.13 (3.50) 
[0-9] 
3.08 (4.03) 
[0-9] 
 
Control  
 
0.39 (0.72) 
[0-3] 
1.45 (2.32) 
[0-9] 
2.00 (2.83) 
[0-9] 
2.13 (2.96) 
[0-9] 
2.47 (3.34) 
[0-9] 
 
Meal times Mean 
(SD) [range] 
Intervention 2.91 (3.01) 
[0-9] 
5.06 (3.09) 
[0-9] 
6.06 (2.91) 
[0-9] 
6.38 (3.05) 
[0-9] 
6.83 2.41) 
[2-7] 
 
Control  
 
3.35 (3.28) 
[0-9] 
5.14 (3.90) 
[0-9] 
6.94 (2.66) 
[0-9] 
6.44 (2.99) 
[0-9] 
6.53 (3.18) 
[0-9] 
 
Basic mobility Intervention 0.73 (0.76) 2.59 (2.76) 3.19 (2.97) 3.94 (3.77) 3.92 (3.83) 
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Mean (SD) [range] [0-2] [0-9] [0-9] [0-9] [0-9] 
 
Control  
 
0.74 (1.05) 
[0-4] 
2.05 (2.48) 
[0-9] 
3.18 (3.59) 
[0-9] 
3.50 (3.78) 
[0-9] 
4.13 (4.22) 
[0-9] 
 
Advanced mobility 
Mean (SD) [range] 
Intervention 0.04 (0.21) 
[0-1] 
1.18 (2.35) 
[0-9] 
1.56 (3.05) 
[0-9] 
2.13 (3.34) 
[0-9] 
2.25 (3.49) 
[0-9] 
 
Control  
 
0.04 (0.21) 
[0-1] 
0.32 (1.09) 
[0-5] 
1.24 (1.86) 
[0-5] 
1.69 (2.70) 
[0-9] 
1.80 (2.43) 
[0-7] 
 
Bed mobility 
Mean (SD) [range] 
Intervention 0.14 (0.64) 
[0-3] 
2.06 (2.73) 
[0-9] 
2.25 (3.32) 
[0-9] 
3.25 (4.07) 
[0-9] 
3.50 (4.17) 
[0-9] 
 
Control  
 
0.22 (0.74) 
[0-3] 
1.68 (2.46) 
[0-9] 
2.47 (3.30) 
[0-9] 
3.00 (3.86) 
[0-9] 
3.93 (4.37) 
[0-9] 
 
Kitchen activities 
Mean (SD) [range] 
Intervention 0.05 (0.21) 
[0-1] 
0.65 (1.97) 
[0-8] 
1.38 (3.07) 
[0-9] 
1.69 (3.24) 
[0-9] 
1.17 (2.73) 
[0-9] 
 
Control  
 
0.05 (0.21) 
[0-1] 
0.73 (1.67) 
[0-6] 
1.59 (2.87) 
[0-9] 
1.50 (2.53) 
[0-7] 
1.27 (2.25) 
[0-7] 
 
Housework activities  
Mean (SD) [range] 
Intervention 0.00 (0) [0] 0.41 (1.70) 
[0-7] 
1.13 (3.07) 
[0-9] 
1.06 (2.91) 
[0-9] 
0.92 (2.61) 
[0-9] 
 
Control  
 
0.00 (0) [0] 0.09 (0.43) 
[0-2] 
0.18 (0.73) 
[0-3] 
0.31 (0.87) 
[0-3] 
0.33 (1.05) 
[0-4] 
Washing  
Median [IQR] 
Intervention 1.00 [1] 1.00 [4] 1.00 [3] 1.00 [4] 1.50 [8] 
Control  
 
0.00 [1] 1.00 [3] 2.00 [3] 1.50 [4] 1.00 [4] 
Grooming 
Median [IQR] 
Intervention 0.00 [4] 4.00 [4] 5.00 [6] 4.00 [9] 5.00 [9] 
Control  
 
1.00 [4] 3.50 [8] 4.00 [8] 6.00 [6] 5.00 [9] 
Dressing 
Median [IQR] 
Intervention 0.00 [0] 0.00 [3] 0.50 [2] 0.00 [2] 1.00 [8] 
Control  
 
0.00 [1] 0.00 [2] 0.00 [3] 0.50 [5] 0.00 [6] 
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Meal times Median 
[IQR] 
 
Intervention 2.5 [5] 6.00 [6] 6.50 [6] 6.50 [4] 7.00 [5] 
Control  
 
3.00 [6] 6.50 [9] 7.00 [3] 7.00 [5] 7.00 [2] 
Basic mobility 
Median [IQR] 
Intervention 1.00 [1] 1.00 [5] 2.00 [5] 3.00 [9] 3.00 [9] 
Control  
 
0.00 [1] 1.50 [4] 1.00 [6] 2.00 [8] 3.00 [9] 
Advanced mobility 
Median [IQR] 
Intervention 0.00 [0] 0.00 [0] 0.00 [2] 0.00 [5] 0.00 [4] 
Control  
 
0.00 [0] 0.00 [2] 0.00 [3] 0.00 [4] 0.00 [4] 
Bed mobility 
Median [IQR] 
Intervention 0.00 [0] 1.00 [4] 0.00 [5] 1.00 [9] 1.50 [9] 
Control  
 
0.00 [0] 0.50 [3] 0.00 [5] 0.50 [8] 2.00 [9] 
Kitchen activities 
Median [IQR] 
Intervention 0.00 [0] 0.00 [0] 0.00 [1] 0.00 [1] 0.00 [1] 
Control  
 
0.00 [0] 0.00 [0] 0.00 [3] 0.00 [3] 0.00 [2] 
Housework activities  
Median [IQR] 
Intervention 0.00 [0] 0.00 [0] 0.00 [0] 0.00 [0] 0.00 [0] 
Control  
 
0.00 [0] 0.00 [0] 0.00 [(0] 0.00 [0] 0.00 [0] 
Table 4.16a Proposed primary outcome data 
The Edmans has included “Associated Problems” as a measurement category which is scored out of 10, with a higher score 
representing increased number of problems. Participants in the intervention group had a higher prevalence of sensory, 
perceptual, dyspraxia, reasoning, memory, urinary continence problems and made the greatest improvements in all these 
domains except perceptual problems (Table 4.16b). Although scores fluctuated at 3, 15 and 29 weeks, the scores decreased 
(indicating reduced prevalence) from baseline in both groups in language, perceptual, sensory, dyspraxia, reasoning, anxiety 
and continence problems. Memory problems increased in the control group and depression problems scores increased in both 
groups. 
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  Time point 
Associated 
problems 
Treatment 
group 
Baseline 
(n=45) 
3 (+/-1) weeks 
(n=39) 
15 weeks (+/-1 
week) 
(n=33) 
29 weeks (+/-1 
week) 
(n=32) 
55 weeks (+/-1 
week) 
(n=27) 
Language 
problems 
Intervention 68.2 (11) 52.9 (9) 62.5 (10) 62.5 (10) 41.7 (5) 
Control  47.8 (15) 50.0 (11) 35.3 (6) 31.3 (5) 33.3 (5) 
Perceptual 
problems  
Intervention 68.2 (15) 41.2 (7) 31.3 (5) 37.5 (6) 25.0 (3) 
Control  56.5 (13) 27.3 (6) 23.5 (4) 25.0 (4) 13.3 (2) 
Sensory 
problems 
Intervention 100.0 (22) 82.4 (14) 75.0 (12) 87.5 (14) 75.0 (9) 
Control  82.6 (19) 72.7 (16) 82.4 (14) 68.8 (11) 93.3 (14) 
Dyspraxia 
problems 
Intervention 27.3 (6) 23.5 (4) 6.3 (1) 12.5 (2) 8.3 (1) 
Control  13.0 (3) 9.1 (2) 0.00 (0) 0.00 (0) 0.00 (0) 
Reasoning 
problems 
Intervention 77.3 (17) 76.5 (13) 56.3 (9) 75.0 (12) 41.7 (5) 
Control  65.2 (15) 59.1 (13) 58.8 (10) 50.0 (8) 53.3 (8) 
Memory 
problems 
Intervention 81.1 (18) 94.1 (16) 81.3 (13) 93.8 (15) 75.0 (9) 
Control  73.9 (17) 90.0 (20) 94.1 (16) 93.8 (15) 93.3 (14) 
Depression 
problems 
Intervention 36.4 (8) 35.3 (6) 75.0 (12) 56.3 (9) 66.7 (8) 
Control  47.8 (11) 18.2 (4) 41.2 (7) 62.5 (10) 46.7 (7) 
Anxiety 
problems 
Intervention 31.8 (7) 23.5 (4) 43.8 (7) 43.8 (7) 25.0 (3) 
Control  47.8 (11) 45.5 (10) 47.1 (8) 37.5 (6) 33.3 (5) 
Urinary 
continence 
problems 
Intervention 90.9 (20) 88.2 (15) 68.8 (11) 81.3 (13) 58.3 (7) 
Control  87.0 (20) 72.7 (16) 70.6 (12) 62.5 (10) 80.0 (12) 
Faecal 
continence 
problems 
Intervention 87.0 (20) 88.2 (15) 56.3 (9) 68.8 (11) 58.3 (7) 
Control  90.9 (20) 63.6 (14) 76.5 (13) 62.5 (10) 66.7 (10) 
Table 4.16b Proposed primary outcome data (Associated Problems for the Edmans ADL Index for Stroke Patients) 
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4.11.2 Ability to self-report proposed primary outcome measures 
Cognitive and/or communication impairment affected some participants' ability to complete the patient report outcome 
measure, therefore a proxy was used (clinician, relative or carer). The proportion of patient and proxy responses for the 
proposed primary outcome measures are shown in Figure 4.20. Ability to self-report was the same for both primary outcome 
measures, which was similar at all time- points: 19 participants (42.2%) at baseline and 22 (48.9%) at 55 weeks. 
 
Figure 4.20 Proportion of participant versus proxy responses for both proposed primary outcome measures 
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4.11.3  Secondary outcome measures 
The secondary outcome measures are a combination of physical measures 
taken by the blinded assessor and patient report outcome measures 
administered by the blinded assessor (Table 4.17a and 4.17b). Fewer 
participants completed the patient report outcome measures than the physical 
measures, due to cognitive and/or communication impairment. One participant 
in the control group declined most of the muscle length, strength and tone 
testing on his hemi-paretic lower limb at baseline because of hypersensitivity, 
pain and anxiety, and then all physical measures at 15, 29 and 55 weeks. This 
participant completed all proposed primary and patient-reported outcome 
measures at all time-points. One participant in the intervention group declined 
all outcome measures except the Trunk Control Test at 55-week visit. One 
participant missed their 3-week visit due to being medically unwell but had their 
15-week visit, then died prior to their 29-week visit. 
Hip flexor length varied in both groups for each of the time points. Hip flexor 
length reduced over time, most notably from 15 weeks to 29 weeks in the 
intervention group, and participants’ right hip in the intervention group had the 
biggest loss of muscle length (4.5 degrees from baseline to 55 weeks). 
Hamstring length reduced over time in both groups. Participants in the 
intervention group had less range of movement than the control group at 
baseline. Dorsiflexor length varied between groups. The change from baseline 
to three weeks varied from -0.50 to -2.50 degrees, and a median loss of -3.00 
degrees seen at 15 and 29 weeks. Ankle plantar flexor length was similar in 
both groups across the different time points. In summary, the changes seen are 
generally small, which did not exceed the five or 10 degrees minimally clinically 
important difference proposed by Katalinic et al350 for range of motion.
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 LEFT RIGHT 
Outcome variable Time 
point 
 
Intervention Group 
median [IQR] (n) 
Control Group 
median [IQR] (n) 
Intervention Group 
median [IQR] (n) 
Control Group 
median [IQR] (n) 
Muscle length using 
manual goniometry 
Hip extension (Hip 
angle) 
Baseline -1.50 [4] (22) -1.0 [10] (22) -0.50 [6] (22), 0.00 [5] (22) 
3 weeks -1.00 [3] (17) 0.00 [5] (21) -2.00 [6] (17) 0.00 [2] (20) 
15 weeks 0.00 [11] (15) 0.00 [4] (16) 0.00 [8] (15) 0.00 [5] (16) 
29 weeks 1.50 [14] (16) 2.00 [6] (15) 1.50 [15] (16) 0.00 [9] (15) 
55 weeks 0.00 [10] (11) 1.50 [9] (14) 4.00 [12] (11) 1.00 [10] (14) 
 
Knee extension 
(popliteal angle) 
Baseline 38.50 [13] (22) 31.00 [14] (22) 37.50 [8] (22) 32.00 [15] (23) 
3 weeks 38.00 [13] (17) 38.00 [14] (21) 35.00 [12] (17) 36.00 [12] (21) 
15 weeks 40.00 [18] (16) 38.50 [8] (16) 41.00 [18] (16) 39.50 [10] (16) 
29 weeks 40.00 [15] (16) 45.00 [11] (15) 43.50 [16] (16) 42.00 [13] (15) 
55 weeks 42.00 [18] (11) 44.00 [12] (14) 47.00 [7] (11) 42.00 [16] (14) 
 
Ankle dorsiflexion Baseline -0.50 [5] (22) -1.00 [8] (22) -2.50 [7] (22) -2.00 [6] (23) 
3 weeks 0.00 [3] (17) -2.00 [5] (21) -2.00 [3] (17) -2.00 [4] (21) 
15 weeks -1.00 [6] (16) -2.00 [7] (17) 0.00 [12] (16) -3.00 [7] (17) 
29 weeks -3.00 [8] (16) -2.00 [11] (15) 0.00 [10] (16) 0.00 [11] (15) 
55 weeks -2.00 [9] (11) -0.50 [21] (14) 0.00 [18] (11) -0.50 [17] (14) 
 
Ankle plantarflexion Baseline 37.50 [9] (22) 39.50 [18] (22) 37.00 [10] (22) 39.00 [14] (23) 
3 weeks 43.00 [10] (17) 42.00 [9] (21) 40.00 [15] (17) 42.00 [12] (21) 
15 weeks 42.00 [11] (16) 38.00 [16] (17) 41.00 [3] (15) 36.00 [16] (17) 
29 weeks 42.00 [7] (16) 39.00 [6] (15) 42.00 [6] (16) 39.00 [10] (15) 
55 weeks 40.00 [16] (11) 40.00 [15] (14) 39.00 [12] (11) 37.00 [14] (14) 
 
Knee extensor 
muscle strength 
measured in Newtons 
(Maximum score of 
three trials) 
Baseline 58.00 [29] (22) 54.00 [48] (22) 40.50 [49] (22) 62.00 [47] (22) 
3 weeks 69.00 [33] (17) 69.00 [59] (21) 60.00 [31] (17) 60.00 [39] (21) 
15 weeks 57.00 [44] (15) 56.50 [40] (16) 57.00 [86] (15) 64.00 [26] (16) 
29 weeks 70.00 [37] (16) 57.00 [37] (15) 57.00 [45] (16) 69.00 [36] (15) 
55 weeks 67.00 [55] (11) 58.00 [56] (14) 73.00 [89] (11) 76.00 [38] (14) 
Modified Ashworth scale 
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Hip adductors Baseline 0.00 [0] (22) 0.00 [0] (22) 0.00 [0] (22) 0.00 [0] (23) 
3 weeks 0.00 [0] (17) 0.00 [0] (21) 0.00 [0] (17) 0.00 [0] (21) 
15 weeks 0.00 [0] (16) 0.00 [1] (16) 0.00 [0] (16) 0.00 [0] (17) 
29 weeks 0.00 [1] (16) 0.00 [1] (15) 0.00 [1] (16) 0.00 [1] (15) 
55 weeks 0.00 [1] (11) 0.00 [1] (14) 0.00 [0] (11) 0.00 [1] (14) 
 
Hamstrings Baseline 0.00 [0] (22) 0.00 [0] (22) 0.00 [0] (22) 0.00 [0] (23) 
3 weeks 0.00 [0] (17) 0.00 [0] (21) 0.00 [0] (17) 0.00 [0] (21) 
15 weeks 0.00 [0] (16) 0.00 [0] (16) 0.00 [1] (16) 0.00 [0] (17) 
29 weeks 0.00 [1] (16) 0.00 [1] (15) 0.00 [2] (16) 0.00 [1] (15) 
55 weeks 0.00 [1] (11) 0.00 [1] (14) 0.00 [0] (11) 0.00 [0] (14) 
 
Ankle flexion Baseline 0.00 [0] (22) 0.00 [0] (22) 0.00 [0] (22) 0.00 [0] (23) 
3 weeks 0.00 [0] (17) 0.00 [0] (21) 0.00 [0)] (17) 0.00 [0] (21) 
15 weeks 0.50 [1] (16) 0.00 [2] (16) 1.00 [2] (16) 0.00 [0] (17) 
29 weeks 0.50 [1] (16) 0.00 [0] (15) 0.50 [2] (16) 0.00 [1]) (15) 
55 weeks 0.00 [0] (11) 0.00 [0] (14) 0.00 [2] (11) 0.00 [0] (14) 
 
Ankle extension Baseline 0.00 [0] (22) 0.00 [0] (22) 0.00 [0] (22) 0.00 [0] (23) 
3 weeks 0.00 [0] (17) 0.00 [0] (21) 0.00 [0] (17) 0.00 [0] (21) 
15 weeks 0.00 [0] (16) 0.00 [0] (16) 0.00 [0] (16) 0.00 [0] (17) 
29 weeks 0.00 [0] (16) 0.00 [0] (15) 0.00 [1] (16) 0.00 [1] (15) 
55 weeks 0.00 [0] (11) 0.00 [0] (14) 0.00 [0] (11) 0.00 [0] (14) 
Table 4.17a Proposed Secondary Outcomes  
Median knee extensor strength fluctuated in both groups but increased from baseline to 55 weeks. However, the CRF did not 
distinguish between the paretic and non-paretic leg as shown in Table 4.17a, thus this score includes an average of the paretic 
and non-paretic legs. Table 4.17b shows that in both groups, participants with left and right hemiparesis increased their 
strength on both paretic and non-paretic legs from baseline to 55 weeks, with most changes seen in participants with left 
hemiparesis.  
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Allocation Time point Participants with left 
hemiparesis 
median [IQR] (n) 
Participants with right 
hemiparesis 
median [IQR] (n) 
Intervention group  LEFT RIGHT LEFT RIGHT 
Knee extensor muscle 
strength measured in 
Newtons (maximum score of 
three trials) 
Baseline 44.0 [40] (7) 65 [39] (7) 59 [23] (15) 29 [43] (15) 
3 weeks 77.5 [54] (6) 60.5 [65] (6) 67.0 [33] (11) 51.0 [51] (11) 
15 weeks 96.0 [57] (6) 112.5 [73] (6) 54.0 [30] (9) 27.0 [51] (9) 
29 weeks 90.5 [66] (6) 86.5 [60] (6) 63.5 [30] (10) 49.5 [40] (10) 
55 weeks 113.5 [93] (4) 139.5 [96] (4) 61.0 [28] (7) 39.0 [78] (7) 
   
Control group  LEFT RIGHT LEFT RIGHT 
Knee extensor muscle 
strength measured in 
Newtons (maximum score of 
three trials) 
Baseline 23.0 [52] (11) 71 [35] (11) 67.0 [53] (11) 29.0 [62] (11) 
3 weeks 63.50 [58] (10) 77.0 [39] (10) 69.0 [74] (11) 56.0 [38] (11) 
15 weeks 44.0 [17] (7) 69.0 [20] (7) 73.0 [39] (9) 52.0 [45] (9) 
29 weeks 41.0 [25] (7) 83.0 [31] (7) 77.0 [53] (8) 57.0 [58] (8) 
55 weeks 47.0 [34] (7) 85.0 [39] (7) 81.0 [56] (7) 64.0 [61] (7) 
Table 4.17b Knee extensor strength for paretic and non-paretic legs for both groups 
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The Trunk Control Test scores at baseline were lowest in the intervention 
group, representing a greater level of impairment. It increased over time and 
was higher in the intervention group at 55 weeks, compared to the control group 
(Table 4.17c). However, as with other measures, this may have been influenced 
by the participant withdrawals. 
Some participants were unable to complete the PHQ-9, therefore, a SADQ-10 
(observational measure) was completed by a clinician, carer or relative. The 
number of participants needing a SADQ-10 reduced from baseline to 55 weeks 
in both groups. PHQ-9 baseline scores were higher in the intervention group 
suggesting participants in this group had lower mood, and scores reduced at 
each time point from baseline.  
At baseline, more participants were able to complete the multiple-choice 
questions for EQ-5D-5L than the SAQoL-39. Some participants were unable to 
complete the health state, which required participants to score their health out 
of 100. 
Outcome variable Time 
point 
 
Intervention 
median [IQR] (n) 
Control 
median [IQR] (n) 
Trunk control Test  
 
Baseline 6.0 [15] (22) 12.0 [37] (23) 
3 weeks 25.0 [55] (17) 24.0 [58] (20) 
15 weeks  24.0 [66] (16) 25.0 [61] (17) 
29 weeks 37.0 [37] (16) 18.5 [84] (16) 
55 weeks 25.0 [84] (12) 12.0 [61] (15) 
 
Patient Health 
Questionnaire 9 
(PHQ-9) 
Baseline 13.0 [3] (17) 10.0 [10] (19) 
3 weeks 12.0 [10] (16) 8.5 [8] (20) 
15 weeks  13.5 [8] (16) 11.0 [11] (17) 
29 weeks 12.0 [12] (13) 9.0 [6] (16) 
55 weeks 9.0 [9] (11) 8.0 [8] (15) 
 
Stroke Aphasia 
Depression 
Questionnaire 
(SADQ-10)* 
 
Baseline (5) (4) 
3 weeks (1) (1) 
15 weeks  (0) (0) 
29 weeks (3) (0) 
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*(n) presented only for 3, 
15, 29 and 55 weeks due 
to insufficient number of 
participants for mean and 
IQR 
55 weeks (1) (0) 
Stroke and Aphasia Quality of Life Scale (SAQoL-39) 
Physical Baseline 1.4 [2.03] (16) 1.8 [1.82] (18) 
3 weeks 3.0 [2.67] (14) 1.8 [1.38] (17) 
15 weeks  1.9 [0.76](15) 2.4 [1.62] (17) 
29 weeks 2.4 [1.96] (14) 2.3 [0.96] (16) 
55 weeks 2.2 [2.00] (11) 2.1 [1.77] (15) 
 
Communication Baseline 3.0 [3.00] (16) 4.0 [2.07] (18) 
3 weeks 4.0 [2.78] (14) 4.5 [1.36] (17) 
15 weeks  4.3 [2.43] (15) 4.7 [1.00] (17) 
29 weeks 3.8 [2.11] (14) 4.5 [0.68] (16) 
55 weeks 3.9 [2.29] (11) 4.9 [1.43] (15) 
 
Psychosocial Baseline 3.2 [1.36] (15) 3.3 [1.14] (18) 
3 weeks 3.7 [1.34] (14) 3.6 [0.87] (17) 
15 weeks  3.1 [1.27] (15) 3.9 [0.73] (17) 
29 weeks 3. [1.12] (14) 3.8 [0.80] (16) 
55 weeks 3.3 [1.25] (11) 3.6 [1.27] (15) 
 
Energy Baseline 3.3 [1.13] (16) 2.9 [1.38] (18) 
3 weeks 3.4 [1.38] (14) 3.3 [1.50] (17) 
15 weeks  3.3 [1.25] (15) 3.5 [1.25] (17) 
29 weeks 3.4 [1.81] (14) 3.3 [1.00] (16) 
55 weeks 3.0 [1.25] (11) 3.3 [1.00] (15) 
 
Total score for all 
four subgroups 
Baseline 2.3 [1.69] (15) 3.1 [1.60] (18) 
3 weeks 3.3 [2.06] (14) 2.7 0.98] (17) 
15 weeks  2.6 [0.46] (15) 3.2 [1.04] (17) 
29 weeks 2.8 1.42] (14) 3.1 [0.60] (16) 
55 weeks 2.8 [0.36] (11) 3.0 [1.08] (15) 
 
European Quality 
of Life-5 
Dimensions (EQ-
5D 5L) 
Mobility 
Baseline 5.0 [0] (18) 5.0 [0] (21) 
3 weeks 4.5 [3] (14) 5.0 [2] (19) 
15 weeks  5.0 [3] (15) 5.0 [3] (17) 
29 weeks 4.0 [3] (14) 5.0 [2] (16) 
55 weeks 4.0 [3] (11) 3.0 [3] (15) 
 
European Quality 
of Life-5 
Dimensions (EQ-
5D 5L) 
Self-care 
Baseline 5.0 [2] (18) 4.0 [2] (21) 
3 weeks 3.0 [2] (14) 3.0 [2] (19) 
15 weeks  4.0 [1] (15) 3.0 [3] (17) 
29 weeks 4.0 [2] (14) 4.0 [3] (16) 
55 weeks 4.0 [4] (11) 3.0 [3] (15) 
 
European Quality 
of Life-5 
Dimensions (EQ-
5D 5L) 
Usual activities 
Baseline 5.0 [3] (18) 5.0 [3] (21) 
3 weeks 3.5 [3] (14) 4.0 [4] (19) 
15 weeks  5.0 [2] (15) 5.0 [2] (17) 
29 weeks 5.0 [3] (14) 5.0 [0] (16) 
55 weeks 5.0 [2] (11) 5.0 [2] (15) 
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European Quality 
of Life-5 
Dimensions (EQ-
5D 5L) 
Pain/discomfort 
Baseline 1.0 [2] (18) 2.0 [2] (21) 
3 weeks 1.0 [1] (14) 2.0 [2] (19) 
15 weeks  1.0 [2] (15) 3.0 [2] (17) 
29 weeks 1.0 [2] (14) 2.5 [3] (16) 
55 weeks 2.0 [2] (11) 2.0 [4] (15) 
 
European Quality 
of Life-5 
Dimensions (EQ-
5D 5L) 
Anxiety/depression 
Baseline 2.0 [2] (18) 2.0 [3] (21) 
3 weeks 1.5 [2] (14) 1.0 [2] (19) 
15 weeks  3.0 [1] (15) 2.0 [3] (17) 
29 weeks 2.0 [2] (14) 2.0 [2] (15) 
55 weeks 3.0 [2] (11) 2.0 [3] (15) 
 
European Quality 
of Life-5 
Dimensions (EQ-
5D 5L) 
Health state score 
Out of 100 where 
higher score 
represents improved 
health 
Baseline 50.0 [50] (17) 52.5 [35] (18) 
3 weeks 50.0 [20] (14) 50.0 [43] (17) 
15 weeks  50.0 [34] (14) 50.0 [50] (15) 
29 weeks 62.5 [39] (10) 50.0 [42] (11) 
55 weeks 54.0 [50] (8) 65.0 [38] (14) 
Table 4.17c Proposed secondary outcomes  
 
4.11.4 Mean differences between the groups for proposed primary and 
secondary outcome data 
Table 4.18a shows the mean difference between baseline and 3, 15, 29 and 55 
weeks for the proposed primary outcome data. For the BI scores, the mean 
difference between each time point increased in both groups, with the highest 
scores in the intervention group at 55 weeks. For the Edmans, the mean 
difference between each time point varied in both groups over all time points. 
The biggest mean differences were in washing, dressing, meal times and basic 
mobility from 3 to 55 weeks. 
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Outcome variable 
  
Treatment Group 
Time point 
3 (+/-1) weeks, 
mean, SD (n) 
15 weeks (+/-1 
week), mean, 
SD (n) 
29 weeks (+/-1 week), 
mean, SD (n) 
55 weeks (+/-1 
week), mean, SD 
(n) 
 
Barthel Index Intervention 5.53, 5.29 (17) 7.0, 6.06 (16) 7.88, 6.88 (16) 8.33, 7.76 (12) 
  
Control 5.05, 4.67 (22) 6.82, 5.99 (17) 7.69, 6.08 (16) 7.47, 6.44 (15) 
  
Mean difference 
(unadjusted 
analysis)* [95% CI] 
 
0.48  
[-2.75, 3.72] 
0.17  
[-4.10, 4.45] 
0.18  
[-4.50, 4.88] 
0.86  
[-4.76, 6.49] 
 
Edmans ADL Index 
for Stroke 
Washing total 
Intervention 2.18, 2.53 (17) 2.63, 2.90 (16) 2.63, 3.40 (16) 3.25, 3.77 (12) 
Control  1.77, 2.18 (22) 2.35, 2.26 (17) 2.63, 2.39 (16) 2.33, 2.29 (15) 
Mean difference 
(unadjusted analysis)* 
[95% CI] 
 
0.41 [-1.13, 1.93] 0.27 [-1.57, 2.11] 0.00 [-2.12, 2.12] 0.92 [-1.50, 3.33] 
Grooming total Intervention 4.41, 2.81 (17) 5.00, 3.16 (16) 4.50, 3.78 (16) 4.83, 3.81 (12) 
Control  4.23, 3.68 (22) 5.06, 3.78 (17) 5.63, 3.14 (16) 4.93, 3.69 (15) 
Mean difference 
(unadjusted analysis)* 
[95% CI] 
 
0.18 [-1.99, 2.36] -0.59 [-2.54, 2.43] -1.13 [-3.63, 1.38] -0.10 [-3.09, 2.89] 
Dressing total Intervention 1.82, 2.74 (17) 1.81, 3.02 (16) 2.13, 3.50 (16) 3.08, 4.03 (12) 
Control  1.45, 2.32 (22) 2.00, 2.83 (17) 2.13, 2.96 (16) 2.47, 3.34 (15) 
Mean difference 
(unadjusted analysis)* 
[95% CI] 
 
0.37 [-1.28, 2.01] -0.19 [-2.26, 1.89] 0.00 [-2.34, 2.34] 0.62 [-2.30, 3.53] 
Meal times total Intervention 5.06, 3.09 (17) 6.06, 2.91 (16) 6.38, 3.05 (16) 6.83, 2.41 (12) 
Control  5.14, 3.98 (22) 6.94, 2.66 (17) 6.44, 2.99 (16) 6.53, 3.18 (15) 
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Mean difference 
(unadjusted analysis)* 
[95% CI] 
 
-0.08 [-2.41, 2.26] -0.88 [-2.86, 1.10] -0.63 [-2.24, 2.12] 0.30 [-1.99, 2.59] 
Basic mobility total Intervention 2.59, 2.76 (17) 3.19, 2.97 (16) 3.94, 3.77 (16) 3.92, 3.82 (12) 
Control  2.05, 2.48 (22) 3.19, 3.59 (17) 3.50, 3.78 (16) 4.13, 4.22 (15) 
Advanced mobility 
total 
Intervention 1.18, 2.35 (17) 1.56, 3.05 (16) 2.13, 3.34 (16) 2.25, 3.49 (12) 
Control  0.32, 1.09 (22) 1.24, 1.86 (17) 1.69, 2.70 (16) 1.80, 2.43 (15) 
Mean difference 
(unadjusted analysis)* 
[95% CI] 
 
0.86 [-0.29, 2.00] 0.33 [-1.45, 2.11] 0.44 [-1.76, 2.63] 0.45 [-1.90, 2.80] 
Bed mobility total Intervention 2.06, 2.76 (17) 2.25, 3.32 (16) 3.25, 4.07 (16) 3.50 4.17 (12) 
Control  1.68, 2.46 (22) 2.47, 3.30 (17) 3.00, 3.86 (16) 3.93, 4.37 (15) 
Mean difference 
(unadjusted analysis)* 
[95% CI] 
 
0.38 [-1.31, 2.06] -0.22 [-2.57, 2.13] 0.25 [-2.62, 3.12] -0.43 [-3.84, 2.98] 
Kitchen activities 
total 
Intervention 0.65, 1.97 (17) 1.38, 3.07 (16) 1.69, 3.24 (16) 1.17, 2.73 (12) 
Control  0.73, 1.67 (22) 1.59, 2.87 (17) 1.50, 2.53 (16) 1.27, 2.25 (15) 
Mean difference 
(unadjusted analysis)* 
[95% CI] 
 
-0.80 [-1.26, 1.10] -0.21 [-2.33, 1.90] 0.19 [-1.91, 2.29] -0.10 [-2.07, 1.87] 
Housework activities 
total 
Intervention 0.41, 1.70 (17) 1.13, 3.07 (16) 1.06, 2.91 (16) 0.92, 2.61 (12) 
Control  0.09, 0.43 (22) 0.18, 0.73 (17) 0.31, 0.87 (16) 0.33, 1.05 (15) 
Mean difference 
(unadjusted analysis)* 
[95% CI] 
3.21 [-0.44, 1.08] 0.95 [-0.62, 2.51] 0.75 [-0.80, 2.30] 0.58 [-0.93, 2.10] 
*calculated using intervention group minus control group. Greater mean differences from baseline = improvement 
Table 4.18a Mean difference from baseline (95% Confidence Interval) between both groups at each time point for proposed 
primary outcome data from baseline  
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The percentage change from baseline in associated problems for the Edmans (nominal data) is presented in Table 4.18b. 
The percentage change fluctuates across all time points for all associated problems. 
 
Outcome 
variable 
 
Treatment Group 
Time point 
3 weeks (+/-1 
week) % (n) 
15 weeks (+/-1 
week) %(n) 
29 weeks (+/-1 
week) % (n) 
55 weeks (+/-1 
week) % (n) 
Language 
problems 
Intervention 52.9 (9) 62.5 (10) 62.5 (10) 41.7 (5) 
Control  50.0 (11) 35.3 (6) 31.3 (5) 33.3 (5) 
% difference* 2.9 27.2 31.2 8.4 
 
Perceptual 
problems  
Intervention 41.2 (7) 31.3 (5) 37.5 (6) 25.0 (3) 
Control  27.3 (6) 23.5 (4) 25.0 (4) 13.3 (2) 
% difference* 13.9 7.8 12.5 11.7 
 
Sensory 
problems 
Intervention 82.4 (14) 75.0 (12) 87.5 (14) 75.0 (9) 
Control  72.7 (16) 82.4 (14) 68.8 (11) 93.3 (14) 
% difference* 9.7 -7.4 18.7 -18.3 
 
Dyspraxia 
problems 
Intervention 23.5 (4) 6.3 (1) 12.5 (2) 8.3 (1) 
Control  9.1 (2) 0.0 (0) 0.0 (0) 0.0 (0) 
% difference* 14.4 6.3 12.5 8.3 
 
Reasoning 
problems 
Intervention 76.5 (13) 56.3 (9) 75.0 (12)  41.7 (5) 
Control  59.1 (13) 58.8 (10) 50.0 (8) 53.3 (8) 
% difference* 14.4 6.3 12.5 8.3 
 
Memory 
problems 
Intervention 94.1 (16) 81.3 (13) 93.8 (15) 75.0 (9) 
Control  90.9 (20) 94.1 (16) 93.8 (15) 93.3 (14) 
% difference* 3.2 -12.8 0 -18.3 
 
Depression 
problems 
Intervention 35.3 (6) 75.0 (12) 56.3 (9) 66.7 (8) 
Control  18.2 (4) 41.2 (7) 62.5 (10) 46.7 (7) 
% difference* 17.1 33.8 -6.2 20 
 
Anxiety 
problems 
Intervention 23.5 (4) 43.8 (7)  43.8 (7) 25.0 (3) 
Control  45.5 (10) 47.1 (8) 37.5 (6) 33.3 (5) 
% difference* -22.0 -3.3 6.3 -8.3 
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Urinary 
continence 
problems 
Intervention 88.2 (15) 68.8 (11) 62.5 (13) 58.3 (7) 
Control  72.7 (16) 70.6 (12) 81.3(10) 80. (12) 
% difference* 15.5 -1.8 -18.8 -21.7 
 
Faecal 
continence 
problems 
Intervention 88.2 (15) 56.3 (9) 68.8 (11) 58.3 (7) 
Control  63.6 (14) 76.5 (13) 62.5 (10) 66.7 (10) 
% difference* 24.6 -20.2 6.3 -8.4 
*calculated using intervention group minus control group. Greater mean differences = improvement 
Table 4.18b Percentage difference from baseline at each follow up time point for Edmans ADL Index for Stroke Patients 
Associated Problems 
 
Figure 4.21 suggests greater change in BI score in the intervention group is associated with lower fatigue scores at baseline 
and higher total standing time, but these relationships are not strong (r = 0.3 total standing time and BI change score; r = -0.2 
fatigue score and BI change score). 
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Figure 4.21 Relationship between adherence, fatigue and change in Barthel Index Scores from baseline (T0) 
to 3 weeks (T1) 
 
r = 0.3 
r = -0.2 
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The mean change from baseline in the proposed secondary outcome measures at 3, 15, 29 and 55 weeks for muscle length, 
strength and tone are shown in Tables 4.19a and 4.19b. Both groups vary (mean scores and SD) at all time-points. 
 LEFT RIGHT 
Outcome variable Time 
point 
(+/-1 
week) 
Intervention 
mean, SD (n) 
Control  
mean, SD 
(n) 
Mean 
Difference 
(unadjusted 
analysis)* 
[95% CI] 
Intervention 
mean, SD (n) 
Control 
mean, 
SD (n) 
Mean 
Difference 
(unadjusted 
analysis)* 
[95% CI] 
Muscle length 
using manual 
goniometry 
Hip flexor (Hip 
angle) 
3 weeks -0.71, 3.54 
(17) 
0.5, 3.354 
(21) 
-0.75  
[-3.03 – 1.52] 
-1.47, 4.24 
(17) 
-0,55, 
3.649 
(20) 
-0.92  
[-3.55 – 1.71] 
15 weeks  1.20, 9.26 
(15) 
1.25, 3.69 
(16) 
-0.05  
[-5.15 – 5.07] 
0.33, 7.06 
(15) 
-0.6, 4.93 
(16) 
0.39  
[-4.05 – 4.84] 
29 weeks 2.31, 10.45 
(16) 
-0.13, 6.20 
(15) 
2.44  
[-3.92 – 8.81] 
3.56, 11.94 
(16) 
-0.40, 
5.87 (15) 
3.96  
[-3.02 – 
10.95] 
55 weeks 0.55, 5.68 
(11) 
2.14, 6.39 
(14) 
-1.59  
[-6.67 – 3.48] 
0.91, 8.33 
(11) 
0.93, 
6.01 (14) 
-0.19  
[-5.95 – 5.91] 
 
Muscle length 
using manual 
goniometry 
Hamstrings 
(popliteal angle) 
3 weeks 36.53, 10.93 
(17) 
36.95, 
13.70 (21) 
-0.42 [-8.72 – 
7.88] 
37.06, 10.16 
(17) 
34.38, 
9.29 (21) 
2.67 [-3.73 – 
9.08] 
15 weeks  40.13, 10.21 
(16) 
39.56, 
5.89 (16) 
0.56 [-5.46 – 
6.58] 
41.5, 10.80 
(16) 
39.69, 
9.98 (16) 
1.81 [-5.69 – 
9.32] 
29 weeks 40.50, 9.18 
(16) 
43.13, 
9.70 (15) 
-2.63 [-9.57 – 
4.30] 
42.0, 11.55 
(16) 
42.60, 
9.19 (15) 
-0.60 [-8.30 – 
7.10] 
55 weeks 42.55, 8.99 
(11) 
42.7, 8.34 
(14) 
-0.16 [-7.36 – 
7.02] 
44.73, 7.57 
(11) 
43.36, 
8.41 14 
1.37 [-5.35 – 
8.09] 
 
Muscle length 
using manual 
goniometry 
3 weeks -4.1, 3.80 
(17) 
-2.10, 4.56 
(21) 
1.68 [-1.12 – 
4.49] 
-0.71, 10.92 
17 
-1.95, 
6.087 
(21) 
1.24 [-4.31 – 
6.92] 
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Ankle dorsi flexion 
(ankle dorsi flexion 
angle) 
15 weeks  -0.56, 6.76 
(16) 
0.00, 5.91 
(17) 
-0.56 [-5.06 – 
3.94] 
0.50, 8.92 
(16) 
-2.71, 
4.51 (17) 
3.20 [-1.77 – 
8.18] 
29 weeks -2.31, 7.65 
(16) 
-2.20, 8.18 
(15) 
-.0.11 [-5.93 – 
5.70] 
1.00, 11.14 
(16) 
-1.80, 
6.88 (15) 
2.80 [-4.06 – 
9.66] 
55 weeks -1.55, 7.27 
(11) 
6.93, 
20.53 (14) 
-8.47 [-21.94 – 
5.00] 
0.09, 11.60 
(11) 
3.14, 
15.86 
(15) 
-3.05 [-14.86 
– 8.76] 
 
Muscle length 
using manual 
goniometry 
Ankle plantar 
flexion (ankle 
plantar flexion 
angle) 
3 weeks 42.84, 6.95 
(17) 
40.33, 
7.80 (21) 
2.49 [-2.42 – 
7.41] 
37.59, 12.95 
(17) 
41.33, 
8.02 (21) 
-3.74 [-10.69 
– 3.20] 
15 weeks  40.44, 6.64 
(16) 
33.53, 
9.24 (17) 
6.90 [1.15 – 
12.65] 
39.33, 8.46 
(15) 
33.24, 
9.07 (17) 
6.09 [-0.23 – 
12.46] 
29 weeks 41.25, 7.93 
(16) 
37.07, 
8.47 (15) 
4.18 [-1.84 – 
10.21] 
41.63, 6.27 
(16) 
37.67, 
8.26 (15) 
3.95 [-1.40 – 
9.32] 
55 weeks 39.91, 10.38 
(11) 
35.57, 
15.05 (14) 
4.33 [-6.93 – 
15.60] 
36.36, 8.62 
(11) 
34.50, 
15.07 
(14) 
1.86 [-8.70 – 
12.43] 
Knee muscle 
strength measured 
in Newtons 
(Maximum score of 
three trials) 
3 weeks 17, 68.59 
(27.38) 
21, 59.71 
(34.15) 
8.87 [-11.85 – 
29.60] 
17, 59.82 
(32.95) 
21, 60.19 
(24.67) 
-0.36 (-19.32 
– 18.59) 
15 weeks  15, 70.33 
(25.43) 
16, 59.19 
(25.89) 
11.14 [-7.69 – 
29.98] 
15, 67.00 
(42.07) 
16, 60.06 
(24.88) 
6.93 (-18.25 
– 32.13) 
29 weeks 16, 71.69 
(28.25) 
15, 60.20 
(35.21) 
11.48 [-11.89 
– 34.86] 
16, 59.81 
(34.77) 
15, 69.73 
(35.39) 
-9.92 (-35.70 
– 15.86) 
55 weeks 11, 79.00 
(38.10) 
14, 67.07 
(43.86) 
11.92 [-22.62 
– 46.48] 
11, 80.27 
(55.20) 
14, 69.36 
(32.27) 
10.91 (-
25.54 – 
47.37) 
Modified Ashworth 
Scale Score 
Hip adductors 
3 weeks 17, 0.06 (0.24) 21, 0.24 
(0.54) 
-0.18 [-0.47 
– 0.11] 
17, 0.12 
(0.33) 
21, 0.19 
(0.51) 
-0.73 [-0.37 
– 0.22] 
15 weeks  16, 0.19 (0.54) 16, 0.31 
(0.60) 
-0.13 [-0.54 
– 0.29] 
16, 0.25 
(0.57) 
17, 0.12 
(0.33) 
0.13 [-0.20 – 
0.46] 
29 weeks 16, 0.50 (1.10) 15, 0.40 
(0.74) 
0.10 [-0.59 
– 0.79] 
16, 0.75 
(1.24) 
15, 0.406 
(0.74) 
0.35 [-0.40 – 
0.79] 
55 weeks 11, 0.36 (0.51) 14, 0.50 
(0.86) 
0.14 [-0.74 
– 0.47] 
11, 0.27 
(0.65) 
14, 0.50 
(1.02) 
-0.23 [-0.96 
– 0.50] 
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Hamstrings 
 
3 weeks 17, 0.12 (0.49) 21, 0.19 
(0.68) 
-0.73 [0.47 
0 – 0.33] 
17, 0.06 
(2.43) 
21, 0.19 
(0.51) 
-0.13 [-0.41 
– 0.14] 
15 weeks  16, 0.31 (0.87) 16, 0.25 
(0.58) 
0.06 [-0.47 
– 0.60] 
16, 0.50 
(0.96) 
17, 0.12 
(0.33) 
0.38 [-0.12 – 
0.89] 
29 weeks 16, 0.50 (0.89) 15, 0.47 
(0.74) 
0.33 [-0.57 
– 0.64] 
16, 0.75 
(1.00) 
15, 0.60 
(0.74) 
0.15 [-0.50 – 
0.80] 
55 weeks 11, 0.36 (0.67) 14, 0.50 
(0.94) 
0.14 [-0.83 
– 0.56] 
11, 0.36 
(0.92) 
14, 0.43 
(0.94) 
-0.07 [-0.84 
– 0.71] 
Ankle flexion 3 weeks 17, 0.18 (0.73) 21, 0.29 
(0.64) 
-0.11 [-0.56 
– 0.34] 
17, 0.24 
(0.97) 
21, 0.14 
(0.48) 
0.92 [-0.39 – 
0.58] 
15 weeks  16, 0.69 (0.87) 16, 0.69 
(1.01) 
0.00 [-0.68 
– 0.68] 
16, 1.13 
(1.30) 
17, 0.59 
(1.32) 
0.54 [-0.38 – 
1.46] 
29 weeks 16, 0.63 (0.72) 15, 0.40 
(0.91) 
0.23 [-0.88 
– 0.83] 
16, 1.06 
(1.34) 
15, 0.53 
(0.99) 
0.53 [-0.34 – 
1.40] 
55 weeks 11, 0.82 (1.25) 14, 0.50 
(1.09) 
0.45 [(-0.91 
– 1.00] 
11, 0.82 
(1.25) 
14, 0.50 
(1.09) 
0.32 [-0.65 – 
1.29] 
Ankle extension 
 
3 weeks 17, 0.12 (0.49) 21, 0.14 
(0.48) 
-0.02 [-0.34 
– 0.29] 
17, 0.24 
(0.97) 
21, 0.14 
(0.48) 
0.92 [-0.40 – 
0.58] 
15 weeks  16, 0.25 (0.78) 16, 0.25 
(0.57) 
0.00 [-0.49 
– 0.49] 
16, 0.38 
(1.03) 
17, 0.29 
(0.70) 
0.08 [-0.54 – 
0.70] 
29 weeks 16, 0.38 (0.89) 15, 0.13 
(0.35) 
0.24 [-0.26 
– 0.74] 
16, 0.50 
(1.03) 
15, 0.00 
(0.00) 
0.50 [-0.05 – 
1.05] 
55 weeks 11, 0.00 (0.00) 14, 0.43 
(1.09) 
-0.43 [-1.11 
– 0.25] 
11, 0.36 
(0.92) 
14, 0.29 
(0.72) 
0.78 [-0.60 – 
0.76] 
* calculated using intervention group minus control group  CI = confidence interval 
Table 4.19a Mean difference (95% Confidence Interval) between the groups at each time point for proposed secondary 
outcome data from baseline 
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Table 4.19b shows the change from baseline in proposed secondary outcome data for the Trunk Control Test and patient-
report outcome measures from baseline for both groups. Trunk Control Test scores had wide 95% confidence intervals and 
scores were similar for both groups. Scores were also similar in both groups for PHQ-9, SAQoL-39, EQ-5D-5L. For the SAD-
Q10, there was only one participant for all time points except 29 weeks, therefore, there is no indication of variance (SD) 
provided. 
Outcome variable Time point 
(+/-1 week) 
Intervention 
group 
Mean, SD (n) 
Control 
group 
Mean, SD (n) 
Mean Difference 
(unadjusted analysis)* 
[95% CI] 
Trunk Control Test  
 
3 weeks 33.24, 33.40 (17) 31.85, 30.96 (20) 1.38 (-20.11 – 22.88) 
15 weeks  35.50, 37.67 (16) 33.35, 34.80 (17) 2.14 (-23.58 – 27.88) 
29 weeks 37.88, 33.94 (16) 37.06, 38.53 (16) 0.81 (-25.10 – 26.73) 
55 weeks 36.25, 40.77 (12) 32, 37.77 (15) 4.25 (-26.96 – 35.46) 
 
Patient Health Questionnaire 9 
(PHQ-9) 
 
3 weeks 11.69, 5.52 (16) 10.55, 4.77 (20) 1.13 (-2.35 – 4.62) 
15 weeks  13.69, 4.75 (16) 10.82, 6.44 (17) 2.86 (-1.17 – 6.90) 
29 weeks 9.85, 6.84 (13) 8.69, 4.19 (16) 1.15 (-3.07 – 5.39) 
55 weeks 8.82, 5.17 (11) 9.07, 6.13 (15) -2.48 (-4.84 – 4.46) 
Stroke Aphasia Depression 
Questionnaire (SAD-Q10) 
 
3 weeks 14.00, 0.00 (1) 12, 0.00 (1) 2.00, 0.00 (1) 
15 weeks  14.00, 0.00 (1) 12, 0.00 (1) 2.00, 0.00 (1) 
29 weeks 12.00, 8.66 (3) (0) - 
55 weeks 17.00, 0.00 (1) (0) - 
 
Stroke and Aphasia Quality 
of Life Scale (SAQOL39) 
Subgroup: Physical 
 
3 weeks 2.92, 1.27 (14) 2.23, 1.12 (17) 0.68 (-0.20 – 1.56) 
15 weeks  2.19, 0.96 (15) 2.47, 0.99 (17) -0.27 (-0.98 – 0.43) 
29 weeks 2.53, 1.28 (14) 2.32, 0.74 (16) 0.27 (-0.56 – 0.97) 
55 weeks 2.33, 1.16 (11) 2.31, 1.03,) (15) 0.15 (-0.88 – 0.91) 
 
3 weeks 3.66, 1.35 (14) 4.22, 0.93 (17) -0.56 (-1.4 – 0.28) 
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Stroke and Aphasia Quality 
of Life Scale (SAQOL39) 
Subgroup: Communication 
 
15 weeks  3.64, 1.27 (15) 4.3, 0.78 (17) -0.71 (-1.46 – 0.41) 
29 weeks 3.68, 1.10 (14) 4,57, 0.39 (16) -0.88 (-1.49 – 0.28) 
55 weeks 3.84, 1.21 (11) 4.29, 0.79 (15) 0.26 (-1.26 – 0.36) 
 
Stroke and Aphasia Quality 
of Life Scale (SAQOL39) 
Subgroup: Psychosocial  
 
3 weeks 3.55, 0.83 (14) 3.54, 0.74 (17) 0.01 (-0.56 – 0.59) 
15 weeks  3.22, 0.71 (15) 3.75, 0.65 (17) -0.52 (-1.02 – -0.02) 
29 weeks 3.46, 0.80 (14) 3.53, 0.64 (15) -0.17 (-0.71 – 0.36) 
55 weeks 3.31, 0.79 (11) 3.47, 0.76 (15) -0.16 (-0.80 – 0.47) 
 
Stroke and Aphasia Quality 
of Life Scale (SAQOL39) 
Subgroup: Energy 
 
3 weeks 3.21, 0.89 (14) 3.30, 0.95 (17) -0.94 (-0.78 – 0.59) 
15 weeks  3.46, 0.66 (15) 3.44, 0.84 (17) 0.02 (-0.52 – 0.57) 
29 weeks 3.39, 1.05 (14) 3.37, 0.81 (16) 0.01 (-0.68 – 0.72) 
55 weeks 3.11, 0.82 (11) 3.30, 0.66 (15) -0.18 (-0.78 – 0.41) 
 
Stroke and Aphasia Quality 
of Life Scale (SAQOL39) 
 
3 weeks 3.26, 1.00 (14) 3.07, 0.77 (17) 0.19 (-0.45 – 0.84) 
15 weeks  2.87, 0.60 (15) 3.27, 0.60 (17) -0.39 (-0.86 – 0.78) 
29 weeks 3.09, 0.94 (14) 3.20, 0.43 (16) -0.11 (-0.64 – 0.42) 
55 weeks 2.95, 0.76 (11) 3.10, 0.64 (15) -0.14 (-0.71 – 0.42) 
 
European Quality of Life-5 
Dimensions (EQ-5D 5L) 
Mobility 
 
3 weeks 3.79, 1.47 (14) 3.79, 1.61 (19) -0.04 (-1.12 – 1.11) 
15 weeks  3.67, 1.65 (15) 3.71, 1.72 (17) -0.03 (-1.25 – 1.17) 
29 weeks 3.43, 1.45 (14) 4.00, 1.26 (16) -0.57 (-1.58 – 0.44) 
55 weeks 3.82, 1.32 (11) 3.33, 1.63 (15) 0.48 (-0.75 – 1.72) 
 
European Quality of Life-5 
Dimensions (EQ-5D 5L) 
Self-care 
 
3 weeks 3.21, 1.36 (14) 2.95, 1.39 (19) 0.26 (-0.72 – 1.26) 
15 weeks  3.40, 1.29 (15) 3.00, 1.50 (17) 0.40 (-0.62 – 1.42) 
29 weeks 3.43, 1.32 (14) 3.56, 1.59 (16) -0.13 (-1.24 – 0.97) 
55 weeks 3.36, 1.80 (11) 3.47, 1.40) (15) -0.10 (-1.40 – 1.19) 
 
European Quality of Life-5 
Dimensions (EQ-5D 5L) 
Usual activities 
 
3 weeks 3.36, 1.59 (14) 3.32, 1.79 (19) 0.41 (-1.19 – 1.27) 
15 weeks  4.07, 1.43 (15) 4.18, 1.28 (17) -0.10 (-.09 – 0.87) 
29 weeks 3.86, 1.70 (14) 4.44, 1.26 (16) -0.58 (-1.69 – 0.53) 
55 weeks 4.09, 1.38 (11) 4.07, 1.38 (15) 0.24 (-1.13 – 1.18) 
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European Quality of Life-5 
Dimensions (EQ-5D 5L) 
Pain/discomfort 
 
3 weeks 1.64, 1.27 (14) 1.89, 0.99 (19) -0.25 (-1.05 – 0.55) 
15 weeks  1.87, 1.12 (15) 2.35, 1.11 (17) -0.486 (-1.29 – 0.32) 
29 weeks 19.3, 1.32 (14) 2.44, 1.45 (16) -0.50 (-1.55 – 0.54) 
55 weeks 2.09, 1.30 (11) 2.60, 1.72 (15) -0.50 (-1.78 – 0.77) 
 
European Quality of Life-5 
Dimensions (EQ-5D 5L) 
Anxiety/depression 
 
3 weeks 2.07, 1.26 (14) 1.74, 1.24 (19) 0.22 (-0.56 – 1.23) 
15 weeks  2.47, 0.99 (15) 2.47, 1.50 (17) -0.004 (-0.93 – 0.93) 
29 weeks 2.29, 1.38 (14) 2.33, 1.29 (15) -0.48 (-1.07 – 0.97) 
55 weeks 2.27, 0.90 (11) 2.40, 1.50 (15) -0.12 (-1.18 – 0.92) 
 
European Quality of Life-5 
Dimensions (EQ-5D 5L) 
  
3 weeks 50.71, 20.17 (14) 55.59, 23.97 (17) -4.87 (-21.37 – 11.62) 
15 weeks  50.14, 24.35 (14) 48.00, 26.78,) (15) 2.14 (-17.40 – 21.69) 
29 weeks 60.00, 31.35 (10) 53.45, 27.22 (11) 7.54 (-19.21 – 34.30) 
55 weeks 52.25, 25.16 (8) 57.50, 27.99 (14) -5.25 (-30.24 – 19.74) 
* calculated by intervention group minus control group 
Table 4.19b Mean difference (95% Confidence Interval) between the groups at each time point for proposed secondary 
outcome data from baseline 
 
4.11.5 Timing of assessments 
The target was to complete the baseline assessments within ± seven days of consent and all other visits within ± seven days 
of the dates stipulated on the trial website (calculated from date of randomisation). Table 4.20 shows the timing of 
assessments throughout the trial. One participant was unwell for their baseline assessment, which was completed within 14 
days, resulting in 97.8% (n=44) baseline assessments completed within target. In all cases and at all time-points, the 
assessments were not completed within this protocolised time frame because the participants had withdrawn from the trial. 
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However, when removing participants who withdrew, the completion rates are much higher for 15, 29 and 55 weeks, as shown 
at the bottom of Table 4.20. 
 Baseline 
(n=45*) 
(T1) % (n) 
3 weeks 
(T2) (n=39*) 
% (n) 
15 weeks 
(T3) (n=33*) 
% (n) 
29 weeks 
(T4) (n=32*) 
% (n) 
55 weeks 
T5) (n=27*) 
% (n) 
Completion status including withdrawals     
Completed within 7 days of consent or ± 7 days 
from the follow-up visit date as per protocol351 
 
97.8 (44) 82.2 (37) 73.3 (33) 71.1 (32) 55.6 (25) 
Completed within +/- 8-14 days of consent or ± 7 
days from the follow-up visit date as per 
protocol351 
2.2 (1) 4.4 (2) 0.00 (0) 0.00 (0) 4.4 (2) 
Not completed 0.00 (0) 13.3 (6) 
[n=6 
withdrawn] 
26.6 (12) 
[n=11 
withdrawn, 
n=1 
unavailable] 
13.3 (13) 
[n=13 
withdrawn] 
40.0 (18) 
[n=18 
withdrawn] 
Completion status excluding withdrawals     
Completed within 7 days of consent or ± 7 days 
from the follow-up visit date as per protocol351 
 
97.8 (44) 94.9 (37) 100.0 (33) 100.0 (32) 92.6 (25) 
Completed within +/- 8-14 days of consent or ± 7 
days from the follow-up visit date as per 
protocol351 
2.2 (1) 5.1 (2) 0.00 (0) 0.00 (0) 7.4 (2) 
*number participants in the trial at each time-point 
Table 4.20 Timing of assessments  
4.12 Missing data 
Missing data for the proposed primary outcome measures is shown in Tables 4.21.. There are more missing data in the 
intervention group, which increased at week 3, 15 and 55. Both proposed primary outcome measures have the same 
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percentage of completeness. With exception of the participants who withdrew, all but one participant completed their primary 
outcome measures (one participant in the intervention group was unwell and missed their 3-week visit). 
 
Outcome Variable 
Time point Completeness of 
Outcome Measure out of 
45 participants 
% (n) 
% (n) missing 
Intervention  Control 
Barthel Index 
 
Baseline 100.0 (45) 0 (0) 0 (0) 
Week 3 87.0 (39) 22.7 (5) 4.3 (1) 
Week 15 73.3 (33) 27.3 (6) 26.1 (6) 
Week 29 71.1 (32) 27.3 (6) 30.4 (7) 
Week 55 60.0 (27) 45.5 (10) 34.8 (8) 
 
Edmans Activities of 
Daily Living Index for 
Stroke Patients 
Baseline 100.0 (45) 0 (0) 0 (0) 
Week 3 87.0 (39) 22.7 (5) 4.3 (1) 
Week 15 73.3 (33) 27.3 (6) 26.1 (6) 
Week 29 71.1 (32) 27.3 (6) 30.4 (7) 
Week 55 60.0 (27) 45.5 (10) 34.8 (8) 
Table 4.21a Summary of missing data for proposed primary outcome measures 
 
Due to participant withdrawals and deaths, the number of physical secondary outcomes measures completed dropped at each 
timepoint from baseline in both groups (intervention group: 100% at baseline to 50% at week-55; control group: 95.7% at 
baseline to 60.90% at week-55). The number of participants able to complete the PHQ-9 increased over time, thus the number 
of SADQ-10 reduced over time. However, comparing participants’ responses over time was affected by switching from one 
measure to another during follow-up periods. At baseline, more participants were able to complete the EQ-5D-5L than the 
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SAQoL-39. However, completeness of the EQ-5D-5L got worse over time for the health state. Blinded assessor 1 (CI) 
captured reasons why outcome assessments were not undertaken or completed, but this was not formally requested therefore 
was not captured for Blinded Assessor 2. Reasons for non-completion for all or component parts of physical outcome 
measures were pain, ankle fracture, fatigue, did not want to lay flat, did not want to be moved, and cognitive and/or 
communication impairment, not wanting to answer a specific question (n=1 participant, one question in EQ-5D-5L about 
depression) for self-report outcome measures. 
Outcome Variable Time 
point 
Completeness of Outcome 
Measure out of 45 participants 
% (n) 
% (n) missing 
  Intervention Control Intervention Control 
PHQ-9 
 
Baseline 77.3 (17) 82.6 (19) 22.7 (5) [completed 
SADQ10] 
17.4 (4) [completed 
SADQ10] 
Week 3 72.7 (16) 87.0 (20) 27.3 (6) [n=1 
completed SAD10, 
n=1 unwell, n=4 
withdrawn] 
13.0 (3) [n=1 
completed SADQ10 
[n=2 withdrawn] 
Week 15 72.7 (16) 73.9 (17) 27.3 (6) [all 
withdrawn] 
26.1 (6) [n=1 
unavailable, n=5 
withdrawn] 
Week 29 59.1 (13) 69.6 (16) 40.9 (9) [n=3 
completed SADQ10, 
n=6 withdrawn] 
30.4 (7) [all 
withdrawn] 
Week 55 50.0 (11) 65.2 (15) 50.0 (11) [n=1 
completed SADQ10, 
[n=10 withdrawn] 
34.8 (8) [all 
withdrawn] 
SAD-Q10 Baseline 22.7 (5) 17.4 (4) 72.3 (17) 82.6 (19) 
Week 3 4.5 (1) 4.3 (1) 72.7 (16) 86.9 (20) 
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This measure was 
only completed if 
participants were 
unable to complete 
the PHQ-9 due to 
aphasia 
Week 15 0.0 (0) 0.0 (0) 100.0 (22) 100.0 (23) 
Week 29 13.6 (3) 0.0 (0) 86.4 (19) 100.0 (23) 
Week 55 4.5 (1) 0.0 (0) 95.5 (21) 100.0 (23) 
 
SAQoL-39 
Physical score 
Baseline 72.7 (16) 78.3 (18) 27.3 (6) 21.7 (5) 
Week 3 63.6 (14) 73.9 (17) 36.4 (8) 26.1 (6) 
Week 15 68.2 (15) 73.9 (17) 31.8 (7) 26.1 (6) 
Week 29 63.6 (14) 69.6 (16) 36.4 (8) 30.4 (7) 
Week 55 50.0 (11) 65.2 (15) 50.0 (11) 34.8 (8) 
 
SAQoL-39 
Communication 
score 
 
Baseline 72.7 (16) 78.3 (18) 27.3 (6) 21.7 (5) 
Week 3 63.6 (14) 73.9 (17) 36.4 (8) 26.1 (6) 
Week 15 68.2 (15) 73.9 (17) 31.8 (7) 26.1 (6) 
Week 29 63.6 (14) 69.6 (16) 36.4 (8) 30.4 (7) 
Week 55 50.0 (11) 65.2 (15) 50.0 (11) 34.8 (8) 
 
SAQoL-39 
Psychosocial score 
 
Baseline 72.7 (16) 78.3 (18) 27.3 (6) 21.7 (5) 
Week 3 63.6 (14) 73.9 (17) 36.4 (8) 26.1 (6) 
Week 15 68.2 (15) 73.9 (17) 31.8 (7) 26.1 (6) 
Week 29 63.6 (14) 69.6 (16) 36.4 (8) 30.4 (7) 
Week 55 50.0 (11) 65.2 (15) 50.0 (11) 34.8 (8) 
 
SAQoL-39 
Energy score 
 
Baseline 72.7 (16) 78.3 (18) 27.3 (6) 21.7 (5) 
Week 3 63.6 (14) 73.9 (17) 36.4 (8) 26.1 (6) 
Week 15 68.2 (15) 73.9 (17) 31.8 (7) 26.1 (6) 
Week 29 63.6 (14) 69.6 (16) 36.4 (8) 30.4 (7) 
Week 55 50.0 (11) 65.2 (15) 50.0 (11) 34.8 (8) 
 
EQ-5D-5L  
Mobility  
Baseline 81.8 (18) 91.3 (21) 18.2 (4) 8.7 (2) 
Week 3 63.6 (14) 82.6 (19) 36.4 (8) 17.4 (4) 
Week 15 68.2 (15) 73.9 (17) 31.8 (7) 26.1 (6) 
Week 29 63.6 (14) 69.6 (16) 36.4 (8) 30.4 (7) 
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Week 55 50.0 (11) 65.2 (15) 50.0 (11) 34.8 (8) 
 
EQ-5D-5L 
Self-care 
 
Baseline 81.8 (18) 91.3 (21) 18.2 (4) 8.7 (2) 
Week 3 63.6 (14) 82.6 (19) 36.4 (8) 17.4 (4) 
Week 15 68.2 (15) 73.9 (17) 31.8 (7) 26.1 (6) 
Week 29 63.6 (14) 69.6 (16) 36.4 (8) 30.4 (7) 
Week 55 50.0 (11) 65.2 (15) 50.0 (11) 34.8 (8) 
 
EQ-5D-5L 
Usual activities 
Baseline 81.8 (18) 91.3 (21) 18.2 (4) 8.7 (2) 
Week 3 63.6 (14) 82.6 (19) 36.4 (8) 17.4 (4) 
Week 15 68.2 (15) 73.9 (17) 31.8 (7) 26.1 (6) 
Week 29 63.6 (14) 69.6 (16) 36.4 (8) 30.4 (7) 
Week 55 50.0 (11) 65.2 (15) 50.0 (11) 34.8 (8) 
 
EQ-5D-5L 
Pain/Discomfort 
Baseline 81.8 (18) 91.3 (21) 18.2 (4) 8.7 (2) 
Week 3 63.6 (14) 82.6 (19) 36.4 (8) 17.4 (4) 
Week 15 68.2 (15) 73.9 (17) 31.8 (7) 26.1 (6) 
Week 29 63.6 (14) 69.6 (16) 36.4 (8) 30.4 (7) 
Week 55 50.0 (11) 65.2 (15) 50.0 (11) 34.8 (8) 
 
EQ-5D-5L 
Anxiety/Depression 
Baseline 81.8 (18) 91.3 (21) 18.2 (4) 8.7 (2) 
Week 3 63.6 (14) 82.6 (19) 36.4 (8) 17.4 (4) 
Week 15 68.2 (15) 73.9 (17) 31.8 (7) 26.1 (6) 
Week 29 63.6 (14) 69.6 (16) 36.4 (8) 34.8 (8) 
Week 55 50.0 (11) 65.2 (15) 50.0 (11) 34.8 (8) 
EQ-5D-5L 
Health State 
Baseline 77.3 (17) 78.3 (18) 22.7 (5) 21.7 (5) 
Week 3 63.6 (14) 65.2 (15) 36.4 (8) 26.1 (6) 
Week 15 63.6 (14) 65.2 (15) 36.4 (8) 34.8 (8) 
Week 29 45.5 (10) 47.8 (11) 54.5 (12) 52.2 (12) 
Week 55 36.4 (8) 60.9 (14) 63.6 (14) 39.1 (9) 
Table 4.21b Summary of missing data for proposed secondary patient report outcome measures 
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4.13 Blinding 
The CI was unblinded to 10 participants after the 3-week assessment for the 
purpose of interview. The CRF asked whether the assessor was unblinded 
during the visit, instead of prior to or during the visit for the 15-, 29- and 55-
week assessments, therefore, this was frequently answered as not unblinded 
during the visit. There were no other instances of unblinding during or between 
visits other than the 10 participants who were interviewed, and Blinded 
Assessor 2 was not unblinded. Table 4.22 shows the extent to which the 
assessors remained blinded. The number of instances the blinded assessors 
guessed group allocation correctly was higher than chance. 
Follow-up 
time point 
post-
randomisation 
Number of 
assessments 
completed 
(n) 
Number of 
instances the 
blinded assessor 
believed they had 
been unblinded 
% (n) 
Number of 
instances the 
blinded assessor 
correctly guessed 
group allocation 
% (n) 
3 weeks 38 0.00 (0) 65.8 (25) 
15 weeks 33 5.98 (3) 75.6 (25) 
29 weeks 32 3.12 (1) 68.8 (22) 
55 weeks 27 0.00 (0) 74.1 (20) 
Table 4. 22 The extent to which the assessors remained blinded 
 
4.14 Responsiveness of proposed outcome measures 
Responsiveness, or sensitivity to change, of the proposed outcome measures 
will be addressed in the discussion chapter (Chapter 5). Caution needs to be 
applied when looking at responsiveness over time because this feasibility trial is 
not powered for this purpose. Looking at the primary outcome measures in 
Table 4.16a (Section 4.12), BI scores initially increase, followed by a slow 
steady increase which then plateaus. Table 4.16a included the whole dataset, 
i.e. participants who did not complete all follow-up assessments that may skew 
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the results. Figure 4.22 below shows the change scores for the 27 participants 
who completed assessments at all time points to show responsiveness. 
 
Figure 4.22 Change scores for the Barthel Index for the 27 participants who 
completed assessments at all time-points for both groups 
The Edmans showed a similar pattern of changes to the BI, with the largest 
increase in scores from baseline to 3-weeks, and a smaller change between 15 
and 29 weeks. There is no overall score for the Edmans, each domain is scored 
separately. Scores increased (indicating improvement) at each of the five time 
points for washing (0.73 to 3.25), dressing (0.42 to 4.83) and kitchen activities 
(0 to 3.93) . Subgroups with the greatest difference between groups were 
advanced mobility 0 to 2.25) (difference seen as early as three weeks 0 at 
baseline 1.5 week-3) and housework activities (0 to 1.5). There was no 
difference in grooming (combing hair, cleaning teeth and shaving) which was 
not expected. 
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Except for basic mobility, advanced mobility and bed mobility, the activities in 
other subgroups can be carried out in either sitting or standing, thus, an 
outcome measure of mobility for a subsequent trial may preferable. 
Secondary outcome measures, such as muscle length did not show any marked 
changes over the period and all changes were less than 3 degrees. However, it 
is unclear whether this reflects a lack of responsiveness of the outcome 
measures or a lack of clinical improvement in this feasibility trial. The Trunk 
Control Test showed the potential to detect change (Figure 4.23) which would 
justify its use in a subsequent main trial, however, this measures trunk control in 
lying and sitting, standing is not included. Caution needs to be applied because 
the sample size is not powered for the purpose of determining a change 
between the two groups. Figure 4.23 includes assessment data for the 27 
participants who completed the trial. 
 
Figure 4.23 Change scores for the Trunk Control Test change for the 27 
participants who completed assessments at all time-points for both 
groups 
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4.15 Endpoint 
Assessment of the change in outcome measures over time highlights that any 
change between groups is evident by 29 weeks and does not tend to increase 
thereafter. The plateau in outcome measures from 29-55 weeks suggests that a 
follow-up at 29 weeks for a subsequent trial will suffice. The discussion 
(Chapter 5) will explore which outcome measure may be suitable. 
4.16 Sample size 
This feasibility trial has produced the necessary parameter estimates (e.g. 
standard deviations of a chosen [continuous] primary outcome) which can be 
used to calculate effect sizes and produce a sample size for a future main trial. 
However, the feasibility objectives (Tables 4.23 and 4.24) suggest that the trial 
will not progress in its current design, therefore, sample size calculations have 
not been undertaken. 
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4.17 Feasibility objectives 
The feasibility objectives have been addressed and are shown in Table 4.23. Many of the objectives were demonstrated to be 
feasible: recruitment, retention and consent rate, eligibility criteria, burden, fidelity, orthostatic hypotension protocol and safety. 
Willingness of physiotherapists to recruit, willingness of patients to be randomised and acceptability of the intervention are 
described in more detail in the qualitative data (Section 4.24) and discussed in Chapter 5. Participant adherence to the 
intervention group was not achieved by any participant. This is described in more detail in the qualitative data (Section 4.24) 
and discussed in Chapter 5. 
Feasibility 
Indicator 
Outcome Measures and Results Parameter for Success Feasible 
(Y/N) 
Suggested 
Modification 
Process 
Recruitment rate 
 
 
7.6% of participants admitted across 
all four SRUs were recruited 
 
90% of the target 50 participants 
were recruited 
 
 
 
 
≥70% of 50 participants 
over 13 months (Scenario 
1 from the Statistical 
Analysis Plan) 
 
 
 
 
Y 
 
Retention rate 
 
Allocated groups 
T1 100% intervention, 100% control  
T2 77.2% intervention, 91.3% control 
T3 72.7% intervention, 91.3% control 
T4 72.7% intervention, 69.6% control 
T5 54.5% intervention, 65.2% control 
 
Groups combined 
T1 100.0% (n=45) 
 
60% of participants 
completed T1, T2, T3, T4, 
T5 (this includes an 
estimated 40% drop out 
rate due to mortality). 
(Scenario 1 from the 
Statistical Analysis Plan) 
 
 
Y 
 
Need to account for 
higher mortality rate 
and reduce follow-
up period to 6 
months 
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T2 77.8% (n=38) 
T3 73.3% (n=33 
T4 71.1% (n=32 
T5 60.0% (n=27) 
 
Ability to consent 
 
63.0% (n=29) participants provided 
informed consent 
 
 Y  
Consent rate 
 
78.0% (n=46 consented divided by 
n=59 eligible) 
 Y  
Eligibility criteria 
 
Scenario 1 (initial screen on 
admission to SRU): 
79.0% of admissions screened 
(462/586) 
91.8% eligible participants 
approached (73 screened minus n=2 
died and n=4 staff shortage; 67 
divided by 73 multiplied by 100) 
 
Scenario 2: (formal screening by 
completing a Screening CRF once 
stroke severity confirmed eligible) 
59.3% screened (n=73 divided by 
123: 586 admitted minus 462 not 
eligible = 124 minus 1 died = 123)  
63.0 % eligible (46 divided by 73 
multiplied by 100) 
 
≥50% of admissions 
screened and ≥75% of 
eligible participants 
approached 
 
 
≥50% of admissions 
screened and ≥75% of 
eligible participants 
approached 
 
Y 
 
 
 
 
Y 
Need to take into 
account reasons not 
enrolled (staff 
shortages, missed 
not screened, site 
not actively 
recruiting) and 
implement trial 
processes to 
address these 
issues, e.g. network 
or R&D clinicians 
identifying and 
consenting 
participants. 
Willingness of 
physiotherapists to 
recruit 
 
92% of admissions pre-screened for 
stroke severity (n=586 admitted: n=13 
missed, n=5 staff shortage, n=2 no 
reasons given, n=27 site not actively 
recruiting equals n=539 screened) 
 
≤10% of participants not 
approached 
 
Y  
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81% eligible participants approached  
 
Willingness of 
patients to be 
randomised 
 
11.9% of eligible participants declined 
to enrol in the trial (n=73 screened, 
n=59 eligible, n=7 declined to enrol) 
All potential participants who declined 
to enrol declined to share reasons for 
their decision (or were too unwell to 
approach), therefore it is not known 
whether it was because they were not 
willing to be randomised, they were 
not interested in intervention, or not 
interested or wanting to participate in 
a research trial. 
≤10% of participants 
declined to enrol 
 
N Utilise current 
available literature 
on ways to optimise 
recruitment. In 
depth training for 
physiotherapists 
and consider a 
video that is 
accessible for 
people with 
cognitive and 
communication 
impairments to 
ensure standardised 
approach 
information, take 
into consideration 
thoughts and 
feelings about the 
Participant 
Information Sheets 
for participants from 
participants, 
relatives and 
physiotherapists. 
Acceptability of the 
intervention 
 
15.6% of withdrawals (n=7 during the 
3-week physiotherapy period, n=5 in 
the intervention group, n=2 in the 
control group) 
 
≤20% of randomised 
participants withdrew 
Y  
Determining usual 
physiotherapy 
In the control group, functional tasks 
were the most commonly 
0% intervention group (e.g. 
≥5 sessions per week, ≥8 
Y  
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implemented treatment activity, and 
supported standing was the most 
frequently adopted position. A 
breakdown of time spent on these 
variables were not captured, 
therefore, it is not possible to know 
how much the control group differed 
from the intervention group. 
 
repetitions of sit to stand 
and standing for 30 
minutes) implemented in 
the control group 
Resources 
Burden 
 
 
 
6.0% of the functional standing frame 
sessions and 4.4% of the control 
sessions were declined. 
 
12 participants (54.5%) participants 
declined one or more sessions. 
0% follow-up assessments declined 
in both groups 
 
 
≤20% of functional 
standing frame sessions 
declined 
≤20% of recruited 
participants declined 
functional standing frame 
sessions 
≤20% of recruited 
participants declined 
follow-up assessments 
 
 
Y 
 
 
N 
Y 
 
Management 
Fidelity 
 
 
Three Stroke Rehabilitation Units had 
fidelity checking from an independent 
observer. Site 1: one control group 
and one intervention group session; 
Site 3: one control group and 
intervention group session; Site 4: 
one control group session. There was 
no fidelity checking at Site 2 because 
this process was not implemented 
until after they had ceased recruiting. 
 
 
≥3 out of the four Stroke 
Rehabilitation Units 
observed 
 
 
 
 
Y 
 
 
 
N 
 
 
 
N 
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Five sessions in total were observed 
at three sites. Three sessions were 
delivered as per protocol 
One functional standing frame 
session was not delivered as 
intended. 
 
Participant 
adherence in the 
intervention group 
 
 
0% completed ≥5 sessions per week 
in each of the three weeks and 30 
minutes standing and ≥8 sit to stand 
repetitions in each session. 
0% completed ≥15 sessions in total 
over the three weeks and 30 minutes 
standing and ≥8 sit to stand 
repetitions in each session. 
 
 
0% participants completed 30 
minutes of standing in ≥5sessions in 
all three weeks 
0% completed ≥8 sit to stand 
repetitions in ≥5 sessions in all three 
weeks 
≥50% unable to undertake 
the intervention, e.g. ≥5 
sessions per week or ≥15 
sessions over 3-weeks. 
 
 
Standing time in minutes 
increased 30% in each 
session up to 30 minutes 
 
≥8 repetitions of sit to 
stand  
 
N 
 
 
 
 
N 
 
 
 
N 
Address treating 
physiotherapist 
adherence. Provide 
in depth training, 
half day on the trial 
processes and 
whole day on 
delivering the 
intervention to 
people with severe 
stroke, incorporating 
the participants’ 
perspectives. 
Implement a graded 
increment of 30% or 
repetitions of sit to 
stand and consider 
a weekly graded 
approach for both 
standing duration 
and sit to stand 
repetitions and 
provide definition of 
sit to stand. 
Participant 
experience of the 
intervention 
91.0% of sessions were enjoyed 
91.0% of sessions required effort 
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93.0% of sessions participants 
experienced fatigue 
66.5% sessions participants did not 
experience any aches or pains 
Orthostatic 
hypotension 
protocol 
Orthostatic hypotension was 
experienced in 8.3% of the 
intervention group sessions 
7.2% of sessions were not completed 
due to OH 
 
≥50% of participants with 
OH unable to undertake 
the intervention 
Y  
Safety 
During 3-week 
physiotherapy 
period 
 
 
 
 
During follow-up 
visits 
 
n=26 AEs (16 in the intervention 
group and 10 in control group) and 
n=2 SAEs, both in the intervention 
group  
0% unexpected or related to trial 
0% unexpected or related to 
intervention 
n=92 AEs and n=26 SAEs 
 
0% unexpected or related to trial 
 
 
0% AE*; 0% SAE* 
 
 
 
 
0% AE*; 0% SAE* 
 
 
Y 
 
 
 
 
Y 
 
* unexpected and related specifically to the functional standing frame intervention. Baseline (T1), post 3-week intervention (T2), 15 weeks post-randomisation (T3), 29 
weeks post-randomisation (T4) and 55 weeks post-randomisation (T5).  
Table 4.23 Feasibility objectives 
 
Progression to a full trial is based on the criteria set out in the Statistical Analysis Plan, which stipulated that if any one of these 
criteria meets scenario 3 the trial would not progress in its current design. Table 4.24 shows that the recruitment target and 
percentage of participants completing their follow-up assessments at 29 and 55 weeks met criteria for scenario 1. However, no 
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participants completed at least 5 sessions per week and within those five sessions completed the required standing time and 
sit to stand repetitions, therefore, the trial will not progress in its current design. 
 Criteria Scenario 1 Scenario 2 Scenario 3 Outcome 
1 
% of recruitment target achieved (50 
participants) 
≥70% of the 
target figure 
51-69% of 
the target 
figure 
≤50% of the 
target figure 
90% recruitment target achieved. 
This criterion meets scenario 1 
2 
Target figure = 75% of the percentage 
of participants randomised to the 
intervention group who participated in 
at least five sessions per week of the 
intervention (e.g. 30 minutes of 
standing, or a 30% increase in 
standing time every session, and 8-12 
sit to stand repetitions). This includes 
an estimated dropout rate of 25% due 
to mortality308,309 
≥70% of the 
target figure 
51-69% of 
the target 
figure 
≤50% of the 
target figure 
0% participants randomised to the 
intervention group participated in at 
least five sessions per week and 
within those five sessions 
completed the required standing 
time and sit to stand repetitions. 
 
This criterion meets scenario 3. 
3 
Target figure = 60% of the percentage 
of participants randomised who 
completed their 29- and 55-weeks 
post-randomisation follow-up 
assessment. This includes an 
estimated 40% drop out rate due to 
mortality308,309. 
≥70% of the 
target figure 
51-69% of 
the target 
figure 
≤50% of the 
target figure 
60% (27 participants) completed 
their 29- and 55-week follow-up 
assessment which equates to 100% 
of the criteria target. 
This criterion meets scenario 1. 
       
 
 Proposed action 
Proceed to 
submitting 
plan to 
funder for 
full trial 
Discuss with 
TSC and 
funder about 
progression  
No 
progression 
to a full trial 
in the current 
design 
 
The trial will not progress without 
addressing adherence 
Table 4.24 Criteria for progression to full trial 
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Chapter 5 qualitative results 
5.1 Introduction to qualitative results 
This chapter presents the interview and focus group data that explored the 
experiences of participants, relatives and physiotherapists involved in the trial to 
determine whether the intervention and trial processes were feasible and 
acceptable. 
5.2 Aim of qualitative component 
The aim of the qualitative component was to explore the experience of using the 
functional standing frame programme and engaging in associated trial 
processes from the perspectives of the person with stroke, their relative and 
physiotherapists. The purpose was to identify challenges that may be overcome 
and ways of resolving and improving them to maximise success of a 
subsequent definitive trial. 
5.3 Objectives of qualitative component 
The objectives of the qualitative component were to explore: 
• Means by which the trial procedures (timing and mode of participant 
recruitment, information provision, methods of data collection for 
example timing and choice of outcome measures) can be refined to 
maximise recruitment, retention and acceptability in a definitive trial 
• Participants’ experiences of engaging in the functional standing frame 
programme 
• Participants’ experiences of being randomised, and reasons for, and 
experiences of, withdrawing from the trial 
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• Relatives’ influence in participants’ decision to consent to participate, 
remain in the trial or act as consultee for their relative 
• Physiotherapists’ attitudes, thoughts and feelings of implementing the 
intervention and trial processes and whether they perceive a subsequent 
RCT to be achievable. 
5.4 Data collection 
Interviews: 
Twenty face-to-face semi-structured interviews were conducted, involving ten 
patient participants (four who had been allocated to the intervention group), four 
relatives (one whose relative was allocated to the intervention group) and six 
physiotherapists were interviewed.  
It was intended to interview an equal number of participants in the intervention 
and control groups, however, due to the number of participants with severe 
communication impairments or whom were medically unwell, interviews for the 
intervention group were limited. 
It was not possible to interview participants who withdrew from the intervention. 
Three participants personally made the decision to withdraw, all of whom died 
shortly afterwards. Three participants were withdrawn by a healthcare 
professional because they were receiving end of life care, therefore, it was not 
appropriate to offer interviews. Four out of five of the participants who were 
withdrawn during the intervention period were in the intervention group. 
All patient participant and relative interviews were conducted in their preferred 
location, e.g. in a SRU either at their bedside behind curtains or in a quiet 
private room off the ward. Patient participants were present during relative 
interviews, which was their preference. All physiotherapist interviews except 
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one were conducted in a private room at their hospital base. One interview was 
conducted in a hotel close to one hospital base. 
Focus group: 
Five physiotherapists, (two of whom had participated in individual interview 
approximately three months after recruitment commenced at their site) 
participated in the focus group. The focus group was conducted five weeks after 
recruitment closed, in a non-clinical building in a location central to all sites 
attending. Three of the four sites were represented at the focus group. One site 
was unable to join the focus due to long-term significant staff shortages. 
5.5 Participant characteristics 
Patient participant names and trial numbers, and relatives’ and physiotherapists’ 
names have been replaced with a participant identifier to ensure confidentiality 
is maintained because they could be identifiable to treating therapists. A 
detailed description of each physiotherapist and their banding is not provided as 
those familiar with the trial and sites would easily be able to identify each 
physiotherapist by this description. 
Patient participants’ age ranged from 51-96 years, all but two were over 65 
years of age and retired. Most had communication impairments that affected 
their ability to express themselves or understand abstract questions. Some 
patient participants had cognitive impairments, two of whom were unable to 
recall any aspects of the trial or being involved in it. Some patient participants 
used few words in response to questions due to cognitive and communication 
impairments. This resulted in short extracts of textual data. Table 4.25 provides 
patient participants’ characteristics. 
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Participant 
Identifier 
Gender Age in 
years 
Communication and/or 
cognitive impairments 
Group 
allocation 
PC1 Female 71 Cognitive Control 
PC2 Male 60 Communication Control 
PC3 Male 65 Communication Control 
PC4 Female 74 Cognitive Control 
PC5 Female 79 Communication Control 
PC6 Male 89 None Control 
PI1 Male 96 Cognitive Intervention 
PI2 Male 51 Communication and cognitive Intervention 
PI3 Male 68 Communication Intervention 
PI4 Female 84 Communication Intervention 
Table 4.25 Patient participants’ characteristics 
 
All but one physiotherapist, and all but one relative was female. The four 
relatives are identified as R1, R2, R3 and R4. Physiotherapists are identified as 
Physio 1, Physio 2, Physio 3, Physio 4, Physio 5, Physio 6, Physio 7, Physio 8 
and Physio 9. Data from the focus group are indicated with an additional FG 
beside the identifier. 
5.6 Themes 
Four main themes were derived from the data, reflecting the underlying 
objectives of the trial: 1) Organisational/cultural factors that impacted on the 
implementation of the trial; 2) Impact of stroke on participation in the trial; 3) 
Experience of trial procedures; 4) Patients, relatives and physiotherapists 
experience of the functional standing frame intervention (Figure 5.1). Data from 
patients and relatives have been separated out from physiotherapists in each 
theme with an overarching synthesis. 
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Figure 5.1 Diagrammatical representation of themes 
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Theme 1) Organisational/cultural factors which impacted on the 
implementation of the trial 
Organisational and cultural factors have the potential to influence the delivery of 
clinical trials and can impact on intervention implementation, recruitment and 
retention352. Data for this theme is from physiotherapists only. 
Staffing 
A common finding across all sites was that inadequate staffing levels due to 
annual and maternity leave, sickness, and new and inexperienced staff made it 
difficult to consistently screen, consent and implement the functional standing 
frame programme.  
“I’ve had a lot of annual leave in the last two months. It’s not helped by B5 
going off sick” [Physio 5] 
“We’ve only had one physiotherapy assistant for the last few months 
because we’ve had someone off sick” [Physio 8FG] 
“It has all been a bit haywire recently as everyone has been off” [Physio 2] 
Several physiotherapists reported that the focus of rehabilitation has changed 
with a greater emphasis on rehabilitation being delivered in the community. 
They commented that this results in a more rapid flow of patients, with a 
common view expressed among the physiotherapists that the pressure of early 
discharge results in rehabilitation focusing on drivers for discharge (e.g. ability 
to perform a safe bed-to-chair transfer and provision of specialist seating) and 
that intensive rehabilitation was a lower priority. 
“Thinking about how rehab has changed, the direction that our Trust has 
been moving is that the majority of the rehab now is being delivered at 
home because people are going home so much earlier.” […] it’s trying to 
get this message across about intensity of practice across really […] 
certainly with the unit we’re on as well, there is so much going on, we find 
that once people get home, that’s where the rehab takes off. The only 
other thing that might have affected intensity of practice, […] the other 
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people who were treating patients were quite new and covering maternity 
posts, quite inexperienced.” [Physio 1] 
“Here you’re under constant pressure to get people out, so you need to 
adapt and change their treatment in order to get them home, get them 
mobile and get them on their feet and safe for discharge.” [Physio 7 FG] 
The implementation of the functional standing frame programme will vary 
depending on how severely impaired patients are, but commonly it relies on the 
availability of two staff members per patient. Some physiotherapists reported 
they needed three staff members, and this affected whether the standing frame 
intervention was used: 
“We tend to see most people as doubles because that’s our staffing allows 
[…] so if we can get them in a standing frame with two people, we will. It’s 
unlikely that we’ll have time every day for three people, so if you can’t get 
them in with two, then they’re probably going to be tilt tabled or sat.” 
[Physio 2] 
Patient flow 
Patient flow across the stroke pathway impacted on how quickly potential 
participants were transferred from acute stroke units to rehabilitation units. This 
affected recruitment as the more acute patients were screened and excluded 
because they were deemed medically unwell for rehabilitation: 
“We had some people like that who were pushed through to us so quickly, 
literally one or two days post-stroke. They’re not having any therapy 
because they’re so acute, so fatigued and we just need to let them wake 
up a little bit” [Physio 5] 
“Some patients will come straight through to the rehab unit and they would 
have their stroke like on the Saturday and then in that really acute stage of 
their stroke […] so, they’re with us within 48 hours of their stroke, so they 
are at a very different stage to others.” [Physio 8 FG] 
In response to this, two months into recruitment, the screening section in the 
protocol was amended from “Within 48 hours of admission (or as soon as 
practicably possible)” to “Within 48 hours of being medically well for 
244 
rehabilitation” to accommodate this organisational process and optimise 
recruitment. 
Competing organisational priorities 
Several physiotherapists identified that trial procedures competed with 
organisational priorities, such as pressure to discharge and the routine clinical 
assessments on admission. The trial protocol required physiotherapists to 
screen and approach new patients within 48 hours of their admission to the 
stroke unit or within 48 hours of being medically well for rehabilitation: 
“I’m finding the 48 hours a little bit tricky to fit in, doing our initial 
assessment, and we do joint seating assessments with the OTs usually 
and all the paperwork that goes with that, then check the inclusion criteria 
and then consent the patient. It feels like 72 hours would be better.” 
[Physio 3] 
Data suggested the physiotherapists wanted to do a good job for both the trial 
and their patients, but this was challenging. It appeared that this was perhaps 
not feasible within existing caseloads, to manage the requirements of the trial 
(paperwork and intervention delivery) and equity of care for both trial and non-
trial patients: 
“We’ve been trying to make it fair across the ward so the participants in 
SPIRES haven’t always been getting five [sessions], whether they’re in 
control or intervention. […] On the days I prioritise SPIRES that may have 
an impact on my case load and then vice versa the next day to try and get 
the right balance” [Physio 5] 
During the recruitment period, at one site, the acute and rehabilitation stroke 
services merged and co-located. As a result of this upheaval, there was a delay 
in that site opening and recruitment was a lower priority. 
“In hindsight for us it was a real challenge because we were combining 
two teams […]. I think it was just to do with the timing of the unit and there 
was so much going on because we were co-locating it and all of that, it 
just took over in the end.” [Physio 1] 
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Research culture and infrastructure 
Although physiotherapists are encouraged to deliver evidence-based practice 
and have an awareness of current relevant research in their field353,354, 
involvement in research locally was reported to be uncommon in most of the 
sites. Some of the physiotherapists remarked that research was not at the 
forefront of their minds and this appeared to affect how the trial was perceived 
and accepted by the wider multi-disciplinary team: 
“I don’t think we’re necessarily in the culture of research and that’s quite 
difficult […] That whole kind of evidence-based approach isn’t thought of 
that highly, it’s quite a sweeping statement, but it’s not at the forefront of 
people’s minds.” [Physio 5] 
Whilst the findings suggest there is not a strong research culture and 
infrastructure across all trial sites, involvement in the trial had prompted some 
physiotherapists to reflect on their current practice: 
“It has made me think about standing people for longer than I might have 
done. Made me think about reducing the length of their rest times and 
thinking about the rep’s of standing up a bit more.” [Physio 3] 
Implementing the trial required the involvement and commitment of the wider 
rehabilitation team. Where this was lacking, some physiotherapists commented 
that they felt unsupported: 
“We really struggled with team dynamics and perceptions of the trial”, 
stating that some staff “felt very unsupported, not just from team leads but 
from other members of the team as well.” [Physio 5 FG] 
The level of support from the wider rehabilitation team appeared to affect 
whether eligible participants were screened and approached resulting in 
selection bias. A suggested potential solution to this was having Clinical 
Research Network staff or Research Nurses undertake screening and consent: 
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“If you had someone completely separate to it, like one of the research 
nurses, it would remove that potential bias from the patients.” [Physio 7 
FG] 
Knowledge and experience 
The participants highlighted that in addition to challenges with staffing, 
competing priorities and lack of research culture impacting on the 
implementation of the trial, so too did their pre-trial level of knowledge and 
experience of using the standing frame. Some physiotherapists lacked 
experience of stroke rehabilitation and the standing frame. Others had 
previously used the standing frame. Both circumstances appeared to affect their 
perceptions of the usefulness of the frame and how they treated and 
progressed their patients. Two sites used the frame more frequently than 
others, but none were routinely implementing prolonged standing and 
repetitions of sit to stand with people with severe stroke, though most had 
previously used the frame for static standing. It was suggested by Physio 1 that 
physiotherapists who are inexperienced in stroke rehabilitation and using the 
standing frame may be less likely to progress patients as much as experienced 
physiotherapists and this may have implications for a subsequent main trial in 
terms of protocol adherence: 
“The other people who were treating patients were quite new and covering 
maternity posts, were quite inexperienced. But it’s also about risk and 
stuff, like pushing and progressing patients as much as you or the regular 
band 6 would have done.” [Physio 1] 
In summary, several organisational/cultural factors impacted on 
physiotherapists’ experience of implementing this feasibility trial. Findings 
revealed that staffing resources are limited in some stroke units, the pressure 
for early hospital discharge is ever present, and change or restructuring of 
services is a constant feature. Nestled within these organisations are 
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experienced and inexperienced physiotherapists struggling to deliver a 
protocolised feasibility trial in departments with a limited research culture and 
infrastructure, whilst maintaining equity of care for all patients. During the 
interviews and focus group, the physiotherapists did not use evidence to 
support their clinical reasoning or reported behaviours. Nevertheless, it was 
apparent that the physiotherapists strived to do their best for both the trial and 
non-trial patients. 
A range of design issues to consider for the main trial have been identified by 
the data so far: i) staffing; ii) early discharge; iii) protocol 48-hour deadline for 
screening and approach; iv) availability of physiotherapists (experienced versus 
inexperienced); and v) building research capacity. 
In addition to how organisational and cultural factors impacted on the 
implementation of the feasibility trial, how patients experienced their stroke 
appeared to shape their perceptions of the functional standing frame 
programme and trial processes, and the reactions of their relatives and 
physiotherapists. The next theme provides insight into the impact of stroke on 
patients, their relatives and physiotherapists. 
Theme 2) Impact of stroke on participation in the trial 
The challenges of conducting clinical trials with people with acute and sub-acute 
stroke are widely acknowledged. Orthostatic hypotension may interfere with or 
limit rehabilitation (Chapter 2). Additionally, cognitive and communication 
impairments may affect potential participants’ ability to provide informed 
consent and understand the intervention, and physical and emotional factors 
may affect their ability and willingness to participate355. 
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Patients’ and relatives’ perspectives 
All patients spoke candidly about the impact of their stroke. Some participants 
shared how their stroke had raised questions about their mortality, and many 
reported changes in cognition, speech, continence, vision, sensation, and 
experienced new symptoms such as fatigue, anxiety and fear. 
“I’ll be honest I didn’t know if I was going to be alive in three weeks’ time. I 
felt so bad that I thought I might die” [PC3] 
“It’s like oh I’ve been hit by a freight train […] difficult concentrating and my 
short-term memory is pretty much non-existent […] it’s affecting my left 
eye really badly.” [PI2] 
“To me this has been worse than my major heart attack and bowel cancer 
because this stroke is not a quick recovery […] the fact that I’ve got no 
control over my continence is devastating. It’s awful, I have never known 
anything like this.” [PI3] 
“But I could barely talk when they came to talk to me about it. But okay, I 
was able to take it all in.” [PC3] 
Patients acknowledged they were fatigued and developed strategies for 
managing fatigue. Patients typically recounted that it was important to “push” 
themselves through the fatigue associated with the stroke and functional 
standing frame programme. They built-in frequent rests before pushing on: 
“It was energy zapping, mentally and physically […] I’ve been able to cope 
even though I’ve been tired” [PI2] 
“Even though I was tired, I pushed myself through it” [PI3] 
Despite physical and mental fatigue, patients and relatives said that people 
should still be asked to be involved in the trial: 
“If you’re of a low mood anything that distracts you or makes you think that 
you’re going to get better is going to be good for you. […] I’m afraid that 
comes with it. I think as long as you understand that comes with it, as long 
as you don’t think it’s personal to you as long as you’ve been told you’re 
going to feel absolutely shattered, then yes.” [R3] 
“You definitely should be offered to be up and moving. If I had a stroke I’d 
probably just lie there and feel sorry for myself, so you need to be 
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encouraged and motivated. Even if you’re fatigued, you should be 
encouraged to get moving” [R2] 
Despite the devastating and life changing impact of their stroke, all patients had 
hopes of recovery and the future: 
“Get back to normal. Just get back to normal. I’ve always been 
independent, I’ve never asked anyone for anything. I just wanted to get 
back to normal” [PI3] 
“Be able to keep myself upright as long as possible to help […] when I got 
home and being able to walk the dog” [PI2] 
“Go where I want to go and do what I want to do. Just a normal life, not to 
be confined to a ruddy bed all the time” [PI1] 
Relatives also described the impact on themselves of their loved one having 
had a stroke. Relatives spoke about how their lives had been turned upside 
down, and how relational and household activities and responsibilities had 
changed: 
“… so much else going on not really stroke related stuff. The stress of him 
having the stroke, not having a job, having to find our rent and probably 
not really stroke related stuff, outside stuff.” [R2] 
“It’s still a strain getting all my meals, and everything done and I’m just in 
the middle sort of thing. She used to do everything and now I’ve got to do 
it all.” [R1] 
Whilst early discharge is an organisational priority, impending return home also 
had an impact: 
“I’ve had to do quite a bit now. I’ve had to alter the house quite a bit 
because she’s going to be downstairs and she can’t make the stairs. I’m 
wondering now if there’s enough room for the carers, but I won’t know that 
until I get the bed”. [R1] 
Family members were occasionally worried about their relative being in the trial 
because of their recent and severe stroke, thinking they had been admitted for 
recuperation, not rehabilitation. However, they still provided consultee 
declaration: 
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“I asked my sons as well and we all agreed for her to do that. We know 
that we can pull out at any time. As long as she isn’t over stressed or 
anything like that.” [R1] 
Altruism and personal relevance 
Despite the devastating and life changing impact of stroke participants were 
willing to enrol in the trial, and the most common reasons for enrolling were 
altruistic: 
“It might put somebody on the right road again” [PI4] 
 “[…] just hope I help somebody else” [PC5] 
 “Because I think it helps everybody … it helps, not me, but other people 
… I want to help.” [PC1] 
Whilst patients mostly hoped the trial would benefit others, some hoped they 
would benefit personally: 
“You might get better. But I want to stand on my own, that’s a big one” 
[PC4] 
“Strengthen my legs” [PI2] 
Relatives hoped their relative would find the intervention advantageous and 
interesting: 
“Anything that we consider an advantage to her and other people later on 
[…] I want her to get as mobile as she can before she comes home.” [R1] 
“Well I just thought he might find it interesting” [R2] 
Physiotherapists’ perspectives 
Post-stroke fatigue was also acknowledged by physiotherapists who reported 
that it prevented or limited implementing the functional standing frame 
programme. Physiotherapists reported that patients were “exhausted” after the 
functional standing frame programme sessions, which impacted on their ability 
to practice other activities pertinent for discharge: 
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“They were so exhausted trying to get them up into standing and their BP 
dropping, they were too tired to do anything else like working on sitting 
and functional bed mobility.” [Physio 1] 
“They couldn’t tolerate it, but they could have but then they would have 
been exhausted for the next professional that sees them and if I did that 
every day, they’d hate me.” [Physio 6] 
Other physiotherapists shared strategies they had implemented to manage 
fatigue such as timetabling and increased communication and co-ordination 
with other members of the multi-disciplinary team. 
“I’ve tried timetabling. And I’m slowly getting the OTs on board in terms of 
coming in on a standing frame session, because they had quite a negative 
feeling towards the study initially, and I’ve been gently, gently progressing, 
getting them to come along and creating a place for them within it and 
reassuring them that there are things within the session they can do” 
[Physio 5] 
Some physiotherapists commented that the severity of stroke affected their 
ability to deliver the functional standing frame programme: 
“We had a couple with really really poor midline, really poor head control 
and it was taking at least four of us to be getting them into the standing 
frame and they weren’t necessarily enjoying it because they felt so scared. 
Sometimes it felt too early” [Physio 5 FG] 
Some physiotherapist also felt that non-physical consequences of stroke 
impacted on patients’ ability to participate in the functional standing frame 
programme: 
“We’ve had one or two that because of their cognition and anxiety have 
struggled” [Physio 4] 
Conversely, one physiotherapist reported that the standing frame was more 
successful than the usual physiotherapy activities she had implemented with a 
patient with cognitive impairment: 
“We were standing him in the standing frame and we had a lot of success 
in the frame […] to try and work with him in sitting was very difficult 
because he had a lot of cognitive and language difficulties, it was very 
difficult to engage him in activities in sitting. You know it was very difficult 
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almost to find that way in. But by getting him up in standing we found that 
we had more success.” [Physio 7 FG] 
Several physiotherapists spoke about the unstable nature of stroke and 
identified that patients have complex needs, commenting that the complexity of 
a patient’s condition sometimes affected whether they were able to fully 
participate in the three-week intervention period: 
“A couple of mine have been consented and then not actually been able to 
commence their therapy for quite a good chunk of the three weeks 
because of being medically unwell or actually having to go away from here 
to the acute hospital". [Physio 4] 
In summary, these findings reveal that stroke is devastating and can turn both 
the patient’s and their relative’s lives upside down; for some there is a sense of 
impending death. Both parties are trying to understand and come to terms with 
life after stroke, dealing with the physical and emotional consequences as well 
as social, occupational and financial issues that can arise. All these issues have 
the potential to affect recruitment and retention in clinical trials. Despite this, 
participants were still willing to take part in the trial and continue with the 
intervention. Hopes of recovery and being able to return to their previous 
functional abilities, and altruism, were predominant factors in influencing 
recruitment and retention. Relatives were profoundly affected by their loved one 
having had a stroke, describing many emotional and practical consequences 
they were having to deal with, within the context of an uncertain future. Despite 
this, they were willing to act as consultee and support their loved one through 
the trial. There were differing beliefs and opinions of physiotherapists as to 
whether the standing frame was an intervention suitable for people with severe 
stroke, and this appeared to affect the way the intervention was delivered within 
the trial. 
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The impact of stroke on both patients and their family is evident in the data. 
Surprisingly physiotherapist’s perception of the impact of stroke and using the 
standing frame with patients were often at odds with patients themselves. Whilst 
physiotherapists reported patients were “too tired” or “couldn’t tolerate it” 
patients described themselves as able to cope and “push through the 
tiredness”. Both patients and their relatives emphasised that despite this 
devastating and life changing event, patients should still be offered the 
opportunity to be involved in the trial. In practice however, physiotherapists 
were the gatekeepers as to whether or not the standing frame was incorporated 
into the rehabilitation programme, on the basis of their clinical judgment.  
This theme highlights the profound impact of stroke, affecting patients, their 
relatives and physiotherapists in diverse ways. The following theme captures 
experiences of the trial procedures from all three perspectives. 
Theme 3) Experience of trial procedures 
Understanding experience of trial processes and procedures is an important 
part of feasibility testing as these data can be used to improve trial procedures 
to maximise the chance of any future trial being successful356. 
Physiotherapists’ perspectives 
Eligibility criteria 
Eligibility criteria was a contentious topic among physiotherapists in both the 
individual interviews and focus group. Opinions about the eligibility criteria were 
varied and perceived as “ideal” or “too broad”: 
“You don’t need to worry about the severe ones, they need to go through 
this” [Physio 6] 
“I think that it’s more ideal for those type of patients anyway [severe or 
very severe stroke] if it’ wasn’t randomised and we could choose, we’d 
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probably choose the more the 5 [mRS score], heavier severe strokes to be 
in it if it was left to us to decide.” [Physio 3] 
“I think it’s just too broad. So, the majority, the vast majority of our patients 
are a 4 [mRS score] and so then, they’re a 4 so on the surface they look 
like they’re eligible for the trial, but actually they’re mobile with one or 
mobile with supervision, they’re not quite reaching that 3 category, but 
then functionally too good for the standing frame.” [Physio 5] 
There was disagreement among physiotherapists about which patients were 
best suited to the functional standing frame programme in terms of (dis)ability. 
However, several physiotherapists acknowledged that no physiotherapy 
intervention is suitable for every patient: 
“I think people who, you know someone could quite happily stand and 
transfer with say a Return and one, I’d be thinking they would be a bit too 
good for the SPIRES trial. So, if someone was doing a transfer like that, 
they’re too good, but maybe they were at the point of using an Encore 
Stand Aid or a hoist, those are the patients would I would be thinking they 
are more appropriate for SPIRES as it were.” [Physio 2] 
“And it was the mRS 5, feeling as though, on a day to day basis I probably 
wouldn’t put someone who didn’t have sitting balance or head control in a 
standing frame, let alone for 30 minutes” [Physio 8 FG] 
“[…] it’s the only option for people with severe stroke” [Physio 6] 
“No physio intervention is going to be suitable for everyone, but for the 
right patients I think it’s a useful and beneficial adjunct.” [Physio 5] 
The mRS is used to classify severity of stroke, and participants were eligible to 
join the trial if they were mRS 4 (moderately severe) or 5 (very severe). It was 
unanimously perceived by physiotherapists as open to interpretation. Some 
physiotherapists reported it is not representative of current clinical practice 
because no patient is “bedridden” (mRS score of 5, very severe) due to current 
early mobilisation practices. Some physiotherapists deemed patients bedridden 
if they were unable to sit out for 2-3 hours because this would prevent them 
from being discharged home with a package of care. This caused “moral 
dilemmas” (Physio 6) for physiotherapists as to how to score patients and who 
to approach for consent. Several physiotherapists shared their thoughts about 
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alternative measures that they deemed more appropriate to use instead of the 
mRS: 
“I’m thinking of something like the FIM FAM [Functional Independence 
Measure and Functional Assessment Measure]” [PhysioFG9] 
“It’s their functional ability isn’t it. I don’t know if the PASS [Postural 
Assessment Scale for Stroke] may be?” [Physio 8 FG] 
“Maybe the Modified Rivermead which is quite functional again” [Physio 
FG7] 
“I think you’re better off going with impairments and activities, rather than 
an outcome measure that is not clear” [Physio 6] 
Several physiotherapists agreed that sitting balance would be an appropriate 
criterion for determining eligibility, but there was no consensus: 
“Maybe something a bit more functional that reflects a little bit more about 
their mobility and their sitting balance and standing, might wheedle it down 
a little bit.” [Physio 7 FG] 
“I think some trunk control to be able to sustain some sitting balance, not 
necessarily be able to sit for half an hour, but just to be able to have 
something” [Physio 8 FG] 
“So, I don’t think there’s enough evidence that you need to be able to have 
independent sitting balance before you try and stand up in a standing 
frame” [Physio 6] 
Factors related to implementing the functional standing frame programme 
Several physiotherapists reported that stroke severity influenced their ability to 
deliver the functional standing frame intervention with people with very severe 
stroke. They highlighted that people with more severe stroke required more 
physiotherapists, which challenged resources: 
“The only negative things with it really is that you need quite a lot of hands; 
sometimes three or four people so it’s obviously just taking other 
therapists off the ward but that’s the only negative thing about it.” [Physio 
4] 
“It is quite resource demanding” [Physio 5] 
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The duration of the functional standing frame programme was three weeks, 
however, opinions varied among physiotherapists about the duration. One 
physiotherapist commented that three weeks was insufficient and ideally the 
intervention should continue in the community post-discharge, whereas others 
said they would prefer the intervention to last two weeks. Some 
physiotherapists commented that regardless of the duration of the intervention, 
it would be preferable to have flexibility to allocate time to other activities that 
they perceived pertinent to discharge: 
“I think three weeks was a good amount to start with […] so, to say it’s 
three weeks ideally, but actually then you can progress your patient.” 
[Physio 6] 
“I don’t know that three weeks is long enough, but also again because of 
our length of stay and stuff, a lot of people are obviously going out into the 
community in that time, so if it could be continued in the community.” 
[Physio 1] 
“I wonder whether a two-week period […] then you’ve got a week to do 
other discharge stuff or you might have a week before they start to do the 
trial to get midline and start the trial, so two weeks would be flexible.” 
[Physio 9 FG] 
 “I’m just wondering if you could keep it for three weeks but say so many 
out of five days you did the standing frame, so rather that it be 10 
consecutive sessions, could you do 10 days out of the three weeks. 
Something like that, so in the early days still be, because you might want 
to do a session with the nursing staff when you’re looking at positioning in 
bed, it could be you a bit of breathing space.” [Physio 3 FG] 
“[…] whether there was any flexibility even it was four sessions for 30 
minutes per week, so there was other sessions where you could still do 
things like bed mobility” [Physio 3] 
The theoretical basis underpinning the choice of a three-week duration of the 
functional standing frame programme in this trial was based on previous studies 
to facilitate intensity of practice95,85. The intensity of the intervention was 
acknowledged by only a few physiotherapists: 
 “you’re trying to get that intensity aren’t you. If you start expanding the 
time they do 21 sessions, you’re not going to get that intensity of practice. 
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In an ideal world, you’d do it for longer and you’d continue the intervention 
in the community.” [Physio 1] 
All physiotherapists unanimously agreed that 30 minutes was a good amount of 
time for each functional standing frame intervention session. However, opinions 
were divided about the 15 minutes of usual physiotherapy: 
“15 minutes often was not enough to do all the other things, perhaps their 
bed mobility, transfers and stuff.” [Physio 3 FG] 
 “Sometimes I’d just think oh god I just want to do this with the patient and 
then it comes to like the 15 minutes at the end and you’d have to do the 
practical things like the transfers, the things that are going to get them 
home because we still only had that length of time with that patient” 
[Physio 8 FG] 
“It is good that you have the 15 minutes of normal physio as well, so you 
can explore other things relevant to their therapy.” [Physio 4] 
The protocol stipulated that participants in the intervention group needed to 
work towards performing eight to 12 repetitions of sit to stand within their 30 
minutes in the standing frame. Most physiotherapists agreed that eight to 12 
repetitions should be a minimum with no upper limit. However, several 
physiotherapists acknowledged that not all participants with very severe stroke 
achieved the recommended number of repetitions, despite adopting a graded 
approach: 
“If you’re not using that [electronic lifter component] you can do loads of sit 
to stands and 12 doesn’t seem like very many then. But I think if you’re 
using the electronic component of the standing frame, and you’ve got a 
patient who sit to stand is hard for, then maybe you wouldn’t.” [Physio 3 
FG] 
“Quite a few never reached the eight” [Physio 5 FG] 
Some of the organisational factors such as the ‘discharge driven culture’ were 
apparent when physiotherapists discussed the duration of the functional 
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standing frame programme and the 15 minutes of usual physiotherapy. This 
was also evident in the next sub-theme, equipment factors. 
Equipment factors 
Design and brands of standing frames varied across sites. Some sites had 
Oswestry standing frames357 that are made mostly of wood, others reported 
having more “robust” and “sturdy frames” made of metal, some with more 
advanced technological and mechanical features, such as the THERA-Trainer 
Balo358. Some physiotherapists had access and/or experience with different 
types of standing frames: 
“The Oswestry takes a long time to get patients in and out of […] and it’s 
not great from a manual handling perspective” [Physio 5] 
“I’m not sure it’s any easier to get them into the Balo” [Physio 7 FG] 
“In terms of manual handling it’s [Balo] so so much better. And the amount 
of adjustments you can do: hips height, knee height, table height, move 
the knee pads individually so in terms of getting the frame to fit the patient 
that’s a benefit as well. […] I would say the Balo is sturdy and more robust 
… the Oswestry is a bit creaky isn’t it and sometimes you’d think oh is this 
going to hold them up.” [Physio 3] 
Some physiotherapists highlighted the standing frame was not transferable to 
the ward or home environments, and suggested equipment routinely used on 
the ward for standing transfers (e.g. Ros-Return, MoLift, Arjo Stand Aid etc.) 
would be more suitable. They remarked that these pieces of equipment would 
allow greater intensity with more frequent opportunities to stand. Some 
physiotherapists stated that if a patient’s goals were to be using a specific piece 
of equipment for discharge, they should be using this in their therapy sessions 
instead of the standing frame. They also commented that using different pieces 
of equipment would enable patients to see themselves progressing: 
“[…] I worry slightly that the patients perceive that I’m still using the same 
piece of equipment that I was three weeks ago, even though we know 
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we’ve made it a lot more challenging […] sometimes that can be hard for 
the patients necessarily to perceive progress.” [Physio 7 FG] 
“We’ve had some patients that had been using the standing frame, but 
they would be using the Ros Return on the ward, so it’s a more 
challenging bit of equipment outside of their therapy. So being able to use 
different bits of equipment would be better.” [Physio 8 FG] 
Some physiotherapists reported feeling the standing frame intervention created 
false hopes for progression in patients with very severe stroke who were 
standing in the frame but required a hoist for transfers on the ward and for 
discharge. This led to difficult conversations with patients and families: 
“[…] the family perceived it was a good thing that they were up and 
standing and in the standing frame, but that wasn’t transferable because 
they weren’t able to use other bits of equipment for discharge. So, they 
had that perception that oh good my family member is standing and able 
to stand, but we felt that they weren’t progressing.” [Physio FG9] 
A couple of physiotherapists reported that patients were concerned with how 
the standing frame looked: 
“It’s a bit daunting isn’t it, seeing that in the corner of the room a little bit” 
[Physio 4] 
“I think it can be quite scary for patients, so I think it can be quite daunting, 
there are lots of straps and poles, so I think it depends patient to patient as 
to whether it is an enjoyable experience for them and the benefits of using 
it.” [Physio 5] 
Foot sensors were supplied for all sites to enable physiotherapists to monitor 
the patient’s weight distribution during standing. There were several iterations of 
the foot sensors following feedback from some physiotherapists. All 
physiotherapists reported that the foot sensors were unreliable and 
temperamental, and this made delivering the intervention more difficult: 
“[…] they were quite temperamental, and they had to be exactly in the 
right place, that added just another element of we were not getting our 
hands on our patients and not keeping them in alignment and midline […]. 
Even with three of us in there, it was just difficult to get feet on the scales 
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in the right place, check the sensors, keep them going back to check the 
sensors” [Physio 5] 
“I’m not sure that the patients we used them with particularly liked them 
either. Because I think they were like well why am I not putting my feet on 
the floor?, why am I putting them on these funny block things?, I think that 
kind of triggers some anxiety with patients as well. There were a couple 
that were cognitively intact and pretty good and understood the 
explanation, but patients with either language or cognitive or perceptual 
difficulties, it was again putting their feet on the scales was abstract well 
why am I standing on those anyway, let alone moving their weight 
around.” [Physio 5 FG] 
“We haven’t had much luck with the foot sensors” [Physio 3] 
The foot sensors were provided to enable physiotherapists to monitor and 
facilitate postural adjustments. They were based on the recommendations of a 
systematic review to improve monitoring of standing in a standing frame. 
However, some physiotherapists emphasised that foot sensors would not 
necessarily facilitate a positive outcome: 
“The problem is if they see that all their weight is all this side they do all 
sorts of things to try and get their weight across, so it doesn’t always work 
even if they get that feedback it doesn’t always get the best outcome for 
them, so sometimes us visualising it is better.” [Physio 3 FG] 
“It wasn’t terribly successful, because similarly it’s very abstract for our 
patients sometimes and I’ve had much more success with either visual 
vertical like a line in the curtain or a line on the window or facilitation” 
[Physio 7 FG] 
Some physiotherapists expressed a preference to use their own clinical 
judgement when evaluating weight bearing in the frame instead of the foot 
sensors, stating “as an experienced therapist that’s what we’re looking for” 
(Physio 5): 
“We used clinical judgement. As physios that’s what we look for; where is 
their midline, is their weight going through that leg or are they just hitching 
off the other one and you can clinically, and yes okay it might not be as 
accurate as they’ve got 50kg on this one and 60kg on that one, but you 
are looking to facilitate for them to take weight on to their affected side and 
get activity that side.” [Physio 5] 
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Recruitment and retention 
Some physiotherapists reported to being selective about which patients they did 
and did not approach for consent to enrol in the trial which they related to who 
they perceived as being “too good” (Physio 5) or “too impaired” (Physio 2) or 
who would not cope with the functional standing frame intervention: 
“Not that we did much cherry picking, but if you had someone else coming 
in it would take away our clinical judgement as to whether somebody was 
suitable may be.” [Physio 3] 
“I wouldn’t say we picked and chose loads, there was only one lady really 
that I can remember thinking actually she does meet the criteria, but it 
wouldn’t be right, and we did record that we’d made that decision, so it’s in 
the log” [Physio 3 FG] 
A few physiotherapists at one site reported there were patients who met the 
eligibility criteria, but they were not approached, stating: 
“As a team I think if there was that better scope of person to be within it, 
maybe we wouldn’t be feeling so much that we don’t want to put them in”. 
[Physio 2] 
Some physiotherapists appeared to be protective of their patients, potentially 
adopting a paternalistic role which affected their decision to approach eligible 
patients. Paternalism in clinical trials is acknowledged as a negative factor in 
recruiting to stroke clinical trials359. Several physiotherapists said that many 
patients should be using the standing frame “earlier and more”, however, some 
revealed that they did not screen or approach patients if they felt the patient 
“couldn’t tolerate” or “cope” with the intervention: 
“I think people are quite protective yeah, and I think there are probably 
quite a lot of other people who should be using the standing frame earlier 
and more.” [Physio 1] 
“I think there was an element that, oh we don’t have time to consent this 
patient and also, it’s probably quite a good thing that we didn’t put them on 
to the trial, because actually if they go into the standing frame I don’t think 
they would cope.” [Physio 8 FG] 
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Most physiotherapists interviewed agreed they would prefer a dedicated person 
(not one of the treating physiotherapists) to screen and consent potential 
participants, e.g. Research and Development or Clinical Research Network staff 
to minimise coercion, selection bias and alleviate physiotherapists having to 
spend time on the consent process and completed associated paperwork: 
“It would also take away from any conflict on the ward if someone external 
was coming in to consent, it would take away that pressure on us” [Physio 
5 FG] 
“[…] the consenting does take time” [Physio 3] 
“I do worry that the patients might think well the physio is coming to talk to 
you about a physio related study that if they don’t say yes, they maybe 
damage their relationship with you already. You know the physio thinks I 
should do it, so I should do it.” [Physio 7 FG] 
Physiotherapists reported to feeling more comfortable involving family in the 
consent process, even when patients were able to provide consent themselves: 
“Slightly for my own piece of mind as well. I was talking to families and 
giving them the information, even if they weren’t going to be the consultee 
consenting and I was consenting the patient, just so they were fully aware 
of what their relative had given consent for” [Physio 7 FG] 
Perceived burden of outcome measures 
One physiotherapist undertook the role of blinded outcome assessor for all 
participants recruited at their site. They shared their experience of conducting 
the patient-report outcome measures and what effect it had on them personally 
as well how they perceived it affected the patient: 
“We use the PHQ-9 regularly on our unit as a screening tool for all 
patients, unless they’ve got aphasia, but when I’m actually having to do it, 
I was like blimey, these are really challenging things to do with people 
when you’ve not built up a rapport with them […] One of the patients did 
start getting very tearful about it and it was a bit uncomfortable and you 
just feel like you’re going in a bit cold really” [Physio 1] 
“I felt stupid asking these questions, you know it’s obvious you’re not able 
to do a lot of these things” [Physio 1] 
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The blinded assessor reported finding the patient report outcome measures 
challenging with people with communication difficulties and fatigue: 
“Quite a lot of them had communication difficulties, which made using the 
outcome measures very challenging” [Physio 1] 
“I think with the nature that people we were recruiting, the length of the 
outcome measures they were getting very fatigued, I found that it was 
really hard, well I couldn’t’ do it all in one sitting really, and a lot of the 
questions. I mean it’s fine because things like the Barthel and the Edmans 
you can fill in on their behalf or from a clinician.” [Physio 1] 
The blinded assessor also said they felt the phrasing of some of the questions 
in the patient report outcome measures were not positive: 
“Well I feel it’s not very positive. It draws attention to what’s hard, difficult, 
what can’t you do” [Physio 1] 
The SAQoL-39 was perceived as having too many questions, many of which 
were not appropriate for people with severe stroke: 
“No, it’s way too much. But also, well I guess, I’m just thinking about the 
people we recruited, but they’re never going to achieve half of these things 
on here. So, it almost seems to be pitched at a very high level.” [Physio 1] 
The blinded assessor commented the proposed physical secondary outcome 
measures were “straight forward” and did not identify or report any problems 
implementing these measures. 
Research effect 
Physiotherapists emphasised that being involved in the trial was “novel and 
exciting” and facilitated awareness of a different evidence-base that can 
improve clinical practice and “a really good way of evaluating your practice and 
challenging your practice and thinking” (Physio 7 FG). Most physiotherapists 
reported that they will be using the standing frame more often in their clinical 
practice and standing their patients for longer, reducing rest times, increasing 
repetitions and encouraging more dynamic movements: 
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“My practice has changed that I would think oh yeah they might be quite 
good in the standing frame and you wouldn’t necessarily do 30 minutes 
five days a week for three weeks, but actually it’s kind of thinking about 
yes that might be quite good for that person.[…] being involved in research 
is quite novel and exciting hopefully that will inspire to be, at least be more 
aware of different evidence base and looking at how that can improve our 
practice” [Physio 5] 
“I think it has made me think about standing people for longer than I might 
have done. […] It has made me think about, may be reducing the length of 
their rest times in between to try and get longer times standing, I think it 
has maybe pushed me a little bit more to get them on their feet for longer 
in the session […] I think it has made me think about the repetitions. I think 
I was very guilty before, using the standing frame a fair amount but getting 
people up in it and they would then just be up in it.” [Physio 3] 
One physiotherapist commented that being involved in the trial had opened a 
“can of worms” for physiotherapists: 
“The real can of worms that you’ve opened is, you’re asking to justify why 
their patients aren’t standing for half an hour every day.” [Physio 6] 
One physiotherapist reported that the trial facilitated them to evaluate the 
outcome measures used in their stroke unit: 
“It has made us look at what screening tools we use in depression, 
because I’m like I don’t know this is the best one [PHQ-9] that we should 
be using with people, especially when the throughput is so quick. […] It’s 
also made me think as well, how do we access standing frames in the 
community for the more severely affected stroke patients.” [Physio 1] 
Workload 
All physiotherapists commented on the workload associated with the trial. 
Physiotherapist who were PIs reported unexpected additional workload and 
responsibilities, specifically around reporting SAEs: 
“I am a little bit worried about it because it did take up quite a bit of my 
time to find out that information, so that was something I wasn’t expecting” 
[Physio 3] 
Throughout the trial an additional PI was appointed at two of the sites which PIs 
said helped share the workload and responsibility. Some PIs remarked that the 
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rest of the therapy team were unaware of the workload and responsibility 
involved in being PI, and this had implications for managing their caseload 
during the trial. 
“There’s not the general understanding of how much work goes into the 
day to day running of the trial. And that’s across the board […] there’s a lot 
behind the scenes. […] I was really worrying about it, it was really 
stressing me out” [Physio 3] 
PIs at two separate sites developed and implemented a checklist to help keep 
track of the processes and documentation associated with the trial which 
treating therapists also said they found helpful: 
“Having that is really helpful because you sign it and you can see what 
you’ve done and if you ask somebody to photocopy something and send it 
off you can see that it has been done. That has been really useful.” 
[Physio 4] 
“I find it so easy [to keep track of everything”]” [Physio 2] 
All physiotherapists noted that familiarisation increased their confidence with 
trial processes. They reported to trial and error in the early stages but made 
adaptations and felt “au fait” with treating therapists at individual sites 
establishing a rhythm when delivering the intervention. 
“By the end we changed how we did quite a lot of things whereas at the 
beginning we were like, we’ll try like this and see how it goes. But adapted 
along the way.” [Physio 9 FG] 
“We’re definitely becoming more ‘au fait’ with using that particular standing 
frame and being able to problem solve how we look after an upper limb. 
Everyone now sort of has their place if you like” [Physio 5] 
Trial design 
Physiotherapists considered that the current trial design was appropriate. They 
acknowledged a cluster RCT may be easier in terms of blinding, but said they 
felt that having both control and intervention groups at each site would have a 
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number of advantages such as helping to maintain motivation and interest for 
physiotherapists as well as challenge their practice: 
“Cluster RCT may be easier in terms of blinding, you just have control or 
just have the intervention” [Physio 1] 
“I think that would be really labour intensive […] if you were the 
intervention site […] I don’t think it would be practical without extra staffing. 
We would need extra help […] if it is completely random to who you’re 
going to get, I think that would help keep the motivation and keep it 
interesting.” [Physio 5 FG] 
“if you just had the control group I think you’d just bob along and do what 
you always do and you wouldn’t have that challenge to your practice” 
[Physio 7 FG] 
“[…] like we’ve all said we’re all doing different things in our control groups 
and you’d get more of a picture of what a normal physio session would 
look like if you had different sites, rather than just a couple.” [Physio 3 FG] 
Documentation 
All physiotherapists commented that there was a lot of paperwork, and the 
photocopying was time consuming. Most physiotherapists implemented 
strategies such as delegating photocopying to administrative staff or assistants. 
Some sites use electronic documentation for patient notes, and they reported 
that having to scan the CRFs into these systems was time consuming. Several 
physiotherapists suggested that electronic CRFs would be preferable: 
“The photocopying was quite onerous” [Physio 3 FG] 
“I don’t know if this is even possible, but I would have found it better to do 
online […] we kept missing bits out and not filling bits in and if there’s 
some way of having it online so that it prompts you to fill it in, then you 
wouldn’t have all those queries” [Physio 2] 
Physiotherapists were required to capture the content of the 15 minutes of usual 
physiotherapy sessions for participants in the intervention group, and the 
content of the control group to enable a description as to what usual 
physiotherapy was for these people with severe sub-acute stroke. Although 
physiotherapists recognised that capturing what they did in usual physiotherapy 
267 
sessions was a good idea, they highlighted there was nowhere to record how 
long the patient spent on individual tasks/activities. This led to some concern 
about what judgements the research team may make about the content of their 
sessions: 
“It sounds like I didn’t do a lot, I felt I did more, but I don’t think it (the CRF) 
recorded it all” [Physio 2] 
Some physiotherapists commented that the CRF for the intervention group also 
failed to capture everything they did with participants: 
“So, the session was 30 minutes but there was only one stand. Well, it 
kind of looked like, well, what were you doing in between. But actually, 
there was a huge amount of getting them onto the plinth, getting them set 
up, getting up in to standing, getting back down on to the plinth and that 
isn’t necessarily captured in the CRF.” [Physio 5 FG] 
“I can imagine someone looking at that and thinking “what were you doing 
with your patients?”. They stood up twice for like 10 seconds and you’ve 
said that you’d been with them for 30 minutes […] So, there were patients 
[…] that we couldn’t really explain what we did.” [Physio 7 FG] 
Physiotherapists appeared to struggle with not being able to write free text to 
justify what had or had not been done during the sessions. They were notably 
frustrated that the CRF did not capture all the activities they had been doing 
with their patients and were concerned that researchers reading the CRFs 
would pass judgement on them. 
There were several versions of PIS: a standard version, a multiple page version 
for people with mild to moderate aphasia, and a double-sided A4 sheet for 
people with severe aphasia. All physiotherapists reported preferring and using 
the PIS’s designed for people with aphasia. The multiple page PIS for people 
with mild to moderate aphasia was the most popular and it was perceived as 
easier for the patient to understand (even if they did not have aphasia) and 
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easier for the physiotherapist to talk through. They suggested that patients and 
families struggled to digest the information in the standard PIS. 
“The multiple page aphasia friendly participant information sheet is really 
useful and even if they don’t have aphasia. Nicely laid out, easy to read, 
it’s really clear what they’re expected to do” [Physio 4] 
“I don’t think I gave anyone the complicated one [standard PIS] even if 
they were cognitively able […] I think even for those who are quite able it’s 
still an awful lot of information, so I tended to give them the middle one 
[multiple page PIS]” [Physio 2] 
“People struggled to digest the standard one [PIS] even families” [Physio 
4] 
Some preferred and used the double-sided PIS for people with severe aphasia: 
“I normally take the double-sided Aphasia friendly one. It’s a lot easier to 
understand […] it’s quite a clear, this is actually what that whole document 
means, broken down into a really simple image. It’s a bit easier to look at I 
think.” [Physio 4] 
“The aphasia friendly one page one has a diagram, it’s simple and they 
can understand” [Physio 5] 
Overall the protocol was reported as being acceptable to all physiotherapists, 
although they acknowledged it contained a lot of information, but it was easy to 
refer to. Some physiotherapists acknowledged that they are not as strict in 
following procedures in clinical practice, but in a research study a protocol is 
necessary and provided protection for them: 
“Some of it is getting to know the protocol and at each stage and each 
session […] Now I know I’m following it and I know it well enough to go 
ahead with it and now and again I go back to it and check.” [Physio 5] 
“…and the fact is, in clinical practice we don’t have a protocol, you have to 
have a protocol that you follow because I think it protects you.” [Physio 6] 
Orthostatic hypotension protocol 
Taking manual blood pressures with people with very severe stroke was 
reported as being challenging for some physiotherapists in terms of the number 
of staff required to assist participants into standing and take the blood pressure. 
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It was apparent that they did not consider this as part of their usual clinical 
practice when standing patients, therefore, had to undergo training to take 
manual blood pressure as part of this trial. Several physiotherapists commented 
that they usually judge the presence of OH on symptoms and were surprised 
that some patients who were asymptomatic had a significant postural drop: 
“[…] it was taking three or maybe four to get the person up into standing 
and then have the extra person to take the blood pressure and it felt quite 
pressured because we wanted to be looking at their alignment and making 
sure they were safe and checking them and having to do the blood 
pressure […] So, I think that felt quite fraught quite a lot of the time.” 
[Physio 5 FG] 
“I think on the blood pressures note, we did them as part of the trial but in 
clinical practice we wouldn’t always do blood pressure checks and that 
took a lot of time” [Physio 9 FG] 
“He had orthostatic hypotension and then we were sitting down because 
we were working with our stroke nurse and she was doing his blood 
pressure and she said you need to sit this man down and he was pretty 
much asymptomatic.” [Physio 7 FG] 
The comments from Physio 7 FG regarding the asymptomatic patient will be 
valuable for future training to emphasise the importance of taking blood 
pressure during standing and optimise adherence to this trial process. 
Some patient participants who were diagnosed with OH during trial 
assessments wore abdominal binders which physiotherapists reported had 
different effects: 
“We used quite a few [abdominal binders]. Some successfully, one I can 
think of not successfully. We used an abdo binder but he was nauseous 
and it made him feel more nauseous quite claustrophobic, hot and he just 
didn’t’ tolerate” [Physio 5 FG] 
“It has an immediate effect” [Physio 9 FG] 
These comments will be valuable for future training to emphasise the effect of 
the abdominal binders. 
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Restrictions in autonomy 
Some physiotherapists said the functional standing frame protocol restricted 
their autonomy in what they could and could not do with their patients in 
intervention sessions: 
“I tend to chop and change and be kind of, I’ll do a little bit of this and a 
little bit of that and I couldn’t do that and it limited the variety of what I was 
doing with the patient […] if you’re constrained to just do standing, I didn’t 
feel that my therapy, my physio sessions could evolve with my patient’s 
needs and changing needs and changing discharge plans.” [Physio 7 FG] 
Although the protocol was perceived as restrictive for some physiotherapists, 
one physiotherapist in the focus group commented that some physiotherapists 
tend to move on too quickly, which may be detrimental to patients: 
“[…] because I think sometimes we do move on too quickly” [Physio 5 FG] 
Some sites that regularly used a standing frame as part of their usual 
physiotherapy prior to the trial perceived the trial as “restrictive” as they 
interpreted the protocol as stating they were “not allowed” to use the standing 
frame at all with participants in the control group. However, the protocol stated, 
“Therapists will be advised not to change their usual physiotherapy practice and 
start to implement a standing frame programme with participants in the control 
group if this is not part of their usual physiotherapy practice”, which was 
emphasised in the face to face training.  
Whilst some physiotherapists expressed that they struggled with the lack of 
flexibility and variation in their practice, others highlighted opportunities to be 
creative: 
“We did get quite creative with the standing frame, like PADLs in the 
standing frame […] and that then helped to involve our OT colleagues as 
well and we’d play games, get the Wii out […] you can make it patient 
specific which is nice because obviously if it was rigid you wouldn’t be able 
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to tailor it to your specific patients and that may have been a problem.” 
[Physio 5] 
Patients’ and relatives’ perspectives 
Eligibility criteria 
Patients and relatives agreed that there should not be an age limit on people 
joining the trial: 
“[…] because some 60-year olds are quite old, and some 80-year olds are 
young. It makes no difference” [R3] 
“No because I think there are some 90-year olds who are very spritely and 
do need to be included as well” [R4] 
“Certainly [is it okay to ask people to join the trial who are a similar age to 
you?]. I look at it like this. I’m 96, you can’t last forever, so you take life as 
it goes.” [PI1] 
Patients and relatives agreed that having co-morbidities should not affect 
people being offered the opportunity to join the trial: 
“Everyone deserves a chance” [PI3] 
“I don’t see any problem as long as they’re sort of well enough to do 
physio, it’s all for their benefit. It will probably benefit their other problems 
as well” [R4] 
Factors related to implementing the functional standing frame programme 
Opinions varied among physiotherapists about the duration of the intervention 
sessions. Despite patient participants not having prior experience or knowledge 
of stroke rehabilitation, they appeared to be accepting of the duration of the 
functional standing frame sessions: 
“I think it’s necessary to have enough time to stand. For me personally yes 
[it was long enough]. I think if you rein it in you’re not learning as much as 
quickly as you should”. [PI2] 
Equipment 
In physiotherapists’ perspectives above, a couple of physiotherapists reported 
that patients were concerns with how the standing frame looked. However, in 
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contrast, when patients were asked what they thought about how the standing 
frame looked, they said  
“No, it didn’t look scary, it wasn’t scary” [PI2] 
“I didn’t think anything […] didn’t think it looked scary” [PI3] 
“[…] no it wasn’t scary” [PI4] 
Most patient participants spoke positively about the standing frame. Some 
participants in the control group had been using the standing frame and they 
also shared their thoughts and feelings 
“No” [Did you ever feel worried using the frame?]. It felt a bit strange, but 
everything is strange […] it gives you back a little bit of independence.” 
[PI3] 
“Bewildered isn’t the right word, I don’t know what the word is […] it wasn’t 
easy, but neither was it difficult.” [PI4] 
“It [standing frame] gives you confidence to do it [stand]. It’s a good design 
because it makes you feel safe, because you’re surrounded.” [PI3] 
“You feel like Robocop, like nothing much else can touch me” [PC2] 
All physiotherapists reported that the foot sensors were unreliable and 
temperamental, and they expressed a preference for using their own clinical 
judgment. Only one patient was able to recall the foot sensors, reporting they 
were beneficial. He also shared suggestions for future modification: 
“The scales need grip underneath them as they tend to slide when you’re 
standing forward, because there’s only 4 pedestals as feet on the scales, 
they slip backwards when you’re pushing yourself forward […] would be 
good in the actual standing frame itself if you had a display on the front 
panel so you could see where your weight was being displaced” [PI2] 
Recruitment and retention 
The protocol stipulated that potential patient participants should be approached 
within 48 hours of being medically well for rehabilitation (or as soon as 
practicably possible), which was often within 48 hours of admission. Most 
patients reported that the timing of approach was acceptable: 
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“I was pleased about that because you feel like you’re moving on. I don’t 
think there’s a time when you shouldn’t speak about it [research]” [PI2] 
“Yes, I think it was the right stage. It might have been a little bit too early 
for me, but it enabled myself to focus on it. I’m ready for it […] We’re all 
different people, lots going on. I’ll be honest I didn’t know if I was going to 
be alive in three weeks’ time” [PC3] 
Relatives were also accepting of the timing of approach for their loved one: 
“I think it’s good. I mean you should be, like falling off a horse and getting 
straight back on it shouldn’t you really.” [R2] 
“…quite soon after, but then I suppose you’ve got to catch these things in 
the bud really eh” [R1] 
“I think it was about right. We had time to land and settle, and then you get 
asked” [R3] 
Most patients said they had never thought about withdrawing from the trial: 
“No, because I’m not a, because I’m not a person who gives up easily. No 
there was never a thought about stopping” [PI4] 
“Sometimes yeah, but only for a split second and I don’t dwell on it” [PI3] 
All relatives knew that they could withdraw their loved one, but all said that they 
never considered it: 
“We know that we can pull out at any time” [R1] 
Relatives who provided consultee declaration said they “didn’t mind” being 
approached and making that decision on behalf of their loved one. Most 
relatives discussed the decision with other family members: 
“I got hold of the boys and we all decided that really we ought to […] 
everybody decided it was the right decision” [R1] 
“I probably wouldn’t have been quite so keen if she wasn’t willing, but then 
if she hadn’t had been able to make the choice I would have talked to X 
[R3’s brother] and we probably would have said yes anyway.” [R3] 
Burden of outcome measures 
Patients reported they did not mind being asked questions about any aspect of 
their stroke and how much help they needed, if the questions were useful: 
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“I don’t find them intrusive, it’s something you need to find out because 
you need to know how people feel. I don’t have a problem, you really 
explained, and we went through what you were doing, why you were doing 
it, it’s all fine, I don’t have a problem with that.” [PC2] 
“I don't mind if it's going to help me or somebody else” [PI1] 
Trial design 
Except for one patient participant, there was a sense of acceptance of group 
allocation: 
“this was my preferred choice” [PC2] 
“I was happy to do either” [PC1] 
“It doesn’t bother me at all, no” [PC5] 
“Don’t mind” [PC3] 
One patient in the control group reported feeling that the group he was allocated 
to suited his needs, stating he would not have wanted to be in the intervention 
group. Conversely, a participant who was allocated to the intervention group 
shared how he would he would have felt if he was allocated to the control 
group: 
“Beginning in the group that I am suits me and what my needs are […] as 
you progress, you do progress to the other group anyway.” [PC2] 
“I would have been quite annoyed” [being allocated to the control group] 
[PI2] 
This may be because patients did not know what was involved in the 
intervention group or that the participant allocated to this group attributed his 
progression during rehabilitation to the standing intervention. It may be 
necessary for a future definitive trial to provide more explanation to patients 
about the trial, specifically that one intervention is not necessarily superior than 
the other.  
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Relatives who acted as consultee or were involved in the decision for their 
relative enrolling in the trial had no preference for group allocation: 
“No, not really. Either one would have been an advantage to her.” [R1] 
“No anything would be good” [R3] 
“No, no I didn’t even think about it to be honest” [R2] 
Documentation 
Most patients and relatives were accepting of the PIS they had been given. 
However, they were only given one, therefore, had nothing to compare it to: 
“It’s clear and easy to read […] pictures were good” [PC6] 
“A good amount of information in terms of knowing what you were 
agreeing to” [PC1] 
“Initially I thought there was quite a lot of it, but there wasn’t really once 
you started reading it, it was fine. Self-explanatory.” [R3] 
One patient suggested some improvements to the PIS: 
“I think the diagram could have been better. I could see within the diagram 
the strong points within the standing frame itself and compared to a 
walking frame [A4 doubled sided PIS], make the picture more specific to 
the description. Have the scales [foot sensors] on the diagram.” [PI2] 
There were mixed views among patients and relatives about whether they 
preferred written or verbal information about the trial: 
“[…] it depends what you like and whether you could understand 
anything” [PC6] 
“Not all stroke patients can take in the information, also most people 
who have a stroke probably forget everything after a few days” [PI2] 
“Not really no, talk to me [would you prefer to have someone talk to 
you about it or have something the read?]” [PI3] 
“There’s no point [keeping a copy of the PIS], I wouldn’t read it again. 
[PC3] 
In summary, there were mixed opinions regarding trial procedures among 
physiotherapists; eligibility criteria and the “ideal patient” being the most widely 
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debated topics. It was apparent that the physiotherapists were accepting of the 
trial design, however, there was no agreement about the duration of the trial; 
most preferred a shorter duration/less sessions per week, although only a few 
physiotherapists acknowledged the impact this would have on intensity of 
practice. Physiotherapists emphasised that the functional standing frame 
intervention is not suitable for every patient and recognised how their beliefs 
about the ideal patient affected recruitment and delivery of the intervention. It 
was evident that physiotherapists’ beliefs and opinions about how the standing 
frame looked, and its transferability to the ward and home environment, 
potentially influenced implementation of the intervention. Conversely, patients 
and relatives were largely positive about both the look of the standing frame and 
the overall trial. Participants and relative expressed how the trial gave them 
hope about recovery, and their strong will and determination positively impacted 
on the very high retention during the intervention period.  
This theme identified positive and negative experiences of trial procedures, and 
patients and physiotherapists offered suggestions to overcome some of the 
barriers or challenges identified. The final theme provides insight into the 
experiences of using and implementing the functional standing frame 
programme from the perspective of patients, relatives and physiotherapists. 
Theme 4) Experience of using and implementing the functional standing 
frame intervention 
Research capturing participants’ perspectives and experiences of being 
involved in randomised controlled trials is increasingly being undertaken to help 
inform and improve the conduct of future trials360. Understanding patients’, 
relatives’ and physiotherapists’ experiences of the functional standing frame will 
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provide insight into which aspects of the intervention may need to be adapted, 
fixed or flexible. 
Physiotherapists’ perspectives 
Patient’s abilities to undertake the intervention 
The thoughts and feelings expressed by patients and physiotherapists differed 
in relation to patients’ ability to tolerate the functional standing frame 
programme. Several physiotherapists considered that patients “can’t tolerate” 
the intervention due to the severity of their stroke and that they were tired, 
bored, scared, and did not enjoy it: 
“Even if you’re using a standing frame if they’re really struggling with their 
head and trunk they might still need lots of hands on, to be able to get 
them up, I think patients can find that quite unnerving. I think my 
experience has been they feel a little bit more secure using the tilt table.” 
[Physio 7 FG] 
“I think as much as we tried to be creative, people often got bored […] and 
they weren’t necessarily enjoying it because they felt so scared, because 
they knew they didn’t have their midline” [Physio 5 FG] 
“They weren’t tolerating it, they were getting really fatigued” [Physio 8 FG] 
Some physiotherapists stated that the intervention was “cruel” or “too extreme” 
for patients with very severe stroke. Physiotherapists highlighted how this 
affected the duration of sessions and the number and frequency of rests breaks 
they provided for patients. “[…]it felt really cruel, they were trying to lift their 
head up and they were tolerating five minutes and it was just pointless for them 
and it would have … yeah, that presentation it’s just felt wrong with […] and it 
just felt like it was too extreme […] it felt cruel. [Physio 8 FG] 
Acceptability of the functional standing frame programme intervention 
One physiotherapist said the intervention was “cruel” or “too extreme” [Physio 8 
FG] for patients with severe stroke. Additionally, another physiotherapist said 
“you need quite a lot of hands; sometimes three or four people so it’s obviously 
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just taking other therapists off the ward but that’s the only negative thing about 
it” [Physio 4]. These comments suggest that the intervention may not have been 
acceptable to some physiotherapists. 
 
Patient’s perspectives  
Adverse events 
Some patients recalled adverse events they had experienced during the 
functional standing frame intervention, and felt the intervention “woke up” an old 
injury or exacerbated pre-existing problems: 
“It exacerbated problems I already had which was restless legs. I found 
that the more I did on the standing frame the more my restless leg became 
active at night […] That’s when I hurt my groin. I put a lot of pressure on 
my hip doing that, that’s when I felt my groin pull.” [PI2] 
“Well I’ve got a back injury from years ago and that kicks in you know, 
bottom of my back. I strained it 30 years ago. It comes back every now 
and again.” [PI3] 
Despite adverse events, this did not affect participants continuing with the 
functional standing frame programme, nor impact negatively on their experience 
of the intervention. 
Patients’ abilities to undertake the intervention 
Patient participants reported that whilst they needed and appreciated rests, they 
were reliant on their physiotherapist to encourage and motivate them, voicing a 
resistance to a protective or paternalistic approach that some physiotherapists 
may have adopted: 
“You've just got to give it a go. I mean the girls say to me do you want to 
sit down, and I say yes please. I don't have a problem if I sit down, then 
I'm okay again then.” [PI3] 
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“The physio said to me the other day, do you want to stop now if you’re too 
tired, if you want to stop we can stop, I went “no”, […] let’s carry on you 
know.” [PI2] 
“I'm in a position that I need to be pushed” [PC3] 
Patients reported valuing the encouragement and support from their 
physiotherapist:  
“I accept their professional opinion […] I trust them. I have confidence in 
professionals […] encouragement of the girls keeps me going.” [PI3] 
Some patients acknowledged that whilst they did not necessarily want to be 
doing physiotherapy, they recognised that it was an integral part of their 
recovery: 
“I don’t fancy doing all this physio to be quite honest, but I’ve got to get 
better and I’ve got to try to do it […] If you want to get better you’ve got to 
put some go yourself into it.” [PC6] 
“I’m in a position that I need to be pushed. Realising that it’s for my own 
good that we’re doing things, but it’s still things that were painful and hard, 
and quite within their right for my benefit. Sometimes I find it hard to put it 
into words and I go around the houses.” [PC3] 
“I didn't want to do it but when I bloody done it I felt great, I did honestly. It 
made me feel great.” [PC4] 
Patients appeared aware that they have severe and profound physical and non-
physical impairments post-stroke, and that undertaking physiotherapy is 
challenging and not something they want to be doing. However, they 
acknowledged that physiotherapy is an integral part of their rehabilitation and 
they need to be encouraged and pushed by their physiotherapists to achieve 
their hopes and goals of recovery. Patients emphasised the trust and 
confidence they had in their physiotherapists, and, it is therefore likely that if 
physiotherapists do not accept or support the intervention, this has the potential 
to affect how much encouragement and support they offer patients, which may 
affect adherence with the intervention. 
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Acceptability of the functional standing frame programme intervention 
Patient participants were mostly positive in their comments about the 
intervention, especially in terms of the opportunity it provided them to get up, 
get out of bed and stand up regularly after their stroke: 
“That would be good, laying down in a bed like this and doing nothing 
except talk to people is not getting anywhere” [PI1] 
“You can't like it all but it's for the great good, so just go with it” [PI3] 
“Gets you where you want to be [standing up]” [PI2] 
“I think it’s useful because it gives you a feeling that you’re not useless 
that you may be able to get some of it back again” [PC5] 
There were no negative comments, but some participants expressed indifferent 
thoughts or feelings about the intervention: 
“it was alright” [PC1] 
“I suppose I’m half inclined to agree, but at the same time I’m not entirely 
convinced” [Is it a good idea to practise standing up after your stroke?] 
[PI4] 
Relatives were positive about the idea of the functional standing frame 
programme, identifying both physical and non-physical potential benefits: 
“The benefits of going through the standing frame are paying dividends 
[…] But also, I think it gives you a bit of sense of purpose and a sense of 
achievement […] I think it’s good. I would imagine you’d lose a lot of 
confidence if you’re lying down a lot” [R2] 
“Definitely yes, it’s a good idea” [R3] 
This theme highlights the impact that the therapeutic relationship had on 
implementing the functional standing frame programme. Some physiotherapists 
adopted a paternalistic approach, believing that patients were unable to tolerate 
the intervention; this affected recruitment and intervention adherence. The data 
suggested that physiotherapists sometimes deviated or violated the protocol by 
not screening and approaching potentially eligible participants. Further potential 
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for protocol non-adherence may also exist that may not overtly be identified as 
a protocol deviation or violation. For example, physiotherapists may not 
progress or encourage patient participants as much as they would if they were 
implementing an intervention that aligned with their beliefs, values or pre-
conceived ideas about the ideal patient for this intervention. These factors all 
have the potential to impact negatively on the results of a subsequent 
effectiveness trial. However, comments from some patients were in direct 
contrast to the beliefs of these physiotherapists; despite saying they felt 
exhausted, and that the intervention was arduous and challenging, they 
expressed a desire to be encouraged and pushed to work hard by their 
physiotherapist. This information will be invaluable for training physiotherapists 
when a subsequent definitive trial is undertaken. 
5.7 Summary 
The results of the qualitative component of this trial have identified a range of 
barriers and facilitators that may be critical to the success of a future definitive 
trial. They encompass factors related to: a) the organisation and culture, 
including teamwork and dealing with changes in working practices as a result of 
implementing the functional standing frame intervention; b) knowledge, 
experience and behaviour of both clinical and research physiotherapists; c) 
patient hopes and expectations and therapeutic relationships with their 
physiotherapists; d) trial procedures, particularly eligibility criteria and how 
stroke severity may impact on the ability of physiotherapists to deliver the 
intervention. The next chapter will discuss these results in more depth to 
determine the feasibility of a future definitive trial. 
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Chapter 6 Feasibility trial discussion 
A randomised feasibility trial of a functional standing frame programme was 
conducted, with the primary aim of determining the feasibility of conducting a 
large scale RCT of such an intervention for people with severe sub-acute 
stroke. 
6.1 Key findings relating to feasibility 
This feasibility trial has identified important factors related to recruitment, 
fidelity, outcome measures, and trial processes. A range of barriers and 
facilitators have been highlighted that may be critical for the success of 
implementing a future definitive multi-centre RCT. Beliefs, attitudes and 
behaviours of physiotherapists influenced many of these factors and will be 
discussed in this chapter. 
6.2 Adherence 
Adherence is a key variable influencing the outcome of clinical trials361. Various 
definitions of adherence and compliance exist with lack of agreement, resulting 
in these terms being used interchangeably. The World Health Organization 
(WHO)362 defines adherence as “the extent to which a person’s behaviour […] 
corresponds with agreed upon recommendations from a healthcare provider”. 
This definition is specific to behaviour of the patient, suggesting the 
responsibility of adherence lies with the patient. But what impact do the beliefs, 
attitudes and behaviour of the healthcare professionals have on participants’ 
adherence in clinical trials? How do healthcare professionals’ beliefs, attitudes 
and behaviours affect their adherence to trial procedures? 
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Physiotherapist-related factors 
Beliefs and attitudes about stroke rehabilitation held by physiotherapists are 
likely to affect behaviour and play a key role in the treatments they implement 
with their patients363. Beliefs have been described as ‘a cognitive process 
resulting in a concrete cognition of how we think things are’364. Attitudes are 
considered ‘a more complex cognitive state involving beliefs and feelings as 
well as values and predispositions to act in a certain way’365. According to the 
theory of planned behaviour, behaviour is determined by the attitudes and 
beliefs that a person has about the likely consequences of the behaviour365. 
This theory may help understand physiotherapists’ clinical decision-making in 
relation to implementation and evaluation of the functional standing frame 
intervention, as well as their approach to recruiting potential participants into the 
trial. Some physiotherapists reported that they felt the intervention was either 
too challenging for people with very severe stroke, or not challenging enough 
for people with moderately severe stroke, which may result in a negative 
attitude to recruitment and delivering the intervention to these patients. The 
converse was also a possibility. Thus, physiotherapists’ beliefs and attitudes in 
this feasibility trial may have affected their behaviour. 
The theory of planned behaviour assumes that human beings are rational and 
make systematic decisions based on available information and experience361, 
and that these decisions are planned. It does not, however, take into 
consideration unconscious bias. Unconscious (implicit) biases are 
unconsciously and unintentionally held preferences and stereotypes of which 
we are not aware366. The presence of unconscious bias among healthcare 
professionals has been identified as a concern because it affects clinical 
decision-making and treatment selection366,367. Some physiotherapists in the 
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interviews and focus group in this feasibility trial reported preferences for 
specific treatments, dependent on patients’ stroke severity. 
Physiotherapists’ and Occupational Therapists’ beliefs were cited as a barrier to 
implementing evidence-based stroke rehabilitation recommended in national 
clinical guidelines368. They had their own beliefs about treatments that were not 
supported by current evidence and this affected their behaviour. Therefore, for 
the success of a future main trial it is important to consider how this behaviour 
may affect physiotherapists delivering a protocolised intervention. For instance, 
one study demonstrated that when considering implementing body weight 
support treadmill training, physiotherapists weighed up the time taken to set up 
patients with a harness and two physiotherapists against the potential outcomes 
of using a much simpler treatment which impacted on their behaviour368. 
Physiotherapists in the SPIRES trial appeared to have similar thoughts, 
weighing up the implementation of SPIRES against their usual practice. For 
example, in the focus group and interviews some emphasised the physical 
effort and staff resources required to facilitate participants with very severe 
stroke in the early stages of the programme. Some physiotherapists in the focus 
group suggested a potential solution for a future main trial would be for 
participants who lack head and trunk control to commence the trial in a tilt table, 
and progress to the standing frame once head control and aligned static sitting 
balance for a specific number of seconds has been achieved. The tilt table 
allows people with severe disability to stand up, weight bear and practice 
movements to improve head and trunk control whilst being fully supported369,180. 
Identifying solutions such as this may increase the willingness of 
physiotherapists to adhere to the protocol and trial procedures in a future main 
trial. 
285 
It is important to consider if the participants’ medical history influenced 
physiotherapists’ adherence to the protocol with regard to implementing the 
intervention, either consciously or subliminally, as this may warrant review of 
the eligibility criteria. Most participants in the intervention group had two or three 
co-morbidities, most commonly osteoarthritis, joint replacement and coronary 
heart disease/hyper- or hypotension. There did not appear to be any 
relationship between co-morbidities and adherence in standing duration or sit to 
stand repetitions, thus data did not suggest participants’ medical history 
affected physiotherapists’ or participants’ adherence. 
Physiotherapists reported that patients were bored and did not enjoy sessions. 
It is notable, however, that 91.0% of sessions were recorded as being “enjoyed” 
by participants, and the interviews highlighted that the participants did not report 
being bored or scared. It is possible that physiotherapists themselves become 
bored over the duration of the recruitment period or had an erroneous 
perception of patient boredom; it would be of interest to explore this in future 
research. Physiotherapists’ attitudes and behaviour appeared to change during 
the trial time course, as evidenced by data from the interviews and focus group 
which were conducted at various time points from three months onwards from 
recruitment commencing. Initially the interviews highlighted how 
physiotherapists spoke positively about the trial and the intervention, but these 
attitudes appeared to change over the course of the trial. Some of the reasons 
for this will be discussed later in this chapter, in relation to organisational 
culture. 
Awareness, understanding and translation of evidence-based interventions for 
stroke rehabilitation varies among physiotherapists370,371 and healthcare 
organisations. Some therapists rely on tacit knowledge and clinical experience 
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instead of research findings when making decisions about which physiotherapy 
treatments to deliver whilst others utilise the evidence base to inform their 
clinical reasoning372,373. This variation was evident in the comments made within 
the interviews and focus groups of the therapists engaged in the trial. One 
physiotherapist, for example, said that delivering the intervention “felt really 
cruel” and “it was just pointless” and deemed that the participant was only able 
tolerate five minutes standing. In contrast, another higher banded 
physiotherapist with more clinical experience and a post-graduate neurological 
practice qualification clearly identified the need for intensity of practice, 
commenting that “physiotherapists with less clinical experience in stroke are not 
adept at pushing and progressing patients on as much as more experienced 
physiotherapists”. These comments support the notion that the way in which 
physiotherapists gain their knowledge may impact on their values and beliefs 
about treatment selection, which, may in turn, influence their conduct in 
implementing a trial intervention, even when it has been protocolised.  
Within the context of the SPIRES feasibility trial, it is important to establish 
physiotherapists’ adherence to the trial protocol and delivering the intervention 
as specified in the protocol. This is known as treatment fidelity374. Attaining and 
demonstrating treatment fidelity is critical in the development and testing of 
evidence-based interventions. Fidelity was assessed at three sites. This 
identified that the intervention was not delivered at one site as specified in the 
protocol, as illustrated by the account of one participant with dementia who 
completed only seven out of 21 sessions. The most common reasons 
documented for non-completion of sessions was: “the participant was not a 
priority” or there was “insufficient staffing”. This could have been reflected at 
other sites but was not identified in the sessions observed for fidelity checking. 
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Rehabilitation potential is judged by clinicians at an individual patient level to 
determine when rehabilitation begins, the intensity of rehabilitation that is 
required and can be tolerated to be effective, and when further rehabilitation 
intervention would fail to deliver meaningful outcomes for patients375. People 
with severe stroke have been reported to make a slower and less complete 
functional recovery during inpatient rehabilitation when compared to those with 
mild or moderate stroke376. Physiotherapists have been shown to focus their 
resources on “high priority” patients who they perceive more likely to have 
greater rehabilitation potential372; providing them with more regular, and longer 
physiotherapy sessions than those perceived as not making much physical 
progress373,374. It may be that physiotherapists in SPIRES deemed some 
participants to lack rehabilitation potential, which may have affected their 
adherence to implementing the protocol. However, this was not overtly 
expressed. A deeper exploration of this may have provided useful insights into 
whether this was the case, and if so, how this might be dealt with in a future 
definitive trial. 
Clinical Guidelines3 recommend daily mobilisations which encompass sitting out 
of bed, standing or walking delivered by appropriately trained staff using 
appropriate equipment. However, there is no specific guidance as to how to 
implement this with varying severities of stroke, and there is a vast difference in 
ability and disability for people with mild, moderate or severe stroke. National 
clinical3 guidelines do not explicitly recommend the use of standing frames, but 
state: “Patients with difficulty moving early after stroke who are medically stable 
should be offered frequent, short daily mobilisations (sitting out of bed, standing 
or walking) by appropriately trained staff with access to appropriate equipment, 
typically beginning between 24 and 48 hours of stroke onset. Mobilisation within 
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24 hours of onset should only be for patients who require little or no assistance 
to mobilise”. There is no definition for “frequent” or “short” and this is left open to 
interpretation, but people with stroke are recommended to accumulate “at least 
45 minutes of each appropriate therapy every day, at a frequency that enables 
them to meet their rehabilitation goals”. The 'active ingredients' of 
neurorehabilitation which includes stroke is unknown237, therefore, the lack of 
specificity in the guidelines are unsurprising. Therefore, this is likely to result in 
physiotherapists selecting treatments based on their preferences and/or 
experience as opposed to evidence. 
Opinions varied about the level of ability required by patients to use the 
standing frame, which is unsurprising given the lack of evidence-based 
guidance about their use. This is likely to have contributed to the variation in 
their use within this trial. Furthermore, there is no consensus on the optimal 
rehabilitation interventions for people with severe stroke377. The AVERT378 trial 
concluded that mobilising within the first 24 hours post-stroke was harmful. It is 
possible that the physiotherapists engaged in SPIRES may have been cautious 
in implementing the standing programme intervention in light of any potential 
negative consequences; as alluded to by some physiotherapists in the 
interviews when they commented that they felt the SPIRES intervention was 
“too early”. It is noted however that SPIRES participants were beyond the 24-
hour timeframe from stroke onset (time to consent was 3-32 days). One further 
explanation for the lack of adherence to the protocol might therefore be that the 
physiotherapists’ interpretation of the AVERT results378 had influenced their 
decision making. 
This explanation also suggests that the physiotherapists may have been 
protective or paternalistic towards their patients. Paternalism in clinical trials 
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implies that clinicians are deciding which patient they believe is most suitable 
for a trial, and patients are being prevented from making decisions for 
themselves379.This suggestion of paternalism was reflected by some of the 
comments made by physiotherapists in the interviews and focus group in 
relation both to recruitment and protocol adherence. It has been shown that 
paternalism within clinical trials erodes patient autonomy and can introduce 
selection bias and reduce the generalisability of a trial’s results379. However, 
approaching patients and relatives within a few days of a life changing severe 
stroke to discuss research is acknowledged as being a daunting prospect, and it 
is understandable that some clinicians may have felt uneasy. Of interest, the 
SPIRES participants appeared to resist a paternalistic or protective approach by 
declining rest breaks and/or continuing the session when the physiotherapist 
suggested they stop. Additionally, all participants and relatives interviewed 
agreed that all patients should be offered the opportunity to enrol in SPIRES, 
despite the devastating and life-changing event and severity of their stroke and 
impairments. 
Physiotherapists' attitudes and beliefs have been highlighted as a common 
barrier in the implementation of stroke clinical guidelines, evidence-based 
interventions, and clinical and rehabilitation trials368,370,250. This also appeared to 
be the case in this feasibility study. How to address these issues in the long-
term for the benefit of future trials including SPIRES will be discussed in Section 
5.13 Future directions. 
Patient-related factors 
Patient-related factors will be discussed using the COM-B model380. COM-B is a 
simple model to understand behaviour and has three layers at its core: 
Capability (psychological or physical ability to enact the behaviour e.g. 
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comprehension and reasoning); Opportunity (the physical and social 
environment that enables the behaviour); and Motivation (reflective and 
automatic mechanisms that activate or inhibit behaviour). COM-B forms the hub 
of the behaviour change wheel380. 
Capability 
So far, this chapter has explored the beliefs, attitudes and behaviour of 
physiotherapists and their potential impact on adherence to the SPIRES trial 
intervention and recruitment. But it is also important to explore patient-related 
factors when discussing adherence and fidelity of the intervention because 
these two factors are related. Fidelity of the intervention was assessed in 
several ways; whether participants attended treatment sessions, reasons why 
they did not attend or complete sessions, and the activities they completed 
during these sessions. As previously described, all SPIRES participants had a 
severe stroke, typically with multiple physical, sensory and sometimes cognitive 
and communication impairments. It would not be unreasonable to surmise that 
the relatively low adherence (only 45.4% of sessions were completed) was 
because of the severity of these impairments. However, the case reports 
recorded that almost a third (27.9%) of sessions were not completed due to 
insufficient staffing, with 10.3% due to participants being unwell, and 11.5% due 
to participant withdrawal. Thus, participant impairments did not appear to be the 
primary reason for non-attendance of sessions. 
Experiencing a stroke can suddenly create a state of dependency, where 
participants may lack control over their daily lives381; with reliance on health 
professionals to guide their rehabilitation. However, patients may want to take 
an active role in their rehabilitation382. If participants are passive during their 
rehabilitation, sessions will be determined by physiotherapists’ knowledge, 
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experience, beliefs and attitudes which may have affected participant’s 
adherence, as discussed in physiotherapist-related factors above. Conversely, 
participants who take an active role in their rehabilitation may request to work 
through the tiredness, request to sustain or increase the intensity which may 
impact on the intensity of the session. 
Opportunity 
Patients needed to be made aware of the research project in order to take up 
the opportunity of engaging in it. However, in SPIRES, as is the case with most 
clinical trials, health professionals to a certain extent acted as “gatekeepers”383 
to their involvement, by the level to which they raised awareness of the trial with 
them. This aligns with the previous discussion of paternalism, in physiotherapist 
related factors. 
Motivation 
Some participants reported they were exhausted during their sessions and were 
reliant on their physiotherapist to encourage and motivate them to continue their 
sessions. Conversely, some participants reported an internal motivation to 
“push through the tiredness”, declining to end a session when their 
physiotherapist suggested they stop. This aligns with existing literature reporting 
that patients do not mind being pushed to work hard during rehabilitation, 
recognising this can be helpful when their motivation is lagging381. 
Correspondingly, it has also been demonstrated that a lack of perceived 
encouragement and support from professionals may demotivate patients during 
their stroke rehabilitation382 which can negatively affect rehabilitation outcomes. 
Motivation is multifactorial but there is no consensus for its concept385. 
However, motivation in rehabilitation is considered important due to its impact 
on patient outcomes384,386. Motivation levels in people after stroke have been 
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distinguished as high and low385 and internal and external386. Highly motivated 
patients are aware of the importance of their active participation in rehabilitation 
and the significant improvements that may occur in their condition. In contrast, 
people with low motivation for rehabilitation show lower commitment to 
achieving fast recovery384. Motivation and adherence are related385; both 
appeared to fluctuate for SPIRES participants, as reflected by their comments in 
relation to acceptance of the stroke, change in function and role, apprehension 
about the future and impending discharge from hospital. Previous authors have 
highlighted that patients consider their motivation toward physical rehabilitation 
as being a fluid condition that can be affected positively or negatively by their 
treating team381. It is possible that in the SPIRES trial, some physiotherapists 
may have affected participants’ adherence and motivation (intentionally or 
unintentionally) due to their beliefs and attitudes about the intervention, as 
indicated by the language used by therapists in the interviews and focus group 
when they referred to the standing programme as being, for example, “ideal” or 
“not suitable”. 
It was anticipated that fatigue and OH may impact on completion of SPIRES 
intervention sessions, hence the minimisation process accounted for these two 
factors, which proved to be appropriate since most participants with fatigue and 
OH spent less time in standing (Section 4.8.4, Chapter 4). Prevalence of OH 
was lower than expected in this sample. Orthostatic hypotension was slightly 
higher in the intervention sessions (n=6) compared to the minimisation 
assessments (n=4) (reflecting differences in how this was measured) but did not 
reflect the high prevalence (52%109) identified in the systematic review (Chapter 
2). It is possible that the lower prevalence of OH may be attributed to the sit to 
stand repetitions undertaken; the systematic review identified that physical 
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manoeuvres such as leg muscle pumping/contractions and bending forward 
minimised OH387. The low prevalence of OH during the physiotherapy sessions 
may also be attributed, at least in part, to low adherence to the sessions, 
because over half of the 945 sessions were not completed. Although 
prevalence of OH in SPIRES was not as high as anticipated, it is important to 
assess and monitor it, due to the risk of increased disability and mortality as a 
result of cerebral hypoperfusion as discussed in Chapter 2. In a definitive main 
trial, it is recommended that OH is recorded as an adverse event. 
Prevalence of fatigue in this sample was high. Although it was not the primary 
reason for non-completion of intervention sessions, several physiotherapists 
commented that they felt some participants were unable to tolerate the 
intervention, and as a consequence chose to either shorten the duration of the 
patients standing session or to cancel it. Given the impact that fatigue appeared 
to have on adherence to the protocolised intervention, it could be argued that a 
systematic review of interventions to treat fatigue is warranted prior to a 
definitive main trial to determine whether these might be utilized in order to 
enhance standing session times/frequency. 
Organisational and cultural factors 
The results of SPIRES feasibility trial were broadly aligned with the findings of a 
qualitative process evaluation undertaken in the AVERT trial, a large multi-
centre international stroke rehabilitation trial delivering a complex intervention of 
early mobilisation in people with acute stroke249. They identified organisational 
or workplace barriers that are mirrored in the results of SPIRES: the fast paced, 
discharge driven culture of acute/sub-acute stroke units, where rehabilitation 
had low priority and there were competing organisational priorities which 
included a resistance or lack of support/encouragement from the therapy team 
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and wider rehabilitation team management, repeated organisational changes, 
and an absence of a research culture. Insufficient time and inadequate staffing 
levels were also identified by Luker et al., (2016). However, neither the 
participants of this process evaluation (the health professionals) nor the authors 
identified any solutions or facilitators to any of these organisational barriers. 
Some organisational barriers such as lack of time and inadequate staffing are 
not exclusive to clinical trials and appear to be reflective of daily clinical practice 
in stroke rehabilitation. They have been commonly reported as barriers to 
implementing evidence-based stroke rehabilitation388. Therefore, it is 
unsurprising that the additional workload of a clinical trial may exacerbate pre-
existing organisational challenges and barriers. The organisational barriers 
identified in SPIRES are worthy of acknowledgement in terms of their impact on 
recruitment and intervention implementation. Such barriers may be modifiable 
or non-modifiable, both of which need to be factored into the planning of a 
future main trial and potential solutions identified. 
Opinion varied among physiotherapists as to how stroke severity affected their 
ability to deliver the intervention in relation to resources. It is widely known that 
rehabilitation of people with severe stroke is associated with increased 
resources compared to people with mild or moderate stroke389. Thus, it was 
unsurprising that physiotherapists identified that delivering the intervention with 
this sample of people with severe stroke challenged existing resources, which 
at many sites were already reduced. Reduced staffing levels are identified in the 
literature as a reason why people with stroke do not receive the recommended 
amount of active therapy during inpatient stroke rehabilitation3. Staffing levels 
for physiotherapists at all four sites were lower than recommended in National 
Clinical Guideline for Stroke349 periodically throughout the trial due to vacancies, 
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annual and maternity leave and sickness etc. This combined with the natural 
ebb and flow of integrating new, (sometimes less experienced) staff members, 
exacerbated difficulties with trial procedures such as the consistent 
implementation of the intervention and recruitment of participants. 
The number of beds in a stroke unit determines the number of staff; bed 
numbers in the four sites ranged from nine to 21. Staffing levels were 
significantly reduced at one site (a nine bedded unit, staffed by two 
physiotherapists) for several weeks which resulted in recruitment stopping at 
this site. This highlights the need to consider the size of the stroke unit prior to 
involving a unit in a definitive main trial. 
The perceived burden of a trial by the staff members within a unit may also 
influence consideration of engaging the unit in a future trial. For example, the 
interviews and focus group highlighted that some physiotherapists remarked 
that the number of physiotherapists required to implement the intervention with 
people with very severe stroke, was too great, especially when it had a negative 
impact on staffing and equity of care between trial and non-trial patients; 
creating moral dilemmas for some of the physiotherapists. For a main trial, there 
may need to be a more flexible approach to recruitment; with a pro rata 
approach to participant recruitment numbers dependent on staffing levels. 
Additionally, changes in the approach to the intervention protocol, such as 
allowing some participants to start standing in the tilt table before progressing to 
the standing frame (Section 5.4) might also help to better manage the 
challenges faced in terms of staffing levels. 
Studies have shown that reduced staffing can determine what interventions 
patients receive372; limiting therapy options, reducing patients’ opportunities for 
standing or walking.  
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In SPIRES the most commonly adopted positions for participants during control 
group sessions were lying and sitting, which could be delivered by one 
physiotherapist, freeing up resources to treat other patients/participants. 
Preference for treating patients in sitting and lying may also be related to 
physiotherapists’ knowledge and understanding of evidence-based stroke 
rehabilitation, which can, in turn, influence the shared beliefs and attitudes of 
physiotherapists and organisational culture. 
Organisational culture is defined as a set of beliefs, values, and assumptions 
that are shared by members of an organisation390. Healthcare organisational 
culture has been described as a metaphor for some of the softer, less visible, 
aspects of health service organisations391 which may influence treatment 
selection or adherence to clinical trial protocols. Healthcare organisational 
culture is complex and has been categorised as three layers (1) visible 
manifestations which include a range of behaviours seen as embedded, normal 
and acceptable clinical practice; (2) shared ways of thinking including shared 
values and beliefs, and (3) deeper shared assumptions that are largely 
unspoken often unconscious expectations, beliefs and values that underpin 
clinical practice392. Together these layers reflect a shared and commonly 
understood view of the clinical workplace. It was observed that the culture within 
each of the four SRUs in SPIRES appeared to vary, in relation to shared values 
and beliefs about the intervention, and that this affected recruitment of 
participants into the trial and adherence to the trial protocol.  
A research culture has been associated with benefits for patients, clinicians, 
and the healthcare organisation through improved treatment interventions, 
enriched career opportunities, and enhanced reputation393,394. However, there 
appears to be a lack of consensus on what defines a successful research 
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culture. Comments in the interviews and focus group drew attention to the 
notion that a weak research culture was evident within in some of the units 
engaged in the SPIRES trial. For example, some physiotherapists reported that 
an evidence-based treatment approach was “not highly thought of within their 
organisation”. This may affect how supportive therapists and the wider multi-
disciplinary team were about being involved in implementing the SPIRES trial. 
Research experience (determined by GCP, curriculum vitae and site visits) 
varied among sites and physiotherapists and this is likely to have influenced the 
implementation of trial processes.  
Adherence summary 
Patient, physiotherapist, organisational and cultural factors all affected the 
implementation of trial processes in this feasibility trial. None of the participants 
in the intervention group achieved complete adherence to any aspect of the 
standing programme (30 minutes of standing and 8-12 sit to stand repetitions or 
graded increase of 30% each week for a minimum of five sessions per week for 
three weeks). 
Physiotherapist and patient-related factors affected adherence however, the 
interviews did not specifically explore adherence in depth. A future study, 
undertaking ethnographic research focusing on this question may be warranted 
to explore in more depth. 
6.3 Safety 
Safety risks were considered an important aspect of feasibility, but the risks 
associated with taking part in this trial were assessed as low351 None of the AEs 
and SAEs were deemed related to the trial and most were reported during the 
follow-up period. Safety was never highlighted as an issue by physiotherapists, 
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participants or relatives at any time during the trial, and did not appear to have a 
profound effect on adherence to the standing programme. 
Just over a quarter of participants died (26.7%, n=12) which was higher than 
the 7.6% deaths reported in AVERT378. This indicates that the appropriate 
participants were recruited because people with severe stroke have an 
increased mortality risk365. It is important to consider age. Age is the strongest 
predictor of adverse stroke outcomes396 and 60% of SPIRES participants were 
≥80 years (mean age 80.3 years), compared to 26% ≥80 years (mean age 72.5 
years) in the AVERT trial. Nearly 40% of patients admitted to UK stroke units 
are ≥80 years of age397, therefore, it is important where possible not to exclude 
people ≥80 years in stroke research. Additionally, people with stroke, their 
relatives and physiotherapists felt there should not be any age restriction for 
entry into the trial. However, increasing age was associated with higher 
mortality rates in SPIRES, which aligns with other research398, therefore, a 
definitive main trial could stratify for age. 
Mortality rates in a six-month trial of prolonged standing for people with severe 
stroke appeared to be similar to SPIRES97. When comparing the 12-month 
mortality for people with stroke, mortality in SPIRES (26.7%) was much lower 
than the 41% and 40.3%309,310 observed in (not rehabilitation) studies 
investigating the long-term survival rates post-stroke. Infection (respiratory) and 
further stroke were the two reasons disclosed for cause of death for five 
SPIRES participants, cause of death was unknown for seven participants. 
Active infections at recruitment were an exclusion factor (medically unstable) 
but given the long term follow up it is not possible to mitigate for these causes of 
death. 
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Frailty is a syndrome of decreased reserve and resistance to stressors resulting 
from a cumulative decline across many physiological systems leading to 
vulnerability and adverse outcome399. Several measures of frailty are used in 
clinical practice400, but pre-stroke frailty was not measured or captured in 
SPIRES. A stroke may be considered as a significant stressor, and low physical 
function components of frailty, measured by walking speed and grip strength, 
are the most consistent determinant of shorter survival and lack of post-stroke 
recovery in cognition and activities of daily living396. A definitive main trial should 
consider including pre-stroke and post-stroke frailty measures which could help 
identify individuals at the greatest risk for poor stroke outcomes. 
6.4 Design 
SPIRES was a multi-centre feasibility RCT, and the justification for this is 
discussed in Chapter 3 (Section 3.5). If SPIRES were to proceed to a definitive 
main trial an alternative design could be a cluster RCT which would randomise 
stroke rehabilitation units as opposed to individual participants, thus avoiding 
treatment group contamination and the possibility of enhancing adherence401. 
However, on questioning, the physiotherapists’ preference was for the current 
trial design. They acknowledged a cluster RCT may be preferable in terms of 
blinding but felt delivering both control and intervention groups at each site 
would help maintain motivation and interest for themselves, challenge their 
practice and be easier to manage the workload associated with the standing 
intervention. Further, implementing a flexible recruitment rate that mirrors 
staffing levels, as stated previously, would help to address workload issues. 
An alternative approach is a cluster stepped-wedge RCT. This would address 
the desire to deliver control and intervention groups at each site because 
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clusters initially serve as a controls before receiving the intervention at a 
subsequent time step; eventually, all clusters receive the intervention402. 
Although a feasibility trial does not enable conclusions to be drawn about 
effectiveness of an intervention238, in SPIRES the greatest improvements in 
function, as evaluated by the outcome measures, occurred in the first three 
weeks with smaller changes continuing up to six months. This links to the 
evolution of physiological changes in stroke (discussed in Chapter 1 Section 
1.3) wherein the most rapid changes in impairment and function occur in the 
first three months but continue at six months and beyond11. Therefore, a 
factorial design could provide the opportunity to determine the clinical and cost-
effectiveness of the SPIRES intervention at two time-points: inpatient sub-acute 
stroke rehabilitation (early) and the community (late) (see Figure 6.1). 
 
Sub-acute and community 
(early and late) 
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Sub-acute inpatient (early) 
 
 
Control (usual 
physiotherapy) 
 
Figure 6.1 Proposed factorial design 
 
A factorial design would allow the effects of two interventions to be investigated 
independently in the same trial as well as testing if two interventions work in 
synergy or are antagonist and has been used for evaluating complex 
interventions in a wide range of health care settings and clinical specialities403. 
However, the trial would need to be appropriately powered to estimate the 
interaction between the two interventions402. Further, the proposed factorial 
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design is limited by the maximum duration of treatment in the inpatient setting 
(~18 days-see below) otherwise there would be a confounding factor of 
differences in treatment duration between groups. 
A factorial stepped-wedge cluster RCT has been proposed recently that could 
be the design a definitive main trial404. However, there are several important 
caveats to the proposed factorial designs for SPIRES: a) the cost implications 
for delivering the intervention in the community needs to be addressed, e.g. 
provision of standing frames and treating therapists because therapy provision 
post-discharge varies geographically, which may be challenging in the current 
financial environment; b) it is a more complex design that may require more 
resources to manage; c) a larger sample size will be required; d) consideration 
of the duration is warranted in relation to the physiological changes the 
intervention aims to facilitate. Future work will aim to collaborate with a 
consensus group/expert panel to determine the future trial design. 
The duration of the intervention was based on the average length of stay in 
2015 when the trial was developed. However, it is important to review whether 
the national model for stroke care has changed and what impact, if any, this 
may have on the duration of a future main trial. The most recent data suggests 
the average length of stay for sub-acute stroke rehabilitation in the UK is 18.1 
days (median 6, low IQR 2, high IQR 20.2)405. Unfortunately, the Sentinel 
Stroke National Audit Programme (SSNAP) do not provide a breakdown of data 
to differentiate length of stay based on stroke severity. This is an average length 
of stay, and for some stroke units this is 7.3 days. Length of stay varies across 
the UK, at least in part due to variations in criteria for ESD services (e.g. level of 
assistance required), and patient case mix. This affects when and where stroke 
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rehabilitation is delivered, which would impact on the delivery of a future trial 
which could potentially span both inpatient and community settings. 
It is important to consider both pragmatic and aspirational views for the future of 
stroke rehabilitation. The refrain that delivering high doses in current healthcare 
settings is not possible has been identified (the pragmatic view)237. This aligns 
with findings from SPIRES that staffing resources and organisational priorities 
impacted on the delivery of the SPIRES standing programme dose. One might 
therefore argue that a lower dose be protocolised for the standing programme. 
A distinct disadvantage of this is that current policy would be the driver for 
dictating treatment selection and rehabilitation trial design, which may have a 
detrimental impact on patient outcome237. It is argued that a higher dose and 
intensity may be more costly initially but may result in reduced dependency 
further along the rehabilitation continuum, a requirement for less formal or 
informal care, and a higher rate of return to work. All of which may have 
significant impact on the economic burden of health and social care. The role of 
clinical research is to challenge current practice in order to reshape and 
improve rehabilitation services (the aspirational view)237; it is maintained that 
post-stroke rehabilitation must adopt the same aspirational approach406. 
Foot sensors 
Foot sensors were provided based on the findings from a systematic review that 
quantified weight bearing should be monitored in future clinical trials of 
supported standing94 and sit to stand practice407. This aligns with more recent 
evidence that asymmetrical weight bearing and weight-shifting ability correlate 
with gait asymmetries, and rehabilitation strategies that increase the 
contribution of the paretic limb to standing balance control may increase 
symmetry of walking post-stroke408. However, some physiotherapists remarked 
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that the foot sensors did not necessarily facilitate a positive outcome and 
preferred to use their own clinical judgement instead. To my knowledge, the 
relative reliability and usefulness of physiotherapists’ observation versus foot 
sensors or biofeedback has not yet been empirically confirmed. Of specific 
relevance to this feasibility trial, despite several iterations in the design and 
manufacture of the foot sensors, they were deemed by the physiotherapists as 
unreliable and temperamental which made delivering the intervention more 
difficult. Some physiotherapists were also not convinced participants liked them, 
suggesting they may have triggered anxiety. 
The foot sensors would therefore need to be developed further with 
physiotherapists and people with stroke if they were to be used in a definitive 
main trial. 
Who should deliver the intervention? 
SPIRES intervention was delivered by physiotherapists, and during the design 
of the trial the potential for OTs and therapy support workers also delivering the 
intervention was discussed. The consensus was that it should be led by 
physiotherapists due to their knowledge and experience in analysis and 
facilitation of movement. However, prior to progressing to a main trial, this 
needs to be discussed on a wider scale because working practices and beliefs 
varied throughout the sites, and OTs and therapy support workers used the 
standing frame in their treatment sessions. This approach may help to address 
the challenges posed by staff shortages and share the workload with other 
members of the multi-disciplinary team. 
Fidelity checking 
Fidelity checking in SPIRES formed part of the process evaluation, and given 
the significant issues identified with low adherence, monitoring fidelity in a 
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definitive main trial is warranted. Caution in the interpretation of the fidelity data 
is important since the number of fidelity checks undertaken in this feasibility trial 
was low (one control and one intervention session once at each site) and may 
not provide a true reflection of the overall fidelity status. More frequent 
monitoring may have had the advantage, not only of increased confidence in 
the fidelity data, but also in affording the opportunity to address implementation 
issues during the trial. Implementation fidelity can affect the credibility and utility 
of research409, and a conceptual framework may facilitate a way of measuring 
and monitoring fidelity in a future main trial. The Implementation Fidelity 
Framework (IFF)409 incorporates components of implementation fidelity and 
factors that may influence the degree of fidelity (moderating factors). 
Measurement of implementation fidelity is a measurement of adherence, which 
includes content, frequency, duration, and coverage (dose). The framework was 
empirically tested and modified with two additional moderating factors: context 
and recruitment410. In a future main trial, it is suggested that the fidelity data 
gathered should be analysed regularly so that any training or logistical issues 
identified could be addressed in a timely manner. 
Assessment timepoints 
It was feasible and acceptable to participants to be assessed at five timepoints: 
baseline, post-intervention period (3-weeks), and 15-, 29- and 55-weeks which 
represent 3-, 6- and 12-months post-intervention period. Previous trials of 
prolonged standing have varied in duration, with final time-points of three and 
12 months95-97. It is important to consider the predicted physiological and 
behavioural changes to determine assessment timepoints for a definitive main 
trial for SPIRES. The Stroke Recovery and Rehabilitation Roundtable 
taskforce11 have developed a framework that encapsulates definitions of critical 
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time-points post-stroke that link to the currently known biology of recovery. They 
report the current understanding of brain repair processes suggests that most of 
the behavioural recovery, and the rapid changes occur in the first weeks-to-
months post stroke for most people, and they recommend assessing from 
hyper-acute to chronic (>6 months) but do not explicitly recommend a final time-
point beyond six months. Assessment at three months is considered essential 
for all stroke trials that are testing sensorimotor interventions, and at least six 
months for trials conducting an economic evaluation411. Therefore, it is 
suggested that a definitive main trial should assess at baseline, post-
intervention, 3- and 6-months post-intervention (but not 12 months). 
In stroke rehabilitation trials, it is also important to consider the impact of other 
therapies beyond the trial that may affect functional outcomes, given the multi-
disciplinary and multi-service nature of input3. It is therefore recommended that 
a resource use questionnaire is used to systematically record the multi-
disciplinary input received over the timeframe of the trial. 
6.5 Recruitment and retention 
Successful clinical trials are dependent on effective recruitment and retention of 
the target sample size352. If this cannot be achieved, there are implications for 
statistical power and internal and external validity4121. Slow recruitment also has 
practical and financial implications, as it can delay trial completion, which, in 
turn, may impact on the timely impact of research findings on clinical practice352. 
Challenges with recruitment and retention are widely known for stroke 
rehabilitation trials and RCTs in different specialities, and several studies have 
provided valuable insight into the barriers and facilitators352,412-414. 
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Recruitment 
SPIRES recruitment target was 50 participants over 12 months, and the 
feasibility indicator for success was ≥70% of 50 participants. Forty-five 
participants were recruited over 10 months representing 90% of 50 participants 
(Section 4.5 Chapter 4) demonstrating success for this feasibility indicator. It is 
also important to determine the willingness of physiotherapists to recruit. This 
was measured by the percentage of patients screened and approached from 
the number of eligible admissions. The feasibility indicator for eligibility (≥50% of 
admissions screened and ≥75% of eligible participants approached) was 
achieved. SPIRES had a two-stage screening approach: 1) to determine 
eligibility for stroke severity (mRS 4 or 5) on admission; 2) formal screening 
once stroke severity confirmed. Whilst the parameters for success were 
achieved, it is important to consider reasons that other potentially eligible 
participants were not screened and/or approached. 
It was apparent from the interviews and focus group that there were instances 
where eligible patients were denied the opportunity to make their own decision 
about participating in SPIRES. Some physiotherapists reported to being 
selective about which patients they did and did not screen or approach, 
deeming that some patients were either “too good” or “too impaired” for the 
intervention.  
Some sites were more “on-board” (as reflected by willingness to recruit etc.) 
than others, and this has been identified in other stroke rehabilitation studies250. 
Willingness to recruit may have been affected by clinical equipoise; the 
assumption that a superior intervention is not present (for either the control or 
intervention group) in a RCT, or personal equipoise; the assumption that the 
clinician involved in the research trial has no preference or is truly uncertain 
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about the overall benefit or harm offered by the treatment to their patient415. On 
reflection it was perhaps naïve to assume that physiotherapists would all have 
clinical and personal equipoise and fully adhere to trial procedures. It raises the 
question as to whether, in addition to the required Good Clinical Practice (GCP) 
training, further training might be necessary on issues of this nature to optimise 
the success of a future definitive trial. 
Recruitment may also have been affected by clinician gatekeeping which has 
previously been identified as problematic in health research. It is a complex 
ongoing process that has a powerful impact on the extent to which a research 
study is successful415 and covers several of the issues identified in Adherence 
(Section 5.2). Cherry picking and gatekeeping have been identified in other 
stroke rehabilitation trials249,412. Gatekeepers have been described as 
‘individuals who have the power or influence to grant or refuse access to a field 
or research setting’383. Gatekeeping in SPIRES may have arisen due to 
physiotherapists’ beliefs and attitudes towards research, an assumption that 
patients preferred not to participate, a perception that they needed to protect 
their patient(s) given the doubts they had regarding the suitability of the 
intervention for the individual patient417. It could also be due to their confidence 
or lack of research expertise as not all physiotherapists had prior research 
experience or post-graduate education. 
A facilitator to minimising recruitment barriers would be a dedicated person (not 
one of the treating physiotherapists) to screen and consent potential 
participants, e.g. Research and Development or Clinical Research Network 
staff. This would address the selection bias and alleviate physiotherapists 
having to spend time on the consent process and complete associated 
paperwork. 
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Consent 
Ability of patients to provide informed consent in stroke trials can be challenging 
due to communication and cognitive impairments that may deem them to lack 
capacity to make an informed decision to enrol352. Ability to consent was a 
feasibility indicator, and 63.0% (n=29) of participants provided informed 
consent. 
When a participant was judged as lacking the capacity to provide informed 
consent, a relative of theirs was approached to act as a consultee. Relatives 
who provided consultee declaration said they “didn’t mind” being approached or 
making that decision on behalf of their loved one. Relatives can also be 
gatekeepers, blocking or allowing access to potential participants when acting 
as consultee418. However, this was not an issue in SPIRES. Additionally, there 
may be a conflict for relatives in their decision making; on one hand considering 
that their loved one may benefit physically by participating in the trial, whilst also 
being concerned that they do not want to overburden them given that they have 
had a severe stroke. This was apparent in the comments from one relative 
where he spoke of his initial refusal for his wife’s participation because of the 
potential for her to become “over stressed” and that it may be “too much for her” 
subsequently reversing this decision following discussions with their children, at 
which time they “all agreed it was a good idea” and provided assent. 
Retention 
The feasibility indicator for retention was successfully achieved with ≥60% of 
participants completing assessments at all five time-points. This included an 
estimated 40% drop out rate due to mortality, because mortality rates are high 
in people with severe stroke309. Drop-out rates in studies of prolonged standing 
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were lower than SPIRES: 11.8%421 24.3%95 and one higher with 52% drop-
out97. 
Relatives are also important gatekeepers in trial retention. They may support 
and encourage their relative to do their best in therapy sessions, continue or 
withdraw even when not acting as consultee417. Due to communication and 
cognitive impairments many participants in this feasibility trial were reliant on 
their relatives to arrange appointments for follow-up assessments. Despite 
many relatives having work and family commitments, all granted access for 
follow-up appointments and were supportive of trial visits.  
It is important to look at who made the decision for withdrawals to determine 
whether any refinements in trial processes are required in relation to this in a 
definitive main trial. 
6.6 Eligibility 
An important aspect of a future main trial is eligibility criteria, and in this 
feasibility trial it was apparent within the interviews and focus group that this 
was a contentious topic for some physiotherapists. People with stroke were 
eligible to enrol in the trial if they were classified as a modified Rankin Scale 
(mRS) Grade 4 or 5. 
 
Physiotherapists identified that including both mRS Grades 4 and 5 
encompassed a wide range of abilities and disabilities. Further, some 
physiotherapists felt the mRS was open to interpretation and several 
physiotherapists identified no patient is bedridden (mRS Grade 5) due to early 
mobilisation practises, and participants who were mRS Grade 4 were “too good” 
because they were walking, even though they needed assistance. This aligns 
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with existing literature that the main limitation with the mRS is the potential for 
substantial inter-rater variability418. Various approaches to reduce inter-rater 
reliability have been produced including structured interview420, training 
programmes including digital training using vignettes421 and a simplified mRS 
questionnaire algorithm422. The Rankin Focused Assessment (RFA) differs from 
other approaches because it encourages the rater to gather information on 
patient functional performance from all available sources, including patient self-
report, caregiver observations, physical therapist notes, medical records, and 
the rater’s own examination and interaction with the patient423. Tested in 50 
participants with stroke enrolled in a clinical trial, agreement between raters was 
93%, (weighted kappa 0.99 (0.98–1.0), and the unweighted kappa was 0.91 
(0.82–1.00)). Given the multiple sources of performance and information, the 
RFA would be beneficial for participants with cognitive impairment including 
anosognosia and communication impairment. 
Some physiotherapists felt that a different measure should be used to 
determine eligibility. Suggested changes to the trial design such as additional 
guidance for the mRS which would be incorporated into future training, may 
alleviate the need for a different measure. However, their suggestion of the 
Rivermead Mobility Index as an alternative way to determine eligibility will be 
discussed in Section 5.10 as a potential secondary outcome measure. 
The NIHSS was used because some sites reported to using it as part of their 
usual practice whilst the mRS score is captured by all sites participating in 
SSNAP audit. The NIHSS has been criticised for limited representation of 
cognitive and visual dysfunction and bias towards dominant hemisphere 
functions424. For example, truncal ataxia, reduced visual acuity and memory 
impairments are neurological deficits that affect mobility and function were not 
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detected by the NIHSS418. The NIHSS is recommended for use in all stroke 
trials by the Stroke Recovery and Rehabilitation Roundtable411, but they do not 
provide any justification for this. The NIHSS takes longer to complete and 
requires training, therefore, it is proposed that the RFA will be used in the 
definitive main trial instead of the mRS. 
6.7 Dose and intensity of rehabilitation 
Improving outcomes post-stroke through higher dose (time in rehabilitation or 
number of repetitions) and intensity (dose per session)83 has been consistently 
highlighted as a critical component of therapy after stroke425. However, clinical 
trials investigating the effectiveness of high-dose and high-intensity have 
predominantly targeted upper limb rehabilitation237,426. These trials have 
included repetitive practice, which several other clinical trials have investigated 
for lower limb function but were of moderate quality evidence98. Although 
repetition of functional movement was a major mechanism of action for studies 
included in this Cochrane review, the number of repetitions was rarely available. 
Therefore, this review investigated the impact of functional task specificity more 
than the element of repetition (dose).  
Studies investigating high-dose and high-intensity training237,426,427 have 
focussed more on time in rehabilitation (hours or minutes per day or a total time 
over weeks), and less on specific activities and repetitions in each session. 
Time in rehabilitation does not necessarily equate to intensity, and it is 
important to consider the activities performed during the session and their 
impact on functional outcome. SPIRES participants in the control group had 
longer sessions but undertook activities in supine and sitting that are not as 
challenging as activities in standing (supported or unsupported). 
Physiotherapists reported that being involved with SPIRES challenged their 
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practice, prompting them to reduce the amount of rest times, and increase 
active movements and time in standing during treatment sessions, suggesting 
contamination. During a high intensity upper limb programme237, a wide variety 
of treatment options were used to supplement two daily sessions each of 
physiotherapy and occupational therapy. 
It is important to discuss the biological and physiological processes that 
SPIRES intervention aimed to address. Within the three weeks, improvements 
in strength were not anticipated, because evidence suggests improvements in 
strength take at least eight weeks to occur428. The main aims were to minimise 
secondary neuromuscular changes (Section 1.5 Chapter 1) and positively 
influence neuroplasticity (Section 1.3 Chapter 1), specifically experience 
dependent plasticity through motor relearning based on motor learning theory. 
Motor learning is the study of the processes involved in acquiring and refining 
motor skills and the variables that promote or inhibit that acquisition429. An in-
depth discussion on motor learning is beyond the scope of this thesis, however, 
some important aspects pertinent to the standardisation of the SPIRES 
intervention group will be discussed.  
Learning is a relatively permanent change in a person’s capability to execute a 
task as a result of practice or experience430 whilst performance is a temporary 
expression of skill430. Repeated, blocked practice may improve performance 
within a session, but less learning gains are made. Conversely, variability of 
practice may result in worse performance within a session but greater learning 
gains and generalisation to new tasks498,430. Generalisation of learning to new 
tasks is deemed of critical importance in stroke rehabilitation, to help improve 
performance in different activities of daily living431. In SPIRES, variability of 
practice could easily be implemented for sit to stand by varying seat heights and 
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seats (with or without arms), feet position and speed, and changing the 
environment by practising in the gym or by the participant’s bedside. However, 
this was not included in the work instruction or captured in the CRFs, thus could 
be incorporated into a future main trial and be emphasised in the training. 
Some physiotherapists reported to “chop and change” and vary what they did 
during treatment sessions. Unfortunately, this was not explored further, 
therefore, it is unknown if this positively resulted in variability within a task or 
variation of tasks. This tendency to frequently vary activities within a single 
session may be attributed to minimising physiotherapist boredom or perceived 
participant boredom, and/or because physiotherapists do not observe any 
change in participant performance during sessions. Participants could become 
fatigued, which may negatively affect their performance of sit to stand or 
walking during the session but learning (structural plasticity) may still occur that 
has a positive impact on functional outcomes post-discharge. Thus, it is 
conceivable that physiotherapists may assume their treatment is not effective 
and change the task. However, switching from one task to another or changing 
the context in which the task is practiced can cause interference where learning 
one motor task interferes with the learning of another similar motor task428. Low 
contextual interference produces superior short-term effects that may be 
observed within one session, but high contextual interferences results in greater 
long-term learning effects which are associated with greater generalisability of 
the practiced tasks to other settings430. 
If physiotherapists are frequently changing activities, this may negatively affect 
dose and intensity. Whilst there is increasing evidence that high intensity stroke 
rehabilitation programmes are effective237,426 these have focussed on the upper 
limb in people with chronic stroke and were not representative of people with 
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severe stroke. Given, however, that the ‘active ingredients’ of 
neurorehabilitation are not yet known237, this approach to varying the practice of 
tasks cannot be supported or refuted. 
Finally, the type of feedback provided during the intervention was not 
standardised. There are two types of feedback in motor learning: response-
produced information that is available to learners through their sensory systems 
both during and because of movement (intrinsic feedback), and augmented 
feedback, which is information received from an external source, e.g. a 
physiotherapist’s comments, during or after movement. Augmented feedback 
can play a motivational role in the learning process428; therefore, it is possible to 
surmise that if physiotherapists are not on-board with the intervention they may 
not motivate and encourage participants; this in turn could negatively affect the 
participants adherence. Motivation is discussed further in Patient-related factors 
(5.2 Adherence). Augmented feedback may be required if sources of intrinsic 
feedback are affected such as sensory loss following a stroke. 
In summary, there are several factors that could influence learning during 
intervention sessions. Many of these factors have been investigated in healthy 
people learning sport-related or artificial complex motor skills, but not in people 
with severe stroke during the sub-acute phase. Thus, there is an urgent need 
for research to investigate the relative importance of scheduling of practice, 
variation of tasks, whole or part practice, manual guidance and feedback for 
people with severe stroke.  
SPIRES participants experienced a range of impairments and fatigue levels that 
physiotherapists reported negatively affected participants’ ability to undertake 
the intervention. Despite scepticism that people with stroke could not tolerate 
high doses of therapy432, participants in two studies were able tolerate and 
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complete either 300 hours over 12 weeks426 or 90 hours237 over three weeks 
despite severe upper limb disability and a range of impairments and fatigue 
levels. In SPIRES, some physiotherapists shared this scepticism, suggesting 
the intervention was not suitable for people with very severe stroke, and stating 
they would prefer a shorter duration (e.g. two weeks instead of three) or less 
sessions per week, with only a few physiotherapists acknowledging the impact 
this would have on intensity. 
Eight to 12 repetitions of sit to stand were recommended in SPIRES (see 
Chapter 3, Section 3.8 for justification). However, in recent years, evidence that 
higher intensity of up to 300 repititions433 has demonstrated greater 
improvement, although these have been for the upper limb and not with people 
with severe stroke. Thus, the minimal number of sit to stand repetitions in 
people with severe stroke required for improved outcomes, and the maximum 
number of repetitions that someone with severe stroke can achieve remains 
unknown103. SPIRES participants achieved a mean of 4.64 (±3.9 SD), median 
3.00, range 0-20 sit to stand repetitions. Recommendations for a future 
definitive trial could be based on available evidence that a minimum number of 
10 repetitions are required and investigate the impact of severity on the 
achievable graded percentage increase per session and maximum number 
repetitions achieved. 
In a definitive main trial, it is suggested that more emphasis should be placed 
on the importance of undertaking the sit to stand repetitions within the training 
sessions. 
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6.8 OH protocol 
The data from the interviews and focus group indicated that the 
physiotherapists did not consider monitoring BP when standing patients as part 
of their usual clinical practice. Instead, they judged the presence of OH based 
on clinical symptoms and appeared surprised that participants who were 
asymptomatic had a significant drop in BP. The literature, however, suggests 
that most patients with OH are asymptomatic or have few non-specific 
symptoms434, which highlights the importance of assessing and monitoring OH 
in SPIRES and other stroke rehabilitation trials involving standing. However, the 
prevalence of OH in SPIRES was lower than anticipated. During the 
minimisation process 15.6% (n=7) of participants experienced OH, compared 
with 20% (n=9) during the intervention period, which is not as high as the 
52%109 as previously reported in the systematic review (Chapter 2). This small 
difference in the prevalence of OH at the point of minimisation compared to the 
intervention period, suggests the screening process of lying to sitting was 
adequate and appropriate for implementation in a definitive main trial. However, 
the knowledge and skills (ability to measure BP manually) of physiotherapists 
about the importance of measuring BP when undertaking standing interventions 
in this patient group needs to be considered. 
The work instruction for the intervention stated blood pressure (BP) needed to 
be monitored for the first three sessions, and once BP was within the 
participants’ normal range for three consecutive sessions, monitoring was no 
longer required. Some physiotherapists reported that taking manual BP with 
people with very severe stroke was challenging in terms of the time, number of 
staff required to assist participants into standing and take the BP, as well as 
monitoring the participant’s position in the standing frame. Experience of using 
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the standing frame and taking manual BP varied which may have affected 
efficiency, confidence and competence of the task. For example, at one site I 
needed to provide training on how to manually measure BP and to facilitate 
patients in and out of the frame. Level of experience and training in the 
procedure and interpretation of manual BP measurement, as well as 
environmental factors and patient factors (e.g. medications, anxiety, time of day 
etc.) may affect the reading435,436. Thus, lack of time, experience and staff may 
have affected the consistency and accuracy of measurement. 
In summary, in light of the evidence from the literature regarding the risk of 
harm from OH in people in the sub-acute phase of stroke (discussed in chapter 
2 ), and the challenges faced by the physiotherapists in undertaking BP 
measurement in this feasibility trial, it is therefore recommended that a definitive 
main trial should include training on BP monitoring and its interpretation, 
emphasising the potential risk of harm by not adhering to the OH protocol. 
Additionally, medical staff should be involved in the training to enable them to 
provide pharmacological interventions as and when required. 
The systematic review (Chapter 2) was completed after recruitment had closed, 
thus other non-pharmacological interventions deemed effective in treating OH 
are now known and can be incorporated into a definitive main trial. This will 
provide therapists with other options (e.g. electrical stimulation, physical 
manoeuvres, lower limb compression stockings/bandages) when an abdominal 
binder is contra-indicated, such as percutaneous endoscopic gastrostomy. 
Thus, the OH protocol needs to be further developed prior to moving forward 
with a definitive main trial, which would potentially include determining the 
effectiveness of the revised OH protocol. 
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6.9 Outcome measures 
The feasibility of the proposed outcome measures was evaluated by 
determining the percentage completion of the primary and secondary outcome 
measures. Their ability to detect change in this sample of severe stroke was 
also explored.  
Proposed primary outcome measures 
The feasibility and acceptability to participants/proxies and blinded assessors of 
two primary outcome measures were determined: the Barthel Index (BI)275 and 
Edmans279. Completion of both primary outcome measures was 100% at 
baseline and, with exception of the participants who withdrew, all but one 
participant completed their primary outcome measures at all timepoints. 
Cognitive and/or communication impairment affected some participants' ability 
to self-report for both proposed primary outcome measures, therefore a proxy 
was used (clinician, relative or carer). The proportion of participant and proxy 
responses were similar at all time-points: 19 participants (42.2%) at baseline 
and 22 participants (48.9%) at 55 weeks.  
Proxy responses are an important alternative to source information when 
participants have cognitive and/or communication impairment that prevent them 
from answering questions in clinical trials. However, disagreement between 
proxy and patient responses may introduce measurement error and bias into 
trial results437. For instance, proxy respondents may under- or overestimate the 
functional status of the patient, and of particular relevance to the SPIRES trial, 
agreement between proxy and patient responses are lowest for patients with 
more severe strokes438. In acute stroke, disagreement is worse at initial 
administration, suggesting the need for an adjustment period or “learning curve” 
for proxy respondents and/or patients439. 
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The use of proxy responses for the Edmans ADL Index for Stroke has not been 
studied. Although wide limits of agreement between patient and proxy 
responses for the BI have been reported, nevertheless, the use of proxy 
responses with this measure is supported for clinical research440. Patient and 
proxy responses should not be used interchangeably to monitor patients 
because of the wide limits of agreement between the two responses. Therefore, 
it is recommended that for a SPIRES definitive main trial, proxy and self-report 
will be collected. It is acknowledged that this will increase the amount of time 
required for the assessment, however, if only one outcome measure of 
functional activity is subsequently used (see below) it is reasonable to presume 
that this will be both acceptable and feasible. 
Whilst the focus of this feasibility trial was to test the procedures of the outcome 
measures and determine feasibility and acceptability238, it also afforded an 
opportunity to explore if the proposed outcome measures were responsive to 
change in people with severe stroke from a sub-acute to chronic stage (12 
months). Both the BI and Edmans ADL Index for Stroke showed similar 
magnitude of improvement in scores at each time-point across the course of the 
trial. Both were able to distinguish between control and intervention groups, 
suggesting they were appropriate measures. Responsiveness of a 
scale/measure refers to the ability to detect change, which is an important 
quality for assessing treatment effectiveness441. However, caution needs to be 
applied when looking at responsiveness over time in SPIRES because this 
feasibility trial is not adequately powered. Thus, it is important to review the 
existing literature for these two measures. The original study suggested that the 
Edmans ADL Index for Stroke was responsive to change, however, this was 
only measured during admission and discharge, the duration of which was not 
320 
reported279. Additionally, they did not provide data on severity of stroke, 
therefore, it’s responsiveness in people with severe stroke is unknown. The BI 
has demonstrated a limited ability to detect change at extremes of ability, 
making it less discriminating in severe stroke278 but is recommended for use 
during the sub-acute phase.  
The minimal clinically important difference (MCID) also warrants discussion. 
This is the smallest meaningful change in score considered clinically important 
as reflected by a meaningful and beneficial change in health status perceived 
by the patient442,443. There is no MCID data on the Edmans ADL Index for 
Stroke. For the BI, a MCID of 1.85 points has been deemed clinically relevant in 
people with stroke even if the change score has not reached statistical 
significance (P> .05)444. In SPIRES a mean of 2 to 3-point increases in BI 
scores were observed between some time-points. Given that this relates to the 
total summed score, this may have reflected an improvement in a range of 
different items such as walking, regaining continence or being able to wash and 
dress independently. Notable, however, is the evidence which suggests that the 
BI is less able to measure change in people with severe disability278, which may 
result in underestimation of treatment-induced changes and will need to be 
considered in both the design and analysis phases of a definitive main trial. 
There is a paucity of data on the Edmans ADL Index for Stroke, which makes 
meaningful comparisons with other rehabilitation trials difficult. Given the BI is 
used extensively in stroke trials277, despite the aforementioned limitations, using 
it in a SPIRES definitive main trial would enable meaningful comparisons or 
meta-analysis with other stroke rehabilitation trials.  
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Proposed secondary outcome measures 
Several proposed physical secondary outcome measures were used: knee 
extensor strength, joint range of movement using goniometry, modified 
Ashworth Scale, Trunk Control Test, the rationale for which are detailed in 
Section 3.12, Chapter 3. This feasibility trial demonstrated that administration of 
these measures was both feasible and acceptable to participants and blinded 
assessors in this sample of people with severe stroke.  
The battery of tests were chosen to reflect the secondary neuromuscular 
impairments commonly observed post-stroke, which the intervention aimed to 
minimise (Chapter 1, Section 1.2). The Trunk Control Test was selected 
because trunk control is strongly correlated to common daily functional activities 
such as the ability to sit, sit to stand and walk284. In SPIRES it was able to 
detect change over time both within and between the groups, however, in some 
participants a ceiling effect was observed. Therefore, exploration of an 
alternative measure is warranted prior to progressing to a definitive main trial. 
Physiotherapists identified the modified Rivermead Mobility Index (MRMI) as a 
possible replacement during the focus group when discussing eligibility criteria. 
The MRMI consists of eight tasks related to mobility in the acute stroke patient: 
turning over in bed, lying to sitting, sitting balance, sit to stand, standing, 
transfers, walking and stairs445. There is a total possible score of 40, with higher 
scores indicating better mobility, and each individual task is scored from 0 
(‘unable to perform’) to 5 (‘independent’). The wide range of activities would 
allow for variation of progression throughout the duration of the trial. Given the 
functional standing frame programme incorporates standing and sit to stand, a 
measure that incorporates this and the elements of trunk control seems 
322 
appropriate. It takes 15 minutes to administer446 which does not appear overly 
burdensome. 
It is essential to target outcomes that are important and relevant to patients and 
clinicians447. Patient and public involvement informed the selection of outcome 
measures used in SPIRES. However, most of the outcome measures used, 
including the patient-reported outcome measures (PROMs) were developed 
several years ago, some over ten years ago271,273,275,296,448,449 and may not have 
involved patients and clinicians in their development. It is possible therefore that 
there is a mismatch between the priorities of people with severe stroke, 
clinicians and current stroke services. For example, the length of stay has 
substantially reduced with greater emphasis placed on community rehabilitation, 
thus patients’ priorities in terms of outcomes may change depending on the 
stage of their stroke rehabilitation continuum. 
In stroke rehabilitation there is no standardised recommendations for outcome 
measures. The Stroke Recovery and Rehabilitation Round Table411, consisting 
of researchers and clinicians, has generated consensus recommendations for 
core data collection across sensorimotor stroke rehabilitation trials, which 
recommends the 10-metre walk test. However, this measure is not appropriate 
for the target population of this trial, people who are unable to walk early post-
stroke. 
The absence of standardisation of outcomes makes pooling results from 
rehabilitation trials and producing meaningful comparisons difficult. Recently a 
mixed-methods study identified that post-stroke rehabilitation research would 
benefit from a reduction in the number of outcome measures currently used, 
and better alignment between what is measured and what is important to stroke 
survivors, carers and clinicians450. Unfortunately, this study only looked at arm 
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outcome measures, but they did include PROMs. Future research needs to 
investigate this in lower limb, gait and mobility outcome measures, ensuring 
inclusion of all stroke severities. 
6.10 Patient-reported outcome measures 
PROMs are standardised, validated questionnaires completed by the patient to 
determine their perceptions of their health status, level of impairment, disability, 
and health-related quality of life451. In stroke rehabilitation trials of early 
standing, PROMs have not been consistently used. Instead, clinician-reported 
outcome measures have been used274,278, which has the limitation of not 
capturing the impact on a patient’s quality of life. However, PROMs require the 
patient to be able to comprehend the question and express a response. An 
objective of this feasibility trial was therefore to evaluate the ability of people 
with severe stroke (who may have moderate to severe cognitive and 
communication impairments) to complete the PHQ-9289, SAQoL-39295 and EQ-
5D-5L296 self-report measures. 
This feasibility trial demonstrated that communication and cognitive impairments 
affected participants ability to complete the PROMs. When comparing the two 
health-related quality of life (HRQoL) questionnaires, at baseline more 
participants were able to complete the multiple-choice questions for EQ-5D-5L 
(86.7%) than the SAQoL-39 (75.6%). However, only 77.8% were able to 
complete the health state for the EQ-5D-5L, which required participants to score 
their health out of 100. Ability to assign a rating can be affected post-stroke due 
to reduced capacity of abstract thinking452 as well as ability to write, point to or 
speak their response, but completion rate was higher than the SAQoL-39. 
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In terms of feasibility and acceptability of these two measures for both 
participants and assessors, the EQ-5D-5L had several advantages. The EQ-5D-
5L has five questions, plus rating overall health status out of 100, compared to 
39 questions for the SAQoL-39. The blinded assessors perceived the SAQoL-
39 took too long to administer, asked too many questions, and was not 
appropriate for people with severe stroke. The SAQoL-39 was developed 
specifically for people with (mild to moderate) aphasia and has shown good 
reliability, validity and responsiveness for change in these individuals454; the 
authors acknowledge it is not suitable for people with severe aphasia. Severe 
physical and/or cognitive deficits may also affect completion of measures of this 
nature. The authors do not appear to have acknowledged the impact of the 
length of the questionnaire on fatigue. 
Cognitive impairment, specifically anosognosia, also affected completion of the 
PROMs in this feasibility trial. Anosognosia is a self-awareness disorder that 
prevents people with brain damage from recognising the presence or 
appreciating the severity of deficits in sensory, perceptual, motor, behavioural or 
cognitive functioning, which are evident to clinicians and caregivers454,455. This 
can impact on an individual’s ability to report their experience of stroke 
accurately, by systematically overestimating their abilities452. Difficulty in 
reporting the degree of disability, distress or impairment accurately due to 
anosognosia affects the validity of PROMs yet is rarely discussed or addressed 
either in clinical practice or clinical trials455. Anosognosia was identified in four 
participants by the SPIRES Chief Investigator, but there was no formal 
screening. Screening for anosognosia and other neuropsychological deficits 
such as spatial neglect, abnormal magnitude estimation and deficits affecting 
semantics and abstraction452 may have identified a higher prevalence. At 
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present no single scale can fully explore all the components of anosognosia and 
development of a scale for use in stroke to address the potential threat to 
validity with PROMs has been identified as a priority for future research452,456. 
This will be explored further prior to progressing to a definitive main trial. 
SPIRES participants reported they did not mind answering the PROM 
questions, did not find them intrusive, and were willing to answer any questions 
if it was going to help them or someone else.  
Not all participants could read and self-complete the PROMS and hence 
needed assistance form the blinded assessor to do so. One blinded assessor 
reported to feeling uncomfortable when asking some questions, especially with 
the PHQ-9 because some participants became tearful. They felt it was 
challenging to ask these questions when they had not had the opportunity to 
build up a rapport with the participant. The blinded assessor also reported that 
the questions in most of the PROMS drew attention to what participants found 
challenging/impossible to do. Of interest, this concern was not expressed by 
any of the stroke participants.  
In summary, it proved feasible within this feasibility trial to collect data using the 
EQ-5D-5L with people with severe stroke, whereas this was not the case for all 
the PROMS. It is therefore anticipated that the EQ-5D-5L will be the only PROM 
used in a definitive main trial, which mirrors the recommendations of the Stroke 
Recovery and Rehabilitation Roundtable411. This has the advantage that it will 
enable a health economic analysis to be conducted, which will be briefly 
discussed in the future directions section. 
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6.11 Training 
Overall, 50 physiotherapists, occupational therapists, speech and language 
therapists, therapy support workers, research nurses and research therapists 
received training across the four sites. Training consisted of an overview of the 
trial (background, rationale, aims and objectives, design) and trial processes 
and procedures (research governance, Work Instruction and documentation). 
All staff completed their GCP training separately. The experience of 
implementing this feasibility trial is that additional training is required for a 
definitive main trial to optimise clinical and personal equipoise (discussed in 
Section 5.5). 
A range of barriers have been identified in relation to implementing the 
intervention and trial processes, many of which could be facilitated with training. 
Training has been identified as both a barrier and facilitator to trial success412, 
however there are no recommendations as to what comprises effective training. 
This is largely attributed to the heterogeneity of trial interventions. However, 
commonality exists in the barriers to trial success that could enable a core set of 
standards for training in stroke rehabilitation trials to be developed, which would 
facilitate recruitment, retention and intervention fidelity. Common themes such 
as clinical and personal equipoise, gatekeeping, the impact of clinicians’ beliefs 
and attitudes and unconscious bias are relevant in all clinical trials352,412. 
Physiotherapists in SPIRES were keen to share their ideas and experiences 
with each other and suggested multi-modal training and support would be 
helpful to implement throughout a definitive main trial. This could include the 
use of: video clips, vignettes, peer support, online resources, a secure forum to 
share ideas or ask questions of other treating therapists involved in the trial and 
more in-depth training prior to commencing recruitment. Web-based training for 
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treating therapists have been used successfully in other rehabilitation trials, 
which have effectively delivered information in multimodal learning formats457. 
An advantage of web-based training is that it could keep training costs to a 
minimum without compromising quality and effectiveness. Clinical vignettes are 
patient-related cases and scenarios to which clinicians are asked to react. 
Demonstrated to be effective in healthcare education458,459, these could be 
developed to include issues related to adherence, gatekeeping and personal 
and clinical equipoise. Whilst there is a wealth of evidence showing that peer-
support is effective for patients in clinical trials460,461 there is a paucity of such 
evidence for training clinicians in clinical trials. Given that peer support is 
deemed effective in clinical practice because it provides opportunities to learn 
from others and develops confidence in clinical practice462, it not unreasonable 
to propose that it could translate into clinical trials. 
Future training should incorporate the perspectives of both physiotherapists and 
patients to address issues identified with adherence (Section 5.2). It is 
anticipated that this would primarily be focused on patients’ desire to be 
motivated by their physiotherapist, encouraged to keep working during their 
sessions and to provide short and frequent rest breaks where appropriate. It 
could also cover theory on motor learning, task specific training, dose and 
intensity to reinforce the underpinning mechanism of action of the proposed 
intervention, thus providing a clear rationale to emphasise the need to adhere to 
the protocolised intervention. Finally, to stress the clinical relevance of the trial, 
it is considered important that those engaged in the trial are made aware that 
the research question originated from clinical practice, and the trial was co-
designed with people affected by stroke and multi-disciplinary clinicians 
involved in management. 
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In this feasibility trial a Work Instruction was provided with two algorithms, which 
focused on the intervention procedure, however, this did not include a training 
protocol detailing any treatment progression. Whilst physiotherapists said they 
found the Work Instruction helpful it could be improved to include treatment 
progression as used in other trials426. This may positively influence protocol 
adherence. 
6.12 Delivery of national targets and rehabilitation trials 
National clinical guidelines for stroke in the UK recommend patients should 
‘accumulate a least 45 minutes of each appropriate therapy every day at a 
frequency that enables them to meet their rehabilitation goals’3[p.25]. The 
SSNAP monitors therapists’ self-reported performance against the guideline 
target469. Published quarterly performance ratings from the SSNAP consistently 
identifies that therapy frequency and intensity are not met in most stroke units. 
Data from studies that have analysed the SSNAP data372 and carried out large 
and comprehensive mixed-methods case-study evaluation of multiple SRUs373 , 
(the ReAcT study) have identified multiple interlinked factors influencing therapy 
provision, many of which were identified in SPIRES. For example, patient 
factors such as fatigue and therapists’ beliefs about patients’ ability to tolerate 
therapy influenced the amount of therapy patients received. There were 
differences in the amount of physiotherapy minutes received based on age and 
stroke severity, with those aged ≥80 years and patients with severe stroke 
receiving less physiotherapy. This was particularly evident with people with 
severe stroke when physiotherapists perceived they had limited rehabilitation 
potential372. Given these factors have been highlighted in clinical practice, it is 
understandable these factors were identified in SPIRES and affected 
intervention adherence. The ReAcT study373, a mixed-methods case study 
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evaluation of eight stroke units, investigated why stroke survivors do not receive 
recommended amounts of active therapy. Staffing numbers in the ReAcT 
study373 were lower than recommended349 thus meeting the SSNAP targets was 
challenging. This was mirrored in SPIRES and some physiotherapists identified 
a tension between meeting the SSNAP target for all patients in the SRU and 
delivering the required length and number of sessions for SPIRES “it can be 
quite strenuous if you’ve got four people standing in the frame in a day and 
you’ve only got two therapists in, being able to meet your stats is difficult” 
[Physio 5]. If therapists are struggling to deliver the number and duration of 
sessions recommended in national clinical guidelines373, it is unsurprising that 
adherence in SPIRES was low due to the additional demands of the trial and its 
associated procedures. 
SSNAP captures the total number of minutes of therapy received by a patient, 
however, the content of the session is not recorded and duration of session 
(minutes) does not necessarily equate to the number of minutes a patient is 
active during therapy. This was highlighted in the ReAcT trial373 where 
therapists reported patients not being ready for scheduled therapy resulted in 
them spending most of a session assisting the patient with personal care and/or 
getting out of bed which limited the amount of time left for active therapy. In 
SPIRES, physiotherapists recorded the duration of standing (minutes), number 
of sit to stand repetitions and total duration of session (minutes). Some 
participants completed a 45-minute session and stood for five minutes and 
performed two sit to stand repetitions. However, therapists were only required to 
record reasons why sessions were not completed, therefore, it is unknown 
whether the duration of stand and number of sit to stand repetitions was due to 
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patient-related, physiotherapist-related or organisational/cultural factors 
identified in Chapter 5. 
Some issues identified with the SSNAP data have also been identified in 
rehabilitation trials which negatively impacted implementation and contributed to 
negative outcome. The TRACS (Training Caregivers After Stroke)470 cluster 
RCT introduced structured caregiver training in stroke care but this did not 
demonstrate any benefit. A process evaluation of the trial concluded factors 
such as short length of stay, discharge driven environment where rehabilitation 
is a low priority, lack of research culture, competing organisational demands, 
staffing levels and experience as well as the additional demands of trial 
participation negatively affected trial implementation and outcome. This aligns 
with SPIRES where physiotherapists identified the increased workload of trial 
procedures, for example, some therapists felt completing and photocopying the 
paperwork “can take up quite a chunk of time” [Physio 3]. Some therapists 
highlighted the number of therapists needed to facilitate people in to standing 
“you need quite a lot of hands; sometimes three or four people so it’s obviously 
just taking other therapists off the ward but that’s the only negative thing about 
it” [Physio 4]. This links back to the challenges with meeting the SSNAP targets. 
Therapists in TRACS470 reported they had ‘very little time to actually do the 
rehab programme’ and researchers observed therapists over-estimate the 
number of minutes of therapy they had delivered to patients for the SSNAP data 
compared with number of minutes they were observed providing therapy. In 
SPIRES physiotherapists were required to document the number of minutes of 
standing and the duration of sessions. The duration of all sessions were 
recorded in five-minute intervals from 5-60 which was not stipulated in the CRFs 
but standing duration was recorded to the nearest whole minute which was 
331 
stipulated in the CRF. However, having to record the number of minutes to the 
nearest whole minute may have challenged usual working practices and/or led 
to estimates of standing time that would potentially affect the reliability of the 
data.  
Another stroke rehabilitation trial with a negative outcome was CIRCIT (Circuit 
class therapy or seven-day week therapy for Increasing Rehabilitation Intensity 
of Therapy after stroke)471. Delivered in inpatient sub-acute SRU’s, participants 
were between 5 and 197 days (mean of 28 days) post-stroke and randomly 
assigned to usual care therapy five days per week, usual care therapy seven 
days per week, or circuit class therapy five days per week. The primary 
outcome was the 6-minute walk test at four weeks post-randomisation. Despite 
a substantial increase in therapy time (three hours over four weeks for seven-
day participants and 22 hours over four-weeks for circuit class participants) 
there were no differences in outcome between groups. Authors concluded the 
content of therapy sessions, e.g. what participants did during therapy time, was 
a likely factor in the negative outcome. Observational data (published 
separately) from sessions to measure fidelity472 identified that participants spent 
a large proportion of time resting and therapists underestimated rest time by 
36% and overestimated active therapy time by 28%. The authors suggest that 
one of the reasons therapy dosage studies have shown small effect sizes may 
be that many have relied on therapist estimations of therapy time. Given the low 
number of sessions observed for fidelity in SPIRES, it is not known if therapists 
over or under-estimated time in therapy (in both groups) or time in standing or 
sit to stand repetitions in the intervention group. 
The outcomes of large rehabilitation trials470,471 and SPIRES feasibility trial 
highlights the challenges of delivering trials using existing staff and resources. 
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Data from observational trials373 have identified multiple interlinked factors 
influencing therapy provision, and it has been suggested that aspirational 
trials237,473 are needed with additional rehabilitation resources and different 
service delivery models. However, addressing the impact of adherence and how 
that is affected by beliefs of therapists and patients and organisational/cultural 
factors is also required to optimise the delivery of evidence-based practice as 
well as optimising the outcome of future rehabilitation trials. 
6.13 Clinician-researcher reflections 
I have been a physiotherapist for 12 years but being Chief Investigator for 
SPIRES gave me a new role: clinician-researcher. A clinician-researcher is an 
individual who conducts research and provides direct patient care463 although 
not at the same time or for the same organisations. It is important to 
acknowledge the potential benefits, challenges, barriers and facilitators of this 
dual role as well as the dual-perspectives and associated boundaries and what 
impact it can have on my research. 
I identified tension between my role as a physiotherapist and a researcher. 
During the follow-up visits some relatives and participants had expectations of 
my visit. For instance, several relatives made assumptions that I was there to 
provide physiotherapy or that I could influence access to physiotherapy or other 
healthcare professionals and services. I acknowledge there is a potential that 
my role as a physiotherapist may influence their decision to grant me access for 
the follow-up visits. On several occasions in participants’ place of residence, 
relatives and staff requested my professional opinion about the participant’s 
environment, safety and absence of physiotherapy. Some participants also 
asked for my professional opinion about their rehabilitation. I felt there was role 
confusion and the relatives and participants were unable to distinguish my 
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clinical and research roles which is not uncommon in clinician-researcher 
roles464. I clarified my role, explaining the purpose of my visits, and signposted 
staff and relatives to members of the participants’ usual clinical care team. On 
three occasions I contacted General Practitioners and a physiotherapist to 
report falls and request a review due to development of secondary 
neuromuscular impairments that warranted urgent intervention. This prompted 
me to change how I introduced myself on the telephone when arranging follow-
up visits. Instead of stating that I was a physiotherapist researcher, I said that I 
was a researcher therapist which reduced role confusion. 
I also acknowledge how my role as physiotherapist-researcher may have 
affected recruitment at my local site. I worked at Site 1 for eight years and was 
familiar with many of the staff, therefore, treating therapists may have wanted to 
support me on a personal level by supporting the trial. Additionally, because I 
lived locally to this site, I was able to drop in and catch-up with the treating 
physiotherapists and ask about recruitment and admissions. 
6.14 Future directions 
The results of this feasibility trial and the discussion chapter have highlighted 
issues that need to be addressed prior to progressing to a definitive RCT. Some 
of these are modifiable and some are not, highlighted in Figure 6.2 and 
summarised in Table 5.1. 
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Figure 6.2 Modifiable and non-modifiable factors 
Short-term Long-term 
Modifiable 
Non-modifiable 
Beliefs & behaviour of 
therapists re: recruitment 
& delivering the 
intervention protocol 
R&D & CRN staff available 
to support clinicians & 
undertake recruitment 
Aspirational view that 
more resources are 
available to deliver 
high dose, high 
intensity treatment as 
well as support and 
implement clinical 
research 
Research culture, 
capacity and capability 
within each Stroke 
Rehab Unit (& all NHS 
sites) 
Partially  
modifiable 
Flexible and adaptive 
approach to 
recruitment to mirror 
number of therapists 
available 
Number of beds in 
Stroke Rehab Units  
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Activity Lessons learned /challenges 
faced 
Recommendations for a definitive trial 
Intervention 
Protocolisation of 
the intervention 
A detailed prescription of starting position 
of sit to stand repetitions was not provided 
in the protocol, which participants 
performing sit to stand for a standard seat 
height. This may be too challenging for 
people with severe or very severe stroke 
and may have attributed to the low number 
of repetitions during sessions. 
 
The qualitative and quantitative data 
suggest that some physiotherapists were 
not invested in the intervention or the 
intervention did not align with their beliefs 
and preferences for treating people with 
severe stroke. This combined with 
competing priorities resulted in low 
adherence of the intervention protocol. 
 
Optimise standardisation of the intervention by prescribing the 
starting position, e.g. perch sitting, raised seat height, natural 
position and progression would include lowering and varying seat 
heights. This could be incorporated into video resources that 
would provide physiotherapists with protocolised procedures as 
well as hints and tips from physiotherapists who have been 
through the feasibility trial. This could include ways of progressing 
participants and activities that can be undertaken in the frame, as 
well as outside the frame for those who progress to walking. 
 
Future training for SPIRES would incorporate clinical and 
personal equipoise, subconscious bias (including belief system) 
as well as rehabilitation potential, paternalism and intervention 
fidelity. Additionally, use data from patient participants to highlight 
the different perspectives and emphasise that although patient 
participants were tired, they are reliant on their physiotherapist to 
motivate and encourage them.  
Pre-hoc, investigate adherence to identify facilitators. 
Overall 
adherence to the 
intervention  
Criteria for overall adherence (total 
standing duration and sit to stand 
repetitions over the 3-week intervention) 
did not incorporate a graded increase of sit 
to stand repetitions and standing time per 
week to allow progression over time. Thus, 
participants were expected to achieve 
100% adherence. 
Pre-hoc, define adherence for each of the three weeks in terms of 
sit to stand repetitions and standing duration.  
Consider different criteria for participants with moderately severe 
(mRS 4) and very severe (mRS 5), e.g. able to achieve placed 
sitting balance for 10 seconds or sitting balance with minimal 
assistance of one person.  
Set adherence for each element of the standing intervention, e.g. 
participants should achieve 80% of the standing duration either 
each individual session or number of minutes in total per week, 
and 80% of sit to stand repetitions per session/or total per week.  
 
Incorporate information gained from the qualitative data from 
patient participants regarding their need to be pushed through the 
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tiredness/fatigue in pre-trial training of physiotherapists delivering 
the intervention. Also incorporate into the training that this trial 
evolved from a physiotherapist working with people with severe 
stroke who identified the lack of opportunities to stand and 
increase intensity of practice, and it was co-designed with 
physiotherapists and occupational therapists working in stroke 
rehabilitation units and with people with stroke and their relatives. 
Monitor adherence closely through a definitive trial and address 
any issues as they arise. Consider implementing stopping rules 
related to adherence. Additionally, consider a run-in period where 
participants receive the functional standing frame programme to 
provide information on treatment adherence. The purpose would 
be to identify poor adherence, or uncooperative attitudes and 
behaviours that can be addressed at the time465. 
Increase the frequency of fidelity monitoring and analyse data 
regularly and address any training or logistical issues in a timely 
manner. 
Review the data from the 100 reps a day by Stroke Education 
Collaboration466 which could be incorporated for those with mRS 
4 and/or those that progress to standing outside the frame. 
Determine the minimum number of sit to stand repetitions 
required to improve outcome and the maximum number of 
repetitions someone with moderately severe and very severe 
stroke can achieve. 
Consider undertaking ethnographic research or using case 
studies with trial participants, physiotherapists from the trial and 
other clinical trialists exploring adherence of both physiotherapists 
and patients in depth. 
Trial procedures 
Minimisation and 
stratification 
There was a higher prevalence of total 
anterior circulatory stroke (TACS) in the 
intervention group and partial anterior 
circulatory stroke (PACS) in the control 
group. TACS is typically associated with 
Stratify for stroke classification for definitive trial to balance 
groups for this variable. 
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greatest severity and worse outcome, 
PACS the highest risk of recurrence, whilst 
LACS has the mildest severity, and POCS 
the most favourable outcome467. 
 
Pre-stroke disability varied between 
groups, with more participants classified as 
mRS 4 in the intervention group (22.7%) 
compared to the control group (13.0%). 
 
 
 
 
Consider stratifying for pre-stroke disability, although this may link 
with the proposed inclusion of a pre-stroke frailty score. 
Measuring OH The method used in the minimisation 
procedure did not accurately assess OH 
as indicated by the higher prevalence of 
OH detected during the intervention 
sessions. 
Incorporate standing into the assessment of OH for a future trial, 
using a tilt table or standing frame. 
OH Protocol The systematic review (Chapter 2) was 
completed after recruitment had closed. 
However, an OH protocol was developed 
in collaboration doctors and therapists and 
literature from the review which resulted in 
compression garments (abdominal 
binders) being used for participants with 
OH. Thus, other non-pharmacological 
interventions deemed effective in treating 
OH are now known and can be 
incorporated into a definitive main trial. 
Pre-hoc, develop the OH protocol algorithm which would 
potentially include determining the effectiveness of the OH 
protocol in a definitive main trial. 
Fatigue Given the high prevalence of fatigue (82% 
scoring 4-10 on a visual analogue scale 
out of 10), a systematic review of 
interventions to manage fatigue may have 
facilitated greater adherence. 
Pre-hoc, a systematic review of interventions to treat fatigue is 
warranted. 
Foot sensors Despite several iterations in the design 
and manufacture, physiotherapists 
deemed them unreliable and 
Further development with physiotherapists and people with stroke 
if they are to be used in a definitive main trial. 
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temperamental and were not convinced 
participants liked them. 
Recruitment Selection bias and paternalism was 
identified in this feasibility trial and this has 
the potential to negatively affect 
recruitment. 
 
 
Reduced staffing negatively affected 
recruitment. 
Unconscious bias and paternalism should form part of the training 
for a future definitive trial. Vignettes could be used to aid learning. 
Additionally, Research and Development or Clinical Research 
Network staff would identify and screen potentially eligible 
participants. This would alleviate any ethical dilemmas for 
therapies or missed opportunities for recruitment 
A flexible recruitment rate allowing the recruitment rate to reflect 
the number therapists employed. Furthermore, sites would need 
to have ≥15 beds as there are likely to be a higher number of 
physiotherapists due to ratios of staff per bed. 
 Research culture within each of the four 
sites varied which affected recruitment of 
participants into the trial and adherence to 
the trial protocol.  
It is acknowledged that a cultural shift may take time to modify, 
however, training as part of a definitive trial could facilitate a 
bottom-up approach to therapists building a research culture 
within their site. 
 
Outcome measures 
Ability of 
participants to 
complete PROMs 
Ability to complete PROMs improved over 
time which resulted in switching between 
proxy and participant responses, e.g. 
changing from SADQ-10 to PHQ-9 at 
different assessment time points which 
may affect the validity of the results. 
The SAQoL-39 was deemed too long by 
blinded assessors and less participants 
(75.6%) completed the SAQoL-39 
compared to the EQ-5D-5L (86.7%). 
Furthermore, the EQ-5D-5L has a question 
on anxiety and depression which perhaps 
negates the need for a separate measure 
for mood. 
Capture both self-report and proxy responses at all time points in 
a future definitive trial for participants who can self-report at 
baseline. 
The EQ-5D-5L will be the only PROM used in a definitive main 
trial, which mirrors the recommendations of the Stroke Recovery 
and Rehabilitation Roundtable 
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Completion of the 
outcome 
measures  
Cognitive impairments such as 
anosognosia affected completion of 
PROMs, which may make it impossible for 
people with this condition to report their 
experience of stroke accurately due to 
systematically overestimating their 
abilities, which has been identified as a 
confounding influence on PROMS 
Screen for anosognosia at baseline, although. However, there is a 
paucity of evidence on this topic which necessitates development 
of a screening tool specifically for anosognosia prior to a definite 
trial 
 
Pre-hoc, consider whether PROMs are appropriate for people 
with severe stroke to complete, and whether observational 
measures would be more appropriate for the definitive trial. 
Participant versus 
proxy responses 
The number of proxy responses reduced 
over time for the proposed primary 
outcome measures; switching from proxy 
to participant may affect the scores due to 
the potentially different perspectives of 
those completing the questionnaires. This 
may result in over- and or under-
estimations of competency in the domains 
depending on who completes the 
questionnaire.  
Consider consistency of proxy responses across all time points. 
Considerations should also be made to the availability of the 
same proxy across all time points, which may be particularly 
challenging for participants who live alone, and the proxy is a paid 
carer (e.g. availability and consistency of staff) 
Evaluation of 
quality of life 
Lower completion rates of the SAQoL-39 
than the EQ-5D-5L occurred. Qualitative 
data from the PI and CI’s field notes 
suggest the SAQoL-39 would not be 
suitable for a definitive trial. Although it 
was devised for people with aphasia, it 
was not able to be used by participants 
with moderately severe or severe aphasia 
or participants with cognitive impairment. 
Use the EQ-5D-5L as the measure of quality of life, which will 
have the additional benefit of being utilised in a health economic 
evaluation. 
Design 
Individual 
participant versus 
site 
randomisation 
Physiotherapists wanted to experience 
delivering both intervention and control 
conditions, but a cluster RCT would avoid 
treatment group contamination and may 
enhance adherence with increased fidelity 
and resources. 
A factorial stepped-wedge cluster RCT should be considered. 
This would provide the opportunity to determine the clinical and 
cost-effectiveness of SPIRES intervention at two timepoints: 
inpatient sub-acute stroke rehabilitation (early) and the community 
(late). 
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Duration of 
intervention 
period 
Opinions varied among physiotherapists 
as to the ideal intervention duration and 
this appeared to be influenced by 
organisational factors. Additionally, the 
national average length of stay has 
reduced since this feasibility trial was 
designed. 
This links to the point above re the factorial stepped-wedge RCT. 
Future work should aim to collaborate with a consensus 
group/expert panel to determine the future trial design including 
duration. 
Dose and 
intensity 
Evidence suggests that increased 
frequency and intensity of therapy leads to 
better outcomes but the dose and intensity 
of SPIRES was not achieved by most 
participants. 
Post-hoc, review evidence from Stroke Education Collaboration466 
and other high intensity rehabilitation trials with PPI to determine 
how intensity could be incorporated into a definitive main trial.  
This could also be incorporated into the suggested run-in period  
Participant 
(dis)ability 
Some physiotherapists were concerned 
that participants without head or trunk 
control were “too impaired” for the 
functional standing frame programme and 
this appeared to affect recruitment 
(selection bias). 
Participants could start their intervention on the tilt table; which 
would address physiotherapists’ concerns about manual handling, 
resources and equity of care. This could be part of the run-in 
period  
Mortality Twenty-seven participants enrolled in the 
trial were aged ≥ 80 years, and 11 of the 
12 participants who died were aged ≥80 
years. An increased risk of mortality is 
associated with age ≥ 80 years. However, 
there was very little difference between the 
number of deaths between groups. Frailty 
is associated with ageing and some 
participants may have been classified as 
frail pre-stroke, which could have 
increased their mortality risk. 
This trial did not use a frailty score therefore, a definitive main trial 
could include pre-stroke and post-stroke frailty measures which 
could help identify individuals at the greatest risk of mortality. 
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6.14.1 Future additional studies for people with severe stroke 
From this thesis it is evident we are still unclear who can recover post-stroke 
and the optimal dose and intensity in severe stroke. These are areas that could 
be subject to separate future studies. 
Predictive modelling 
As highlighted in this discussion chapter, the trial has identified further areas 
that could be researched outside of the proposed RCT. 
Some participants in SPIRES demonstrated functional recovery and returned to 
walking and independence in ADLs. Accurately predicting functional recovery 
and outcome following stroke for the lower limb (balance and mobility) would 
enable realistic goal setting, guide the type and duration of rehabilitation and 
help to manage expectations133. There is a paucity of evidence for predicting 
recovery of standing and walking in people with severe stroke (as discussed in 
Chapter 1 Section 1.3). Existing literature suggests that stroke severity and age 
have consistently emerged as powerful predictors134,135. However, ability and 
duration of standing following severe stroke is affected by OH and fatigue, thus 
these factors need to also be considered in any predictive model. Future 
research needs to develop a predictive model for the lower limb that includes 
balance and mobility, and has sufficient number of people with mild, moderate 
and severe stroke to make meaningful predictions to people with all stroke 
severities. A consensus group should utilise current available evidence on 
physiological changes post-stroke to develop a predictive model that is 
applicable for people with severe stroke and testable. 
  
342 
Dose and intensity in severe stroke 
High dose and high intensity is deemed effective for people with stroke 
however, this has focussed on upper limb rehabilitation. There is an urgent 
need to research high dose and high intensity in rehabilitation of the lower limbs 
that stratify for stroke severity and include people with mild, moderate and 
severe stroke to make meaningful recommendations. 
There is very little evidence of the impact findings from motor relearning 
literature on the recovery of people with stroke, and none in severe stroke. 
Therefore, future research during sub-acute stroke rehabilitation needs to 
investigate the relative importance of scheduling of practice, variation of tasks, 
manual guidance and feedback for people with severe stroke, as discussed in 
Section 5.7 
6.15 Limitations and contributions to knowledge, clinical practice and theory 
Limitations 
The primary limitation of this feasibility trial was the absence of weekly graded 
adherence criteria over the three-week intervention. Further, fidelity checking 
was not as frequent as it could have been and was undertaken by different 
independent assessors. If fidelity checking was undertaken more frequently and 
the data analysed by one person, this may have provided the opportunity to 
conduct more training and address adherence. This will be implemented in a 
definitive trial and should be included in future feasibility trials of complex 
interventions. 
The delay in completing the systematic review resulted in the recommendations 
from the review not directly informing the non-pharmacological interventions to 
treat OH protocol used in the trial. However, people with stroke may likely have 
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impaired swallow (limiting the ability to use drinking water to address OH and 
already wear pneumatic compression stockings. Therefore, abdominal binders 
were pragmatically used in the trial OH protocol and their use was supported by 
the systematic review. However, the OH protocol will need further development 
prior to implementing in a definitive trial including other potential interventions 
depending on patient presentation/ability. The absence of a systematic review 
on interventions to treat post-stroke fatigue has been identified, given the high 
prevalence of fatigue among participants in the trial. However, the high 
prevalence was not known until the data was available after the last participant 
had completed their 55-week follow-up assessment, therefore, a systematic 
review on post-stroke fatigue interventions is recommended prior to progressing 
to a definitive trial. 
The small sample size of 50 participants is acknowledged as a limitation, as is 
not recruiting to target. However, 45 participants were recruited in ten months 
thus the actual monthly recruitment rate exceeded the target recruitment rate. 
All SRUs were in the South West of England, therefore, behaviour and attitudes 
of physiotherapists, patients and relatives are not representative of all SRUs. 
However, the Proximal Similarity Model used by AVERT trialists468 considers 
the person, place, setting and practice and literature reviewed for the discussion 
chapter in this thesis regarding therapists’ beliefs, organisation and patient 
factors have been identified in other trials nationally and internationally. 
A feasibility trial has been conducted; it has not determined if the intervention is 
clinically and cost effective. This will be the aim of the definitive trial. 
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6.16 Original contributions to: 
Knowledge 
The thesis determined the feasibility of a novel combination of two existing 
physiotherapy treatments: prolonged standing and sit to stand repetitions (task 
specific training) (Chapter 1). 
Several non-pharmacological interventions exist to treat OH in people with 
stroke and neurological conditions (Chapter 2). There are treatment options 
available for people with mild, moderate and severe stroke and some of the 
equipment for these interventions are already available in SRUs, e.g. microstim 
for electrical stimulation and cycle ergometers. 
It is possible to include people with severe stroke who have communication and 
cognitive impairments in rehabilitation trials. 
Beliefs and behaviours of physiotherapists can affect success of a trial, e.g. 
fidelity 
Whilst GCP training was a requirement from NHS Trusts and the trial Sponsor, 
it does not sufficiently cover aspects of clinical/personal equipoise and fidelity. 
Many of the barriers identified in this thesis have been identified in other 
rehabilitation trials (Chapter 6), therefore a training template is required for 
rehabilitation trials to optimise success. 
Clinical practice 
It is feasible for people with sub-acute severe stroke to undertake a functional 
standing frame programme of sit to stand repetitions and prolonged standing 
although adherence was low (Chapters 4, 5 and 6). Taking manual blood 
pressures is not part of physiotherapist core skills and some physiotherapists 
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did not understand the importance of checking blood pressure in sitting and 
standing when delivering the functional standing frame programme. This may 
cause harm to people with stroke due cerebral hypoperfusion (Chapters 2 and 
6).  
Anosognosia is a common phenomenon post-stroke but is not routinely 
screened for in clinical practice or in clinical trials. Assessment and treatment of 
this condition is required as it may affect the validity of using PROMs. (Chapter 
6). 
There is a disconnect between some physiotherapists and patients regarding 
what patients’ abilities are following severe sub-acute stroke and the most 
appropriate treatment interventions which should be offered to people with 
severe sub-acute stroke (Chapters 4 and 5). 
Theory 
The feasibility trial did not aim to generate theory; the aim was to determine if it 
was feasible for people with severe sub-acute stroke to undertake a functional 
standing frame programme. However, it has highlighted how physiotherapists 
are engaging with evidence-based treatment and research and factors affecting 
this. There is a potential that years in practice versus education or banding may 
affect engagement with literature and delivery of stroke rehabilitation in SRUs. 
Research culture is not embedded in all NHS settings and needs addressing as 
this affects the success of clinical trials. 
6.17 Thesis conclusions 
This thesis has been driven by my clinical practice and interactions with people 
with severe stroke. The thesis has highlighted practical issues of undertaking 
research within the NHS, in a discharge driven environment. The qualitative 
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work with patients and physiotherapists highlighted different perspectives of 
practicalities and complexities of providing rehabilitation for people with severe 
and very severe stroke. It has also highlighted issues with the SSNAP data in 
clinical practice, whereby delivering a rehabilitation trial when resources are 
challenging increases workload and negatively impacts on the success of the 
trial. 
There are several unknowns that need addressing prior to progressing to a 
definitive main trial, such as contamination. Risk of contamination was identified 
as a potential problem in the feasibility RCT where individuals allocated to the 
control group may inadvertently receive some aspects of the standing frame 
intervention as physiotherapists at each of the sites were treating participants in 
both groups. There was evidence of possible contamination because 
physiotherapists reported that delivering the intervention challenged their 
practice, prompting them to reduce the amount of rest times, and increase 
active movements and time in standing during treatment sessions. 
Recent rehabilitation trials conducted early post-stroke470,471 and observational 
data373 identified issues affecting adherence that were mirrored in SPIRES, 
highlighting the need to address these prior to allocating funds for other 
complex intervention rehabilitation trials.  
The thesis has indicated that a future definitive trial is not feasible in its current 
design, however, potential solutions have been identified to address a range of 
challenges and areas of future research that could improve clinical practice in 
this under-represented patient group. 
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Appendix 1 Search strategy 
Example from one database search. 
Limiters for all searches: English Language 
Updated search date: 26th and 27th April 2018 
MEDLINE 
Search ID # Search Formula Results 
S1 orthostatic adj2 hypotension AB 641 
S2 hypotension, orthostatic/ MeSH, AB 843 
S3 postural adj2 hypotension AB 88 
S4 orthostasis AB 138 
S5 dizziness/ MeSH AB 2367 
S6 “low blood pressure” AB 322 
S7 hypotension/ MeSH AB 5181 
S8 vascular adj2 response AB 645 
S9 “autonomic dysfunction” AB 1519 
S10 “cerebral blood flow” or “cerebral bloodflow” AB 5119 
S11 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR 
S9 OR S10 
16541 
S12 Elder* OR “older people” OR “older person” OR 
aged/ OR ageing OR aging OR senior OR geriatric 
AB 
485281 
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S13 S11 AND S12 2436 
S14 "non-pharmacological treatment*" OR 
"nonpharmacological treatment*" OR "non 
pharmacological treatment*" AB 
455 
S15 "non-pharmacological management" OR 
"nonpharmacological management" OR "non 
pharmacological management" AB 
79 
S16 "non-pharmacological intervention*" OR 
"nonpharmacological intervention*" OR "non 
pharmacological intervention*" AB 
547 
S17 14 OR 15 OR 16 1081 
S18 Physical AB 218418 
S19 S13 AND S18 396 
S20 S11 AND S12 AND S17 9 
S21 S11 AND S17 19 
S22 compression ajd2 garment* AB 90 
S23 compression adj2 stocking* AB 411 
S24 compression adj2 bandag* AB 386 
S25 compression adj2 wrap* AB 8 
S26 stockings, compression/ AB 321 
S27 abdominal binder AB 13 
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S28 S22 OR S23 OR S24 OR S25 OR S26 OR S27 1229 
S29 S13 AND S28 11 
S30 S11 AND S28 23 
S31 S13 AND S17 8 
S32 rehabilitation AB 954 
S33 S13 AND S32 0 
S34 S11 AND S32 1 
S35 exercise AB 12723 
S36 S35 AND S11 56 
S37 S11 AND “physical maneuvers” or “physical 
manoeuvres” or “physical man*” or “physical 
measures” AB 
25 
S38 diet and S11 0 
S39 fluid AND S11 0 
S40 water AND S11 0 
S41 meals AND S11 0 
S41 food AND S11 0 
S43 vasovagal AND management OR treatment AB 0 
S44 S11 AND “head up” OR “head-up” AB 16 
S45 S11 and “electrical stimulation” AB 2 
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S47 Parkinson* OR Alzheimer* OR dementia OR 
“multiple sclerosis” OR “motor neuron*” OR stroke 
AB 
188454 
S47 exp stroke/ MeSH AB 25475 
S48 exp neurodegenerative disease*/ MeSH AB 52263 
S49 exp dementia/ MeSH AB 24907 
S50 exp multiple sclerosis/ MeSH AB 16962 
S51 exp cerebrovascular disorder/ MeSH AB 47426 
S52 exp brain ischemia/ MeSH AB 19725 
S53 exp spinal cord injuries/ MeSH AB 19147 
S54 exp brain injuries/ MeSH AB 15167 
S55 craniocerebral trauma/ MeSH AB 2014 
S56 exp central nervous system disease/ MeSH AB 197427 
S57 exp brain damage, chronic/ MeSH AB 22074 
S58 Parkinson* adj2 disease AB 20277 
S59 S47 OR S48 OR S49 OR S50 OR S51 OR S52 
OR S53 OR S54 OR S55 OR S56 OR S57 OR 
S58 
197363 
S60 S11 AND S59 2689 
S61 S11 AND S17 AND S59 8 
351 
S62 S11 AND “functional electrical stimulation” OR FES 
OR “electrical stimulation” OR “neuromuscular 
stimulation”  
0 
AB: Abstract; KW: keyword; MeSH: medical search heading 
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Appendix 2 Excluded studies 
Quasi-experimental studies 
Chao CY and Cheing GL. The effects of lower extremity FES on the orthostatic 
responses of people with tetraplegia. Archives of Physical Medicine and 
Rehabilitation. 2005; 86(7):427-33. 
Reason for exclusion based on inclusion criteria: Included a participant aged 15 
years of age, therefore, did not meet eligibility criteria which was missed during 
full-text assessment. Inclusion criteria is ≥18 years. Unable to identify this 
participant in data presented. 
Hilz MJ, Ehmann EC, Pauli E, Baltadzhieva R, Koehn J, Moeller S, DeFina P, 
Axelrod FB. Combined counter-maneuvers accelerate recovery from orthostatic 
hypotension in familial dysautonomia. Acta Neurologica Scandinavica. 2012; 
126(3):162-70. 
Reason for exclusion based on inclusion criteria: Included participant aged 15 
years of age, therefore, did not meet eligibility criteria which was missed during 
full-text assessment. Inclusion criteria is ≥18 years. Unable to identify this 
participant in data presented. 
Hohler AD, Amariei DE, Katz DI, DePiero TJ, Allen VB, Boyle S, et al. (2012) 
Treating orthostatic hypotension in patients with Parkinson’s Disease and 
atypical Parkinsonism improves function. Journal of Parkinson’s Disease. 2012; 
2(3):235-240. 
Reasons for exclusion based on methodological quality: Too many variables 
(reducing antihypertensive medications, maintaining hydration with 1500cc/day, 
decreasing dietary salt, wearing high compression stockings, and keeping the 
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head of bed elevated at 30 degrees when supine) This study has been 
excluded due to combined treatments and it is not possible to understand the 
effect of a given intervention. 
Huang CT, Kuhlemeier KV, Ratanaubol U, McEachran AB, DeVivo MJ, Fine 
PR. Cardiopulmonary response in spinal cord injury patients: effect of 
pneumatic compressive devices. Archives of Physical Medicine and 
Rehabilitation. 1983; 64(3):101-6. 
Reason for exclusion based on inclusion criteria: Included one participant aged 
17 years of age, therefore, did not meet eligibility criteria which was missed 
during full-text assessment. Inclusion criteria is ≥18 years. Unable to identify 
this participant in data presented. 
Sasaki K, Kaneyuki M, Fujii M, Ota A, Ota T and Nishigaki M (2013) Blood 
Pressure Dynamics During Long Sitting Position In Acute Ischemic Stroke 
Patients: Prevalence Of Orthostatic Hypotension. International Stroke 
Conference Poster Abstract. 
Reason for exclusion based on inclusion criteria: Not an intervention. Testing for 
prevalence. 
Sampson EE, Burnham RS and Andrews BJ. Functional electrical stimulation 
effect on orthostatic hypotension after spinal cord injury (2000). Archives of 
Physical Medicine and Rehabilitation. 139-143. 
Reason for exclusion based on inclusion criteria: One of the six participants was 
aged 17 years of age. Inclusion criteria is ≥18 years. Unable to identify this 
participant in data presented. Did not meet eligibility criteria which was missed 
during full-text assessment. 
354 
Case report 
Mikula J, Smith Pl, Meuleman, J and Levy CE. (201) Effects of a recreation 
therapy aquatics intervention: a case study of an older adult with uncontrolled 
orthostatic hypotension. American Journal of Recreation Therapy. American 
Journal of Recreation Therapy. 2010; 9(3):13-6. 
Reason for exclusion based on inclusion criteria: Did not measure BP; HR not 
consistently measured, and no measurements reported. Did not meet eligibility 
criteria which was missed during full-text assessment. 
Taylor PN, Tromans AM, Harris KR and Swain ID. (2002) Electrical stimulation 
of abdominal muscles for control of BP and augmentation of cough in a C3/4 
level tetraplegic. Spinal Cord. 2002; 40(1):34-6. 
Reason for exclusion based on inclusion criteria: No orthostatic tests therefore 
did not meet eligibility criteria which was missed during full text-assessment. 
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Appendix 3 Summary of findings table 
Resistance exercise compared to no resistance exercise for older people and 
people with a neurological condition to treat orthostatic hypotension 
Bibliography: 
Brilla LR, Stephens AB, Knutzen KM, Caine D. Effect of strength training on 
orthostatic hypotension in older adults. Journal of Cardiopulmonary Rehabilitation. 
1998; 18: 295-300. 
Kanegusuku H, Silva-Batista C, Peçanha T, Nieuwboer A, Silva ND, Cost LA. et al. 
Effects of progressive resistance training on cardiovascular autonomic regulation in 
patients with Parkinson’s disease: A randomized controlled trial. Archives of Physical 
Medicine and Rehabilitation. 2017; 98: 2134-2141. 
Zion AS, De Meersman R, Diamond BE, Bloomfield DM. A home-based resistance-
training program using elastic bands for elderly patients with orthostatic hypotension. 
Clinical Autonomic Research. 2003; 13: 286-292. 
Outcomes № of 
participants 
(studies) 
Follow-up 
Certainty 
of the 
evidence 
(GRADE) 
Relative 
effect 
(95% CI) 
Anticipated absolute 
effects 
Risk with 
no 
resistance 
exercise 
Risk 
difference 
with 
resistance 
exercise 
Change in systolic blood 
pressure from supine to 
one-minute standing or 60 
degrees head up tilt (sBP 
change) 
Assessed with: mmHg 
Scale from: 96 to 102.3 
Follow up: range 8 to 12 
weeks  
148 
(2 
observational 
studies 1 
RCT)  
⨁◯◯◯ 
VERY 
LOW a,b,c 
-  -  SMD 
0.04 SD 
higher 
(0.31 
lower to 
0.4 
higher)  
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Electrical stimulation compared to no electrical stimulation for older people 
and people with a neurological condition to treat orthostatic hypotension 
Bibliography: 
Yoshida T, Masani K, Sayenko DG, Miyatani M, Fisher JA, Popovic MR. 
Cardiovascular response of individuals with Spinal Cord Injury to functional 
electrical stimulation and passive stepping. Topics in Spinal Cord Injury 
Rehabilitation. 2013; 19: 40-41. 
Kuznetsov AN, Rybalko NV, Daminov VD, Luft AR. Early poststroke rehabilitation 
using a robotic tilt-table stepper and functional electrical stimulation. Stroke 
Research and Treatment. 2013: 1-9. 
Outcomes № of 
participants 
(studies) 
Follow-up 
Certainty 
of the 
evidence 
(GRADE) 
Relative 
effect 
(95% 
CI) 
Anticipated absolute 
effects 
Risk with 
no 
electrical 
stimulation 
Risk 
difference 
with 
electrical 
stimulation 
Change in mean arterial 
blood pressure when 
moving from supine to 
one-minute standing or a 
vertical position on a tilt 
table (MAP change) 
Assessed with: mmHg 
Scale from: 94.2901 to 
110.5333333  
268 
(2 
observational 
studies)  
⨁◯◯◯ 
VERY 
LOW d,e,f 
-  -  SMD 
0.24 SD 
lower 
(0.54 
lower to 
0.07 
higher)  
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Compression bandaging compared to no compression bandaging for 
older people and people with a neurological condition to treat orthostatic 
hypotension 
Bibliography: 
Gorelik O, Almoznino-Sarafian D, Litvinov V, Alon I, Shteinshnaider M, Dota E. 
Seating-induced postural hypotension is common in older patients with 
decompensated heart failure and may be prevented by lower limb 
compression bandaging. Gerontology. 2009; 55: 138-144. 
Gorelik O, Shteinshnaider M, Tzur I, Feldman L, Cohen N, Almoznino-Sarafian 
D. Factors associated with prevention of postural hypotension by leg 
compression bandaging. Blood Pressure. 2014; 23: 248-254. 
Outcomes № of 
participants 
(studies) 
Follow-up 
Certainty 
of the 
evidence 
(GRADE) 
Relative 
effect 
(95% CI) 
Anticipated absolute 
effects 
Risk with no 
compression 
bandaging 
Risk 
difference 
with 
compression 
bandaging 
Change in mean 
arterial blood 
pressure from 
supine to one-
minute in sitting 
(MAP change) 
Assessed with: 
mmHg 
Scale from: 92.8 
to 102.0666667  
252 
(2 
observational 
studies)  
⨁◯◯◯ 
VERY 
LOW g,h,i 
-  -  SMD 0.16 
SD lower 
(0.41 lower 
to 0.09 
higher)  
 
*The risk in the intervention group (and its 95% confidence interval) is 
based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI).  
 
CI: Confidence interval; SMD: Standardized mean difference; SD: Standard 
deviation; MAP: Mean arterial pressure; sBP: systolic blood pressure 
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GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of 
the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The 
true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect 
may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The 
true effect is likely to be substantially different from the estimate of effect  
Explanations 
a) Before and after study, non-blinded, or blinding of investigators not reported; 
b). Variation in intervention: supervised sessions in Brilla; training performed 
four days per week in Zion, and three days per week in Brilla, twice a week in 
Kanegusuku; c) Small sample size in Zion, one third of which were withdrawn 
during the intervention phase; d). Observational study. No allocation 
concealment in Kuznetsov, participants randomised on day of admission; e) 
Heterogeneity in population, (e.g. stroke or spinal cord injury) and length of 
intervention (up to 30 days in Kuznetsov versus all testing on one-day Yoshida); 
f) Yoshida made conclusions based on muscle strength and cerebral blood flow, 
they did not make any conclusions about effect of intervention on orthostatic 
reactions, yet this was one of their objectives; g) Observational study (residual 
confounding, evidence); h) Before and after study, long-term effects not 
investigated. Study investigated seating induced orthostatic hypotension and 
did not measure effects in standing; i) Lead author and multiple co-authors were 
the same in both papers. 
 
359 
 
Appendix 4 Characteristics of included studies 
Eight non-pharmacological interventions for OH were identified under two general categories: physical modalities (exercise, 
electrical stimulation, compression, compression and physical counter-maneuvers, physical counter-maneuvers, sleeping with 
head up) and dietary measures (food and fluid intake). 
Physical Modalities 
Exercise 
Study Country and 
Setting 
Participant 
characteristics 
Experimental 
Intervention 
Control 
Intervention 
Outcomes 
measured 
Description of main 
results 
Luther et al. 
2008. 
 
Randomised 
crossover 
pilot trial 
using 
sequential 
testing 
Germany, 
Neuro 
Rehabilitation 
Unit 
N=9 
unconscious 
within first three 
months of brain 
injury; (5 male) 
Mean age 51 (± 
20) years 
Tilt table with 
an integrated 
stepping 
device  
Intervention 
and control 
delivered in a 
random order 
on different 
days, one 
week 
between 
testing.  
 
Conventional 
tilt table 
Primary: interruption 
of verticalization due 
to a syncope or pre-
syncope symptoms 
such as tachypnoea, 
tachycardia, pallor or 
increase in sweating. 
Secondary: state of 
consciousness 
according to Coma 
Recovery Scale-
Revised (CRS-R); 
influence of treatment 
on muscle tone using 
There were significantly 
more incidences of pre 
syncope on the 
conventional tilt table 
(p<0.05) at tilts of 50 or 70 
degrees compared to the 
tilt table with integrated 
stepping. The binominal 
test as a cross-check 
showed significantly more 
treatment discontinuations 
on the conventional tilt 
table than on the tilt table 
with integrated stepping 
(p=0.031). 
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Modified Ashworth 
Scale. 
Takahagi et 
al. 2014 
 
Randomised 
controlled 
trial 
Brazil, 
Outpatient 
N=21 recurrent 
neuro 
cardiogenic 
syncope with 
had positive 
head up tilt test 
(three male) 
Mean age: 32 
(±10) years in 
intervention 
group; 26 (±8) 
years in control 
group 
N=11 
undertook 
aerobic 
physical 
training using 
cycle 
ergometer for 
12 weeks.  
Two 
supervised 
sessions plus 
two 
unsupervised 
sessions. 
N=10 
undertook 15 
minutes of 
stretching 
and 15 
minutes of 
light walking 
for 12 weeks.  
two 
supervised 
sessions. 
Resting and training 
HR, VO2 peak, VO2 
anaerobic threshold, 
sBP and dBP before 
and after 12-week 
training. 
The Training Group 
exhibited a tendency for 
higher peak HR, with VO2 
peak and VO2 anaerobic 
threshold than the control 
group. The training group 
exhibited a statistically 
significant 
difference(p<0.01) in 
syncope episodes 
between pre- and post-
intervention.  
There was a significant 
difference (p<0.05) in the 
number of negative Head 
up tilt (72.7% in the 
training group versus 30% 
in the control group).  
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Taveggia G 
RI. 2015. 
 
Randomised 
controlled 
trial 
Italy, Neuro 
Rehabilitation 
Unit 
N=12 with 
vegetative state 
or minimally 
conscious state 
3-18 months 
after acute 
acquired brain 
injury (eight 
male) 
Mean age: 65 
(±8) years in 
intervention 
group; 63 (±16) 
in control group 
N=6 tilted to 
65 degrees 
with a robotic 
tilt table 
system 
performing 18 
steps per 
minute of the 
lower limbs 
(hip and knee 
flexion) for 30 
minutes three 
times a week 
for 24 
sessions. 
N=6 tilted to 
65 degrees 
for 30 
minutes with 
no lower-limb 
movement. 
HR and BP 
monitored at every tilt 
angle 
Coma recovery scale 
and level of 
consciousness scale 
pre- and post 
treatment; OH 
occurrence and 
length. 
n=4 withdrawn due to 
medical events. 
Intervention group showed 
a progressive reduction in 
OH during treatment; n=3 
showed a complete 
absence of OH at the end 
of rehabilitation therapy.  
Control group showed 
more serious OH after 24 
sessions of treatment. 
BP readings not reported, 
but the group tilted with 
robotic stepping 
experienced less OH 
during verticalization (48 
and 4 seconds) compared 
to the control group (120 
and 187 seconds). 
Rocca et al. 
2016 
Randomised 
controlled 
trial 
Switzerland, 
inpatient 
hospital 
N=30 (n=14 
sub-arachnoid 
haemorrhage; 
n=4 severe 
brain trauma; 
n=4 intra-
parenchymal 
haemorrhage, 
n=2 ischemic 
stroke, n=3 
brain anoxia, 
n=3 other (17 
male) 
Age range: 18-
88 years 
N=10 passive 
cycling in 
supine 
(Protocol 
Two) 
N=10 passive 
stepping with 
robotic tilt 
table 
(Protocol 
Three) 
N=10 
standard 
physiotherapy 
(Protocol 
One) 
sBP and dBP, HR, 
respiratory rate, 
cerebral blood flow 
for participants with 
sub-arachnoid 
haemorrhage, 
venous blood and 
blood plasma 
samples. 
No significant absolute or 
relative difference in any 
of the BP components 
with passive cycling or 
passive stepping.  
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Mean age: 54.2 
years 
 
Study Country 
and 
Setting 
Participant 
characteristics 
Groups Outcomes measured Main description of results 
Brilla LR SA. 
1998. 
 
Quasi-
experimental 
USA, 
Community 
N=24 elderly with 
orthostatic 
hypotension (a 
subset of n=53 
participants from a 
larger study on a 
high-resistance 
strength training in 
older adults’ study; 
all 24 showed 
orthostatic 
hypotension in the 
pre-test) (7 male) 
Mean age: 71 (±-
5.8) years 
All participants 
underwent eight weeks 
heavy resistance, 
progressive strength 
training program upper 
and lower limb.  
Participants were 
discontinued from the 
study if more than two 
consecutive sessions 
were missed. 
1) Resting BP in supine, 
sitting and standing 
positions 
2) Resting HR in supine, 
sitting and standing 
positions 
3) Response to 
orthostatism in rising 
from supine after 10 
minutes and rising from 
a chair after five minutes 
Significant changes (p<0.05) in 
supine dBP (+3.2mmHg), 
sitting systolic BP (-3.9), and 
standing HR (+4.9 beats / 
minute). In response to 
orthostatic challenge, 
significant (p < 0.05) 
improvements in sBP 
(+9.7mmHg), dBP (+4.7) and 
HR (+3.2 beats/min) for the 
rise from chair, and in dBP 
(+6.7mmHg) rise from cot. 
Gains in strength were also 
noted. 
Zion et al. 
2003. 
 
Quasi-
experimental 
USA, 
Autonomic 
Function 
Laboratory 
at the 
Irving 
Centre of 
Clinical 
Research, 
Columbia 
University 
N=12 orthostatic 
hypotension. Only 
eight completed 
the protocol.  
N=8 (four male) 
Age range: 63–81 
years 
N=8 completed an 
eight-week home-
based resistance-
training (HBRT) 
program using elastic 
resistance bands. Ten 
exercises 
(incorporating upper 
and lower limbs) were 
assigned and 
Orthostatic testing: ECG 
and beat-to-beat BP 
continuously monitored 
and recorded. 
BP in supine, seated, 
standing one minute, 
standing two minutes, 
and during tilt table 
testing weeks one and 
eight at rest, 60 degrees 
tilt, end tilt. 
At eight weeks, significant 
increases occurred in dynamic 
strength in the chest press 
(p<0.017), quadriceps 
extension (p<0.017), and leg 
press (p<0.025); no significant 
differences occurred in 
isometric strength or in BPs. 
Functional mobility increased 
in seven out of eight 
participants.  
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customized to each 
participant. 
Muscle strength testing 
(isometric and dynamic) 
Functional test of gait 
and mobility (Timed Up 
and Go) at baseline and 
eight weeks 
No falls during the 
investigation period. 
 
Study Country 
and 
Setting 
Participant 
characteristics 
Experimental 
Group 
Control Group Outcomes 
measured 
Main description 
of results 
Kanegusuku 
et al. 2017 
Randomised 
controlled 
trial 
Brazil, 
Parkinson 
Association 
N=30 Parkinson’s 
Disease and n=16 
healthy controls 
(33 male) 
Age range: 67 +/- 
8; (Parkinson’s 
Disease Training 
Group) 
Age range: 63+/- 8 
(Parkinson’s 
Disease Control 
Group) 
Age range: 68+/- 
10 (healthy 
controls) 
Parkinson’s 
disease 
progressive 
resistance 
training (PDT) 
 
Parkinson’s 
disease control 
group (PDC) 
Healthy controls 
(HC) 
sBP, HR, R-R 
intervals (Valsalva 
manoeuvre and 
orthostatic stress), 
muscle strength 
using one repetition 
maximum. 
Compared with 
baseline, sBP fall 
was significantly 
reduced in the PDT 
group (14 
±11mmHg versus -6 
±10mmHg; PDC: -
12 ±10mmHg 
versus 11 
±10mmHg; 
interaction P<0.05) 
In addition, after 12 
weeks, these 
parameters in the 
PDT group achieved 
values similar to 
those in the HC 
group.) 
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Study Country and 
Setting 
Participant 
characteristics 
Group A 
description and 
sample 
Group B 
description and 
sample 
Exposures/variables 
measured 
Description of main 
results 
Galizia 
et al. 
2013. 
 
Case 
control 
study 
Italy, 
Rehabilitation 
Hospital 
N=42 elderly 
(Subset of 
n=90 
diagnosed with 
orthostatic 
hypotension 
and proceeded 
to “active 
phase”) (four 
male) 
Mean age: 76.8 
(±7.9) years  
N=21 performed 
10 full 
extensions of the 
ankle, knee, and 
hip joints of both 
limbs against a 
resistance band 
(6kg load) held 
under their feet 
whilst supine in 
bed 
N=21 underwent 
testing, but did 
not perform any 
exercise prior to 
testing BP and 
HR 
 
sBP and dBP after 10 
minutes supine rest, 
immediately upon 
standing up, and after 
one, three- and five-
minutes standing, 
HR, self-report 
orthostatic symptoms. 
Pre- and post-
intervention.  
Medications taken at 
time of testing and 
intervention were 
recorded. 
The reduction of sBP 
was significantly smaller 
(p<0.01) at each time 
interval after standing up 
in the exercise group 
than in the control group 
(10mmHg in the 
exercises group versus 
27mmHg in the control 
group), but no difference 
observed in dBP or HR. 
Trend towards fewer OH 
symptoms in the 
exercise group 
compared to control 
during active testing (not 
significant). 
 
Study Country and 
Setting 
Participant 
characteristics 
Groups Outcomes measured Main description of 
results 
Lopes P FS. 
1984. 
 
Quasi-
experimental 
USA, 
Inpatient in 
Veterans 
Administration 
Medical 
Centre 
N=12 SCI (12 
male)  
Experimental 
group: n=5 with 
quadriplegia; 
n=1 with 
paraplegia, 
mean time 
N=6 experimental 
group performed upper 
limb exercises whilst 
undergoing orthostatic 
training (tilted from 0 to 
70 degrees at 10 
degree increments at 
five-minute intervals on 
a tilt table)  
BP and HR at 30 secs, 1.5, 
2.5, three, four and five-
minute intervals during tilt 
training. 
Each participant received a 
score 1-10 depending on 
step level at which they 
experienced orthostatic 
hypotension (at which time 
Pre-test termination angle 
score homogenous 
between experimental and 
control groups (p<0.1). 
Mean differences in the 
termination angle 
Active, reciprocal, bilateral 
extremity exercise does not 
result in a significant 
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since injury 7.2 
weeks 
Mean age 40.3 
years 
Control group: 
n=6 with 
quadriplegia, 
mean time 
since injury 8.2 
weeks 
Mean age: 22.5 
years 
N=6 control group 
underwent orthostatic 
training (tilted from 0 to 
70 degrees at 10 
degree increments at 
five-minute intervals on 
a tilt table) 
the test was terminated). 
Credit was given for partial 
completion of time 
specified at each angle by 
awarding 0.2 of a score for 
each 30-seconds 
completed. 
change in tolerance of 
progressively higher 
vertical angles of tilt. The 
experimental group did not 
show increases in BP, nor 
demonstrate improved 
orthostatic tilt tolerance 
over the control group. 
Control group mean BP 
was 122/70mmHg and 
experimental group was 
117/76mmHg 
 
Electrical stimulation 
Study Country and 
Setting 
Participant 
characteristics 
Groups Outcomes 
measured 
Main description of results 
Faghri and 
Yount 2002. 
 
Randomised 
controlled 
trial 
Repeated 
measures 
USA, 
Rehabilitation 
Hospital 
N=14 SCI (n=7 
paraplegic n=7 
tetraplegic, n=4 
incomplete, 
n=10 complete) 
(11 male) 
n=15 healthy 
able bodied 
(gender not 
reported) 
Mean age SCI: 
35 (±9.41) 
years 
Fourteen SCI 
participants used a 
standing system: 
stationary standing for 
30 minutes and dynamic 
standing using 
Functional Electrical 
Stimulation (FES) for 30 
minutes. Four 
electrodes, balanced 
symmetrical biphasic 
waveform with 35 Hz 
frequency, duty cycles 
Stroke Volume, 
cardiac output, HR, 
sBP, dBP, TPR, 
mean arterial 
pressure: measured 
in sitting, standing, 
after five minutes and 
30 minutes of 
Significant reduction in sBP 
and dBP (p<0.05) and mean 
arterial pressure during 
stationary standing in SCI 
subjects, whilst maintained in 
able-bodied. All of BP values 
were maintained to pre-
standing levels in SCI during 
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Mean age able 
bodied: 29 (±6) 
years 
of 11 seconds on, 60 
seconds off for channel 
one (tibialis anterior and 
gastrocnemius muscles) 
and seven seconds on 
and 64 seconds off for 
channel two (quadriceps 
and hamstrings muscle 
groups). 
Fifteen able-bodied 
participants performed 
stationary standing for 
30 minutes and 
voluntary tiptoe 
contractions during 30 
minutes of standing. 
 
standing in all 
participants for both 
static and dynamic 
standing. 
standing with FES. No changes 
in any variables for able-bodied 
participants.  
SCI participants demonstrated 
significant reductions (p<0.05) 
in all hemodynamic values for 
stationary standing at five and 
30 minutes (able bodied- 
reduction in stroke volume and 
cardiac output at 30 min); 
compared to no change at five 
minutes when standing with 
FES, but at 30 minutes 
standing with FES there was 
significant increase in 
hemodynamic values (HR and 
stroke volume)- able-bodied 
maintained at five minutes, but 
at 30 minutes dynamic 
standing cardiac output 
decreased and HR increased. 
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Study Country and 
Setting 
Participant 
characteristics 
Groups Outcomes 
measured 
Main description of results 
Faghri et al. 
2001 
 
Quasi-
experimental 
Repeated 
measures 
 
 
USA, 
Rehabilitation 
Hospital 
N=14 SCI (n=7 
paraplegic n=7 
tetraplegic, n=4 
incomplete, 
n=10 complete) 
(11 male) 
n=15 healthy 
able bodied 
(gender not 
reported) 
Mean age SCI: 
35 (±9.41) 
years 
Mean age able 
bodied: 29 (±6) 
years 
SCI participants used a 
standing system for 
stationary standing for 
30 minutes and dynamic 
standing using 
Functional Electrical 
Stimulation (FES) for 30 
minutes (Active 
Standing Group). Four 
electrodes, balanced 
symmetrical biphasic 
waveform with 35 Hz 
frequency, duty cycles 
of 11 seconds on, 60 
seconds off for channel 
one (tibialis anterior and 
gastrocnemius muscles) 
and seven seconds on 
and 64 seconds off for 
channel two (quadriceps 
and hamstrings muscle 
groups).Able-bodied 
participants performed 
stationary standing for 
30 minutes and 
voluntary tiptoe 
contractions during 30 
minutes of standing 
(Passive Standing 
Group). 
Central hemodynamic 
responses of stroke 
volume, cardiac 
output, HR, mean 
arterial BP, total 
peripheral resistance, 
and rate pressure 
product during 
supine, sitting and 
standing positions, 
and every five 
minutes during the 30 
minutes standing. 
Overall, the tetraplegic group 
had a significantly lower sBP 
(p=0.013) and mean arterial 
pressure (p=0.048) than the 
paraplegics during passive 
standing. These differences 
were not detected during active 
standing. 
Moving from sitting to standing 
sBP increased 1.6% in the 
active standing group 
compared to a decrease in sBP 
of 8% in the passive standing 
group. When data were pooled 
from both groups and the 
overall groups response to 
active and passive standing 
were compared, the results 
showed that cardiac output, 
stroke volume, and BP 
significantly decreased (p<0.05) 
during 30 minutes of passive 
standing, whereas TPR 
significantly increased (p<.05). 
All hemodynamic variables 
were maintained during 30 
minutes of active standing, and 
there were increases in RPP 
and HR after 30 minutes of 
active standing. 
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With versus without 
order was 
counterbalanced. 
Elokda AS 
ND and SR. 
2000 
 
Quasi-
experimental 
USA, 
Rehabilitation 
Hospital 
N=5 SCI, 2-4 
weeks post-
injury (n=2 
tetraplegic and 
n=3 paraplegic) 
(all male) 
Age range: 26-
36 years 
All participants 
underwent repeated 
measures: supine on tilt 
table with feet in contact 
with footboard. Six 
minutes rest at 0 
degrees for baseline 
measurements, followed 
by six four-minute 
stages for each tilt angle 
(0, 15, 30, 45 and 60 
degrees), followed by a 
four-minute recovery. 
Repeated with and 
without electrical stim 
(Biphasic waveform, 20 
Hz frequency without 
any ramping, alternating 
two seconds on and four 
seconds off periods of 
the quadriceps and 
ankle plantar flexors 
during the tilting 
procedure) 
Test terminated if 
SBP<60 or DBP<40 or 
severe orthostatic 
symptoms reported 
(fainting/headache). 
sBP, dBP and HR 
taken at one-minute 
intervals during 
resting and tilting 
procedures (tilt 
angles: 0, 15, 30, 45 
and 60 degrees).  
Subjective perception 
of orthostatic 
tolerance measured 
at one-minute 
intervals during tilting. 
sBP showed a progressive 
decrease with increasing tilt 
angle without the electrical stim. 
The electrical stimulation 
treatment appeared to 
attenuate the rate of sBP 
decrease. sBP at each degree 
of tilt with Functional 
Neuromuscular Stimulation was 
higher. dBP was lower for all tilt 
angles without Functional 
Neuromuscular Stimulation. 
Hamzaid et 
al. 2015. 
Malaysia, 
Rehabilitation 
N=2 sub-acute 
SCI (C7), 2 
Both participants 
underwent four weeks of 
sBP and dBP pre- 
and post-testing, 
Subject A improved his 
orthostatic symptoms but did 
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Quasi-
experimental 
ward in 
medical 
centre and at 
one subject’s 
residence 
after 
discharge 
weeks since 
injury (both 
male) 
Age: 62 and 65 
years 
electrical stimulation 
(ES) therapy, four times 
per week for one hour 
per day. ES was applied 
on the rectus abdominis, 
quadriceps, hamstrings 
and gastrocnemius with 
35 Hz frequency, pulse 
width 250 µs. The 
current amplitude was 
increased incrementally 
from 0 mA to the 
maximum tolerated by 
patients which was 130 
mA. 
every minute 0 to 65 
degrees on tilt table, 
mean arterial 
pressure (MAP) and 
HR were obtained 
during pre-test and 
post-tests with and 
without ES-evoked 
muscle contractions. 
Symptom Scale 
Questionnaire for 
Orthostatic 
Intolerance was 
conducted during all 
tests to measure their 
OH symptoms. 
not recover from clinically 
defined OH based on the 20-
minute duration requirement. 
With concurrent ES therapy, 60 
degrees head up tilt BP was 
89/62mmHg compared with 
baseline BP of 115/71mmHg. 
Subject B fully recovered from 
OH demonstrated by BP of 
105/71mmHg during the 
60degrees head up tilt 
compared with baseline BP of 
124/77mmHg. Both patients 
demonstrated longer tolerance 
time during head up tilt with 
concomitant ES (subject A: pre-
test four minutes, post-test 
without ES six minutes, post-
test with ES 12 minutes; subject 
B: pre-test four minutes, post-
test without ES 28 minutes, 
post-test with ES 60 minutes). 
Kuznetsov 
et al. 2013. 
 
Quasi 
experimental 
Russia, 
Inpatient 
Stroke 
Rehabilitation 
Unit 
N=128 mild or 
moderate 
stroke 4.6 ± 1.2 
days post-
stroke (56 
male) 
Mean age: 58.3 
(±1.2) years 
 
N=38 were treated with 
ROBO-FES (robotic tilt 
table and functional 
electrical stimulation) for 
30 days. A six channel 
stimulator was used and 
electrodes placed over 
biceps femoris, 
quadriceps femoris and 
gastrocnemius of either 
leg. Stimulation was 
synchronized with 
British Medical 
Research Council 
Strength Scale; sBP 
and dBP; SV; 
cerebral blood flow 
using transcranial 
doppler 
ultrasonography, 
Barthel Index, 
Pulsatility Index, 
Resistance Index. 
None of the participants in the 
ROBO and ROBO-FES groups 
had OH or orthostatic reactions 
when put into a vertical 
position, but 52% of the control 
participants showed OH.  
Does not state whether 
participants were doing any 
standing/vertical activities in the 
usual therapy as part of their 
rehabilitation. 
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robotic leg movements 
varying between five 
and 100 mA. 
N=35 were treated with 
ROBO (robotic tilt table 
only)  
N=31 were the control 
group  
N=24 dropped out.  
All measures taken at 
baseline and post-
intervention 
Yoshida et 
al. 2013. 
 
Quasi-
experimental 
Canada, 
Outpatient 
Rehabilitation 
Centre 
N=10 SCI, n=4 
cervical spine; 
n=5 thoracic 
spine injury; 1-
29 years since 
injury (6 male) 
Age range: 27-
59 years  
N=10 underwent the 
same testing and acted 
as their own controls. 
Tilted head-up to 70 
degrees from supine; 
four 10-minute 
conditions involved, with 
a 10-minute rest 
between each condition: 
1) passive head-up tilt 
with no intervention, 2) 
passive stepping using 
a motorized stepper 
(described in 
intervention section) 3) 
isometric Functional 
Electrical Stimulation 
(FES) of leg muscles 
(described in 
intervention section), 
and 4) dynamic FES of 
leg muscles combined 
with passive stepping 
(described in 
intervention section).  
Participant report of 
any symptoms of 
orthostatic 
hypotension, such as 
headache, dizziness, 
and light-
headedness. Inferior 
vena cava imaging in 
the transverse plane. 
EMG signals of the 
leg muscles were 
recorded only during 
STEP because cyclic 
passive movements 
of the legs can induce 
rhythmical EMG 
activities. Beat-to-
beat BP recorded 
non-invasively every 
minute for 10 minutes 
during each of the 
testing conditions. 
sBP decreased significantly 
during HUT and increased 
significantly during DFES, 
especially toward the end. dBP 
increased significantly during 
STEP and DFES. Mean BP 
increased significantly only 
during DFES. Statistical 
significance data for individual 
conditions not provided. 
However, results of a three-way 
ANOVA demonstrate that sBP, 
mean BP and HR all increased 
significantly (p=0.004, p=0.006 
and p=0.026) during FES. 
Passive stepping significantly 
increased sBP, dBP and mean 
BP (p=0.009, p=0.182, 
p=0.0102). 
The effects of FES on SV and 
mean BP were greater than 
those of passive stepping. 
When combined, FES and 
passive stepping did not 
interfere with each other, but 
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FES was applied to four 
muscle groups: tibialis 
anterior, hamstring, 
quadriceps femoris and 
triceps surae of both 
legs. Stimulation was 
bipolar and biphasic, 
with a maximum pulse 
width of 300 µs and 
stimulation frequency of 
40Hz. 
did not synergistically increase 
stroke volume or mean BP. 
Thus, the present study 
suggests that FES delivered to 
lower limbs can be used in 
individuals with SCI to help 
them withstand orthostatic 
stress.  
Phillips et al. 
2018 
 
Quasi-
experimental 
Canada, 
Laboratory 
N=5 SCI; n=4 
cervical, n=1 
thoracic), 3 
years post-
injury, (three 
male), all with 
OH. 
Age range: 23-
32 years 
All participants 
underwent the same 
testing, attending two 
testing sessions 
separated by at least 
one day. 
Once OH occurred, 
transcutaneous 
stimulation was applied 
to the skin between 
thoracic 7-8 spinous 
processes. The 
stimulation was 
delivered at 30Hz as 
monophasic, 1-ms 
pulses, to provide 
afferent input to the 
region of the spinal cord 
where sympathetic 
preganglionic neuron 
cell bodies are located. 
The current was 
increased from 10mA 
Following 10 minutes 
of rest in supine, the 
test began with 15 
minutes of supine 
measurements, after 
which participants 
were passively 
moved to the sit-up 
position and 
supported while sBP 
and dBP and HR 
measurements were 
recorded for an 
additional 15 minutes. 
Participants ranked 
their symptoms of 
nausea/ dizziness 
one to 10 (10 being 
most severe) each 
minute of the test 
During the orthostatic 
challenge, all individuals 
experienced hypotension 
characterized by a 37–4mm Hg 
decrease in sBP, a 52–10% 
reduction in cardiac 
contractility, and a 23–6% 
reduction in cerebral blood flow 
(all p<0.05), along with severe 
self-reported symptoms. 
Electrical stimulation completely 
normalized BP, cardiac 
contractility, cerebral blood 
flow, and abrogated all 
symptoms. Non-invasive 
transcutaneous electrical spinal 
cord stimulation may be a 
viable therapy for restoring 
autonomic cardiovascular 
control after SCI. 
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until BP normalized, up 
to a maximum 70mA, 
and maintained for at 
least one minute. 
Electromyography of the 
lower-limb skeletal 
muscles was recorded 
to confirm skeletal 
muscle contractions 
were not occurring and 
therefore the pressor 
responses were not 
attributed to the skeletal 
muscle pump of the 
venous vasculature. 
 
Compression 
Study Country and 
Setting 
Participant 
characteristics 
Experimental 
Intervention 
Control 
Intervention 
Outcomes 
measured 
Description of main 
results 
Podoleanu 
C MR. 2006. 
 
Single-blind 
randomised 
controlled 
trial  
 
 
Participants 
were 
blinded to 
treatment. 
Computer 
(blocked per 
Italy, Hospital 
Clinic 
N=21 elderly 
with 
symptomatic 
progressive OH 
(nine male) 
Mean age: 70 
(± 11) years 
All 21 underwent 
same testing 
conditions. 
Elastic 
compression 
bandage applied 
over the legs (40-
60mmHg at the 
ankles and 30-
40mmHg at the 
hips) for 10 mins, 
then an 
abdominal 
bandage was 
added for a 
During active 
sham treatment, 
the same elastic 
bandages were 
applied (5mmHg 
overall). 
Specific Symptom 
Scale 
Questionnaire for 
Orthostatic 
Intolerance (SSS-
OI) (baseline and 
one-month post-
treatment with 
elastic leg 
compression 
stockings.  
sBP and HR: 
supine and 60 
degrees, pre- and 
post-leg bandage 
In the intervention 
group, 90% of all 
participants remained 
asymptomatic versus 
53% in the control 
group (p<0.02). 
During the month 
before evaluation, the 
mean SSS-OI score 
was 35.2 (± 12.1) with 
dizziness, weakness 
and palpitations 
accounting for 64% of 
the total score. The 
SSS-OI score 
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centre) 
randomised 
sequential 
order of 
treatments. 
further 10 
minutes (20-
30mmHg). 
The modified 
Italian tilt protocol 
was used, 
consisting of 60 
degrees passive 
tilting for 20 
minutes followed 
by 0.4mg nitro-
glycerine 
challenge for a 
further 20 
minutes when the 
passive phase 
failed to induce 
syncope. 
Participants were 
trained and wore 
compression 
stockings (40-
60mHg at ankles 
and 30-40mmHg 
at hips) for one 
month after 
testing. 
phase, end of leg 
plus abdomen 
phase 
 
decreased to 22.5 
(±11.3) after one 
month of therapy 
(p<0.01). In the 
control group, sBP 
decreased from 125 
(±18) mmHg 
immediately after 
tilting to 112 (±25) 
mmHg after 10 
minutes of sham leg 
bandaged and to 106 
(± 25) mmHg after 20 
minutes despite the 
addition of sham 
abdominal bandage. 
In comparison, active 
therapy group BP was 
129 (±19) mmHg, 127 
±17mmHg (p<0.003vs 
control), and 127 
(±21) mmHg (p<0.002 
vs. control). 
 
Vijayakumar 
et al. 2012. 
 
Randomised 
controlled 
trial 
 
India, 
Department 
of 
Rehabilitation 
Medicine 
N=26 
acute/sub-acute 
stroke (duration 
< 4 weeks post-
stroke) with OH 
(18 male) 
N=13 received 
Pneumatic 
abdominal binder 
(PAB) 40mmHg 
pressure and 
Pneumatic Calf 
Compression 
N=13 received 
Elastic 
Compression 
Bandaging 
(ECB) from the 
metatarsal head 
to the popliteal 
Number of days 
taken to attain 
orthostatic stability 
Modified Rankin 
scale (mRS) to 
measure 
The percentage of 
participants <4 weeks 
post-stroke wearing 
pneumatic abdominal 
binder and pneumatic 
calf compression 
achieving orthostatic 
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Mean age: 
59.77 (±17.03) 
years in 
intervention 
group and 
63.33 (±15.83) 
in control group 
(PCC) 30mmHg 
pressure 
fossa in a single 
layer spiral 
manner with 
overlap 
independence of 
specific tasks. 
Hemodynamic 
responses, 
measuring sBP and 
dBP, and HR 
parameters at 0, 
30, 45 and 60 
degrees tilt. 
stability was 
significant on the third 
(50%) (p<0.019) and 
sixth day (100%) 
(p<0.007). 
No significant 
difference in the mRS 
scores between 
groups. 
Fanciulli et 
al. 2016. 
 
Single-blind 
crossover 
RCT 
Austria, 
Laboratory 
and 
community 
N=15 with 
Parkinson’s 
Disease and 
orthostatic 
hypotension; 
(eight male) 
Age range: 66-
75 years 
After three days 
of testing, all 
participants 
received an 
elastic abdominal 
binder (20 ±2 mm 
Hg pressure). 
Binder worn for 
two hours and 
then assessed 
(pre- and post). 
After a one-day 
interval 
abdominal binder 
(20 ± 2mmHg) 
worn daily 
(daytime) for four 
weeks. 
All participants 
underwent 
baseline tilt-
testing, wore an 
abdominal 
binder (20 ±2 
mm Hg 
pressure) or 
placebo binder 
(3 ±2 mm Hg 
pressure 
applied on the 
abdominal wall) 
for two hours, 
re-tested on the 
tilt table and 
subsequently 
removed the 
binder. After 
one-day 
washout, the 
tests were 
repeated to 
ensure all 
participants had 
Primary: mean BP 
changes at three, 
five and 10 minutes 
in supine, 60 
degrees 
verticalization and 
active standing. 
Secondary: 
Orthostatic 
Hypotension 
Questionnaire 
(OHQ), Orthostatic 
Hypotension 
Symptom 
Assessment 
(OHSA) and 
Orthostatic 
Hypotension Daily 
Activity Scale 
(OHDAS) scores 
after four-week 
open-label period. 
Compared to the 
placebo binder, the 
abdominal binder was 
associated with an 
increase of the third 
minute tilt mean BP 
by 10 (±10.2 mmHg; 
+3.5, +14.5 (p<0.006).  
During the open-label 
phase, 12 patients 
wore the abdominal 
binder an average of 
5.6 ±0.6 days/week, 
50% to 75% of 
daytime. At 4-week 
follow-up, the OHQ 
score decreased by -
2.2 points (p<0.003), 
the OH Symptom 
Assessment (OHSA) 
sub score by -1.7 
points (p< 0.003) and 
the OHDAS by -3.9 
(p< 0.007). No side 
effects occurred 
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been tested in 
both abdominal 
and placebo 
binder. 
Participants 
then wore an 
abdominal 
binder (20 ± 
2mmHg 
pressure 
applied on the 
abdominal wall) 
every day 
during the 
daytime for four 
weeks 
during the crossover 
phase. 
Wadsworth 
B. 
Randomised 
crossover 
trial 
Australia, 
Large 
university-
affiliated 
referral 
hospital 
N=14, SCI T5 
or above Age 
range: 18-73 
years 
Abdominal binder 
fitted to provided 
firm support 
around the 
abdomen from 
the anterior 
superior iliac 
crest to the costal 
margin of the rib 
cage (no mmHg 
pressure 
provided) 
Participants wore 
the abdominal 
binder daily for 
the duration of 
the trial (6 
months) 
Participants 
acted as their 
own controls 
and underwent 
testing in both 
conditions 
Mean arterial BP 
Respiratory 
measures (peak 
expiratory flow, 
forced expiratory 
flow, forced vital 
capacity)  
Voice measures 
Measured at three 
time points: six 
weeks, three and 
six months, in 
supine and sitting 
in own wheelchair. 
There was no 
statistically significant 
improvement in mean 
arterial pressure, 
maximal expiratory 
pressure or sound 
pressure level. 
Overall, an abdominal 
binder resulted in a 
statistically significant 
improvement in forced 
vital capacity 
(p<0.005), forced 
expiratory volume in 
one second (p<0.05), 
peak expiratory flow 
(p<0.02), maximal 
inspiratory pressure 
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N=3 participants 
ceased wearing 
the binder daily. 
No data provided 
on daily wearing 
time. 
(p<0.01), and 
maximum sustained 
vowel time (p<0.01).  
Figueroa JJ 
SW. 2015. 
 
Randomised 
crossover 
trial 
USA, 
Laboratory 
N=13 with 
neurogenic 
orthostatic 
hypotension, 
(n=5 PAF; n=4 
multiple system 
atrophy; n=2 
Parkinson’s 
disease; n=1 
post-radiation 
baroreflex 
failure; n=1 
autoimmune 
autonomic 
neuropathy. 
(seven male) 
Age range: 62-
79 years 
Participants 
were 
ambulatory and 
able to stand 
for at least 3 
minutes without 
developing pre-
syncope. 
Abdominal and 
physical 
maneuvers 
All participants 
performed four 
maneuvers: 
moving from 
supine to 
standing without 
abdominal 
compression; 
moving from 
supine to 
standing with 
either a 
conventional or 
adjustable 
abdominal 
binder, 
application of 
subject-
determined 
maximum 
pressure 
tolerable while 
standing; and 
whilst still erect, 
subsequent 
All participants 
moved from 
supine to 
standing without 
abdominal 
compression, 
then with either 
a conventional 
or adjustable 
abdominal 
binder. The 
adjustable 
binder involved 
the application 
of participant 
determined 
maximum 
pressure 
tolerable while 
standing. 
Participants 
were asked to 
stand up and 
adjust the 
compression to 
a maximal 
tolerable level, 
and then 
Primary: 
Continuous sBP, 
dBP and HR in 
supine, and 
standing 
Secondary: The 
Orthostatic 
Symptom Scale 
(OSS) (Visual 
Analogue Scale); 
The Symptom 
Change Scale 
(SCS) (Visual 
Analogue Scale) 
Standing without 
abdominal 
compression resulted 
in a large orthostatic 
fall (∆sBP, -57mmHg) 
and severe orthostatic 
intolerance (OSS, five 
points).  
Compared with no 
abdominal binding, 
10mmHg of 
abdominal 
compression while 
supine prior to rising 
was effective in 
attenuating OH with 
both the conventional 
(ΔsBP, −50mmHg; 
IQR, −33 to 
−70mmHg; p=<0.03) 
and pull string (ΔsBP, 
−46mmHg; IQR, −34 
to −75mmHg; p<0.01) 
binders. 
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reduction of 
compression to a 
level the subject 
believed to be 
tolerable for a 
prolonged period. 
subsequently 
reduce the 
compression to 
a level the 
subject believed 
to be tolerable 
for a prolonged 
period. It was 
unclear if this 
was immediate 
or within a 
specific time of 
standing. 
Gorelik et al. 
2004. 
 
Randomised 
crossover 
trial 
Israel, 
Hospital 
inpatient 
N=61 admitted 
with acute 
medical 
conditions 
requiring bed 
rest (n=11 
acute coronary 
syndrome; 
n=10 
pulmonary 
oedema; n=14 
cerebrovascular 
accident; n=21 
infectious 
diseases; other 
n=5) (41 male) 
Mean age: 77.8 
(±9.7) years 
All participants 
underwent 
testing with or 
without 
compression 
bandages 
applied to both 
legs from ankle 
to thigh before 
moving from 
supine to seating. 
Extensible 
bandages were 
used obtain a 
uniform pressure 
of about 30 
mmHg. The 
bandages were 
stretched along 
both legs so that 
the designed 
 BP, ECG tracing, 
HR, O2 saturation, 
dizziness and 
palpitations were 
recorded prior to 
seating and during 
one, three, and five 
minutes in sitting. 
Prevalence of postural 
hypotension was 
identical in the 
unbandaged versus 
bandaged state 
(55.7%). However, 
dizziness, 
palpitations, 
accelerated HR and 
decreased oxygen 
saturation over five 
minutes were more 
prevalent in the 
unbandaged versus 
bandaged state 
(p<0.01, p<0.001, 
p<0.05, p<0.001, 
respectively). In the 
unbandaged state, 
presence versus 
absence of OH was 
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rectangles were 
transformed into 
squares. 
associated with 
significantly greater 
incidence of 
palpitations, 
tachycardia and 
decline of oxygen 
saturation over time 
(p< 0.04, p<0.03, 
p<0.03, respectively. 
 
Study Country and 
Setting 
Participant 
characteristics 
Groups Outcomes measured Main description of results 
Gorelik et al. 
2009. 
Israel, 
Inpatient 
Medical 
Department 
N=108 acute 
decompensated 
heart failure 
(n=53 postural 
hypotension, 
n=27 dizziness 
and/or 
palpitations, 
n=10 cardiac 
arrhythmias) (48 
male) 
Mean age: 75.1 
(± 8.3) years  
 
Compression 
extensible bandages 
were applied along 
both legs from the 
ankle to the thigh 
before seating. The 
bandages were 
stretched so that the 
designed rectangles 
were transformed into 
squares to obtain a 
uniform pressure (40 
mm Hg at the ankle). 
All participants 
underwent the same 
testing: Two sessions. 
Day one bandages but 
without compression; 
Day two compression 
bandages of 
approximately 
40mmHg pressure. 
BP, HR, Oxygen 
saturation, and the 
occurrence of 
dizziness or 
palpitations were 
recorded prior to, and 
during one, three and 
five minutes in sitting. 
Compression bandages 
prevented postural 
hypotension in 21 of 49 
patients and decreased the 
degree of postural BP fall 
(p<0.001). sBP and dBP were 
higher in the bandaged group 
(sBP 146.6±31.1mmHg 
bandaged versus 
141±28.1mmHg unbandaged 
p=0.055; dBP 72±13.9 
bandaged versus 68.7±16.9 
unbandaged p=0.05) following 
one minute of sitting, and 
147±28.6mmHg bandaged 
versus 141±27.1 p=0.03 sBP; 
72.4±14.6 bandaged versus 
67.9±17.4 unbandaged p=0.01 
for dBP following five minutes 
of sitting. 
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Participants assisted 
from supine to sitting - 
not standing 
Gorelik et al. 
2014. 
Israel, 
Hospital 
inpatient 
N=73 bedridden 
for ≥8 hours with 
diagnosed OH 
with various 
acute medical 
conditions (22 
male) 
Mean age: 75.2 
(±9.0) years 
Before moving from 
supine into sitting, 
compression 
extensible bandages 
were stretched along 
both legs from the 
ankle to the end of the 
thigh, so that the 
designed rectangles 
became transformed 
into squares, to obtain 
a uniform pressure of 
about 30–40 mmHg at 
the ankle. All 
participants underwent 
same testing: day one 
no compression, day 
two compression. 
sBP and dBP, Heart 
Rhythm with ECG, 
self-report symptoms 
of OH in supine and at 
one, three and five 
minutes of sitting. 
Compared with the non-
bandaged state, OH was 
registered in only 53.4% of 
bandaged participants 
(p<0.001). Moreover, the 
appearance of orthostatic 
hypotension symptoms 
decreased to 34.2% (p<0.001).  
On the second day 
(bandaged), supine dBP 
values were higher in the 
persisting 82.1±18mmHg 
versus non-persisting OH 
group 73.6±14mmHg 
(p<0.027). In the bandaged 
state, OH symptoms were 
significantly reduced in the 
non-persisting OH group 
35.3% (p<0.003).  
In participants with persistent 
OH, sBP was significantly 
increased wearing bandages 
(147.0±28mmHg) versus 
unbandaged (136.2±26.5) 
(p<0.004) 
Henry et al. 
1999. 
Quasi-
experimental 
United 
Kingdom, 
Outpatient 
Falls Clinic 
N=10 elderly 
with OH (six 
male) 
Age range: 62-
89 years (mean 
77.2 years) 
All participants 
underwent same 
testing: supine rest 
then positioned into 
standing 90 degrees 
upright with tilt table 
sBP and dBP, HR in 
supine; one, two and 
three minutes in 
supine and 90 degrees 
tilt. 
Short-term efficacy with 
compression hosiery in elderly 
people with symptomatic OH 
and a history of falls. (Not 
reported if OH was reason for 
falling or other factors) 
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for three minutes, then 
positioned into supine. 
Elastic compression 
hosiery (tights) fitted to 
bilateral lower limbs 
Authors refer to the 
fact that orthostatic 
dizziness was 
abolished in seven out 
of 10 participants, but 
do not report how this 
was measured. 
Denq JC O-
GT. 1997. 
 
Quasi-
experimental 
USA, setting 
not reported 
N=14 confirmed 
diagnosis of OH 
(n=3 Multiple 
System Atrophy; 
n=9 PAF; n=2 
diabetic 
autonomic 
neuropathy) (five 
male) 
Age range: 31-
78 years 
All participants 
underwent testing from 
supine to 80 degrees 
head-up tilt ± 
compression 
(40mmHg) to 
calves/thighs/abdomen 
and all compartments 
combined to evaluate 
the impact 
compression of 
different body parts on 
orthostatic BP and 
tolerance. 
Visual Analogue Scale 
(numerical) rating 
change in symptoms 
and duration of stand 
with compression 
garments; sBP and 
dBP in supine and 80 
degrees 
verticalization, HR, 
end diastolic volume 
index, CO, index 
peripheral resistance 
index. Visual Analogue 
Scale of severity of 
symptoms after each 
session. 
Head-up tilt with compression 
resulted in significant 
improvement (p<0.001) of sBP 
115.9±7.4mmHg compared to 
89.6±7.0mmHg without 
compression. Maximum 
improvement was with all 
combinations of compression. 
Abdominal compression alone 
was the only single 
compartment to significantly 
reduce OH (p<0.01). 
Participants reported that a 
combination of all 
compartments was most 
efficacious in reducing 
symptoms. 
Lucas and 
Ainslie, 2012 
 
Quasi-
experimental 
New 
Zealand, 
Laboratory 
N=12 healthy 
older and 
younger adults 
N=6 older adults 
(six male) 
Mean age: 70 
(±4) years 
 
N=6 younger 
adults (six male) 
All 12 participants 
stood up rapidly (<5 
secs) and remained 
free standing for three 
minutes, then returned 
to supine for six 
minutes and repeated 
the supine-to-stand 
protocol. Standing was 
terminated and 
Oesophageal 
temperature, skin 
temperature, blood 
flow velocity, arterial 
BP (beat-to-beat 
changes in BP), 
cardiac output from 
HR and SV, TPR in 
supine and standing. 
All participants completed the 
normothermic and passive 
heat conditions of both control 
and compression leggings. No 
difference in supine or initial 
seconds in standing in either 
groups. In minute six of 
standing those wearing 
compression leggings in the 
normothermia increased total 
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Mean age: 29 
(±4) years 
 
participants positioned 
supine with legs 
elevated if pre-
syncope symptoms 
presented. This was 
completed at normal 
body temperature and 
repeated at elevated 
body temperature (0.5 
degrees Celsius). In 
the elevated 
temperature trials 
participants wore long-
sleeved and legged, 
two-pieced, tube-lined 
perfusion suit. Passive 
heating was achieved 
by circulating warm 
water through the suit 
and wrapping 
participants in 
reflective foil blanket 
with periodic warm 
water circulation to 
maintain the elevated 
temperature. 
peripheral resistance in older 
participants but dropped in 
younger participants. In 
contrast, standing and heated, 
wearing compression leggings 
lowered total peripheral 
resistance in older and 
younger adults. 
Rimaud D 
CP. 2012. 
 
Quasi-
experimental 
France, 
Department 
of Physical 
Medicine and 
Rehabilitation 
N=9 SCI (n=4 
above T6, n=5 
below T6), at 
least 2 years 
post injury (nine 
male) 
Age range: 25-
54 years 
All participants 
performed two 
maximal wheelchair 
exercise tests using a 
wheelchair ergometer 
(increasing Watts 
every two minutes) 
without and with 
VO2/ VCO2 
measurement during 
test, sBP, dBP, finger 
arterial pressure, SV, 
Q, Total peripheral 
resistance, HR 
variability, wavelet 
No differences in VO2, W max, 
HR or BP with or without GCS. 
Significantly higher (p<0.05) LF 
wavelet and lower HF Wavelet 
(HF wavelet is a 
parasympathetic marker) with 
GCS 3-8 minutes post 
exercise. Decrease in mean 
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Garment Compression 
Stockings (GCS) 
(21mmHg (ankle) to 15 
mmHg (calf).  
The progressive 
wheelchair test started 
with a 30-minute rest 
period using the 
wheelchair ergometer 
to stabilize various 
cardiorespiratory 
variables. This was 
followed by a six-
minute warm up at a 
constant speed with no 
load. The load was 
then increased by 10W 
increments for low-
level paraplegics and 
5W for high-level 
paraplegics, every two 
minutes until volitional 
exhaustion, or the 
subjects were unable 
to maintain the 
required speed. 
high and low and very 
low frequency power.  
All tested pre- and 
post-exercise sitting in 
wheelchair, without 
GCS and with GCS. 
Norepinephrine and 
epinephrine 
relative risk with GCS 
immediately after exercise. 
Norepinephrine at rest was 
significantly higher (p<0.05) 
with GCS. Epinephrine and 
norepinephrine both increased 
with exercise with and without 
GCS. 
Helmi M LA. 
2013. 
Case Report 
Netherlands, 
Intensive 
Care Unit 
N=1 post-
operative 
cervical C3/C4 
laminectomy 
tetraplegic with 
clinically 
significant 
compromise of 
Tilt table testing from 
supine 0 to 45 degrees 
and 60 degrees and 
back to supine) 
without, and then with 
inflatable external leg 
compression (ELC) to 
sBP and dBP in 0, 45 
and 60 degrees tilt, 
SVI, HR, PI, peripheral 
perfusion tissue 
oxygenation. 
With the application of 15 
mmHg pressure during 45 and 
60 degrees head up, SVI and 
HR were maintained, and no 
presyncope symptoms 
occurred.  
With the ELC constantly 
inflated with a pressure of 15 
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cardiovascular 
control, (male) 
Age: 61 years 
bilateral lower limbs 
(calf and thigh) 
mmHg, the participant could 
remain in the upright position 
and could be mobilized during 
physiotherapy wearing 
inflatable ELC.  
ELC succeeded in improving 
presyncope symptoms and 
preventing OH for several 
hours. 
 
Physical counter maneuvers 
Study Country 
and Setting 
Participant 
characteristics 
Groups Outcomes 
measured 
Main description of results 
Ten Harkel 
et al. 1994. 
 
Randomis
ed 
crossover 
trial 
Netherlands
, Academic 
Medical 
Centre 
N=13 (n=7 
orthostatic 
hypotension 
(n=4 PAF, n=1 
Hodgkin's 
disease, n=1 
medulla 
oblongata 
bleed, n=1 
multiple 
sympathectomie
s); n=6 healthy 
controls) (11 
male) 
Age range: 20-
65 years 
Intervention group: 
leg muscle pumping 
(tiptoeing) or tensing 
(leg crossing) for one 
minute, started after 
two minutes of active 
standing. Maneuvers 
were performed in a 
random order, each 
for one minute, with 
one minute of quiet 
standing in between. 
 
Control group: active 
standing  
sBP and dBP, HR; 
SV, CO, peripheral 
resistance assessed 
before standing (10 
seconds) and after 
one minute of tiptoe, 
quiet standing and 
leg crossing 
assessed over 10 
seconds at first and 
after one and two 
minutes in standing. 
Mean BP, sBP and dBP significantly 
decreased in patient group (p<0.01) 
following one minute of standing; 
SVR did not change from supine; 
rise in HR seen mainly in patients 
due to non-PAF patients. 
Tiptoeing did not result in a clear 
distinction between initial and 
sustained effects between PAF and 
non-PAF patients. 
Leg-crossing induced an initial 
increase in BP, SV and CO both in 
normal participants and patients 
with PAF and non-PAF. There was 
a small increase in mean arterial 
pressure of only 13mmHg in the 
patient group, but the authors 
suggested that this increase is of a 
similar magnitude to the changes 
seen in pharmacological 
interventions such as 
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fludrocortisone, erythropoietin and 
midodrine. 
Bouvette 
CM MB. 
1996. 
USA, 
Laboratory 
and 
community 
N=9 with 
neurogenic OH 
(n=5 PAF; n=3 
autonomic 
neuropathy; n=1 
multiple system 
atrophy) (4 
male) 
Mean age: 53 (± 
18) years 
N=9 underwent four 
training sessions in 
the laboratory, then 
performed the 
physical counter-
maneuvers at home 
for 3-4 months 
Physical counter-
maneuvers: 
Squatting; 
genuflection-
contraction; leg 
crossing; knee 
flexion; toe raise; 
neck flexion; 
abdominal 
contraction; thigh 
contraction. 
Session one: all 
physical counter-
maneuvers 
performed in random 
order; Sessions two 
and three: 
biofeedback training 
on three maneuvers 
selected by the 
participant that 
provided the best 
symptomatic relief to 
optimize 
performance; 
Global Symptomatic 
Improvement Score 
(GSIS) judging the 
effectiveness of 
physical counter-
maneuvers; 
improvement in 
orthostatic BP and 
continued 
improvement with 
follow-up telephone 
survey. BP measured 
at baseline, before 
and after each 
counter-manoeuvre. 
GSIS: The findings support the 
hypothesis that physical counter-
maneuvers can significantly 
increase BP. Squatting produced 
the most dramatic change in arterial 
pressure (40.6 +23.2mmHg) 
(p<0.0004). Continued 
improvement: Standing time 
improved by 8.33 ±5.8mmHg 
minutes. Participants reported 
continued counter-manoeuvre 
performance of 3.83 ±3.1mmHg 
maneuvers per day. Biofeedback 
training: Statistically significant 
improvement seen with 
genuflection-contraction (p<0.002), 
leg crossing (p<0.016) and thigh 
contraction (p<0.007) after three or 
four 45 minutes sessions. 
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Session four: 
practicing maneuvers 
without feedback. 
van 
Lieshout et 
al. 1992. 
 
 
Netherlands
, Outpatient 
N=13 (n=7 
hypo-adrenergic 
OH; n=6 
healthy) 
OH (four male); 
age range 18-65 
years 
N=6 healthy 
controls (gender 
not reported); 
age range: 28-
34 years 
All participants 
performed exercises 
in fixed order: Stand 
up; cross legs; squat. 
Stand for 10 minutes 
max or until 
symptoms. Then 
cross legs for 30 
seconds then resume 
standing. Squat when 
"BP became low 
again" (BP cut off not 
described) 
sBP and dBP 
measured in all three 
positions. 
Standing without any physical 
maneuvers, five out of seven 
participants reported orthostatic 
dizziness within 10 minutes (four 
unable to remain standing). After 
leg-crossing all participants could 
stand for 10 minutes or more with a 
difference of 14mmHg (SD±6) in 
mean BP. A larger increase in sBP 
was observed with squatting with a 
difference of 44 (SD±18). 
Smit AA 
HM. 1997. 
 
 
Netherlands
, Laboratory 
N=8 OH (n=5 
autonomic 
failure, n=2 
post-acute 
panautonomic 
neuropathy, n=1 
post-extensive 
sympathectomy) 
(three male) 
Age range: 35-
70 years 
Each participant sat 
on seats of varying 
heights (48cm, 38cm, 
20cm) and performed 
different maneuvers 
such as squatting, 
crossing legs and 
standing in a 
crossed-leg position. 
sBP and dBP, HR, 
CO, SV and TPR. 
All measures taken: 
Standing: with and 
without contraction of 
crossed legs; Sitting: 
with and without leg-
crossing sat on Derby 
chair, Fishing chair 
and footstool; 
Squatting. 
BP was higher in sitting than 
standing. Due to increase in SV and 
CO. Lower chairs associated with 
high increment in BP. Crossing legs 
on the Derby chair produced greater 
increment in sBP and dBP (p<0.01) 
(mean change 16mmHg and 
9mmHg no leg crossing and 
49mmHg and 25mmHg with leg 
crossing). Standing crossing legs 
increased sBP and dBP significantly 
(p<0.01) (14mmHg and 7mmHg 
standing and no leg crossing versus 
29mmHg and 15mmHg crossing 
legs in standing) and in seven out of 
eight of the participants, produced a 
higher increase than sitting on the 
derby chair. Sitting on a fishing chair 
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was perceived as most comfortable. 
Derby chair was deemed unstable / 
did not relieve symptoms/ small 
seat. Low stool was hard to stand 
up from; uncomfortable or 
experienced dizziness on standing. 
Tutaj M 
MH. 2006. 
 
Quasi-
experiment
al 
Not reported 
(author has 
been 
contacted)  
N=17 familial 
dysautonomia 
(nine male) 
Mean age: 26.4 
(±12.4) years 
Physical counter-
maneuvers: bending 
forward, squatting, 
leg crossing, and 
abdominal 
compression using 
an inflatable belt. 
Counter-maneuvers 
were initiated after 
standing up, when 
sBP had fallen by 
40mmHg or dBP by 
30mmHg, or 
presyncope had 
occurred. 
HR, sBP and dBP, 
mean BP, CO, TPR 
and calf volume 
 
Mean BP increased significantly 
(p<0.005) during bending forward 
20.0mmHg, squatting (p<0.002) 
50.8mmHg and abdominal 
compression 5.8mmHg (p<0.04) but 
not during leg-crossing. Squatting 
and abdominal compression also 
induced a significant increase in 
cardiac output during squatting 
(p<0.02) 18.1mmHg and during 
abdominal compression 7.6mmHg 
(p<0.014).  
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Physical counter-maneuvers and compression 
Study Country 
and Setting 
Participant 
characteristics 
Groups Outcomes 
measured 
Main description of results 
Smit AA 
WW. 
2004. 
Netherlands, 
Laboratory 
N=23 neurogenic 
orthostatic 
hypotension (n=4 
PAF, n=7 multiple 
system atrophy, 
n=8 progressive 
autonomic 
neuropathy, n=3 
subacute 
panautonomic 
neuropathy, n=1 
OH post 
extensive 
sympathectomies) 
(10 male) 
Age range: 35-79 
years 
All participants 
performed Protocol 
one: evaluated in a 
40–60 degrees head 
up-tilt position, the 
effect of abdominal 
compression on 
caval vein and 
femoral diameter, 
arterial BP and 
haemodynamics 
wearing an anti-
gravity suit.  
Protocol two: anti-
gravity suit standing, 
then standing and 
legs crossed with 
20mmHg abdominal 
compression, 
40mmHg abdominal 
compression 
All participants 
performed Protocol 
three: investigated 
the ability to maintain 
standing BP by an 
elastic binder (nine or 
12 inch), 
sBP and dBP in 
supine, 40 degrees 
head-up-tilt, 15 
seconds preceding 
compression, first 15 
seconds of 40mmHg 
lower abdominal 
compression, last 15 
seconds of 40mmHg 
compression and 5 
seconds after 
compression and in 
standing with graded 
pressure 20/40mmHg 
± leg crossing. HR, 
CO, TPR, and 
changes in the 
inferior caval and 
femoral vein 
diameter. 
Protocol one (n=7) HUT from 
supine. Compression resulted in 
an increase in BP with increase in 
SV and CO and no change in 
peripheral resistance diameter of 
veins, decreases caval vein but 
femoral vein increases.  
Protocol two (n=12) binding and 
countermeasures increased BP 
but there was no significant 
difference between conditions.  
Protocol three n=9 significant 
increase in BP (p<0.05) (11mmHg 
sBP and 6mmHg dBP) and 
increase SV (13% p<0.05) and CO 
(12% P<0.05) and reduction in 
peripheral resistance -7% P<0.05) 
Elastic abdominal compression 
increased standing BP with 
15/6mmHg (range -3/3 to 36/14, 
p<0.05). 
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compression 15-
20mmHg 
 
Sleeping with head-up 
Study Country and 
Setting 
Participant 
characteristics 
Groups Outcomes 
measured 
Main description of results 
Ten Harkel 
et al. 1992. 
 
Quasi-
experimental 
Netherlands, 
Academic 
Centre (Two 
patients were 
tested on an 
out-patient 
basis, while 
the other four 
were 
admitted to 
hospital) 
N=6 hypo 
adrenergic OH 
(three male) 
Age range: 23-
65 years  
 
Each patient received 
a diet containing 150-
200mmol sodium and 
a minimal water 
intake of 2000 ml per 
day. This three-week 
study was divided into 
one-week phases. To 
assess changes 
during the steady 
state alone, the first 
three days of each 
week were excluded 
from the analysis; 
values are presented 
as the average for the 
last four days of each 
period. Interventions 
were delivered in 
one-week blocks. In 
the first week 
(control) they did not 
have medication 
(apart from two 
bedridden patients 
Orthostatic tolerance 
as measured by 
Orthostatic Disability 
Score; maximum 
standing time, 
terminated either at 
the onset of severe 
orthostatic dizziness 
or after a maximum 
period of 10-minute 
standing; sBP, dBP 
and mean BP) for 
control; head-up tilt; 
head-up tilt and 
fludrocortisone, and 
follow-up; Fluid 
balance (changes in 
total body water 
content assessed by 
measuring changes 
in body weight).  
Follow up at 14 
months  
Combined treatment reduced 
orthostatic dizziness in all patients 
(p < 0.001), and increased the 
maximal standing period to at 
least 10 min. 
HUT alone (n=4) reduced the BP 
decrease after 1 minute of 
standing from -64/-42/-
25±27/21/17mmHg to -53/-37/-
23±31/24/20mmHg (p<0.01 for 
sBP). The addition of 
fludrocortisone to HUT 
(HUT/fludro) (n=5) further reduced 
the BP decrease after one minute 
of standing from -63/-40/-
24±20/12/11mmHg to -21/-19/-
8±12/10/5 (p<0.05 for sBP, mean 
and dBP). BP at maximal 
standing time increased during 
combined treatment 
58/47/42±9/8/7mmHg initially to 
95/69/57±27/22/20mmHg (p<0.05 
for sBP and mean BP), and 
remained unchanged during the 
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because of severe 
OH who had 0.1 mg 
fludrocortisone) or 
head tilt. In the 
second week all 
patients started to 
sleep in the 12 
degrees HUT 
position. During the 
third week treatment 
involved a 
combination of 
sleeping in the HUT 
position and 
fludrocortisone 
administered at 2200 
hours. 
14-month (range 8-70 month) 
follow-up period. 
Fan et al. 
2011 
Randomised 
controlled 
trial 
In 
participants’ 
own homes. 
Country not 
reported 
N=100 with OH 
Mean age 76 
years 
Intervention group 
n=66, control group 
n=34. 
Intervention group 
had the head of their 
bed elevated six 
inches with blocks for 
six weeks. 
Hemodynamic 
variables: sBP, dBP 
(24-hour ambulatory 
blood pressure), 
MAP, HR, cardiac 
output, stroke 
volume, total 
peripheral resistance. 
Plus, weight, 
frequency of 
dizziness, 24-hour 
urinary sodium and 
volume, and 
presence of ankle 
oedema. 
Sleeping with head up six inches 
for six weeks was tolerated by 
participants and both groups 
reported overall improvement and 
had fewer episodes of dizziness 
per week before versus after 
(p=0.0039). Participants sleeping 
with head up were more likely to 
have leg oedema. Compliance to 
the treatment was 77%. 
However, there were no 
significant differences between 
the two groups in hemodynamic 
variables. Changes in sBP 
between pre and post were: -
1.45mmHg supine and 1.98 
mmHg standing; dBP 2.42 mmHg 
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supine and 2.61mmHg standing, 
MAP 0.94 mmHg sitting and 2.07 
mmHg standing. 
Study concluded that sleeping 
head up six inches for six weeks 
is not recommended as an 
outpatient treatment for OH in 
elderly people. 
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Dietary measures 
Food intake 
Study Country 
and Setting 
Participant 
characteristics 
Groups Outcomes measured Main description of results 
Loew F GL. 
1995. 
Switzerland, 
Teaching 
Hospital 
N=10 PD (n=2 
diagnosed with 
OH) (five male)  
Mean age: 81.6 
(± 9.02) years 
 
N=10 age 
matched 
hospital in-
patient controls 
(3 male) 
Mean age: 85.3 
(± 5.23) years 
 
Testing over two 
consecutive days. 
Day one: BP 
monitoring every 30 
minutes in supine 
between 0800 and 
1800 hours. Supine 
sBP readings were 
used before the start 
of lunch and 60 
minutes after a 
normal 2500kj lunch 
to measure the 
postprandial sBP 
change 
Day two: participants 
received their usual 
breakfast and 
pursued their usual 
activities in the ward 
(newspaper reading 
or rest). PD 
participants received 
their usual physio 
mid-morning and 
afternoon, 
orthostatic BP in 
active standing and 
head-up tilting tests 
performed after a 
sBP, HR in supine, 
active standing and 
head-up tilt testing 
both pre- and post-
prandial. dBP was 
recorded but not 
presented in the 
literature. Day one BP 
testing in supine, day 
two testing in sitting. 
PD participants had a significant 
(p<0.01) postprandial sBP drop 
from 154.3±26.2 to 
127.7±18.1mmHg in supine 
position compared to healthy 
controls; in PD participants the 
drop was moderately correlated 
to orthostatic sBP responses and 
significantly correlated to the pre-
prandial supine baseline systolic 
BP. There was a greater fall of 
sBP with passive than with active 
standing with both groups, which 
was greater in the PD group. No 
difference in orthostatic HR 
responses between groups. 
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normal 2500kj lunch 
(lunch eaten in 
sitting). All 
participants 
underwent 
orthostatic tests: 
active standing and 
head-up tilting tests, 
performed 60 and 40 
minutes before the 
start of lunch. 
Mader SL. 
1989. 
USA, Clinical 
Research 
Centre 
N=26 healthy 
elderly and 
young adults (16 
male) 
N=10 healthy 
young  
Age range: 19-
31 years 
 
N=16 healthy 
elderly  
Age range: 55 to 
78 years.  
All participants 
underwent the same 
testing: Three 
recumbent BPs 
measured two 
minutes apart after 
five minutes supine 
rest. The subject 
stood up and BP 
was measured one 
minute later. 
Protocol was 
performed beginning 
at 2.30pm on 
admission and 1pm 
the following day at 
discharge. Readings 
included first thing in 
the morning 7am, 
before and after 
meals, mid-morning, 
mid-afternoon, mid 
evening and bedtime 
sBP and dBP, HR. Supine BP: elderly had higher 
sBP and dBP. HR was higher in 
both groups after meals. Standing 
sBP and dBP was similar 
between groups. The younger 
group had higher HR with 
standing. Older showed drop pre- 
to post-meal BP (not seen in 
young). HR was higher post-meal 
in both groups. After overnight 
rest standing BP was the same. 
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(1030pm). Postural 
BP protocol was 
performed 45 
minutes after the 
beginning of each 
meal. 
Puvi-
Rajasingham 
S and 
Mathias CJ. 
1996. 
United 
Kingdom, 
Inpatient 
N=7 primary 
autonomic 
failure with 
severe OH (n=3 
PAF with no 
other 
neurological 
deficit; n=4 Shy-
Drager 
syndrome 
(Multiple System 
Atrophy) (four 
male) 
Age range: 45-
69 years 
All participants 
underwent same 
conditions: first day 
three meals, versus 
second day (at least 
one day apart) six 
meals. Total calorie 
intake was the 
same. 
BP monitoring and 
self-initiated readings 
after five minutes of 
lying, sitting or 
standing. With only 
three meals 
participants have extra 
set of positional 
recordings (six in total 
same as a six-meal 
day). Participants kept 
a symptom diary. 
Regardless of meal the size, drop 
in BP with positional change was 
similar but three meals showed a 
significantly lower BP in all 
positions than six meals 
(131mmHg after large meals and 
151mmhg after small meals 
p<0.005).  
Between meals a larger drop in 
BP was seen with three meals 
(88mmHg versus 104mmHg sBP 
p<0.002 and 48mmHg versus 
63mmHg p<0.0001 dBP). Fewer 
OH symptoms were experienced 
with six meals. 
 
Fluid intake 
Fluid intake AND exercise 
Study Country 
and Setting 
Participant 
characteristics 
Groups Outcomes measured Main description of results 
Humm AM 
ML. 2008. 
 
Quasi-
experimental 
UK, 
Laboratory 
N=8 PAF 
diagnosed with 
OH, all able to 
walk (three 
male) 
Mean age: 63.9 
(±6.1) years 
All participants 
underwent same 
testing: Supine 10 
minutes rest, standing 
10 mins, rest in 
supine, exercises in 
supine (pedal 
ergometer), rest in 
sBP and dBP in supine 
one (rest), standing 
one (five minutes 
standing), supine two 
(rest), cycling 
(exercise), supine 
three (rest), stand two. 
All participants had severe OH 
pre-exercise with prompt recovery 
of BP in supine. Five minutes after 
drinking water, there was a 
significant (p<0.05) rise in BP in 
supine position. With exercise 
there was a clear fall in BP (sBP 
42.1 (SD±24.4) mmHg and dBP 
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supine, standing five 
minutes. Identical 
protocol followed on 
two separate 
occasions: one of 
which participants 
drank 480ml distilled 
water at room 
temperature within 
five minutes after first 
stand. Participants 
were randomly 
assigned to start with 
the protocol without 
water (n=3) and with 
water (n=5) with on 
average 10.8 days 
between the two 
assessments. 
Participants were 
asked to drink the 
water within five 
minutes. 
HR, subjective 
perception of 
hypotension related 
symptoms. 
25.9 (SD±10.0) mmHg) with a 
modest risk in HR, this occurred 
even after water ingestion. sBP 
remained low after exercise but 
was significantly higher (p<0.05) 
after water intake two and five 
minutes of standing (74.5 
(SD±32.9) mmHg and 74.3 
(SD±28.4) mmHg without water 
versus 103.5 (SD±34.4) mmHg 
89.0 (SD±16.7) mmHg with 
water), resulting in better 
tolerance of post-exercise 
standing. 
Shannon et 
al. 2002. 
 
Quasi-
experimental 
Germany, 
Autonomic 
Dysfunction 
Centre 
N=18 primary 
autonomic 
failure (n=9 
PAF, n=9 
multiple system 
atrophy) (12 
male) 
Age range: 35-
70 years 
Plus an 
additional n=9 
Participants drank 
120mls, 240mls, and 
480mls of tap water at 
room temperature (20 
degrees Celsius) in 
less than five minutes 
on separate days.  
All participants 
underwent Protocol 
one: drinking 480mL 
of tap water at room 
Blood pressure 
(supine, seated, 
upright); HR  
Protocol one: Seated, 
BP and HR measured 
every five minutes for 
30 minutes, standing, 
returned to seated for 
a further 35 minutes 
with BP and HR taken 
every five minutes, 
Before water drinking, seated BP 
was 117± 23/67±10mmHg which 
fell to 83± 20/53±11mmHg after 
one minute of standing. Thirty-five 
minutes after drinking 480mls of 
water at room temperature in less 
than five minutes improved seated 
BP increased to 150± 25/78 ±13 
mmHg and after standing for one-
minute BP was 114± 30/66 
±18mmHg. 
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females with 
idiopathic 
orthostatic 
intolerance  
Mean age: 36 
(± 4) years 
temperature (20 
degrees C) in less 
than five minutes. 
All participants 
underwent Protocol 
two: consumption of 
standardized high 
carbohydrate 
breakfast. 
standing BP 
determined. 
Protocol two: seated 
for 30 minutes and BP 
and HR taken every 
five minutes, 
participants ate a 
meal, then BP and HR 
taken every five 
minutes for 90 minutes 
whilst seated. 
Repeated twice (once 
with water before the 
meal, one meal only). 
Valsalva manoeuvre, 
hyperventilation, cold 
pressor, hand grip. 
Pre-meal BP 138± 41/77 ±17 
mmHg. Within 20 minutes after 
starting to eat, BP decreased, 
reaching a nadir of 43± 36/20 
±13mmHg below baseline after 90 
minutes. Drinking 480mls of water 
in less than five minutes prior to a 
test meal, BP increased with a 
peak that was 36± 23/9 ±10mmHg 
above baseline after 20 minutes 
(p<0.001 ANOVA compared to 
meal with no water). 
Drinking water attenuated 
orthostatic tachycardia in patients 
with idiopathic orthostatic 
intolerance (123 ±23 beats per 
minute at baseline to 108 ±21 
beats per minute after water 
drinking.) 
[Inconsistencies in reported 
number of participants between 
the methods and participant 
characteristics.] 
Young and 
Mathias, 
2004. 
 
Quasi-
experimental 
United 
Kingdom, 
Inpatient 
Neurological 
Hospital 
N=14 chronic 
autonomic 
failure and 
severe OH 
(n=7 multiple 
system 
atrophy) (four 
male) 
Mean age: 62 
(±9.5) years 
 
All 14 participants 
underwent the same 
testing: Standing BP 
and HR were 
measured before and 
15- and 35-minutes 
following ingestion of 
480 ml distilled water 
within five minutes. 
Patients remained 
seated for 15 minutes 
sBP and dBP before, 
and 15 and 35 minutes 
after ingestion of 
480ml distilled water. 
Calculation of CO, 
TPR, and SV using 
Modelflow analysis. 
Standing prior to water ingestion 
caused a significant fall in sBP in 
all patients (110.6 ±25.1mmHg 
seated and 79.5 ±21.5mmHg 
standing p<0.01). After water 
ingestion standing sBP was 
significantly higher (p<0.001) at 
15 minutes (101.0 ±23.3mmHg) 
and 35 minutes (99.6 
±24.0mmHg), with an 
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(n=7 PAF) (3 
male) 
Mean age: 59 
(±10) years 
after water ingestion, 
with beat to beat 
cardiovascular indices 
measured with the 
Portapres II device 
with subsequent 
Modelflow analysis. 
improvement in orthostatic 
symptoms. 
The time to first significant rise in 
seated BP occurred at five 
minutes post-water ingestion in 
PAF and at 13 minutes in MSA. 
These increases were 
accompanied by increases in total 
minutes post peripheral 
resistance, reaching significance 
by five minutes in PAF and 13 
minutes in MSA. There were no 
significant changes in CO, SV, or 
ejection fraction. 
Abbreviations: BP: blood pressure; sBP: systolic BP; dBP: diastolic BP; HR: heart rate; O2: oxygen; VO2: maximum rate of 
oxygen consumption; VCO2: maximum rate of expired carbon dioxide; OH: orthostatic hypotension; CO: cardiac output; SVR: 
systemic vascular resistance; SV: stroke volume; SVI: stroke volume index; PI: perfusion index; SCI: spinal cord injury; PD: 
Parkinson’s disease PAF; pure autonomic failure; TPR: total peripheral resistance; ECG: electrocardiogram; R-R: intervals 
between successive heartbeats; RPP: rate pressure product; HUT: head up tilt; FES: functional electrical stimulation; DFES: 
dynamic FES; IFES: isometric FES; STEP: passive stepping; USA: United States of America; UK: United Kingdom 
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Appendix 6 Treating therapist control group Case Report 
Form 
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Pages 2 and 3 represent one session and are repeated in the CRF to provide 
21 sessions.  
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Appendix 7 Screening Case Report Form 
 
442 
 
443 
 
444 
 
445 
 
 
 
  
446 
 
Appendix 8 Post-screening Case Report Form 
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Appendix 9 Participant information sheet (standard version) 
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Appendix 10 Participant information sheet (multiple page for 
people with aphasia) 
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Appendix 11 Participant information sheet (for people with severe aphasia) 
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Appendix 12 Work instruction for the intervention 
1.0 Purpose of this document 
This Work Instruction provides detailed instructions to achieve safety and 
consistency when implementing the functional standing frame programme and 
recording the content of the usual physiotherapy group for the SPIRES trial 
across the four sites. 
2.0 Definitions 
Orthostatic hypotension: a sustained drop in systolic blood pressure of at least 
20mmHg and/or diastolic blood pressure of at least 10mmHg within three minutes of 
moving from supine or sitting into standing. 
Brief questionnaire: This is a double-sided A4 sheet which contains visual analogue 
scales with pictures to ensure people with aphasia can use. The questionnaire asks 
participants to rate their perceived level of enjoyment, fatigue, effort and any aches or 
pains. 
Physiotherapy Intervention Recording Tool: A checklist which 
physiotherapists can tick boxes to indicate specific activities undertaken during 
physiotherapy sessions for both the functional standing frame programme and 
usual physiotherapy interventions. For the functional standing frame 
programme, boxes will be provided for you to record the number of minutes the 
participant stood for, number of repetitions of sit to stand and any AEs.  
3.0 Scope 
This Work Instruction applies to all clinicians and support staff involved in the 
SPIRES trial in all four sites: 
• Lanyon Stroke Rehabilitation Unit, Camborne and Redruth Community 
Hospital 
• Woodfield Stroke Rehabilitation Unit, Bodmin Community Hospital 
• Elizabeth Stroke Rehabilitation Unit, Bideford Community Hospital 
• Skylark Stroke Rehabilitation Unit, Mount Gould Hospital 
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4.0 Responsibilities 
The PIs and treating physiotherapists at each site are responsible for adhering 
to the Good Clinical Practice guidelines and undertaking the trial specific 
training delivered by the Chief Investigator, Angie Logan. 
The Principal Investigators and treating physiotherapists at each site are 
responsible for the safe and appropriate use of the standing frame and ensuring 
all its component parts are fit and safe for purpose. 
The Principal Investigators and treating physiotherapists at each site are 
responsible for ensuring each participant is medically stable and continues to 
meet the inclusion criteria before they undertake the functional standing frame 
programme. 
5.0 Specific Procedure 
Flow chart 1 demonstrates the procedure for implementing the functional 
standing frame programme for at least the first three sessions where monitoring 
of cardiovascular responses is required. This requires blood pressure to be 
taken and recorded whilst in bed (supine for at least 3 minutes) and taken again 
within 1 minute of being transferred into a chair. If no signs of orthostatic 
hypotension, the participant can be taken to the gym to begin their functional 
standing frame programme. If the participant demonstrates a drop in systolic 
blood pressure of at least 20mmHg and/or diastolic blood pressure of at least 
10mmHg within three minutes of moving from supine or sitting into standing, 
please refer to the Orthostatic Hypotension protocol. 
Flow chart 2 demonstrates the procedure for participants who have three 
consecutive blood pressure readings within the participant’s normal range (≥ 
90/60 to 120/80) where orthostatic hypotension was initially present but now 
resolved, or for those that do not have orthostatic hypotension. 
Duration of standing 
Thirty minutes’ maximum, however, this should be graded. The aim is to 
incrementally increase this by 30% during every subsequent session until the 
30 minutes is achieved. For example, if a participant stood initially for 7 minutes, 
then the subsequent session aims for a 9-minutes stand). However, if this is not 
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achievable, then a shortened increase in time based on the participants’ ability 
should be implemented. 
 
Repeated sit to stand 
Aim for eight to 12 repetitions to facilitate strengthening, however, this should 
be graded. The aim is to incrementally increase this by 30% during every 
subsequent session until the maximum 12 is achieved. For example, if a 
participant achieved three sit to stands, then the subsequent session aims to 
achieve four. However, if this is not achievable, then a lower number of 
repetitions based on the participants’ ability should be implemented. 
 
Upper limb exercise and/or table top activities 
These can be any activities that involve the hemi-plegic/paretic upper limb or 
both upper limbs. For example, muscle activation techniques; sensory input; 
facilitation of functional reach in tasks such as taking a drink, coming hair, 
washing face, table top games such as dominoes, Connect 4. 
 
Reductions in postural support  
Physiotherapists should use their clinical reasoning to progress the amount of 
postural support provided to participants by reducing the hip and trunk strap 
tension during standing and/or eliminating of the electronic power lifter for sit to 
stand. 
 
Progression of participants 
Should participants improve to the extent where support from the standing 
frame is not required, then unsupported standing/ walking can be progressed 
outside of the frame to optimise physical recovery for the remainder of the 3-
week intervention if indicated. Repeated sit to stand (8–12 repetitions) should, 
however, be continued throughout the 30-minute session. 
 
Use of foot sensors under feet 
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Customised foot sensors will be inserted under participants’ feet. The aim is for 
the foot sensors to be used as biofeedback to encourage equal weight 
distribution during quiet standing and sit to stand. Participants are not expected 
to maintain equal weight distribution for the entire session, especially when 
undertaking table top activities. Physiotherapists will use their clinical reasoning 
to undertake any additional activities to facilitate equal weight distribution, and 
document this on the Physiotherapy Content Recording Tool. Physiotherapists 
will record the weight distribution during quiet standing at the beginning and end 
of each session. 
 
Please go to the SPIRES trial website: 
(https://www.plymouth.ac.uk/research/spires) which will include videos 
demonstrating standing, examples of how to progress the programme using 
case scenarios, downloadable schema of suggested task-specific exercises/ 
activities, advice on safety issues, what to do in the event of AEs and 
“frequently asked questions”. It will also include trial details (e.g. background, 
rationale) and the CI’s contact details. This will complement this SOP and the 
verbal training and support provided by the CI. A checklist of training 
undertaken by each of the treating physiotherapists will be recorded. 
 
Recording the content of your physiotherapy sessions 
Please use the Physiotherapy Recording Tool (in the Case Report Form) to 
record the content of every session for both the functional standing frame 
programme and usual physiotherapy.  
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Appendix 13 Orthostatic hypotension protocol 
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Appendix 14 Treating therapist intervention Case Report Form 
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Pages 2-4 represent one session and are repeated in the CRF to provide 21 
sessions.   
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Appendix 15 Assessor Case Report Form (all timepoints are 
the same content) 
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Appendix 16 Fidelity checklists 
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13. Physiotherapist(s) facilitates participant to 
undertake activities in standing 
       
14. Physiotherapist(s) facilitates participant to 
undertake repeated sit to stand aiming for 8-12 
repetitions 
       
15.  Physiotherapist(s) explains progression of 
standing time and repeated sit to stand 
    
16.  Physiotherapist(s) follows safe and 
appropriate procedures for sitting the participant 
down 
    
17. Physiotherapist records number of sit to 
stand repetitions in Case Report Form 
    
18.  Physiotherapist records duration of 
standing time in Case Report Form 
    
19.  Physiotherapist undertakes brief interview 
with participant using the aphasia friendly Visual 
Analogue Scales 
    
20. Physiotherapist explain potential adverse 
events e.g. muscle stretch pain, fatigue.  
       
20. Physiotherapist(s) undertakes 15 minutes of 
usual physiotherapy with participant 
       
21. Physiotherapist documents activities 
undertaken in usual physiotherapy time 
      
22. Physiotherapist documents if participant is 
receiving any treatment of Orthostatic 
Hypotension 
   
23. Physiotherapist documents reasons why 
participant was unable to take part in today’s 
session and, if appropriate, records Adverse 
Events in the relevant section of the Case 
Report Form. 
   
22. Physiotherapist checks for adverse events 
and records appropriately. 
      
 
Comments: 
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Appendix 17 Topic guides for interviews and focus group 
 
Participants’ Topic Guide 
Main question Possible probes 
Aims: to understand what led you to decide to participate in the study 
• Can you tell me why you agreed to take part in this study? 
• How were you approached by the clinical and research staff to participate in the study? 
• What is your understanding of about the study? 
• What were your thoughts about the amount and complexity of information about the 
study? 
Aims: to understand the communication between you and research team 
• What did you think about the information that was given to you about the study? 
• What do you think about the communication between you and the research team? 
• What are your thoughts do you think about the communication between you and the 
physiotherapists who treated you? 
• What, if anything, could have made it better? 
Aims: to understand how you felt about being randomised in to a particular group 
• How do you feel about being in the usual physiotherapy group? Would this influence 
your decision to be involved in future research studies?  
 
 
What interested you about the study? 
 
 
 
Was it clear? 
Was it good, satisfactory, poor? 
Was it good, satisfactory, poor? 
 
 
Would you agree to participate in 
another research study in the future if 
there was a chance that you wouldn’t 
get allocated to the group you 
preferred? 
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• What were your reasons for staying in the study even though you were randomised 
into the usual physiotherapy group? [omit as appropriate] 
• How do you feel about being in the functional standing frame programme group? 
Would this influence your decision to be involved in future research studies? 
• Did you have a preference for a particular treatment? 
 
Main questions Possible probes 
Aims: to understand participants’ overall experience of the functional standing 
frame programme 
• What was your overall experience of the functional standing frame programme? 
• Was there anything you liked about the standing frame programme? 
• Was there anything you didn’t like about the standing frame programme?  
• Would you agree to take part in it again if it were offered to you? 
 
• Talk to me about what it as like physically standing and practising standing up and 
sitting down? 
o Any muscle aches and pains during or after? 
o Fatigue during or after? 
o Did you experience any other issues similar to those you’ve already mentioned? 
• Do you have suggestions about how we could change or improve the standing frame 
programme? 
 
 
Did you enjoy it? 
Why did you like/not like it? 
Do you think 30 minutes was too long 
to be using the frame or about right? 
Did you experience any muscle 
soreness or other aches and pains 
during or after the standing frame 
programme? 
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Main questions Possible probes 
Aims: to understand what participants though about the study assessments 
• What did you think of study assessments? 
• What did you like about the study assessments? 
• What did you dislike about the study assessments? 
• Do you have suggestions to change or improve the study assessments? 
 
Were they easy to complete? 
Were they challenging to complete? 
Were there too many different tests?   
Were they carried out too frequently or 
about right? 
Did you find them tiring? 
Were there too many or about right? 
 
Topic guide for people who declined to participate in the study 
Main questions Possible probes 
Aims: to understand why people do not want to participate in the study 
• What were your reasons for not wanting to participate in the study? 
• Do you feel the study was explained clearly to you? 
• What were your understandings of the study? 
• What were your thoughts about the amount of information about the study? 
• What were your thoughts about being asked to be involved in our research study? 
Did they say anything that you didn’t 
like or that concerned you? 
Did you read the Participant Information 
Sheet? What do you think about it? 
Was it easy to read? Too much 
information? Not enough information? 
Approached at the wrong time? 
 
  
514 
 
Topic guide for people who withdrew from the study 
People who withdrew from the study  
• What was your overall experience of the study? 
• Can you tell me why you decided to stop the research study? 
• Do you think you knew enough about the study before agreeing to participate? 
• Did you speak to your family about agreeing to participate in the study? 
• Did you speak to anyone about stopping the research study? 
• What were your thoughts about how information about the study was presented to 
you?  
• What do you think about the idea of the functional standing frame programme? 
 
Was there anything that you enjoyed? 
Was there one specific reason for 
deciding to withdraw or several? 
 
E.g. family, clinical care team, 
researcher? 
Thoughts about Participant Information 
Sheet. Easy to read? What about the 
person who approached you about 
participating in the study?  
Good idea? Too difficult/challenging? 
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Relatives’ Topic Guide 
Carers’ perspectives  
• How do you feel about your husband/wife/mum/dad participating in the research 
study? 
• What are your thoughts and feelings about your husband/wife/mum/dad being 
randomised into one of two different physiotherapy treatment groups? 
• What support or advice did you offer your husband/wife/mum/dad in agreeing or 
declining to participate in the study? 
• What support or advice did you offer your husband/wife/mum/dad throughout the 
research study? 
• You were asked to be a consultee to provide advice on behalf of your 
husband/wife/mum/dad (agree for them to participate in the research study)… 
what are your thoughts about the consent process? [for consultees only] 
• What is your understanding of what the study was about? 
• What do you think about the communication between the research team and 
you/your relative? 
• What do you think about the communication between the physiotherapists who 
undertook the standing frame sessions with your relative? 
• Do you have any suggestions about how we can change or improve the study? 
Did you think it was a good/bad idea?  
Were you hoping that they would have 
been allocated into a particular group? 
Do you feel your relative needed 
support to agree to participate and 
complete the physiotherapy 
programme? 
 
 
Were you and your relative given 
enough information? Too much? 
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Clinicians’ Topic Guide 
Functional standing frame intervention Prompts 
• What is your overall experience of delivering the functional standing frame 
programme intervention? 
• What do you think about the standing frame as a treatment for people with stroke? 
 
• Do you feel there were specific things that made it easier or more difficult to 
implement the functional standing frame with people with severe stroke? 
 
• In your opinion, do you think this intervention is feasible/appropriate for people who 
have suffered a severe stroke? 
Did you find it easy or challenging to 
implement? 
More suitable for a particular severity: 
mild, moderate or severe? Useful? Not 
useful? 
E.g. the level of ability/disability of the 
participants? Time? Resources? 
Training received or required related to 
implementing the functional standing 
frame programme? 
 
 
  
517 
 
 
Study processes Prompts 
• What are your thoughts about the design of the study? What do you think about a 
cluster RCT [explain this term] 
• What did you think about the study protocol? 
 
 
 
• What do you think about the study documentation? Do you have a preference for a 
specific PIS when introducing the idea of the research to potential 
participants/relatives? 
• What are your thoughts about the consent process? How much time did 
participants/relatives need/want to make decision to join/decline? 
 
• What are your thoughts about participant inclusion and exclusion criteria?  
• What do you think about the communication between the research team and 
yourself? 
• What do you think about communication between the participants, relatives and 
yourself? 
• What do you think about the number of participants required for the study? 
• Did you have anyone drop out of the research study (from either group)?  
Do you think it answered the research 
question?  
Easy to follow? Too much or too little 
information? Too strict?  About right?  
Did you worry about breaching the 
protocol? 
Too strict? Too broad? 
 
Did you have to spend a lot of time 
talking about the study? 
 
Too many? Unachievable? About right? 
Were you aware of the reasons why?  
Do you think there was anything you or 
the research team could have done to 
prevent this? 
 
Was the training and protocol 
helpful/useful? 
 
Did you find it easy? Complicated? 
Time consuming? 
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• Did you have any participants who you suggested to withdraw from the research 
study? Why? 
• What are your thoughts and feelings about the overall management of the study? 
 
• What would you suggest or recommend to change or improve the study? 
 
• What are your thoughts about the procedure for reporting adverse events? 
 
Research in clinical practice  
• What are your thoughts about implementing research in clinical practice?  
 
 
 
• What are your thoughts and feelings about the impact of delivering this research on 
your workload? 
Is implementing research into clinical 
practice important to you? Do you think 
research helps inform/change your 
clinical practice? Does it require a lot of 
time and effort? Do you think it’s worth 
the time and effort?  
Do you think implementing the 
functional standing frame programme 
has had an impact on your clinical 
practice? Do you think you would 
change your clinical practice as a result 
of being involved in delivering this 
research? 
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Appendix 18 Relative participant information sheet for 
interview 
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Appendix 19 Physiotherapist participant information sheet 
for interview and/or focus group 
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Appendix 20 Patient consent form 
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Appendix 21 Consultee declaration form and information sheet 
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